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1. Introduction 
 
1.1. Cancer, Chemotherapy and Multidrug Resistance 
 
Cancer is a malignant tumor characterized by an (i) uncontrollable, (ii) infiltrating, (iii) 
destructive and (iv) metastasizing growth of cells.1 The fundamental mechanisms behind 
these malignancies are diverse. Most important is an (i) enhanced proliferation or (ii) 
insufficient apoptosis of cells due to multiple defects in the genetic material.1,2 Besides 
surgery and radiotherapy, chemotherapy is the main treatment of cancer.2 Several classes of 
antineoplastic drugs have been developed during the last decades affecting different stages 
of cell metabolism. Amongst these are (i) alkylating (e.g. cyclophosphamide) or (ii) 
intercalating agents (e.g. doxorubicin), (iii) topoisomerase II inhibitors (e.g. etoposide), (iv) 
antimetabolites (5-fluorouracil), (v) mitosis inhibitors (vincristine) or (vi) tyrosine kinase 
inhibitors (e.g. gefitinib). A regimen for antineoplastic therapy is often composed of a 
combination of chemotherapeutic agents.1,2,3,4 
Multidrug resistance (MDR) is a serious problem in cancer chemotherapy and broadly 
impairs its outcome. It is defined as cross-resistance toward structurally diverse anticancer 
drugs.5 MDR is either (i) acquired after initial chemotherapeutic intervention, or (ii) inherent 
(already existing). It leads in most cases to an altered accumulation of cytostatics in terms of 
decreased intracellular concentration.4 Several mechanisms are causative, such as (i) 
decreased influx / reduced uptake of the chemotherapeutic agent, (ii) alteration of the cell 
cycle and thereby reduced apoptosis / changed drug target, (iii) increased repair of DNA 
damage caused by the antineoplastic agent, (iv) altered metabolism of the drug due to 
upregulation / mutation of metabolism-related enzymes or (v) increase of energy-dependent 
efflux.5,6 The last mechanism is in focus of the present study, since the active efflux of xeno- 
and endobiotics is mediated by ABC-transport proteins under expense of energy. 
 
 2 Introduction 
 
1.2. ABC-Transport Proteins 
 
The human ATP-binding cassette transport proteins (ABC-transporters) are a group of 
integral membrane proteins that recognize and extrude specific substrates against a 
concentration gradient. Amongst them are representatives that efflux solutes of structural 
diversity.5 This process is accompanied by a conformational change of the transporter and 
release of the solute into the extracellular space. The catalytic cycle is completed by attaining 
the initial conformation of the ABC-transporter by binding and hydrolyzation of ATP 
comparable to a mouse trap that has to be re-tensed.6 There are 48 known expressed drug-
transporting ABC-proteins in the human body that are classified in seven subfamilies ABCA-
ABCG, based on their sequence homology.7,8 In this thesis, the focus lies on the three main 
ABC-transport proteins involved in MDR, namely MRP1, P-gp and BCRP, each having 
distinct biochemical and pharmacological properties. 
Attempts to treat ABC-transporter-related cancers include (i) targeting / inhibition by small 
molecules, peptides or antibodies or (ii) downregulation of overexpressed ABC-transporter 
genes (mimic microRNAs / short interfering RNA / antisense oligonucleotides / hammerhead 
ribozymes).5 The former approach is the main topic of this thesis. 
 
1.2.1. Multidrug Resistance-associated Protein 1 (MRP1, ABCC1) 
 
The central transporter of this thesis, MRP1, consists of 1531 amino acids. It contains three 
membrane-spanning domains (MSDs) and two nucleotide-binding domains (NBDs; Figure 
1.1). The NBDs are responsible for ATP hydrolysis and provide the energy for the transport 
process. MSD1 and MSD2 consist of six transmembrane (TM) α-helices each and are 
suggested to build a membrane spanning pore for solute extrusion.6 The role of the 
additional MSD0 is still not clarified, but it was found being important for trafficking of the 
protein to the membrane.9 Figure 1.1 gives a proposed topology. 
The function of structural parts of MRP1 as well as possible binding sites of endo- or 
xenobiotics10,11 have extensively been studied, showing tryptophanes,12,13 cysteines14,15 and 
charged amino acids16,17 being of greater importance. But specific mechanistic aspects like 
drug recognition, drug binding, drug translocation via expense of energy or drug release are 
still not yet elucidated. 
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Figure 1.1. Proposed topology of MRP1 (blue). While the MSD1 and MSD2 form a channel for extrusion of 
xenobiotics, the N-terminal MSD0 is supposed to be responsible for correct trafficking of the transport protein to 
the membrane (yellow). 
 
MRP1 is ubiquitously distributed in the human body,6,18,19 and its overexpression is connected 
to several cancers like lung cancer,20,21 especially non-small cell lung cancer,22 colon 
carcinomas and certain leukemias.6,23,24,25 It extrudes xenobiotics out of cells as phase II drug 
metabolites, such as glucuronate, glutathione (Figure 1.2) or sulfate conjugates.26,27,28,29 
Since MRP1 has affinity toward mediators of oxidative stress and cell apoptosis like 
LTC4,27,30 or oxidized glutathione (GSSG; Figure 1.2),31 it is suggested to participate in the 
regulation of cellular distress.22,32,33 
 
                     
Figure 1.2. Molecular formulas of reduced (left) and oxidized (right) glutathione. GSH is a tripeptide consisting of 
the amino acids glutamine (Glu), cysteine (Cys) and glycine (Gly). GSSG consists of two GSH units connected by 
a disulfide bound, which gives it also the name glutathione disulfide. 
 
In 1992, the 190-kDa protein MRP1 was firstly described by Cole et al. in the human small 
cell lung cancer cell line NCI-H69. It conferred resistance toward several structurally 
unrelated cytotoxic agents, such as anthracyclines, e.g. doxorubicin (adriamycin), 
daunorubicin (daunomycin; Figure 1.3), epirubicin or menogaril, but also etoposide, 
mitoxantrone, Vinca alkaloids like vincristine (Figure 1.3) or vinblastine, colchicine, acivicin 
M S D 1
NBD1
H2N
extracellular space
cancer cell; intracellular
NBD2
M S D 2
COOH
M S D 0
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and gramicidin D.34 The same resistance pattern was also observed using different MRP1 
cDNA transfected HeLa cells, giving the direct connection between MRP1 overexpression 
and MDR.35,36 Additionally, resistance toward the antiandrogene flutamide37 and the 
antifolates methotrexate, raltitrexed (ZD1694) and GW184338 have been observed in MRP1 
transfected cells. Recently, the human lung cancer cell line A549 and the human leukemia 
cell line HL60/ADR were shown to be resistant toward geldanamycin. This natural compound 
is an inhibitor of the heat shock protein 90 (Hsp90), a protein involved in cancer.39 
 
 
   
Figure 1.3. Molecular formulas of selected anticancer agents that are substrates of MRP1: daunorubicin (left) and 
vincristine (right). 
 
The structural diversity is explained by a polymorphous drug-binding domain within the 
MSDs.6 Many of these cytostatics are effluxed in co-transportation with reduced glutathione 
(GSH; Figure 1.2),40,41,42,43,44,45,46 and some are coupled to GSH via glutathione-S-transferase 
(GST)47,48 before extrusion.49,50,51 Besides GST, several enzymes related to GSH metabolism 
are critical in chemotherapy,52 such as the γ-glutamylcystein synthase (GCS), glutathione 
synthase (GSH-S), glutathione reductase (GSR), glutathione peroxidase (GPx)47 as well as 
γ-glutamyl transpeptidase (γ-GTP).53 Simultaneous expression of these enzymes and MRP1 
has been reported in MDR cell lines.54 
 
1.2.2. Permeability-Glycoprotein (P-gp, ABCB1) 
 
Since its discovery by Juliano and Ling at the end of the 70’s of the last century,55 the 170-
kDa P-gp became the most studied ABC-transporter. The 1280 amino acid protein has a 
similar topology to MRP1, but does not feature the additional MSD0. A topology model is 
seen in Figure 1.4. 
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Figure 1.4. Proposed topology of P-gp (blue). The MSD1 and MSD2 form a channel through the membrane 
region (yellow) while the energy necessary for the conformational change comes from binding and hydrolyzation 
of ATP at the NBDs. 
 
P-gp was found to be expressed in several cancers such as acute myeloid leukemia, bladder 
cancer, breast cancer or myeloma.56 It confers resistance to many structurally unrelated 
anticancer agents, like camptotecins (topotecan), epipodophyllotoxins (etoposid, teniposid), 
intercalators (doxorubicin, daunorubicin), taxanes (paclitaxel,  docetaxel) and Vinca alkaloids 
(vinblastine, vincristine). Although P-gp and MRP1 share only 15% sequence identity,32 the 
substrate pattern of these two transporters is very similar with only few differences (e.g. 
camptotecins and taxanes). Inhibitors of this transport protein are discussed in detail below. 
Amongst these are the cardiovascular drug verapamil, the immunosuppressant cyclosporine 
A or the estrogen receptor modulator tamoxifene.57,58 
 
1.2.3. Breast Cancer Resistance Protein (BCRP, ABCG2) 
 
BCRP was discovered most recently by Doyle et al. in 1998 in the breast cancer cell line 
MCF-7.59 It consists of 655 amino acids and has a structure different from the other two ABC-
transporters consisting only of one MSD and one NBD, which gave it the name ‘half 
transporter’ (Figure 1.5). Polymerization has been discussed since its discovery, most likely 
is dimerization, although tetramerization60,61,62 and polymerization up to 12 units was also 
observed.60,63 Interestingly, although a function as monomer of both transporters is highly 
likely, several reports showed MRP164,65 and P-gp66,67,68 also to occur as dimers under 
specific circumstances. 
 
M S D 1
NBD1H2N
extracellular space
cancer cell; intracellular
NBD2
M S D 2
COOH
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Figure 1.5. Proposed topology model of BCRP. Consisting only of one NBD and one MSD, it is considered to be a 
half-transporter which agglomerates to polymers, most likely a tetramer. 
 
BCRP confers resistance to mitoxantrone, several camptotecins, like irinotecan and its active 
metabolite SN-38, or epipodophyllotoxins (like etoposide and teniposide). Although with a 
smaller substrate spectrum than MRP1 or P-gp, it is still an important mediator of MDR in 
certain cancers, like acute myeloid leukemia or breast cancer,56 but also colorectal, ovarian 
and small cell lung cancer.69 As a matter of fact, single-amino acid mutants of BCRP (R482S 
and R482G) were able to transport different anthracyclines (doxorubicin, daunorubicin and 
epirubicin), although these anticancer drugs are not substrates of the wild-type BCRP.70 
Though, marginal changes in the amino acid sequence of the protein can lead to an 
additional substrate profile. Inhibitors of BCRP are discussed in detail below, most famous 
representatives are fumitremorgin C as well as its synthetic analog Ko143 and several 
tyrosine kinase inhibitors (e.g. gefitinib and imatinib).  
 
1.3. Modulators of ABC-Transport Proteins 
 
The word ‘modulators’ is used in the sense of influencing the ABC transporter-mediated 
function and is differentiated between (i) inhibition and (ii) activation of transport function. 
Both processes are characterized by a difference to the basal transport activity which is 
omnipresent in living cells. 
 
 
NBD1
H2N
extracellular space
cancer cell; intracellular
NBD2
M S D 1
COOH
Introduction  7 
 
1.3.1. Inhibitors of MRP1 
 
Since its role in MDR was evident, many structurally diverse compounds have been found to 
inhibit MRP1-mediated transport. 71,72, Generally, one can differentiate between five classes: 
(i) pharmacological drugs and corresponding synthetic analogs; (ii) natural product drugs and 
synthetic analogs; (iii) intrinsic substrates and metabolism-related drugs; (iv) macromolecules 
that influence MRP1 expression or function, and (v) HTS compounds and synthetic 
approaches. Of course there are overlaps between these groups, but the categorization 
makes it easy to classify inhibitors of this transport protein and highlights the importance of 
certain discoveries. In this section, a detailed overview of found compounds is given that 
inhibit MRP1 and intervene with the MRP1-related metabolism. 
 
1.3.1.1. Pharmacological Drugs and Corresponding Synthetic Analogs 
 
Already known for its P-gp inhibition,73,74 the cardiovascular drug verapamil, especially the 
(R)-enantiomer (Figure 1.6), 75 was found to restore sensitivity of small cell lung cancer 
cells.76 Several analogs of verapamil were synthesized, with moderate success.77 The P-gp 
inhibitors78,79,80,81 and dihydropyridine derivatives NIK-250 (Figure 1.6) and PAK-104-P 
(Figure 1.21) restored sensitivity of MRP1 overexpressing glioma,82 leukemia and sarcoma 
cells.83,84 The immunosuppressant cyclosporine A, a calcineurin antagonists and P-gp 
inhibitor, was also found to sensitize MRP1 overexpressing human lung cancer COR-L23/R 
cells,85,86,87 as well as its non-immunosuppressant derivative valspodar (PSC-833).88 The 
clinically evaluated biricodar (VX-710; Figure 1.6)89,90 and its derivative V-104 inhibited not 
only P-gp,91 but also MRP1 in transfected Madin-Darby canine kidney (MDCK) II MRP1 and 
transfected human ovarian carcinoma 2008/MRP1 cells.92,93 The P-gp inhibitor MS-209 
(dofequidar; Figure 1.6)94,95,96 could also restore sensitivity of human leukemia cells 
HL60/ADR and human small cell lung cancer cells UMCC-1/VP.97,98 The protein kinase C 
inhibitor GF 109203X (Figure 1.6), a bisindoylmaleimide derivative, was shown to restore 
sensitivity in MRP1 expressing GLC4/ADR and HL60/ADR cells.99 
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Figure 1.6. Molecular formulas of unspecific MRP1 inhibitors: verapamil (upper left), the dihydropyridine analog 
NIK-250 (upper right), the pipecolinate derivative biricodar (VX-710; lower left) and the quinoline derivative MS-
209 (lower middle). Lower right: the bisindoylmaleimide derivative GF 109203X. 
 
More specific MRP1 inhibitors are the uricosuric drugs probenecid (Figure 1.7), 
sulfinpyrazone,100 or benzbromarone (Figure 1.7).101 Several non-steroidal antiinflammatory 
drugs (NSAIDs), already known for their antiproliferative properties,102 have also been shown 
to be specific MRP1 inhibitors, like acemetacin,103 ibuprofen,104 indomethacin (Figure 
1.7),105,106 mefenamic acid104 sulindac, tolmetin and zomepirac.103 The active metabolite of 
sulindac, sulindac sulfone, was extensively evaluated as chemosensitizer in vitro.107,108,109,110 
Indomethacin analogs have been synthesized and evaluated with respect to their structure-
activity relationship (SAR).111,112,113  
 
 
 
 
 
Figure 1.7. Molecular formulas of specific MRP1 inhibitors: the uricosuric drugs probenecid (left) and 
benzbromarone (middle) as well as the NSAID indomethacin (right). 
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The already as P-gp and BCRP inhibitors known tyrosine kinase inhibitors 
(TKIs)114,115,116,117,118 were also shown to affect MRP1, e.g. AG-1393, OBF-1834, EKI-785, 
OL-57 and imatinib (STI-571).119 Lapatinib, clinically evaluated against breast cancer,120,121,122 
was able to sensitize MRP1 overexpressing human epidermoid carcinoma C-A120 cells 
toward doxorubicin and vincristine.123 The TKI and pyrazolopyrimidine derivative ibrutinib 
sensitized human leukemia HL60/ADR as well as MRP1 transfected HEK293 MRP1 cells 
against vincristine, vinblastine and doxorubicin.124  
The HIV therapeutic emtricitabine125 as many other reverse transcriptase inhibitors block 
MRP1 function.126 This was also observed for several antibacterial agents like 
ciprofloxacin,127 norfloxacin,128,129 grepafloxacin,130 penicillin G,129 rifampicin, rifamycin and 
rifamycin B.131 The antidiabetic drug glibenclamide,132 the anti-abuse drug disulfiram133 and 
the abortion-inducer mifepristone (RU486)134 are also MRP1 inhibitors, the latter is also 
known to affect P-gp.135,136 
Several compounds have only rarely been reported as MRP1 inhbitors. The farnesyl protein 
transferase inhibitor lonafarnib (SCH66336; Figure 1.8) led to accumulation of calcein AM in 
MDCK MRP1 cells.137 The p53 activator and clinic aspirant nutilin-3 (Figure 1.8) was shown 
not only to affect P-gp, but also MRP1.138 Several pyrazolopyrimidine compounds showed 
inhibitory power toward MRP1, especially reversan (CBLC4H10; Figure 1.8).139 Finally, the 
experimental drug CBT-1, developed as P-gp inhibitor, showed also to enhance intracellular 
calcein concentration in MRP1-transfected HEK293 cells.140  
 
 
 
 
Figure 1.8. Molecular formulas of drugs that have rarely been reported as MRP1 inhibitors. Left: the farnesyl 
protein transferase inhibitor lonafarnib (SCH66336); middle: The p53 activator nutilin-3; right: the 
pyrazolopyrimidine derivative reversan (CBLC4H10). 
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1.3.1.2. Natural Product Drugs and Synthetic Analogs 
 
Besides many cytostatics, like anthracyclines, Vinca alkaloids, or podophyllotoxins, many 
natural drugs were found to be substrates of ABC-transport proteins. Flavonoids for example 
are known for their anticancer properties,141,142,143,144 and affection of ABC-transporters like P-
gp,145,146 BCRP,147,148 and MRP1 as well.149 Table 1.1 shows selected flavonoids reported to 
inhibit MRP1. Figure 1.9 gives the molecular structure of selected flavonoids. 
 
Table 1.1. List of flavonoids known to interact with MRP1. 
 
 
flavonoid cell line reported by 
apigenin GLC4/ADR Versantvoort et al. 1993 [150] 
biochanin A 
 
GLC4/ADR 
Panc-1 
Versantvoort et al. 1993 [150] 
Nguyen et al. 2003 [151] 
chrysin Panc-1 Nguyen et al. 2003 [151] 
daidzein COR-L23/R, MOR/R Versantvoort et al. 1996 [152] 
euchrestaflavanone A erythrocytes Bombrowska-Hägerstrand et al. [101] 
genistein GLC4/ADR 
Panc-1 
Versantvoort et al. 1993 [150] 
Nguyen et al. 2003 [151] 
genistin COR-L23/R, MOR/R Versantvoort et al. 1996 [152] 
hesperetin HEK293 MRP1 Wu et al. 2005 [153] 
kaempferol GLC4/ADR 
HeLa T5 vesicles 
Panc-1 
Hooijberg et al. 1999 [154] 
Leslie et al. 2001 [155] 
Nguyen et al. 2003 [151] 
morin Panc-1 Nguyen et al. 2003 [151] 
myricetin HeLa T5 vesicles 
MDCK II MRP1 
Leslie et al. 2001 [155] 
van Zanden et al. 2005 [156] 
naringenin HEK293 MRP1 Wu et al. 2005 [153] 
quercetin GLC4/ADR 
HeLa T5 vesicles 
Panc-1 
MDCK II MRP1 
Versantvoort et al. 1993 [150] 
Leslie et al. 2001 [155] 
Nguyen et al. 2003 [151] 
van Zanden et al. 2005 [156] 
robinetin MDCK II MRP1 van Zanden et al. 2005 [156] 
sophoraflavanone B erythrocytes Wesolowska et al. 2010 [157] 
sophoraflavanone H erythrocytes Bombrowska-Hägerstrand et al. 2003 [101] 
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Figure 1.9. Molecular formulas of the naturally occurring flavonoids apigenin (left) and genistein (middle) as well 
as the synthetic flavonoid flavopiridol (right). 
 
Besides flavonoids, flavolignans (e.g. silybinin151,153 and dehydrosilybinin158) or chalcones 
(e.g. chalcone and phloretin),151 some stilbenoids were found to inhibit MRP1 like 
piceatannol159 or resveratrol (Fig 1.10)153,160 and its oligomers (+)-α-viniferin, sophorastilbene 
A and (-)-ε-viniferin.161 Synthetical flavonoid derivatives were also developed, like flavopiridol 
(Figure 1.9),162 or apigenin derivatives.163,164 Some compounds found the way into the 
clinic,165,166,167,168 and had properties like inhibition of angiogenesis,169 cancer cell 
proliferation,170 and expression of MDR-related proteins.171 
Besides flavonoids and flavonoid-related molecules, many diverse natural compounds were 
found to modulate MRP1, like diterpenes (e.g. latilagascene B),159 dietary sterols 
(guggulsterone, Figure 1.10)172 dibenzocyclooctadiene lignans (schisandrin B (Figure 1.10) 
schisandin A, schisandrol A, schisandrol B) 173,174 or synthetic norlignans.175 
 
 
 
 
Figure 1.10. Molecular formulas of selected natural compounds that are not flavonoids: the stilbenoid resveratrol 
(left), the sterole guggulsterone (half left), the dibenzooctadiene lignan schisandin B (half right) and the sterole 
agosterole A (right). 
 
Furthermore, curcumin, already evaluated in clinical trials with respect to malignancies,176,177 
and known to inhibit P-gp,178 was found as MRP1 inhibitor.179 Derivatives like 
demethoxycurcumin, bisdemethoxycurcumin, and caffeic acid phenethyl ester showed also 
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inhibitory activity.180 The lacton antibiotic brefeldin A and the macrolide antibiotic bafilomycin 
A1 proved to sensitize COR-L23/R cells overexpressing MRP1.181 The known P-gp 
inhibitor182 dendroamide A also inhibited MRP1.183 Finally, agosterol A (Figure 
1.10),184,185,186,187 and its derivative 4-deacetoxyagosterol A were shown to have affinity 
toward P-gp and MRP1, respectively.188 
 
1.3.1.3. Intrinsic Substrates and Metabolism-related Drugs 
 
In general, the impact of intrinsic substrates with respect to MRP1 overexpressing cells can 
be categorized in four subclasses: (i) GSH extrusion via stimulation of MRP1-mediated 
transport; (ii) inhibition of the GSH coupling enzyme GST; (iii) reduction of intracellular GSH 
via its chemical elimination or inhibition of its synthesis (GSH depletion); (iv) analogs of 
intrinsic substrates as MRP1 inhibitors. 
 
1.3.1.3.1. GSH Extrusion 
 
As mentioned before, GSH is an important co-substrate of MRP1.40,41,42,43,44,45,46 The lack of 
GSH due to enhanced extrusion or depletion can also sensitize MRP1 overexpressing cells. 
Table 1.2 shows pharmacological drugs and natural compounds that are also connected to 
GSH extrusion. 
 
Table 1.2. Survey of pharmacological drugs and natural compounds that were found to stimulate GSH extrusion 
out of cells. 
 
calcium channel blocker cell line reported by 
diltiazeme CCRF-CEM/E1000 Cullen et al. 2001 [189] 
nifedipine CCRF-CEM/E1000 Cullen et al. 2001 [189] 
verapamil CCRF-CEM/E1000 
BHK-21 MRP1 
BHK-21 MRP1 
Cullen et al. 2001 [189] 
Trompier et al. 2004 [190] 
Barattin et al. 2010 [191] 
   
flavonoids and chalcones   
biochanin A Panc-1 Nguyen et al. 2003 [151] 
chalcone Panc-1 Nguyen et al. 2003 [151] 
genistein Panc-1 Nguyen et al. 2003 [151] 
phloretin Panc-1 Nguyen et al. 2003 [151] 
quercetin Panc-1 Nguyen et al. 2003 [151] 
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HIV protease inhibitors cell line reported by 
indinavir brain astrocytes Brandmann et al. 2012 [192] 
nelfinavir brain astrocytes Brandmann et al. 2012 [192] 
 
 
1.3.1.3.2. GST Inhibition 
 
GSH is sometimes needed to be coupled with some anticancer drugs like melphalan50 or 
chlorambucil51 before extrusion. Table 1.3 gives an overview of pharmacological drugs and 
natural compounds that are known to inhibit GST. 
 
Table 1.3. Survey of pharmacological drugs and natural products that were reported to be GST inhibitors. 
 
flavonoids and chalcones cell line reported by 
butein COLO 320HSR Zhang et al. 1997[193] 
eriodictyol MCF-7 van Zanden et al. 2004 [194] 
galangin MCF-7 van Zanden et al. 2004 [194] 
kaempferol MCF-7 van Zanden et al. 2004 [194] 
morin COLO 320HSR Zhang et al. 1997[193] 
quercetin COLO 320HSR 
MCF-7 
Zhang et al. 1997 [193] 
van Zanden et al. 2004 [194] 
   
NSAIDs   
indomethacin CHO Hall et al. 1989 [195] 
zomepirac CHO Hall et al. 1989 [195] 
   
polyphenols   
tannic acid COLO 320HSR Zhang et al. 1997 [193] 
   
steroles   
gossypol MCF-7/ADR Fort et al. 1991 [196] 
 
 
High throughput screenings (HTS) gave GST inhibitors of structural diversity.197 Among them 
were α,β-unsaturated carbonyl compounds,198,199,200 the loop diuretics indacrynic acid, tienilic 
acid201,202 and ethacrynic acid (Figure 1.11)201,202,203,204 and derivatives,205,206 or the phenol 
derivative caffeic acid.207 Ethacrynic acid is by far the most studied compound. It is a MRP1 
substrate,208 and some derivatives are inhibitors of this transport protein.209 This perspective 
also led to a clinical trial in combination with thiotepa.210 But also diethyl maleate,211,212 p-
aminohippurate and probenecid,212,213 clofibrate,214 misonidazol,215 piriprost,216 GSH 
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conjugates of tetrachloro-1,4-benzoquinone,217,218 sulfasalazin,219,220 and the GSH analog 
TER286221 amongst other TER compounds222,223 were found to be GST inhibitors. 
 
 
 
 
Figure 1.11. Molecular formulas of the loop diuretic ethacrynic acid (left) as a GST inhibitor and buthionine 
sulfoximine as inhibitor of the γ-glutamylcystein synthase (right). 
 
1.3.1.3.3. GSH Depletion 
 
Acrolein and chloroacetaldehyde are GSH depleters224,225 and can sensitize MRP1 
overexpressing cells.226 Agosterol A is also suspected to deplete intracellular GSH.187 The 
role of GSH in MDR was in focus of several studies before MRP1 was known.227,228 Griffith et 
al. reported already in 1979 on methionine sulfoximine (MSO), prothionine sulfoximine (PSO) 
and buthionin sulfoximine (BSO; Figure 1.11) as potent inhibitors of the γ-glutamylcystein 
synthase, an enzyme crucial for GSH synthesis.229,230 
 
1.3.1.3.4. Analogs of Intrinsic Substrates as MRP1 Inhibitors 
 
Since leukotriene C4 (LTC4) is a natural substrate of MRP1,27 it was found that the 
leukotriene receptor antagonists like MK571 (verlukast; Figure 1.12),231 ONO-1078 
(pranlukast; Figure 1.12),232 montelukast, LY171883, HAMI 3379, BayCysLT2 and BAY-
u9773,233 inhibit MRP1 function.  
 
 
 
 
Figure 1.12. Molecular formulas of the leukotriene receptor antagonists MK571 (verlukast; left) and ONO-1078 
(pranlukast; right). 
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Glutathione is important part in cell detoxification.234,235 Especially as a co-substrate of MRP1 
it helps to remove several anticancer agents from cells.40,41,42,43,44,47,48,49,236,237 Analogs of GSH 
were generated to modulate MRP1-mediated transport. TER199 (ezatiostat) is not only a 
good inhibitor of GST238 but also of MRP1.239 Long-chain S-alkylated GSH analogs were 
found to inhibit MRP1-mediated transport of LTC4, especially S-octyl-GSH, 240 S-nonyl-
GSH241 and S-decyl-GSH,240 but also S-p-nitrobenzyl-GSH and S-p-chlorphenacyl-GSH.242 
The GSH analogs GIF-0017, GIF-0019, GIF-0068, GIF-0069, GIF-0071 and GIF-0072 were 
also shown to be potent MRP1 inhibitors.243 Even analogs of the tripeptide GSH with 
exchanged amino acids were evaluated as MRP1 inhibitors.244 
 
1.3.1.4. Macromolecules that Influence MRP1 Expression or Function 
 
Downregulation of MRP1 is a possible mechanism to sensitize MDR cells. This was shown 
by introducing oligonucleotides into cancer cell lines. ISIS 7597 for example, a 
phosphorothioate oligonucleotide, could reduce intracellular MRP1 mRNA about 90% by an 
incubation time of four hours using H69AR cells.245 Another phosphorothioate 
oligonucleotide, PS-TMR10, was able to reduce mRNA MRP1 levels in HL60/ADR cells 
down to 24% of control.246 In both cases, the absolute protein amount of MRP1 was 
significantly reduced. This was also observed with the same group of oligonucleotides in 
MRP1-overexpressing glioma cells T98G-VP and Gli26-VP.247 Similar results were obtained 
using the oligonucleotide named MRP1-ASO, which increased sensitivity of neuroblastoma 
cells toward etoposide.248 
Selected cell lines that overexpress MRP1 were shown via micro array hybridization to have 
elevated levels of microRNAs (miRs). Liang et al. showed that miR-326 is down-regulated in 
MCF-7/VP cells and mimics of this nucleotide can cause sensitivity toward doxorubicin and 
etoposide.249 In the human small cell lung cancer cell line H69AR, miR-7 was shown to 
decline MRP1 expression.250 Up to now, other miRs have been found via micro array 
analysis to intervene with MRP1 expression, especially miR-134,251,252 miR-145.253,254 Short 
hairpin RNAs (shRNAs), such as shAbcc17, were also proven to down-regulate MRP1.255 
Another approach is targeting MRP1 itself via antibodies. Since most of them are known to 
bind intracellularly,256,257 and diffusion of such big proteins is difficult, this field of MRP1 
inhibition is still in its infancy. 
 
1.3.1.5. HTS Results and Synthetic Approaches 
 
Many working groups and pharmaceutical companies carried out HTS of huge compound 
libraries to find hits for further synthetic improvement. This approach led to compounds that 
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were further optimized with respect to inhibition of MRP1, like aromatic 2-
(thio)ureidocarboxylic acids (Figure 1.13),258,259 4-aminobenzoic acid derivatives (Figure 
1.13),260 or chalcogen pyrylium compounds (Figure 1.13),261,262 as well as galloyl-based small 
molecules (Figure 1.17).263 
The Eli Lilly company reported on many different structures affecting MRP1, such as the 
raloxifene derivatives LY117018 and LY329146,264 the PI3K inhibitor LY294002265 as well as 
tricyclic isoxazoles (Figure 1.13; e.g. LY475776266) as selective and very potent MRP1 
inhibitors. 267,268,269 
 
 
 
 
Figure 1.13. Molecular formulas of HTS-derived compounds: the thioureidothiophene derivative no. 48 (left), the 
4-aminobenzoic acid derivative 1 (half left), the chalcogen pyrylium compound no. 2 (half right) and the tricyclic 
oxazole no. 21b (right). 
 
Xenova Ltd. reported on quinazolinones (Figure 1.14),270 pyrrolo- (Fig 1.14),271 and 
indolopyrimdines (Figure 1.14)272 as inhibitors of MRP1 and P-gp. These compounds are the 
most potent inhibitors of MRP1-mediated transport and represent the objective of this thesis. 
 
 
 
 
 
 
 
 
 
 
Introduction  17 
 
 
 
Figure 1.14. Molecular formulas reported by Wang et al.: The quinazolinone derivative no. 40, the 
pyrrolopyrimidine no. 57 as well as the indolopyrimidine no. 78. The latter two substance classes are in focus of 
this thesis and are members of the compound class of 9-deazapurines as expressed in the title. 
 
1.3.2. Activators of ABC-Transport Proteins 
 
1.3.2.1. General Information 
 
There is only few information about transport activation of ABC-transport proteins. Prazosine 
and progesterone were reported to stimulate P-gp-mediated transport,273,274 but also                 
(-)epicatechin,275 aged garlic extracts,276 the tyrosine kinase inhibitor erlotinib,277 the 
imidazothioazole-derivative QB102278 and other benzimidazole and benzthiazole 
derivatives.279,280,281,282 Furthermore, certain thiophenopyrimidines showed to activate P-gp-
mediated efflux of daunorubicin in A2780/ADR cells.283284 Certain flavonoids were shown to 
stimulate P-gp-mediated transport.285,286,287 Several of these compounds were also firstly 
known as inhibitors of P-gp.288 Activators of the P-gp ATPase have also been described, 
such as synthetic hydrophobic peptides,289 several flavonoids290,291 or pharmacological drugs 
like verapamil.292 
With respect to MRP2, another MDR-conferring efflux pump, the leukotriene receptor 
antagonists MK571, ONO-1978, montelukast and LY171883 stimulated the transport of 
E217βG, a substrate of MRP2. The latter compound also stimulated MRP3-mediated 
transport of this intrinsic substrate.233 The benzothiophene derivative Gü658 was also shown 
to stimulate MRP2-mediated transport of E217βG.293 
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1.3.2.2. Activators of MRP1 
 
Different mechanisms are conceivable leading to a decreased intracellular concentration of 
an anticancer drug or fluorescence dye, such as (i) enhanced expression / reduced 
downregulation of the transporter, (ii) modulation of processes influencing protein trafficking 
or integration into the membrane or (iii) increased transport activity of the transport protein 
itself. Table 1.4. gives an overview of compounds that are connected to activation of MRP1 
mediated transport. 
 
Table 1.4. Survey of pharmacological drugs, natural compounds, intrinsic substrates and their derivatives that are 
considered to activate MRP1-mediated transport. a = ATPase activation. 
 
calcium channel blockers cell line reported by 
verapamil and derivatives 
 
 
 
 
HeLa T14 MRP1 vesicles 
HeLa T14 MRP1 vesicles 
CCRF-CEM/E1000 
BHK-21 MRP1 
BHK-21 MRP1 
Loe et al. 2000 [294] 
Loe et al. 2000 [77] 
Cullen et al. 2001 [189] 
Trompier et al. 2004 [190] 
Barattin et al. 2010 [191] 
   
curcuminoids   
curcumin I-III HEK293 MRP1a Chearwae et al. 2006 [295] 
   
GSH analogs   
GSH 2008/MRP1, GLC4/ADR Hooijberg et al. 2000 [296]  
methyl-S-GSH H69AR Leslie et al. 2003 [244] 
ethyl-S-GSH H69AR Leslie et al. 2003 [244] 
γ-Glu-Leu-Gly H69AR Leslie et al. 2003 [244] 
γ-Glu-Phe-Gly H69AR Leslie et al. 2003 [244] 
GSSG H69AR Mao et al. 1999 [297]  
   
flavonoids and chalcones   
apigenin GLC4/ADRa 
HeLa T5 vesicles 
HeLa MRP1, H69AR 
Hooijberg et al. 1999 [154] 
Leslie et al. 2001 [155] 
Leslie et al 2002 [298] 
biochanin A Panc-1 Nguyen et al. 2003 [151] 
chalcone Panc-1 Nguyen et al. 2003 [151] 
daidzein HEK293 MRP1 Wu et al. 2005 [153] 
flavopiridol GLC4/ADRa Hooijberg et al. 1997 [299] 
genistein GLC4/ADRa 
HeLa MRP1, H69AR 
Panc-1 
Hooijberg et al. 1997 [299] 
Leslie et al. 2002 [298] 
Nguyen et al. 2003 [151] 
hesperetin HEK293 MRP1 Wu et al. 2005 [153] 
Introduction  19 
 
flavonoids and chalcones cell line reported by 
kaempferol GLC4/ADRa Hooijberg et al. 1997 [299] 
myricetin HeLa T5 vesicles Leslie et al. 2001 [155] 
naringenin HeLa T5 vesicles 
HeLa MRP1, H69AR 
HEK293 MRP1 
Leslie et al. 2001 [155] 
Leslie et al 2002 [298] 
Wu et al. 2005 [153] 
phloretin Panc-1 Nguyen et al. 2003 [151] 
quercetin COR-L23/R, MOR/R, 
 HeLa T5 vesicles 
HeLa MRP1, H69AR 
Panc-1 
Versantvoort et al. 1996 [152] 
Leslie et al. 2001 [155] 
Leslie et al. 2002 [298] 
Nguyen et al. 2003 [151] 
   
HIV protease inhibitors   
indinavir brain astrocytes Brandmann et al. 2012 [192] 
nelfinavir brain astrocytes Brandmann et al. 2012 [192] 
 LS-180V Perloff et al. 2001 [300] 
   
stilbenoids   
resveratrol HEK293 MRP1a Wu et al. 2005 [153] 
 
 
The reverse transcriptase inhibitor ritonavir (Figure 1.15) was reported by Perloff et al. to 
enhance expression of MRP1 in the human colon adenocarcinoma cell line LS-180V. More 
recently in 2011, Park et al. found that α-tocopherol (vitamin E; Figure 1.15) can prevent 
MRP1 downregulation targeting intracellular microRNA (miR-199a-5p) that is a known 
regulator of MPR1 expression.301 The authors also used glutamine to cause intracellular 
oxidative stress (GSSG overload), which was also a trigger for MRP1 upregulation. One year 
later the collagen/β-1-integrin was reported to prevent chemosensitivity toward doxorubicin in 
HSB2 leukemic T-cells by MRP1 upregulation.302 
With respect to transport activation, the phenothiazine maleates (Figure 1.15), a known class 
of MRP1 and P-gp inhibitors,303 were shown to stimulate MRP1-mediated transport of the 
MRP1 substrates BCPCF and BCECF.304 Other phenothiazines were found to stimulate 
MRP1 in MRP1-expressing erythrocytes305. 
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Figure 1.15. Molecular formulas of compounds that enhance MDR in cancer cells that overexpress MRP1. Left: 
the reverse transcriptase inhibitor ritonavir enhances MRP1 expression; middle: vitamin E (α-tocopherol) affects 
the microRNA miR-199a-5p, a known regulator of MPR1 expression; right: the phenothiazine maleate derivative 
4HPhM as the most potent activator of MRP1-mediated transport.  
 
Hummel et al. showed in 2011, that MRP1-mediated efflux was dependent on actin 
polymerization of the cytoskeleton.306 This was also found by El Azreq et al.302 While the 
disrupter latrunculin B (Figure 1.16) lowered MRP1 function, the actin polymerization 
enhancer jasplakinolide (Figure 1.16) enhanced the transport of the fluorescence dye and 
MRP1 substrate CFDA. 
 
 
 
 
Figure 1.16. Molecular formulas of compounds that influence the polymerization of the intracellular actin skeleton, 
latrunculin B (left) and jasplakinolide (right). The latter compound enhanced polymerization and therefore MRP1 
function, while the former did vice versa. 
 
1.3.3. Dual Inhibitors of MRP1 and P-gp 
 
Several of the pharmacological drugs, natural compounds and synthetic HTS-derived 
compounds have been reported to affect both, MRP1 and P-gp. Table 1.5 summarizes the 
known compounds. 
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Table 1.5. Survey of pharmacological drugs, natural products and HTS-derived compounds that are known to 
affect both, MRP1 and P-gp. 
 
pharmacological drug reference 
CBT-1 [140] 
cyclosporine A [85],[86],[87],[88] 
disulfiram [133] 
mifepristone [134],[135],[136],[307] 
MS-209 [94],[95],[96],[97] 
NIK-250 [82],[308] 
nutilin-3 [138] 
verapamil [73],[74],[76],[309],[310] 
  
natural compounds  
agosterol A [184],[185],[186],[187] 
curcumin [178],[179] 
4-deacetoxyagosterol A [188] 
dendroamide [182],[183] 
genistin [152] 
8-prenylnaringenin [157] 
schisandrin B [173],[311],[312] 
  
synthetic HTS-derived compounds  
galloyl-based derivative 11f [263] 
LY117018 [264] 
LY329146 [264] 
LY335979 [267],[268] 
LY465803 [267],[268] 
LY475776 [267],[268] 
 
 
The tricyclic isoxazole derivatives published by Norman et al. as well as the quinazolinones 
and 9-deazapurine derivatives reported by Wang et al. were very potent dual inhibitors with 
IC50 values in the low micromolar range or even better. Galloyl-based compounds reported 
by Pellicani et al. showed also dual inhibitory activity toward MRP1 and P-gp. Figure 1.17 
gives an overview of the best dual inhibitors. 
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Figure 1.17. Molecular formulas of most recently published dual inhibitors of MRP1 and P-gp: the tricyclic 
isoxazole derivative no. 13 (left), the pyrrolopyrimidine derivative no. 47 (half left) and the indolopyrimidine 
derivative no. 49 (half right). The most recent report has been made for galloyl-based compounds, where 
derivative no. 11f (right) showed best inhibitory activities toward MRP1 and P-gp. 
 
1.3.4. Dual Inhibitors of MRP1 and BCRP 
 
Dual inhibition of MRP1 and BCRP has rarely been reported in the literature. The 
(thio)ureidocarboxylic acids by Häcker et al.258 affected besides MRP1 also BCRP, but only 
at high concentrations. Specific dual flavonoids were shown to inhibit both transporters 
(Figure 1.18).313,314  
 
 
 
Figure 1.18. Molecular formula of a rare dual inhibitor of MRP1 and BCRP: the triazole containing flavonoid 
named ‘AclOAzl’. 
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1.3.5. Dual Inhibitors of P-gp and BCRP 
 
Many compounds were reported as dual inhibitors of P-gp and BCRP, such as elacridar 
(GF120918)315 or tariquidar (XR9567).316 Also several synthesized analogs of these 
reversers showed to be dual inhibitors (Figure 1.19).317,318 BCRP inhibitors derived from 
known P-gp inhibitors were also reported to affect both transport proteins, like tetrazolic 
HM30181 derivatives (Figure 1.19) by Köhler et al.,319 or tetrahydro-β-carboline analogs 
reported by Spindler et al. (Figure 1.19).320 And since flavonoids were already discussed as 
inhibitors of MRP1, P-gp and BCRP,145,146,147,148,149 many flavonoids (Figure 1.19),321 as well 
as their precursors, the chalcones and derivatives (Figure 1.19),322,323,324,325 proved to be dual 
inhibitors of P-gp and BCRP. Quinazoline moieties (Figure 1.19) were also shown to be 
effective in blocking P-gp- and BCRP-mediated transport of fluorescence probes.326,327,328,329 
Analogs of the antiarrhythmic drug propafenone were found to affect both transport proteins 
using human myeloid leukemia cells PLB985 transfected with BCRP as well as the human T-
lymphoblast cell line CCRF VCR1000 overexpressing P-gp.330 Most recently, 
acryloylphenylcarboxamides (Figure 1.19)331 and acryloylphenylcarboxylates (Figure 1.19)332 
were shown to inhibit both, P-gp and BCRP, using in A2780/ADR and MDCK II BCRP cells 
overexpressing P-gp and BCRP, respectively. 
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Figure 1.19. Molecular formulas of potent dual inhibitors of P-gp and BCRP. 
 
1.3.6. Triple Inhibitors of MRP1, P-gp and BCRP 
 
An exciting field of transporter science is multiple inhibition of transport proteins. The natural 
compound piperine (Figure 1.20) was found to cause accumulation of specific MRP1, P-gp 
and BCRP substrates in the corresponding overexpressing cell lines.333 The clinical trial 
candidate biricodar89,90,91,92 is nowadays considered to affect all three transporters.334 The 
same applies for the standard inhibitor of BCRP, Ko143 (Figure 1.20), although the 
concentration needed to affect MRP1 is rather high.335 A tariquidar analog (no. 14; Figure 
1.20), a compound class providing some dual inhibitors, was investigated by Pick et al. using 
2008/MRP1, A2780/ADR and MCF-7/MX cells, respectively. Although all three major 
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transporters were affected,317 the effect on MRP1 was in low magnitude.336 Some quinazoline 
(Figure 1.20)337 and quinoline (Figure 1.20)338 derivatives were also shown to be triple 
inhibitors. 
 
 
 
 
Figure 1.20. Molecular formulas of compounds known to affect all three ABC-transport proteins, MRP1, P-gp and 
BCRP. 
 
1.3.7. Partial Inhibitors of ABC-transport proteins 
 
Partial inhibition can be defined differently. It can refer to the ratio of the current effect and 
the maximal achievable effect of a standard compound expressed as percentage of control. 
For example the natural drug cepharanthine (Figure 1.21), known to reverse MRP7-mediated 
MDR,339 was only partially able to reverse vincristine, etoposide and doxorubicin resistance 
in the glioma cell lines IN500 and T98G, both overexpressing MRP1.82 Another example is 
the pyridine analog PAK-104 P (Figure 1.21), which could reverse doxorubicin resistance in 
HL60/ADR cells only partially.83 Also MK571 (Figure 1.11), the most widely used standard 
inhibitor of MRP1, was shown to reverse doxorubicin-related MDR only partially in GLC4/ADR 
cells.231 The authors speculated that an altered topoisomerase II activity or co-expression of 
the lung resistance protein (LRP) might be responsible. 
In screening experiments, as also performed in this work, a fixed compound concentration 
(e.g. 10 µmol · L-1) is compared to a reference compound. The result is expressed as 
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percentage inhibition compared to the standard, and if less than 100% one can consider this 
effect being partial. 
Different from this point of view, partial inhibition can also be defined as the maximal effect of 
a compound (e.g. measured plateau of its concentration-effect curve) which is distinct from 
the maximal effect of the standard compound. This was reported in 2000 with respect to 
many known P-gp inhibitors,340,341 and was also observed for the quinazoline-chalcones in 
case of P-gp inhibition.326 The tetrazolic HM30181 derivatives (Figure 1.21)319 and their 
analogs,342 but also some quinazolines (Figure 1.21)338 result in maximum inhibition levels 
distinct from the used standard inhibitors.  
The reasons for partial inhibition are diverse: (i) solubility can limit effectiveness of a drug if 
precipitation occurs;343 (ii) fluorescence quenching of the substrate caused by the inhibitor 
might lead to reduced measured effects; (iii) protein binding could lead to a reduced fraction 
of inhibitor which is free to act, which is rather unlikely in cell-based in vitro assays; (iv) the 
transport function can be blocked only partially, that would result in a residual efflux. 
 
 
Figure 1.21 Molecular formulas of reported partial inhibitors of ABC-transport proteins. The tetrazolic HM30181 
derivative reported by Köhler et al. possessed an IC50 value of 78.9 nmol · L-1 but with only 58% inhibition as 
compared to the standard compound Ko143. The quinazoline-chalcone no. 17 had good affinity toward P-gp with 
an IC50 of 0.42 µmol · L-1, but with a maximum inhibition level of only 66%. The aniline-quinazoline no. 4 
possessed an IC50 value of 80 nmol · L-1 but with 79% inhibition. 
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2. Aim of the Thesis 
 
Chemotherapy still fails due to resistant cancers. Upregulation of ABC-transport proteins is 
one major mechanism behind this phenomenon. Colon carcinomas, lung or breast cancer 
are the most common malignancies in Germany,344 mostly involved with the expression of 
MRP1, P-gp and BCRP.56 This makes these proteins important targets in cancer 
chemotherapy. Unfortunately, clinical trials with the purpose to overcome MDR by inhibition 
of ABC-transporters failed due to severe side effects amongst other reasons.74,345,346,347  
Hence, the development of new, potent, selective, but also broad-spectrum inhibitors is 
desirable to overcome ABC-transporter-mediated MDR. Furthermore, critical key points of 
the function of ABC-transport proteins are still unknown as useful tools like modulators / 
activators are missing. The aim of this thesis is (i) the synthesis and biological evaluation of 
new purines and 9-deazapurines as inhibitors of MRP1 based on the previous reports on 
pyrrolo- and indolopyrimidines;270,271,348 (ii) investigation of the selectivity of the compounds 
toward P-gp and BCRP, and evaluation of selected compounds with respect to dual and 
triple inhibition; (iii) elucidation of structure-activity relationships of the compounds; (iv) 
characterization of the toxicity of the compounds toward different cancer cell lines; (v) 
evaluation of their MDR-reversing property; (vi) evaluation of the type of inhibition regarding 
the three herein presented ABC-transport proteins; (vii) analysis of the activating property of 
the compounds, their MDR-enhancing feature and activation type; (viii) establishment of the 
calcein AM and daunorubicin assay using the small-cell lung cancer cell line H69AR; (ix) 
development of new, potent and reliable standard inhibitors of MRP1 for further biological 
investigations. 
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3. Synthesis 
 
3.1. Synthesis of Intermediates 
 
3.1.1. Synthesis of 9-deazapurine Precursors 
 
3.1.1.1. Synthesis of the 7,8-alicyclic-9-deazapurine Scaffold 
 
The alicyclic educts 59 and 60 for the target compounds 74-87, 111-117, 126-127 and 130-
131 were prepared as already described in the literature271,348 with minor modifications.349 
Methylation of the lactam oxygen of the educts δ-valerolactam and ε-caprolactam was 
performed with dimethyl sulfate (DMS; Scheme 3.1) as described in detail in section 6.1.3.1.  
 
 
 
 
Scheme 3.1. Methylation of δ-valerolactam or ε-caprolactam with dimethyl sulfate to yield compounds 1 and 2. 
 
The obtained O-methylated intermediates 1 and 2 were treated with CH-acidic malononitrile 
resulting in spontaneous formation of the malononitrile derivatives 3 and 4 through 
nucleophilic substitution (Scheme 3.2; see section 6.1.3.2). 
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Scheme 3.2. Depiction of nucleophilic substitution of O-methylated derivatives 1 and 2 with CH-acidic 
malononitrile to yield compounds 3 and 4. 
 
The malononitrile derivatives 3 and 4 were exposed to ethyl bromoacetate and excess 
potassium carbonate to yield the pyrrole derivatives 17 and 18 as described in section 
6.1.3.5. Scheme 3.3 gives an overview of the reaction. 
 
 
 
 
Scheme 3.3. Alkylation of the alicyclic secondary amine and formation of the pyrrole derivatives 17 and 18. 
 
Dimethylformamide dimethyl acetale (DMF-DMA) as a one-carbon synthon was added to the 
pyrrole derivatives 17 and 18 to give the formimidamides 31 and 32 (Scheme 3.4). The 
complete synthesis is presented in section 6.1.3.6. 
 
 
 
 
Scheme 3.4. The one-carbon synthon dimethylformamide dimethyl acetale introduces a carbon at the primary 
amine of compound 17 and 18 leading to the formimidamide derivatives 31 and 32. 
 
Gaseous ammonia was streamed through the reaction mixture containing the intermediates 
31 and 32 leading to the pyrimidinon 45 and 46 as depicted in Scheme 3.5 and described in 
section 6.1.3.7. 
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Scheme 3.5. Formation of the pyrimidinone derivatives 45 and 46 by exposure of intermediates 31 or 32 to 
gaseous ammonia. 
 
Finally, the lactam intermediates 45 and 46 were aromatized using phosphoryl chloride as 
discussed in detail in section 6.1.3.8, resulting in the chlorinated precursors 59 and 60 
(Scheme 3.6) of the target compounds 74-87, 111-117, 126-127 and 130-131. 
 
 
 
 
 
Scheme 3.6. Formation of the pyrimidine derivatives 59 and 60 as chlorinated precursors of the target compounds 
74-87, 111-117, 126-127, 130-131. 
 
3.1.1.2. Synthesis of the 7-N-substituted-9-deazapurine Scaffold 
 
The synthesis of the chlorinated precursors with aliphatic (61-65), aromatic (66-68) and 
arylaliphatic (69-71) residues of the target compounds 88-106, 118-125, 128-129 and 132-
135 started from (ethoxymethylene)malononitrile and different commercially available primary 
amines (see section 6.1.3.4) resulting in the malononitrile derivatives 6-16 (Scheme 
3.7).349,350 
 
 
 
Scheme 3.7. Nucleophilic substitution of (ethoxymethylene)malononitrile by different primary amines resulting in 
the malononitrile derivatives 6-16. 
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The reactions to form the chlorinated precursors 61-71 are similar to the above described 
synthesis (see section 6.1.3.5-8). In short, the malononitrile derivatives 6-16 were treated 
with ethyl bromoacetate to form the pyrrole analogs 19-29. Exposure to dimethylformamide 
dimethyl acetale gave the formimidamide derivatives 33-43. Ring closure was achieved using 
gaseous ammonia giving the pyrimidinones 47-57. Finally, treatment with phosphoryl 
chloride yielded the aromatic, chlorinated 9-deazapurine precursors 61-71. These reactions 
are summarized in Scheme 3.8. 
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Scheme 3.8. Summary of the synthesis of chlorinated precursors 61-71 for synthesis of target compounds 88-
106, 118-125, 128-129 and 132-135. 
 
3.1.1.3. Synthesis of the 8,9-annulated-9-deazapurine Scaffold 
 
Since the yield of the reaction between 2-aminobenzonitrile and ethyl bromoacetate was not 
satisfactory, the educt was acylated using acetic anhydride (Scheme 3.9; see section 
6.1.3.3) forming compound 5. 
 
 
 
 
Scheme 3.9. Formation of the acylated benzonitrile derivative 5 with acetic anhydride. 
 
The following reactions to form the chlorinated precursor 72 are similar to the above 
described synthesis (see section 6.1.3.5-7). In short, the acylated benzonitrile derivative 5 
was exposed to ethyl bromoacetate to form the pyrrole derivative 30. Treatment with 
dimethylformamide dimethyl acetale resulted in intermediate 44. Exposure to gaseous 
ammonia yielded the ring-closed analog 58. Treatment with excess phosphoryl chloride gave 
the chlorinated precursor 72. Scheme 3.10 summarizes the described synthesis steps. 
 
 
Synthesis  33 
 
 
 
Scheme 3.10. Summary of the synthesis of chlorinated precursor 72 for synthesis of target compounds 136-144. 
 
3.1.2. Synthesis of the Piperazine Derivative No. 73 
 
The 1H-indole-containing compound 73 was not commercially available and had to be 
synthesized.351 Excess piperazine (4 eq.) was alkylated with 3-(2-bromoethyl)-1H-indole in 
the presence of Hünig’s base (diisopropylethylamine; 6 eq.) yielding compound 73 as 
depicted in Scheme 3.11. Further information is provided in section 6.1.3.9. 
 
 
 
Scheme 3.11. Synthesis of piperazine derivative 73 via nucleophilic substitution of 3-(2-bromoethyl)-1H-indole by 
piperazine. 
 
3.2. Synthesis of Purine and 9-deazapurine Compounds 
 
3.2.1. Synthesis of Piperazine-containing Derivatives 
 
In general, this work presents purines or 9-deazapurines with piperazine substituent at 
position 6 (74-79, 84-100, 107-112, 114-144), or 9-deazapurines with amino residues at 
position 6 (80-83, 101-106 and 113). The piperazine-bearing compounds were synthesized 
by nucleophilic substitution using either 6-chloropurine, the chlorinated precursors with 7,8-
alicyclic variations (59-60), 7-N-aliphatic (61-65), -aromatic (66-68) or -arylaliphatic (69-71) 
variations or the 8,9-annulated-9-deazapurine precursor 72 (see also section 6.1.4).349,350 
Employing microwave-assisted synthesis at fixed parameters (200 W, 110 °C), equimolar 
amounts of the chlorinated precursors and piperazine derivatives solved in 1.5 mL 
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dimethylformamide in the presence of 1.5 eq. trimethylamine yielded the target compounds 
(Schemes 3.12-14). Tables 3.1-3 summarize the synthesized purines with variations at 
position 6 as well as 9-deazapurines with variations at positions 7, 8 and 9 with piperazine 
substituents. 
 
 
 
 
Scheme 3.12. Nucleophilic substitution of 6-chloropurine with a piperazine derivative resulting in the purine 
analogs 107-110. 
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Scheme 3.13. Nucleophilic substitution of the chlorinated precursors 59-71 for synthesis of target compounds 74-
79, 84-100, 111-112, 114-135. 
 
 
 
 
Scheme 3.14. Synthesis of 8,9-annulated-9-deazapurines with variations at position 6 using the chlorinated 
precursor 72 resulting in compounds 136-144. 
 
Table 3.1. Summary of synthesized purine analogs 107-110. 
 
 
 
no. 
 
R1 
 
no. 
 
R1 
107 phenethyl 109 benzhydryl 
108 benzyl 110 phenyl 
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Table 3.2. Summary of synthesized 9-deazapurines with variations at positions 7 and 8 with piperazine-bearing 
structure at position 6 (74-79, 84-100, 111-112, 114-135). 
 
1
N
N
N
N
R
R N
N
R
2
3
8
7 6
 
 
no. 
 
R1 
 
R2 
 
R3  
 
no. 
 
R1 
 
R2 
 
R3  
74 phenethyl cyclohexyl 111 2-(1H-indole-3-yl)ethyl cyclohexyl 
75 benzyl cyclohexyl 112 2-(1H-indole-3-yl)ethyl cycloheptyl 
76 benzhydryl cyclohexyl 114 2-(pyridin-4-yl)ethyl cyclohexyl 
77 phenyl cyclohexyl 115 2-(pyridin-4-yl)ethyl cycloheptyl 
78 methyl cyclohexyl 116 pyridin-2-yl cyclohexyl 
79 H cyclohexyl 117 pyridin-2-yl cycloheptyl 
84 phenethyl cycloheptyl 118 2-(1H-indole-3-yl)ethyl methyl H 
85 benzyl cycloheptyl 119 2-(1H-indole-3-yl)ethyl ethyl H 
86 benzhydryl cycloheptyl 120 2-(1H-indole-3-yl)ethyl propyl H 
87 phenyl cycloheptyl 121 2-(1H-indole-3-yl)ethyl cyclopropyl H 
88 phenethyl methyl H 122 2-(1H-indole-3-yl)ethyl phenyl H 
89 phenethyl ethyl H 123 2-(1H-indole-3-yl)ethyl benzyl H 
90 phenethyl propyl H 124 2-(1H-indole-3-yl)ethyl phenethyl H 
91 phenethyl isopropyl H 125 2-(1H-indole-3-yl)ethyl phenylpropyl H 
92 phenethyl cyclopropyl H 126 piperonyl cyclohexyl 
93 phenethyl phenyl H 127 piperonyl cycloheptyl 
94 benzyl phenyl H 128 piperonyl phenyl H 
95 phenethyl benzyl H 129 piperonyl phenethyl H 
96 benzyl benzyl H 130 2-furoyl cyclohexyl 
97 phenethyl phenethyl H 131 2-furoyl cycloheptyl 
98 benzyl phenethyl H 132 phenethyl 2-methoxyphenyl H 
99 phenethyl phenylpropyl H 133 benzyl 2-methoxyphenyl H 
100 benzyl phenylpropyl H 134 phenethyl 4-ethoxyphenyl H 
    135 benzyl 4-ethoxyphenyl H 
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Table 3.3. Summary of synthesized 8,9-annulated-9-deazapurines 136-144. 
 
 
 
no. 
 
R1 
 
no. 
 
R1 
136 phenethyl 141 2-(pyridin-2-yl)ethyl 
137 benzyl 142 pyridin-2-yl 
138 benzhydryl 143 piperonyl 
139 phenyl 144 2-furoyl 
140 2-(1H-indole-3-yl)ethyl 
 
 
3.2.2. Synthesis of Amine Derivatives 
 
Additionally, 9-deazapurines were synthesized via nucleophilic substitution of the chlorinated 
precursors 59, 61 and 66-68 using a primary amine resulting in the target compounds 80-83, 
101-106 and 113.349,350 The procedure is similar to the above described synthesis of the 
piperazine derivatives and is summarized in Scheme 3.15 and section 6.1.4. Table 3.4 
summarizes the synthesized compounds. 
 
 
 
Scheme 3.15. Nucleophilic substitution of the chlorinated precursors 59, 61 and 66-68 giving the amino-
derivatives 80-83, 101-106 and 113. 
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Table 3.4. Summary of synthesized compounds 80-83, 101-106 and 113. 
 
3
1
2
8 N
N
N
N
R
R HN
R
7 6
 
 
no. 
 
R1 
 
R2 
 
R3  
 
no. 
 
R1 
 
R2 
 
R3  
80 phenethyl cyclohexyl 103 benzyl benzyl H 
81 benzyl cyclohexyl 104 phenylpropyl benzyl H 
82 benzhydryl cyclohexyl 105 phenethyl phenethyl H 
83 phenyl cyclohexyl 106 phenylpropyl phenethyl H 
101 benzyl methyl H 113 2-(1H-indol3-yl)ethyl cyclohexyl 
102 benzyl phenyl H 
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4. Biological Investigation 
 
4.1. Evaluation of 7,8-alicyclic and 7-N-alkyl-, -aryl- or -arylalkyl-
9-deazapurines 
 
4.1.1. Inhibition of MRP1-mediated Transport of Calcein AM and 
Daunorubicin 
 
The calcein AM and daunorubicin assays were used to evaluate the synthesized compounds 
with respect to MRP1 inhibition. The exact procedures are described in the experimental 
sections 6.2.4.2 and 6.2.4.3. In brief, the non-fluorescent calcein acetoxymethyl (AM) is a 
high-affinity substrate of MRP1. It easily diffuses through the cell membrane into the cell. 
During membrane passage, it is recognized and extruded by MRP1. Intracellularly, the ester 
is cleaved by unspecific esterases giving the fluorescent calcein. Inhibition of MRP1 transport 
function leads to an increased intracellular concentration of calcein AM which is then cleaved 
by these esterases. Therefore, fluorescence increases with inhibition of MRP1. Plotting of the 
fluorescence values against the logarithmic concentration of the used inhibitor gives a 
sigmoidal relation from which the half-maximal inhibitory concentration (IC50) can be 
deduced. 
In principle, the same applies for the antineoplastic drug daunorubicin, although no 
intracellular esterases are involved. Daunorubicin diffuses passively through the cell 
membrane into the cell, and gets extruded via MRP1-mediated transport. Inhibition of MRP1 
leads to increased intracellular concentrations of daunorubicin, which can be determined 
fluorometrically. Again, the measured fluorescence increases with the degree of MRP1 
inhibition. This assay was established and performed by Katja Stefan. The compounds and 
activities presented in this subchapter have already been published.349 
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Starting point of this series was compound 74, which was already described by Wang et al. 
(compound 30 in reference [271]). This compound was established as standard inhibitor 
(together with compound 126) as described in section 6.2.4.2.3. While the 7,8-cyclohexyl 
moiety was kept, the side chain at position 6 was changed to elucidate structural preferences 
with respect to MRP1 inhibition. Table 4.1 summarizes half-maximal inhibition concentrations 
(IC50) determined in both performed assays. Additionally, the molecular weight as well as the 
calculated partition coefficient of the neutral molecule (logP) of the compounds is listed. 
 
 
Table 4.1. Summary of calcein and daunorubicin assay results of 7,8-cyclohexyl-9-deazapurines with variations at 
position 6 (compounds 74-83). Additionally, the molecular weight as well as the calculated logP value is depicted. 
Given is IC50 value of at least three independent experiments with duplicate measurements ± standard error of the 
mean (SEM) as described in section 6.3.1.2. Furthermore, the negative decadic logarithm of the IC50 value (pIC50) 
± SEM is listed; a = compound 81 has already been published (compound 25 in ref. [271]). 
 
 
 
no. 
 
 
 
R1 
 
 
 
Mr  
[Da] 
 
 
logP 
(calc.) 
 
 
calcein AM 
IC50 ± SEM 
[µmol · L-1] 
 
calcein AM 
pIC50 ± SEM 
 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
 
daunorubicin  
pIC50 ± SEM 
74 
 
 
4-phenethyl- 
piperazine-1-yl 
 
386.50 
 
 
2.81 
 
 
0.369 ± 0.007 
 
 
6.433 ± 0.012 
 
 
0.195 ± 0.012 
 
 
6.710 ± 0.041 
 
 75 
 
 
4-benzyl- 
piperazine-1-yl 
 
372.48 
 
 
2.36 
 
 
0.672 ± 0.041 
 
 
6.173 ± 0.040 
 
 
0.634 ± 0.028 
 
 
6.198 ± 0.029 
 
 
76 
 
 
4-benzhydryl- 
piperazine-1-yl 
 
448.57 
 
 
3.82 
 
 
1.62 ± 0.07 
 
 
5.791 ± 0.027 
 
 
1.07 ± 0.03 
 
 
5.971 ± 0.020 
 
 
77 
 
 
4-phenyl- 
piperazine-1-yl 
 
358.45 
 
 
2.02 
 
 
2.54 ± 0.23 
 
 
5.598 ± 0.059 
 
 
2.90 ± 0.07 
 
 
5.538 ± 0.015 
 
 78 
 
 
4-methyl- 
piperazine-1-yl 
 
296.38 
 
 
0.86 
 
 
5.06 ± 0.15 
 
 
5.296 ± 0.020 
 
 
2.85 ± 0.19 
 
 
5.546 ± 0.043 
 
 
79 
 
 
piperazine-1-yl 
 
 
282.35 
 
 
0.17 
 
 
26.6 ± 3.0 
 
 
4.578 ± 0.075 
 
 
10.8 ± 0.2 
 
 
4.966 ± 0.015 
 
 
80 
 
 
phenylpropyl- 
amino 
 
331.42 
 
 
3.92 
 
 
2.46 ± 0.28 
 
 
5.611 ± 0.076 
 
 
2.82 ± 0.18 
 
 
5.550 ± 0.042 
 
 
81 
 
 
phenethyl- 
aminoa 
 
317.40 
 
 
3.45 
 
 
8.22 ± 0.90 
 
 
5.088 ± 0.072 
 
 
4.97 ± 0.27 
 
 
5.305 ± 0.036 
 
 82 
 
 
benzyl- 
amino 
 
303.37 
 
 
2.89 
 
 
14.2 ± 1.2 
 
 
4.851 ± 0.054 
 
 
8.72 ± 0.66 
 
 
5.061 ± 0.050 
 
 
83 
 
 
aniline 
 
 
289.34 
 
 
2.73 
 
 
14.1 ± 0.8 
 
 
4.850 ± 0.037 
 
 
9.40 ± 0.30 
 
 
5.027 ± 0.021 
 
 
 
 
Figure 4.1 shows a scatter plot of the pIC50 values determined in both assays. As indicated 
by the slope of 0.90 ± 0.07 and a R2 value of 0.94, the data is highly correlated. While for the 
whole compound set no obvious correlation could be observed between pIC50 and the 
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calculated logP values, this could be achieved by classification into (i) piperazine-bearing  
and (ii) amine-bearing compounds. This applied for the calcein AM (Figure 4.1 B) and the 
daunorubicin (Figure 4.1. C) assay, respectively. Compound 76 constituted an outlier, which 
could be explained by its bulky and sterically demanding benzhydryl residue at position 6. 
Compared to compounds 80-83 (ii), it is obvious that the piperazine linker of compounds 74-
79 (i) at the same position is more beneficial for MRP1 inhibition than the secondary amine of 
compounds 80-83. But taken together, high lipophilicity seemed to be preferred with regard 
to MRP1 inhibition. This was shown before for thioureidothiophenes.352 
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Figure 4.1. (A): Correlation of calcein AM and daunorubicin assay results for compounds 74-83. (B): Correlation 
between inhibitory activity obtained in the calcein AM assay and the calculated logP values of tested compounds. 
(C): Correlation between inhibitory activity obtained in the daunorubicin assay and the calculated logP values of 
tested compounds; open circles: piperazine-bearing derivatives (i); open squares: secondary amine-bearing 
structures (ii). 
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The interrelationship between inhibitory activity and calculated logP value can also be seen 
in the corresponding concentration-effect curves. Figure 4.2 compares compound 74 to 
compounds 75 and 77 (calcein AM assay; A) and to compounds 78 and 79 (daunorubicin 
assay; B). The selected compounds are 7,8-cyclohexyl-9-deazapurine derivatives with 
reduced linker length at position 6. The decreased inhibitory power of these compounds is 
indicated by a shift of the corresponding concentration-effect curves to the right. Hence, the 
phenethylpiperazinyl residue at position 6 is most preferred with respect to MRP1 inhibition.  
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Figure 4.2. (A): Concentration-effect curve of compound 74 (closed circles) in comparison to compounds 75 
(closed squares) and 76 (closed upward triangles) evaluated in the calcein AM assay. (B): Concentration-effect 
curve of compound 74 (closed circles) in comparison to compound 78 (closed squares) and 79 (closed upward 
triangles) evaluated in the daunorubicin assay as determined by Katja Stefan. Depicted are representative 
experiments of at least three independent experiments with duplicate measurements. Ordinate (F/F0): quotient of 
measured fluorescence at different compound concentration and basal fluorescence without compound 
supplementation (-∝). Data points are expressed as mean ± SEM. The grey arrow indicates the decrease of 
inhibitory activity accompanied by change of the phenethylpiperazinyl side chain at position 6. 
 
Enlargement of the alicyclic ring system to a cycloheptyl residue at positions 7 and 8 gave 
compounds with inferior inhibitory activity in comparison to their 7,8-cyclohexyl counterparts 
(74-77). Figures 4.3 A-B show the plots between inhibitory property of the 7,8-cycloheptyl-9-
deazapurines 84-87 and calculated logP values. Compound 86 resulted in a decreased 
inhibitory activity toward MRP1 in spite of its high logP value. This was already shown for its 
7,8-cyclohexyl counterpart no. 76. Though, the bulky benzhydryl residue was not beneficial 
for MRP1 inhibition. Table 4.2 summarizes the determined biological data. In summary, the 
increase of lipophilicity due to the enlarged alicyclic ring system at positions 7 and 8 resulted 
not in the expected enhanced inhibitory power. This might – in analogy to the benzhydryl 
residue of compound 76 and 86 – caused by the steric demands of the binding pocket(s). 
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Figure 4.3. Correlation between inhibitory activity obtained in the calcein AM assay (A) and daunorubicin assay 
(B) and calculated logP values of compounds 84-87. 
 
 
Table 4.2. Inhibitory activity data of 7,8-cycloheptyl-9-deazapurines with variations at position 6 (compounds 74-
83) as well as their molecular weight and calculated logP value. 
 
 
no. 
 
 
 
R1 
 
 
 
Mr  
[Da] 
 
 
logP 
(calc.) 
 
 
calcein AM 
IC50 ± SEM 
[µmol · L-1] 
 
calcein AM 
pIC50 ± SEM 
 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
 
daunorubicin  
pIC50 ± SEM 
84 
 
 
4-phenethyl- 
piperazine-1-yl 
 
400.53 
 
 
3.38 
 
 
0.833 ± 0.022 
 
 
6.080 ± 0.022 
 
 
0.641 ± 0.037 
 
 
6.194 ± 0.038 
 
 85 
 
 
4-benzyl- 
piperazine-1-yl 
 
386.50 
 
 
2.93 
 
 
1.06 ± 0.02 
 
 
5.976 ± 0.013 
 
 
0.980 ± 0.041 
 
 
6.009 ± 0.028 
 
 86 
 
 
4-benzhydryl- 
piperazine-1-yl 
 
462.60 
 
 
4.38 
 
 
1.94 ± 0.08 
 
 
5.712 ± 0.026 
 
 
1.01 ± 0.02 
 
 
5.998 ± 0.016 
 
 
87 
 
 
4-phenyl- 
piperazine-1-yl 
 
372.48 
 
 
2.59 
 
 
8.90 ± 0.84 
 
 
5.053 ± 0.062 
 
 
15.1 ± 1.4 
 
 
4.824 ± 0.060 
 
  
 
Since the phenethyl- and benzylpiperazine residues of the 7,8-alicyclic-9-deazapurines (74-
77 and 84-87) seemed to be most accepted by MRP1, these structural elements were 
adopted for the 9-deazapurines with variations at the pyrrole nitrogen at position 7. The 7,8-
alicyclic substituent was removed and different N-alkyl- or -alkylaryl linker were introduced to 
elucidate the preference with respect to MRP1 inhibition. Table 4.3 gives the determined 
biological data. 
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Table 4.3. Inhibitory activity data of 7-N-substituted-9-deazapurines. Aliphatic, aromatic or arylaliphatic variations 
were introduced at position 7. Position 6 contained either a phenethylpiperazine or benzylpiperazine residue. 
Additionally, the molecular weight and the calculated logP value are depicted. 
1
2
67
8 N
N
N
R N
N
R
N
 
 
no. 
 
 
 
R1 
 
 
 
R2 
 
 
 
Mr  
[Da] 
 
 
logP 
(calc.) 
 
 
calcein AM 
IC50 ± SEM 
[µmol · L-1] 
 
calcein AM 
pIC50 ± SEM 
 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
 
daunorubicin  
pIC50 ± SEM 
88 
 
phen- 
ethyl 
methyl 
 
346.44 
 
1.75 
 
0.712 ± 0.032 
 
6.148 ± 0.029 
 
0.695 ± 0.049 
 
6.159 ± 0.046 
 
89 
 
phen- 
ethyl 
ethyl 
 
360.47 
 
2.28 
 
1.05 ± 0.05 
 
5.977 ± 0.031 
 
0.785 ± 0.053 
 
6.106 ± 0.045 
 
90 
 
phen- 
ethyl 
propyl 
 
374.49 
 
2.81 
 
0.540 ± 0.035 
 
6.269 ± 0.043 
 
0.417 ± 0.016 
 
6.380 ± 0.025 
 
91 
 
phen- 
ethyl 
iso-
propyl 
374.49 
 
2.63 
 
0.813 ± 0.064 
 
6.091 ± 0.052 
 
1.23 ± 0.07 
 
5.909 ± 0.036 
 
92 
 
phen- 
ethyl 
cyclo-
propyl 
372.48 
 
1.76 
 
0.243 ± 0.018 
 
6.615 ± 0.049 
 
0.199 ± 0.014 
 
6.703 ± 0.047 
 
93 
 
phen- 
ethyl 
phenyl 
 
408.51 
 
3.97 
 
0.752 ± 0.052 
 
6.130 ± 0.046 
 
0.340 ± 0.004 
 
6.469 ± 0.008 
 
94 
 
benzyl 
 
phenyl 
 
394.48 
 
3.52 
 
1.20 ± 0.14 
 
5.923 ± 0.079 
 
0.863 ± 0.042 
 
6.064 ± 0.032 
 
95 
 
phen- 
ethyl 
benzyl 
 
422.54 
 
3.46 
 
1.00 ± 0.05 
 
6.002 ± 0.031 
 
0.619 ± 0.052 
 
6.210 ± 0.055 
 
96 
 
benzyl 
 
benzyl 
 
408.51 
 
3.01 
 
2.74 ± 0.21 
 
5.563 ± 0.051 
 
0.876 ± 0.019 
 
6.058 ± 0.015 
 
97 
 
phen- 
ethyl 
phen-
ethyl 
436.56 
 
3.90 
 
0.920 ± 0.067 
 
6.037 ± 0.048 
 
1.11 ± 0.08 
 
5.955 ± 0.046 
 
98 
 
benzyl 
 
phen-
ethyl 
422.54 
 
3.44 
 
0.891 ± 0.131 
 
6.055 ± 0.096 
 
0.973 ± 0.097 
 
6.014 ± 0.066 
 
99 
 
phen- 
ethyl 
phenyl-
propyl 
450.59 
 
4.34 
 
 0.947 ± 0.066 
 
6.025 ± 0.046 
 
0.585 ± 0.015 
 
6.233 ± 0.017 
 
100 
 
benzyl 
 
phenyl-
propyl 
436.56 
 
3.89 
 
3.15 ± 0.11 
 
5.502 ± 0.024 
 
2.36 ± 0.07 
 
5.628 ± 0.020 
 
 
 
These compounds were found to be very active, most possessing IC50 values of 1 µmol · L-1 
or less. Interestingly, no correlation could be observed with respect to calculated logP values. 
Categorization of the tested compounds 88-100 into the subclasses (i) 7-N-alkyl-substituted-
9-deazapurines (88-92), (ii) 7-N-aryl- or -arylalkyl-substituted-9-deazapurines with 
phenethylpiperazine moiety at position 6 (93,95,97 and 99) and (iii) 7-N-aryl- or -arylalkyl-
substituted-9-deazapurines with benzylpiperazine moiety at position 6 (94,96,98 and 100) 
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showed that that molecular weight is a moderately good descriptor for prediction of inhibitory 
activity (see Figures 4.4 A-B). Compound 91 is an outlier, giving less inhibition than could be 
expected with respect to its molecular weight. 
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Figure 4.4. Plot of biological data and molecular weight for evaluated compounds 88-100. Depicted are (i) 7-N-
alkyl-substituted-9-deazapurines (open circles), (ii) 7-N-aryl- or -arylalkyl-substituted-9-deazapurines with 
phenethylpiperazine moiety at position 6 (open squares) and (iii) 7-N-aryl- or -arylalkyl-substituted-9-deazapurines 
with benzylpiperazine moiety at position 6 (open upward triangles) evaluated in the calcein AM assay (A) and 
daunorubicin assay (as determined by Katja Stefan; B). 
 
 
Except for compound 91, the inhibitory activity increases with length of the side chain of 
compound subset (i). The alicyclic cyclopropyl substituent of compound 92 was mostly 
preferred and represents the best compound of this thesis. Vice-versa, compound 93 
represents the best compound of subset (ii), while the increase of the aliphatic side chain 
lowered MRP1 inhibition. Finally, the compounds of subset (iii) with the benzylpiperazine 
residue at position 6 (94, 96, 98 and 100) were all inferior compared to their 
phenethylpiperazine counterparts (93,95,97 and 99). Thus, the extended side chain at 
position 7 cannot be compensated by a shorter side chain at position 6. But as can be seen 
from Figures 4.4 A-B, the inhibitory activities of subsets (ii) and (iii) showed only a low 
correlation to molecular weight. 
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4.1.2. Analysis of Inhibition Type 
 
The type of inhibition is important with respect to comparability of biological data. In case of 
competitive inhibition, the IC50 depends on the used concentration of the fluorescence dye. 
This does not apply to noncompetitive inhibitors. Table 4.4 gives representatives of known 
MRP1 inhibitors and their inhibition type with regard to selected MRP1 substrates. 
 
Table 4.4. List of common MRP1 inhibitors and their mode of action with respect to selected MRP1 substrates. 
 
inhibitor MRP1 substrate type of inhibition 
benzbromarone BCPCF competitive [353] 
cyclosporine A BCPCF noncompetitive [353] 
genistein daunorubicin competitive [354] 
PAK-104 P daunorubicin noncompetitive [84] 
 
 
Compound 74 is a noncompetitive inhibitor of MRP1-mediated calcein AM (Figure 4.5 A) as 
well as daunorubicin (Figure 4.5 B) transport as indicated by the intersection at the abscissa. 
The interpretation and evaluation of the obtained data was in collaboration with Katja Stefan. 
The basic mathematical equations behind this can be drawn from reference [355]. 
Experimental section 6.3.10.1 gives a short summary. 
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Figure 4.5. Evaluation of the type of inhibition of standard inhibitor 74 with respect to MRP1-mediated transport of 
calcein AM (A) and daunorubicin (B). Left graphic: calcein AM was used at concentrations of 0.2, 0.3, 0.5, 0.6 and 
0.7 µmol · L-1; compound 74 was used at concentrations of 31.6 (closed squares), 100 (closed upward triangles), 
177 (closed downward triangles) 316 (closed rhombs) and 562 (closed stars) nmol · L-1. Right graphic: 
daunorubicin was used at concentrations of 1, 2, 3 and 5 µmol · L-1; compound 74 was used at concentrations of 
3.16 (closed squares), 10.0 (closed upward triangles), 32.6 (closed downward triangles), 100 (closed rhombs) 
and 316 (closed stars) nmol · L-1; the control is depicted as closed circles in both assay; the grey upward oriented 
arrow indicates the inhibitory manner. The latter assay was performed by Katja Stefan. 
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4.1.3. Inhibition of P-gp-mediated Transport of Calcein AM 
 
The synthesized compounds were also evaluated with regard to inhibition of P-gp and 
BCRP. Figure 4.6 summarizes the screening results for inhibition of P-gp-mediated calcein 
AM transport. The assay was performed as described in section 6.2.4.2. Table 4.5 gives the 
obtained biological results. Compounds showing more than 25% inhibition compared to the 
standard inhibitor were further characterized with respect to their inhibitory power (IC50; Table 
4.5). Compounds below 25% were not further characterized since their estimated IC50 equals 
25 µmol · L-1 or higher. 
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Figure 4.6. Summary of P-gp screening data obtained in the calcein AM assay using A2780/ADR cells. The Imax 
values of the compounds at 10 µmol · L-1 is compared to full inhibition caused by the standard inhibitor 
cyclosporine A (CsA) at 10 µmol · L-1. The dashed lines represent the 25, 50 and 100% boundaries. Shown are at 
least three independent experiments with duplicate measurements. 
 
As one can see, the obtained IC50 values ranged mostly in double-digit micromolar range. 
The most potent P-gp inhibitors were compounds 74, 84-85, 93 and 95, all reaching around 
40-70% inhibition at 10 µmol · L-1 compared to cyclosporine A at the same concentration. 
Though, these compounds were still 50- (74), 23- (84), 20- (85), 9.1- (93) and 11-fold (95) 
more potent toward MRP1 than P-gp (see Tables 4.1-3 and 4.5 as well as section 6.3.5). The 
other evaluated compounds can be considered as rather selective. In contrast to the 
standard inhibitor 74, the equally potent MRP1 inhibitor 92 had no affinity toward P-gp. 
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Table 4.5. Summary of P-gp screening results (Imax at 10 µmol · L-1, IC50 and pIC50) obtained in the calcein AM 
assay using A2780/ADR cells; n.d. = not determined due to lack of inhibitory activity (Imax ≤ 25%). The IC50 values 
were determined by fitting the resultant concentration-effect curve to the top value of the standard inhibitor 
cyclosporine A using the statistically preferred parameter model (see section 6.3.2.2). The compounds were 
constrained to the top value resulting from the concentration-effect curve of cyclosporine A. 
 
no. 
 
 
calcein AM  
Imax  
 [%] ± SEM 
calcein AM 
IC50 ± SEM 
[µmol · L-1] 
calcein AM 
pIC50 ± SEM 
 
no. 
 
 
calcein AM 
Imax  
 [%] ± SEM 
calcein AM 
IC50 ± SEM 
[µmol · L-1] 
calcein AM  
pIC50 ± SEM 
 
74 
 
40.0 ± 1.2 
 
18.6 ± 1.5 
 
4.733 ± 0.053 
 
88 
 
2.6 ± 1.1 
 
n.d. 
 
n.d. 
 75 
 
29.7 ± 3.0 
 
32.0 ± 2.1 
 
4.496 ± 0.043 
 
89 
 
23.7 ± 0.6 
 
n.d. 
 
n.d. 
 76 
 
17.3 ± 1.0 
 
n.d. 
 
n.d. 
 
90 
 
30.5 ± 0.9 
 
39.2 ± 6.4 
 
4.412 ± 0.213 
 77 
 
10.7 ± 2.5 
 
n.d. 
 
n.d. 
 
91 
 
11.6 ± 0.3 
 
n.d. 
 
n.d. 
 78 
 
0.2 ± 0.3 
 
n.d. 
 
n.d. 
 
92 
 
8.4 ± 3.7 
 
n.d. 
 
n.d. 
 79 
 
5.1 ± 5.2 
 
n.d. 
 
n.d. 
 
93 
 
42.6 ± 2.3 
 
6.81 ± 0.20 
 
5.167 ± 0.020 
80 
 
11.0 ± 0.7 
 
n.d. 
 
n.d. 
 
94 
 
1.56 ± 2.1 
 
n.d. 
 
n.d. 
 81 
 
14.0 ± 0.5 
 
n.d. 
 
n.d. 
 
95 
 
53.4 ± 1.4 
 
10.6 ± 0.4 
 
4.977 ± 0.054 
 82 
 
0.8 ± 0.9 
 
n.d. 
 
n.d. 
 
96 
 
9.5 ± 0.1 
 
n.d. 
 
n.d. 
 83 
 
0.8 ± 0.9 
 
n.d. 
 
n.d. 
 
97 
 
34.1 ± 3.1 
 
32.2 ± 1.9 
 
4.493 ± 0.069 
 84 
 
57.1 ± 1.0 
 
19.1 ± 1.0 
 
4.719 ± 0.035 
 
98 
 
-1.4 ± 2.4  
 
n.d. 
 
n.d. 
 85 
 
46.4 ± 2.1 
 
21.6 ± 1.0 
 
4.667 ± 0.030 
 
99 
 
15.3 ± 2.2 
 
n.d. 
 
n.d. 
 86 
 
36.1 ± 3.9 
 
28.0 ± 2.7 
 
4.555 ± 0.063 
 
100 
 
-3.2 ± 0.1 
 
n.d. 
 
n.d. 
 87 
 
13.5 ± 0.7 
 
n.d. 
 
n.d. 
 
 
 
 
 
 
 
 
  
 
 
Figure 4.7 A shows that the determined Imax of the screening is coherent with the determined 
pIC50 value of the compounds that reached over 25% inhibition compared to the standard 
inhibitor of P-gp, cyclosporine A, except for compound 93. This makes this method valid for 
initial compound evaluation. Concomitant to MRP1, the inhibitory property of the compounds 
correlated strongly with the calculated logP value (Figure 4.7 B) and molecular weight 
(Figure 4.7 C). 
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Figure 4.7. (A): Correlation of inhibitory activity obtained in the calcein AM assay (pIC50) and the logit (see section 
6.3.2.3) of the maximal inhibition level (Imax) of the screening of compounds at 10 µmol · L-1 that reached more 
than 25% maximal inhibition (74-75, 84-86, 90, 93, 95, 97); the dashed lines indicate the extrapolated pIC50 value 
of compounds with a maximum inhibition level of 25% or less (pIC50 ≤ 4.3). (B): Plot of the determined pIC50 and 
calculated logP values. (C): Correlation of the determined pIC50 value and molecular weight. 
 
 
Compound 93 with its phenyl substituent at position 7 represents an outlier, since its 
determined inhibitory activity toward P-gp was better than the maximum inhibition at            
10 µmol · L-1 suggested. As already found for MRP1, an increase of the logP (3.5-4) as well 
as molecular weight (400-420 Da) is also beneficial for P-gp inhibition. This was shown 
before for specific P-gp inhibitors.282 But as compounds 86 and 97 indicate, this relationship 
is limited as these two compounds do not fit into this pattern. The reason might be less 
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related to the partition coefficient but more to the binding pocket(s) and its steric demands. 
Another possibility is that a logP of 4 and a molecular weight of 400 conform a local 
maximum. Another uncertainty of this postulation is the small range of the values: since there 
was only one order of magnitude difference in the activity data and the inhibitory activity was 
generally low (between 10-40 µmol · L-1), the interpretation should be handled with care. 
 
 
4.1.4. Inhibition of BCRP-mediated Transport of Pheophorbide A 
 
The synthesized compounds were also evaluated with respect to BCRP inhibition, as 
described in the experimental section (6.2.4.4). This assay was performed by Katja Stefan. 
Figure 4.8 visualizes the screening results of the compound at 10 µmol · L-1. Table 4.6 shows 
the obtained biological data. 
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Figure 4.8. Summary of BCRP screening results obtained in the pheophorbide A assay using MDCK II BCRP 
cells. The Imax value of the compounds at 10 µmol · L-1 is compared to full inhibition caused by the standard 
compound Ko143 at 10 µmol · L-1. The dashed lines represent the 25, 50 and 100% boundaries. Shown are at 
least three independent experiments with duplicate measurements. 
 
Generally, the 7,8-alicyclic-9-deazapurines had moderately good affinity to BCRP. 
Compounds 74-75, 77-78, 80, and 83-86 reached around 50% or more in the screening at  
10 µmol · L-1 and showed all inhibitory activity in the single-digit micromolar range. The best 
MRP1 inhibitors of this set, compounds 74-75 and 84, were still 22-, 12-, and 12-fold more 
potent against MRP1 than BCRP (see Tables 4.1-2 and 4.6 as well as section 6.3.5). Two 
compounds, 78 and 83 had more affinity to BCRP than MRP1 (1.2-fold and 1.8-fold, 
respectively). They represent two moderately good dual inhibitors. The 7-N-alkyl, -aryl-, or     
-arylalkyl-9-deazapurines had no noteworthy affinity to BCRP. The best compound of this 
thesis, 92, showed to be a very selective MRP1 inhibitor. 
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Table 4.6. Summary of BCRP screening results (Imax at 10 µmol · L-1, IC50 and pIC50) obtained in the pheophorbide 
A assay using MDCK II BCRP cells; n.d. = not determined due to lack of inhibitory activity (Imax ≤ 25%). The IC50 
values were determined by fitting the resultant concentration-effect curve to the top value of the standard inhibitor 
Ko143 using the statistically preferred parameter model (see section 6.3.2.2). 
 
no. 
 
 
 
 
pheophorbide A 
Imax 
 [%] ± SEM 
pheophorbide A 
IC50 ± SEM 
[µmol · L-1] 
pheophorbide A 
pIC50 ± SEM 
 
no. 
 
 
pheophorbide A 
Imax 
[%] ± SEM 
pheophorbide A 
IC50 ± SEM 
[µmol · L-1] 
74 
 
44.6 ± 5.4 
 
8.06 ± 0.84 
 
5.096 ± 0.069 
 
88 
 
9.0 ± 2.5 
 
n.d. 
 75 
 
49.1 ± 5.5 
 
8.11 ± 0.74 
 
5.093 ± 0.060 
 
89 
 
8.7 ± 2.6 
 
n.d. 
 76 
 
29.1 ± 3.8 
 
14.3 ± 0.7 
 
4.846 ± 0.031 
 
90 
 
11.9 ± 3.9 
 
n.d. 
 77 
 
62.8 ± 4.8 
 
5.80 ± 0.56 
 
5.238 ± 0.063 
 
91 
 
10.1 ± 1.8 
 
n.d. 
 78 
 
52.2 ± 8.3 
 
4.24 ± 0.21 
 
5.374 ± 0.033 
 
92 
 
22.8 ± 4.2 
 
n.d. 
 79 
 
5.8 ± 4.6 
 
n.d. 
 
n.d. 
 
93 
 
13.0 ± 2.1 
 
n.d. 
 80 
 
66.6 ± 5.3 
 
6.01 ± 0.49 
 
5.223 ± 0.053 
 
94 
 
11.4 ± 2.0 
 
n.d. 
 81 
 
3.6 ± 0.5 
 
n.d. 
 
n.d. 
 
95 
 
8.6 ± 1.5 
 
n.d. 
 82 
 
26.9 ± 6.2 
 
15.6 ± 1.3 
 
4.808 ± 0.057 
 
96 
 
22.3 ± 4.8 
 
n.d. 
 83 
 
55.2 ± 3.4 
 
7.66 ± 0.65 
 
5.118 ± 0.056 
 
97 
 
15.9 ± 2.8 
 
n.d. 
 84 
 
47.2 ± 2.7 
 
9.91 ± 0.45 
 
5.005 ± 0.030 
 
98 
 
8.7 ± 3.2 
 
n.d. 
 85 
 
63.0 ± 4.3 
 
4.66 ± 0.33 
 
5.333 ± 0.046 
 
99 
 
13.4 ± 3.1 
 
n.d. 
 86 
 
48.4 ± 3.2 
 
8.70 ± 0.32 
 
5.061 ± 0.024 
 
100 
 
14.3 ± 3.6 
 
n.d. 
 87 
 
5.6 ± 1.4 
 
n.d 
 
n.d 
 
 
 
 
 
 
  
 
As for P-gp, the biological data of the pheophorbide A assay was plotted against the Imax of 
the screening data (Figure 4.9 A). This data correlated strongly. Compound 78 seems to be 
an outlier, but still fits into the correlation line (with 78: R2 = 0.75; without 78: R2 = 0.91). 
Furthermore, the data was correlated with respect to the calculated logP value (Figure 4.9 B) 
and molecular weight of the compounds (Figure 4.9 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52 Biological Investigation 
 
 
4.6 4.8 5.0 5.2 5.4
-0.6
-0.4
-0.2
0.0
0.2
0.4
A
78
pIC50 pheophorbide  A
lo
gi
t (
I m
ax
 p
he
op
ho
rb
id
e 
A)
1 2 3 4
4.6
4.8
5.0
5.2
5.4
B
85
80
82
logP  (calculated)
pI
C 5
0
ph
eo
ph
or
bi
de
 A
 
250 300 350 400 450 500
4.6
4.8
5.0
5.2
5.4
C
82
Mr [Da]
pI
C 5
0
ph
eo
ph
or
bi
de
 A
 
Figure 4.9. (A): Correlation of inhibitory data obtained in the pheophorbide A assay (pIC50) and the logit (see 
section 6.3.2.3) of the maximal inhibition level (Imax) of the screening of compounds showing more than 25% 
maximal inhibition (74-78, 80, 82-86); the dashed lines indicate the extrapolated pIC50 value of compounds with a 
maximum inhibition level of 25% or less (pIC50 ≤ 4.8). (B): Correlation between the pIC50 and calculated logP 
values of piperazine-bearing compounds (open circles) or non-piperazine-bearing compounds (open squares). 
(C): Plot of the pIC50 values and their molecular weight. 
 
While no correlation could be observed with respect to pIC50 versus logP for the non-
piperazine-bearing structures (80, 82-83), the piperazine derivatives 74-78 and 84-86 
showed correlations between pIC50 values and calculated logP or molecular weight. In 
constrast to P-gp, the data is inversely proportional to these descriptors. The bigger the 
molecules and the higher their logP, the less active are the compounds referred to BCRP 
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inhibition. But as already stated for P-gp, the range of the data set with respect to inhibitory 
activity is rather limited. 
 
 
4.1.5. Determination of Intrinsic Toxicity of Selected Compounds 
 
A MTT-based viability assay was employed for compound evaluation as described in section 
6.2.4.5. This was performed by Katja Stefan. Representatives from each structural class – (i) 
6-piperazinyl-7,8-cyclohexyl- (74, 79), (ii) 6-amino-7,8-cyclohexyl- (80), (iii) 6-piperazinyl-7-N-
alkyl- (92) and (iv) 6-piperazinyl-7-N-aryl-9-deazapurines (93) - were evaluated with respect 
to their intrinsic toxicity. The impact of the compounds at 10 µmol · L-1 on H69AR cells over 
72 hours was measured (Figure 4.10). Table 4.7 shows the half-maximal growth inhibition 
concentration (GI50) as well as the residual viability (Vres) at 10 µmol · L-1 compound 
concentration and the therapeutic ratio calculated using the data obtained in the 
daunorubicin assay (see Tables 4.1 and 4.3) 
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Figure 4.10. Evaluation of the toxicity of compounds 74, 79-80 and 92-93 using a MTT-viability assay. The 
negative control was regular cell growth in pure cell culture medium without further supplementation and was 
defined as 100% (grey dashed line). The positive control was DMSO at 10%, defining 0% cell viability. The 
compounds were used at 10 µmol · L-1. Shown are at least three independent experiments with duplicate 
measurements. 
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Table 4.7. Summary of the cell viability data using H69AR cells conformed by the value of residual viability (Vres at 
10 µmol · L-1) after 72 hours of exposure, half-maximal growth inhibition concentration (GI50) as well as the 
negative decadic logarithm of the GI50 (pGI50) and the therapeutic ratio (tr) calculated from the IC50 value obtained 
in the daunorubicin assay which is also depicted in the Table (see section 6.3.6). 
 
 
no. 
 
 
Vres 
[%] ± SEM 
 
GI50 ± SEM [µmol · L-1] 
 
 
pGI50 ± SEM 
 
IC50 ± SEM [µmol · L-1] 
daunorubicin  
 
tr 
 
74 
 
73.1 ± 1.9 
 
37.7 ± 5.0 
 
4.428 ± 0.087 
 
0.195 ± 0.012 193 
 79 
 
76.8 ± 2.1 
 
42.9 ± 5.5 
 
4.370 ± 0.069 
 
10.8 ± 0.2 3.97 
 80 
 
89.1 ± 2.9 
 
127 ± 14 
 
3.898 ± 0.074 
 
2.82 ± 0.18 45.0 
 92 
 
72.1 ± 4.7 
 
35.8 ± 2.1 
 
4.447 ± 0.038 
 
0.199 ± 0.014 180 
 93 
 
54.7 ± 3.1 
 
22.4 ± 4.0 
 
4.657 ± 0.116 
 
0.340 ± 0.004 65.9 
   
 
 
Except for compound 93, which resulted in diminished cell growth (Vres = 54.7%), the 
compounds were nontoxic. These results are reflected in the half-maximal growth inhibition 
values (GI50). Even the most toxic compound 93 had a GI50 value of more than 20 µmol · L1. 
The standard compound 74 and the N-alkyl derivative 92 had a therapeutic ratio of nearly 
200. This makes them good candidates for in vivo evaluation. This applies most notably to 
compound 92, which had no significant affinity toward the other two tested transport proteins, 
P-gp and BCRP. 
 
 
4.1.6. MDR Reversal-efficacy of Selected Compounds 
 
The most important in vitro evaluation of chemosensitizers is their ability to restore sensitivity 
of MDR-conferring cell lines. Selected compounds – (i) 6-piperazinyl-7,8-cyclohexyl- (74, 79), 
(ii) 6-amino-7,8-cyclohexyl- (80), (iii) 6-piperazine-7-N-alkyl- (92) and (iv) 6-piperazine-7-N-
aryl-9-deazapurines (93) – were tested with respect to their capability to reverse 
daunorubicin resistance in H69AR cells. The same MTT-viability assay was employed as 
stated above (see section 6.2.4.6). This was performed by Katja Stefan. Tables 4.8 A-B 
summarize the results.  
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Table 4.8 A. MDR reversal-efficacy data obtained for compounds 74, 79-80, and 92-93. The GI50 values of 
daunorubicin tested in the resistant and the sensitive cell lines H69AR and H69 without compound were 
compared to the GI50 values of daunorubicin in combination with 1, 5 and 10 µmol · L-1 of the corresponding 
compound. 
 
 
 
Table 4.8 B. Negative decadic logarithm of the GI50 values of compounds 74, 79-80, and 92-93 taken from Table 
4.8 A. 
 
 
 
As can be seen from Table 4.8 A-B, the resistance against daunorubicin is gradually 
reversed with increased concentration of the compounds. The potency ranking of the 
compounds determined in the calcein AM and daunorubicin assay (Tables 4.1 and 4.3) is 
related to efficacy of reversal (e.g. 74 vs. 79). The concentration-effect curves of compound 
92 as the best, most selective and nontoxic compound are depicted in Figure 4.11. The 
concentration-effect curve of daunorubicin gets shifted to the left, which is an indicator that 
the cells get sensitized toward this cytotoxic agent. 
 
no. 
 
 
resistant cells 
GI50 ± SEM  
[µmol · L-1] 
1 µM  
GI50 ± SEM 
 [µmol · L-1] 
5 µM  
GI50 ± SEM  
[µmol · L-1] 
10 µM  
GI50 ± SEM 
[µmol · L-1] 
sensitive cells 
GI50 ± SEM 
[µmol · L-1] 
74  0.879 ± 0.220 0.611 ± 0.124 0.362 ± 0.068  
79  2.89 ± 0.39 2.44 ± 0.29 1.80 ± 0.24  
80 2.75 ± 0.15 2.33 ± 0.44 0.747 ± 0.055 0.446 ± 0.041 0.361 ± 0.016 
92  0.807 ± 0.128 0.566 ± 0.111 0.384 ± 0.065  
93  0.745 ± 0.166 0.508 ± 0.115 0.375 ± 0.075  
no. 
 
resistant cells 
pGI50 ± SEM 
1 µM 
pGI50 ± SEM 
5 µM 
pGI50 ± SEM 
10 µM 
pGI50 ± SEM 
sensitive cells 
pGI50 ± SEM 
74  6.069 ± 0.162 6.223 ± 0.132 6.449 ± 0.123  
79  5.543 ± 0.088 5.615 ± 0.079 5.750 ± 0.087  
80 5.563 ± 0.035 5.641 ± 0.124 6.128 ± 0.049 6.353 ± 0.061 6.444 ± 0.029 
92  6.099 ± 0.104 6.255 ± 0.128 6.421 ± 0.111  
93  6.139 ± 0.145 6.305 ± 0.147 6.436 ± 0.131  
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Figure 4.11. Sensitization of H69AR cells by compound 92 determined in the MDR reversal-efficacy assay. The 
shift of the concentration-effect curve from the resistant (closed circles) to the sensitive (open circles) cells is 
indicated by the grey arrow. Compound 92 was used at concentrations of 1 (closed square), 5 (closed upward 
triangle) and 10 µmol · L-1 (closed downward triangle). 
 
 
Plotting of the negative decadic logarithm of the GI50 values of daunorubicin with or without 
compound addition and the logarithmic compound concentration resulted in a sigmoidal 
relation (Figure 4.12). The top and bottom values were fixed to the values obtained for the 
sensitive (H69) and resistant (H69AR) cancer cells that are shown in Table 4.8 B. The 
derived half-maximal effect concentration (EC50) is a measure for the compound efficacy. 
While the GI50 as determined in Table 4.8 is related to the daunorubicin concentration-effect 
curve, the calculated EC50 in the new plot (Figure 4.12) is related to the tested compound. It 
gives the concentration of the compound at which resistance is reduced by 50% with respect 
to the used cytostatic agent (daunorubicin). The lower the value, the better the MDR 
reversing property of the compound. Table 4.9 summarizes the calculated EC50 values. 
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Figure 4.12. Evaluation of the efficacy of compounds 74 (closed circles), 79 (closed rhombs) 80 (closed 
downward triangles), 92 (closed squares) and 93 (closed upward triangles) using a MTT-based MDR reversal-
efficacy assay. On the ordinate the determined pGI50 values are plotted. On the abscissa the used compound 
concentrations are presented. Each resultant curve is calculated from 5 data points and fixed to the data of the 
resistant (H69AR, -∝, bottom) and sensitive cell line (H69, ∝, top). Shown is EC50 of at least three independent 
experiments with duplicate measurements. 
 
Table 4.9. MDR reversal-efficacy data obtained for compounds 74, 79-80, and 92-93. Shown is EC50 and pEC50 of 
at least three independent experiments with duplicate measurements. 
 
 
no. 
 
H69 AR 
EC50 ± SEM [µmol · L-1] 
H69 AR 
pEC50 ± SEM 
74 0.741 ± 0.229 6.150 ± 0.199 
79 99.8 ± 74.4 4.097 ± 0.759 
80 3.01 ± 0.65 5.531 ± 0.141 
92 0.831 ± 0.445 6.135 ± 0.331 
93 0.575 ± 0.419 6.333 ± 0.430 
 
 
 
Although the relationship should be interpreted with caution due to the number of data points, 
one can see the difference between a less potent compound (79), a moderately potent 
compound (80) and very potent compounds (74, 92 and 93). The obtained EC50 values and 
the IC50 values of the calcein AM and daunorubicin assay correlated strongly, making the 
latter two assays very good surrogates for the real effectiveness of a compound with respect 
to reversal of MDR (Figures 4.13 A-B). The slope of the linear regression line is 0.79 ± 0.18 
in Figure 4.13 A. Taking the deviation into account, it can be concluded that the calcein AM 
assay gives an adequate evaluation with respect to MRP1 inhibition and MDR reversal. 
Furthermore, not only the efficacy is correctly mirrored in the results, but also the direct 
connection of MRP1 inhibition and MDR reversal. Figure 4.13 B shows the same for the 
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daunorubicin assay (slope = 0.85 ± 0.16). The R2 values of the data sets are 0.86 and 0.90, 
respectively. 
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Figure 4.13. Correlation between the pEC50 values of compounds 74, 79-80, 92-93 as shown in Table 4.9 and the 
pIC50 values obtained in the calcein AM (A) and daunorubicin assay (B). Left graphic: slope = 0.79 ± 0.18, R2 = 
0.86. Right graphic: slope = 0.85 ± 0.16, R2 = 0.90. 
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4.1.7. Summary of Evaluation of 7,8-alicyclic-, 7-N-alkyl-, -aryl- or              
-arylalky-9-deazapurines 
 
In this subchapter a variety of 9-deazapurines with variations at positions 6, 7 and 8 have 
been synthesized and biologically evaluated in two different cell-based fluorescence assays, 
the calcein AM and daunorubicin assay. With respect to MRP1 inhibition, it was shown that 
the phenethylpiperazine residue at position 6 is superior to other side chains, and that 
shortening of the side chain is not beneficial for activity against MRP1. Piperazine-bearing 
compounds were superior in comparison to their amine-bearing counterparts. Additionally, it 
could be shown that the cyclohexyl residue at position 7 and 8 of the starting compound 74, 
which was used as standard inhibitor of MRP1, could be replaced by other aliphatic side 
chains. Especially the cyclopropyl residue at position 7 of compound 92 seemed equally 
beneficial compared to the cyclohexyl residue, while position 8 has not to be occupied by a 
substituent for potent MRP1 inhibition. 
In different subsets, a correlation could be observed between the inhibitory activity and the 
calculated logP values of the compounds as well as their molecular weight. Obviously bigger 
(molecular weight around 370 Da) and more lipophilic molecules (logP around 3 for 
piperazine-bearing compounds) are preferred with respect to MRP1 inhibition. 
Some compounds had affinity toward P-gp (74, 84-85, 93 and 95), which is clear since this 
compound class was already reported to provide dual inhibitors of MRP1 and P-gp.271 Their 
IC50 ranged from about 7-21 µmol · L-1. The same tendency as for MRP1 could be observed 
with regard to logP and molecular weight. 
Furthermore, some compounds were also BCRP inhibitors (74-75, 77-78, 79, and 83-86), 
with IC50 values ranging from about 8-16 µmol · L-1. This is a new fact, since this compound 
class has never been reported before to inhibit BCRP. In contrast to MRP1 and P-gp, 
inhibitory activities were better with decreased logP and molecular weight. 
While the standard inhibitor 74 is a rather unselective MRP1 inhibitor, the equally potent 
compound 92 had no noteworthy affinity toward the other two transport proteins, P-gp and 
BCRP.  
Representative compounds of the first compound set were shown to have only a slight 
influence on cell viability. Standard inhibitor 74 and the best compound in this set, no. 92, 
had therapeutic ratios of 180 and more. The same compound set was analyzed with respect 
to MDR reversal. Here, the two best compounds, 74 and 92, were shown to completely 
reverse MDR in H69AR lung cancer cells. 
Compound 74 as a representative of the first compound set was analyzed with regard to its 
inhibition type and showed to be a noncompetitive inhibitor of calcein AM and daunorubicin 
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transport. Furthermore, it could be proved that the inhibitory activities obtained in both assay 
equal with nearly a slope of 1. Additionally, the same applied for the MDR reversal-efficacy 
and the calcein AM as well as the daunorubicin assay. Since these assays give comparable 
results, the latter a two are good surrogates for the former. 
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4.2. Evaluation of 7-N-alkyl, -aryl- or -arylalkyl- and 6-
aminoarylalkyl-9-deazapurines as well as 6-piperazinyl-purine 
Analogs 
 
4.2.1. Inhibition of MRP1-mediated Transport of Calcein AM and 
Daunorubicin 
 
4.2.1.1. 9-Deazapurine Derivatives 
 
In order to generate more new, potent and selective inhibitors of MRP1, 6-aminoarylalkyl-9-
deazapurines with variations at position 7 and 6-piperazinyl-purine analogs were synthesized 
and evaluated with respect to their inhibitory power against MRP1, but also P-gp and BCRP. 
The compounds and activities presented in this subchapter have already been published.350 
Table 4.10 summarizes the molecular formula of the compounds and the inhibitory power in 
the daunorubicin assay, which was performed by Katja Stefan. Additionally, the calculated 
logP value as well as the molecular weight of the compounds is listed. These descriptors 
were plotted against the obtained inhibitory activities (Figures 4.14 A-B).  
 
Table 4.10. Inhibitory activity of 7-N-alkyl, -aryl- or -arylalkyl- and 6-aminoarylalkyl-9-deazapurines obtained in the 
daunorubicin assay (IC50 ± SEM and pIC50 ± SEM) using H69AR cells. Additionally, the molecular weight as well 
as the calculated logP value of each compound is depicted. 
 
 
no. 
 
 
 
R1 
 
 
 
R2 
 
 
 
Mr  
[Da] 
 
 
logP 
(calc.) 
 
 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
 
daunorubicin 
pIC50 ± SEM 
 
101 
 
benzyl 
 
methyl 
 
263.30 
 
1.82 
 
16.7 ± 2.5 
 
4.781 ± 0.097 
 102 
 
benzyl 
 
phenyl 
 
325.38 
 
4.04 
 
3.96 ± 0.40 
 
5.404 ± 0.066 
 103 
 
benzyl 
 
benzyl 
 
339.40 
 
3.53 
 
7.28 ± 0.85 
 
5.141 ± 0.077 
 104 
 
phenylpropyl 
 
benzyl 
 
367.46 
 
4.56 
 
0.782 ± 0.081 
 
6.109 ± 0.068 
 105 
 
phenethyl 
 
phenethyl 
 
367.46 
 
4.53 
 
1.42 ± 0.22 
 
5.852 ± 0.099 
 106 
 
phenylpropyl 
 
phenethyl 
 
381.48 
 
5.00 
 
0.822 ± 0.051 
 
6.086 ± 0.041 
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Figure 4.14. Correlation between the inhibitory activity of compounds 101-106 toward MRP1 determined in the 
daunorubicin assay and the calculated logP value (A) and the molecular weight (B) of the compounds. The most 
potent compounds (104-106) are characterized by a calculated logP of at least 4.5 and a molecular weight of 
approximately 370 Da as indicated by the grey dashed circles. 
 
The inhibitory power of the compounds is strongly dependent on the partition coefficient, as 
this was already found for their 6-piperazinyl-7,8-alicyclic-9-deazapurine counterparts (see 
subchapter 4.1). The same applies for the correlation to molecular weight, although 
compound 103 represented an outlier. The inhibitory power of the compounds is rather poor, 
only compounds over 370 Da or a logP value above 4.5 had an IC50 around 1 µmol · L-1 (104-
106). But compared to 6-piperazinyl-7,8-alicyclic-9-deazapurines (e.g. compound 74;       
logP = 2.81; Mr = 386.50 Da) or 6-piperazinyl-7-N-alkyl-9-deazapurines (compound 92;    
logP = 1.76; Mr = 372.48 Da), the non-piperazine-bearing structures proved to be inferior with 
respect to MRP1 inhibition. Their activity is more comparable to the above described non-
piperazine-bearing compounds 80-83. Here again, the piperazine plays a crucial role 
concerning MRP1 inhibition, as already found before (see subchapter 4.1). 
 
 
4.2.1.2. Purine Analogs 
 
Purine analogs of the 6-piperazinyl-9-deazapurines 74-77 were generated to evaluate the 
inhibitory potential of this compound class. Table 4.11 gives the obtained biological data. As 
done before for compounds 84-87 (see Figures 4.3 A-B), the calculated logP value and the 
molecular weight of the compounds were correlated. But due to the low inhibitory power and 
therefore low accuracy of the measurements, the plot is rather inconclusive (Figures 4.15 A-
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B). The parabola suggests a logP of more than 2 and a molecular weight of approximately 
320-350 Da to be the optimum. These values are lower than the optima of other 9-
deazapurines (except for compounds 88-92). This might occur because purines form an own 
class of MRP1 inhibitors and behave differently with respect to membrane partition, binding 
pocket(s) or intracellular accumulation.  
 
Table 4.11. Inhibitory activity of 6-piperazinyl-purine derivatives. The data (IC50 ± SEM and pIC50 ± SEM) was 
obtained in the daunorubicin assay by Katja Stefan using the H69AR cells. Additionally, the molecular weight as 
well as the calculated logP value of each compound is depicted. The compounds were constrained to the top 
value resulting from the concentration-effect curve of compound 74. 
 
 
no. 
 
 
 
R1 
 
 
 
Mr 
[Da] 
 
 
logP 
(calc.) 
 
 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
 
daunorubicin 
pIC50 ± SEM 
107 
 
phenethyl 
 
308.39 
 
1.97 
 
20.0 ± 0.6 
 
4.699 ± 0.019 
 108 
 
benzyl 
 
294.36 
 
1.52 
 
22.7 ± 5.2 
 
4.655 ± 0.149 
 109 
 
benzhydryl 
 
370.46 
 
2.97 
 
18.0 ± 4.5 
 
4.758 ± 0.162 
 110 
 
phenyl 
 
280.34 
 
1.17 
 
30.5 ± 7.7 
 
4.529 ± 0.164 
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Figure 4.15. Correlation between the inhibitory activity of compounds 107-110 obtained in the daunorubicin assay 
and the calculated logP value (A) as well as molecular weight (B) of the compounds. A dashed grey line is used to 
underline the high deviation due to the lack of effective inhibitory power. 
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4.2.2. Activation of MRP1-mediated Transport of Calcein AM and 
Daunorubicin 
 
A specialty of these 9-deazapurines and purine analogs is their capability to accelerate the 
transport velocity of calcein AM and daunorubicin mediated by MRP1. This effect was firstly 
observed for the 6-aminoaryl- and 6-aminoarylalkyl-7,8-cyclohexyl-9-deazapurine analogs 
80-83 as well as for the 4H-piperazine-bearing compound 79 (see Figures 4.16 A-E). The 
concentration-effect curves show a two-phase progression. First, at low concentrations, 
calcein AM transport is accelerated (approx. 10 nmol · L-1). Second, the substrate efflux is 
inhibited at concentrations of 1 µmol · L-1 or more. Table 4.12 gives the half-maximal 
activation concentration (AC50) and the maximal activation level (Amax; percentage of basal 
fluorescence F0) of these compounds in correlation to their IC50 and pIC50 value as stated in 
Table 4.1. 
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Figure 4.16. Biphasic concentration-effect curves of compounds 79 (A), 80 (B), 81 (C), 82 (D), and 83 (E) 
determined in the calcein AM assay using H69AR cells. The grey arrow indicates the concentration of 10 nmol · L-
1 which was used for further evaluation of the compounds 101-110. 
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Table 4.12. Summary of half-maximal activation concentration (AC50), maximal activation (Amax) of compounds 
79-83 as determined in the calcein AM assay using H69AR cells. Additionally, the IC50 values obtained in the 
calcein AM and daunorubicin assays are depicted as already stated in Table 4.1. The latter assay was performed 
by Katja Stefan. 
 
no. 
 
 
calcein AM 
AC50 ± SEM 
[nmol · L-1] 
calcein AM 
pAC50 ± SEM 
calcein AM 
Amax 
 [%] of F0 
calcein AM 
IC50 ± SEM 
[µmol · L-1] 
calcein AM 
pIC50 ± SEM 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
daunorubicin  
pIC50 ± SEM 
79 9.25 ± 3.19 8.058 ± 0.221 82.7 ± 2.2 26.6 ± 3.0 4.578 ± 0.075 10.8 ± 0.2 4.966 ± 0.015 
80 0.479 ± 0.320 9.401 ± 0.401 83.0 ± 2.7 2.46 ± 0.28 5.611 ± 0.076 2.82 ± 0.18 5.550 ± 0.042 
81 2.04 ± 1.33 8.768 ± 0.393 84.8 ± 2.3 8.22 ± 0.90 5.088 ± 0.072 4.97 ± 0.27 5.305 ± 0.036 
82 1.57 ± 0.36 8.816 ± 0.149 81.0 ± 4.2 14.2 ± 1.2 4.851 ± 0.054 8.72 ± 0.66 5.061 ± 0.050 
83 0.772 ± 0.283 9.140 ± 0.234 77.2 ± 2.4 14.1 ± 0.8 4.850 ± 0.037 9.40 ± 0.30 5.027 ± 0.021 
 
 
 
Since inhibition and activation are opposing effects, a suitable concentration is needed for a 
proper evaluation of the activating property of the compounds. A concentration of                
10 nmol · L-1 was chosen to compare the compounds to each other because it is around 100 
times lower than the IC50 of the best compound (104¸ ~ 0.8 µmol · L-1.). Figure 4.17 gives the 
activation ratio (see section 6.3.4.2) of compounds 79-83 at 10 nmol ⋅ L-1. The value of the 
ordinate gives the multiple of the basal transport velocity of calcein AM by MRP1 in presence 
of the corresponding compound. The same mathematical procedure was used for 
compounds 101-110 (Figures 4.18 A-B). The daunorubicin assay data was determined by 
Katja Stefan. 
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Figure 4.17. Activation ratio (see section 6.3.4.2) of compounds 79-83 at 10 nmol ⋅ L-1 determined in the calcein 
AM assay using H69 AR cells. The lower grey dashed line indicates the basal pump velocity, which is defined as 
1.0; the upper grey dashed line indicates the average accelerating power of the compounds of approximately 1.5. 
Significance was calculated using one sample t-tests (see section 6.3.1.3) and is given as *: p ≤ 0.05, **: p ≤ 0.01, 
***: p ≤ 0.001, ****: p ≤ 0.0001, hypothetical value = effect of DMSO (0.0001%; 1.175; middle grey dashed line). 
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Figures 4.18. Activation ratio (see section 6.3.4.2) of compounds 101-110 at 10 nmol ⋅ L-1. Basal activity is defined 
as 1.0 (lower grey dashed line). Shown is mean ± SEM of at least three independent experiments with duplicate 
measurements. (A): calcein AM assay using the MRP1 overexpressing cell line H69AR. (B): daunorubicin assay 
using the MRP1 overexpressing cell line MDCK II MRP1. Significance was calculated using one sample t-tests 
(see section 6.1.3.1) and is given as *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001, hypothetical value = 
effect of DMSO (A: 1.175; B: 1.115), in each case indicated by the middle grey dashed line; upper dashed line 
indicates the approximate accelerating character of the corresponding compounds. 
 
 
The calcein AM assay was performed using H69AR cells, while the daunorubicin assay was 
accomplished with MDCK II MRP1 cells. Since activation was observed in both cell lines, the 
observed effect is not cell line specific and occurs in selected (H69AR) as well as transfected 
(MDCK II MRP1) cells. Furthermore, no effect was seen in sensitive cell lines (Figure      
14.19 A). The significance of the effect is confirmed by one-sample t-test (see section 
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6.3.1.3), which gave p values of less than 0.05 for all compounds. Tables 4.13 A-B give the 
activation ratio (Ar) as well as the half-maximal activation concentration (AC50). The latter was 
determined on the basis of (i) the measured concentration-effect curves (see Figure 4.19 A) 
as well as on the basis of (ii) the concentration-effect curves resulting from the calculated 
activation ratio (see Figure 4.19 B; see section 6.3.4.2). The values are very similar, and 
differ in average only by a factor of 1.2 (calcein AM) and 1.3 (daunorubicin). 
 
Table 4.13 A. Activation ratio (Ar) and half-maximal activation concentration (AC50) on the basis of (i) measured 
concentration-effect curves and on the basis of (ii) concentration-effect curves derived from calculated activation 
ratio of compounds 101-110 obtained in the calcein AM assay using H69AR cells; n. d. = not determined. 
 
no. 
 
 
Ar 
(calcein AM) 
[fold increase] 
AC50 (measured) (i) 
(calcein AM) 
[nmol · L-1] 
pAC50 (measured) (i) 
(calcein AM) 
 
AC50 (calculated) (ii) 
(calcein AM) 
[nmol · L-1] 
pAC50 (calculated) (ii) 
(calcein AM) 
 
DMSO 1.175 ± 0.017 n. d. n. d. n. d. n. d. 
101 1.527 ± 0.057 0.059 ± 0.004 10.23 ± 0.042 0.074 ± 0.006 10.13 ± 0.049 
102 1.324 ± 0.047 0.077 ± 0.004 10.12 ± 0.033 0.093 ± 0.005 10.03 ± 0.037 
103 1.428 ± 0.048 0.060 ± 0.005 10.23 ± 0.057 0.064 ± 0.008 10.19 ± 0.08 
104 1.420 ± 0.088 0.064 ± 0.003 10.20 ± 0.030 0.093 ± 0.004 10.03 ± 0.08 
105 1.717 ± 0.190 0.087 ± 0.016 10.07 ± 0.117 0.101 ± 0.021 10.00 ± 0.134 
106 1.439 ± 0.110 0.053 ± 0.003 10.28 ± 0.033 0.062 ± 0.003 10.21 ± 0.027 
107 1.362 ± 0.036 0.038 ± 0.001 10.42 ± 0.015 0.041 ± 0.001 10.38 ± 0.015 
108 1.433 ± 0.083 0.136 ± 0.009 9.869 ± 0.045 0.169 ± 0.011 9.773 ± 0.041 
109 1.371 ± 0.025 0.068 ± 0.004 10.17 ± 0.042 0.079 ± 0.006 10.10 ± 0.049 
110 1.315 ± 0.031 0.025 ± 0.006 10.61 ± 0.162 0.028 ± 0.007 10.56 ± 0.162 
 
 
Table 4.13 B. Activation ratio (Ar) and half-maximal activation concentration (AC50) on the basis of (i) measured 
concentration-effect curves or on the basis of (ii) concentration-effect curves derived from calculated activation 
ratio of compounds 101-110 obtained in the daunorubicin assay using MDCK II MRP1 cells; n.d. = not 
determined. The assay was conducted by Katja Stefan. 
 
no. 
 
Ar 
(daunorubicin) 
[fold increase] 
AC50 (measured) (i) 
(daunorubicin) 
[nmol · L-1] 
pAC50 (measured) (i) 
(daunorubicin) 
AC50 (calculated) (ii) 
(daunorubicin) 
[nmol · L-1] 
pAC50 (calculated) (ii) 
(daunorubicin) 
DMSO 1.115 ± 0.092 n. d. n. d. n. d. n. d. 
101 1.808 ± 0.086 0.133 ± 0.056 9.910 ± 0.264 0.182 ± 0.082 9.781 ± 0.283 
102 1.705 ± 0.090 0.119 ± 0.047 9.955 ± 0.251 0.151 ± 0.065 9.859 ± 0.274 
103 1.678 ± 0.103 0.106 ± 0.033 9.994 ± 0.203 0.149 ± 0.052 9.852 ± 0.223 
104 1.934 ± 0.173 0.110 ± 0.040 9.986 ± 0.232 0.139 ± 0.060 9.893 ± 0.270 
105 1.777 ± 0.231 0.353 ± 0.146 9.486 ± 0.261 0.355 ± 0.218 9.519 ± 0.372 
106 1.979 ± 0.164 0.062 ± 0.002 10.21 ± 0.02 0.089 ± 0.002 10.05 ± 0.02 
107 1.823 ± 0.191 0.322 ± 0.139 9.529 ± 0.272 0.567 ± 0.264 9.289 ± 0.291 
108 1.457 ± 0.046 0.227 ± 0.050 9.654 ± 0.145 0.311 ± 0.083 9.522 ± 0.173 
109 1.937 ± 0.120 0.615 ± 0.647 9.373 ± 0.569 0.757 ± 0.814 9.288 ± 0.578 
110 1.916 ± 0.142 0.189 ± 0.068 9.750 ± 0.231 0.210 ± 0.063 9.697 ± 0.193 
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As one can see, the activation ratio calculated in the calcein AM assay is generally lower 
than in the daunorubicin assay. This can be explained by the lipophilicity of calcein AM and 
daunorubicin. The former is a highly lipophilic molecule (see Figure 6.1) that diffuses into the 
cell through the membrane rather fast. In case of an enhanced efflux of calcein AM, which is 
a good MRP1 substrate, it can easily diffuse back through the membrane into the cell 
increasing its intracellular concentration. The intracellular concentration of calcein AM is 
critical for its hydrolysis by unspecific esterases to the fluorescent dye calcein. Hence, the 
fluorescence increase is a function of time, transport and diffusion velocity of calcein AM. 
Since the last parameter is higher with respect to calcein AM than to daunorubicin, the 
activation ratio determined using former must be lower than for using the latter. Because in 
contrast to calcein AM, daunorubicin is a more hydrophilic molecule (Figure 1.3) which slowly 
diffuses into the cell. This is reflected in the incubation time needed to perform the assay (3 
hours). Due to higher passive diffusion velocity the intracellular clearance of calcein AM by 
MRP1 is less effective than for daunorubicin. This explains the difference in the activation 
ratio of the both assays. 
Figures 4.19 A-B show compound 104 as a dual modulator (activation and inhibition). Since 
no effect was observed using the sensitive MDCK II cells (Figure 4.19 A), it is highly likely 
that the membrane integrity was not affected by the compounds and the difference in the 
distribution of calcein AM and daunorubicin is due to real activation. 
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Figure 4.19. (A): compound 104 (closed squares) in comparison to standard inhibitor 74 (closed circles) in the 
daunorubicin assay using MDCK II MRP1 cells. The sensitive cell line MDCK II is depicted by open circles. (B): 
Calculation of the activation ratio of compound 104 resulting in a parabola. The assay was performed by Katja 
Stefan. 
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4.2.3. Screening with Respect to P-gp Activation and Inhibition 
 
Compounds 101-110 were evaluated with respect to their capability to affect P-gp (see also 
6.2.4.2). Figure 4.20 summarizes the obtained results of the calcein AM assay using 
A2780/ADR cells. The lower dashed line marks the -5% boundary. Only compounds at       
10 nmol · L-1 that resulted in significantly lower response values than -5% were further 
investigated. The upper dashed line indicates 25% inhibition, which was reached by 
compound 104 only. It possessed an IC50 value of 14.0 ± 0.4 µmol · L-1                            
(pIC50 = 4.855 ± 0.018). The whole compound set had no activating properties. 
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Figure 4.20. P-gp screening of compounds 101-110 in the calcein AM assay using A2780/ADR cells. Shown is 
percentage inhibition compared to the standard inhibitor cyclosporine A (CsA, 10 µmol · L-1) of at least three 
independent experiments with duplicate measurements; light grey bars: effect at 10 µmol · L-1; black bars: effect 
at 10 nmol · L-1. The IC50 value of compound 104 was determined by fitting the resultant concentration-effect 
curve to the top value of the standard inhibitor cyclosporine A using the statistically preferred parameter model 
(see section 6.3.2.2). 
 
4.2.4. Screening with Respect to BCRP Activation and Inhibition 
 
Furthermore, the activating and inhibiting properties of compound 101-110 were evaluated 
using concentrations of 10 nmol · L-1 and 10 µmol · L-1 (see also 6.2.4.4). This was performed 
by Katja Stefan. Figure 4.21 gives the obtained results. Since the black bars were not 
significantly different to -5%, none of these marginal effects have been evaluated in detail. 
Compound 101 and 104 showed more than 25% inhibition compared to the standard inhibitor 
Ko143 at 10 µmol · L-1. They possessed an IC50 value of 19.9 ± 2.7 µmol · L-1 and              
19.5 ± 3.0 µmol · L-1, respectively (pIC50 value = 4.705 ± 0.088 µmol · L-1 and 4.715 ± 0.100 
µmol · L-1, respectively). Although their inhibitory power against BCRP is poor, compound 
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101 represents a rare example of a dual inhibitor of MRP1 and BCRP. The other compounds 
showed only a slight increase of fluorescence below 25% compared to Ko143 and were not 
further investigated. 
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Figure 4.21. BCRP screening of compounds 101-110 in the pheophorbide A assay using MDCK II BCRP cells. 
Shown is percentage inhibition compared to the standard inhibitor Ko143 (10 µmol · L-1) of at least three 
independent experiments with duplicate measurements; light grey bars: effect at 10 µmol · L-1; black bars: effect 
at 10 nmol · L-1 The IC50 values of compounds 101 and 104 were determined by fitting the resultant concentration-
effect curve to the top value of the standard inhibitor Ko143 using the statistically preferred parameter model (see 
section 6.3.2.2). 
 
4.2.5. Determination of Intrinsic Toxicity  
 
The intrinsic toxicity of compounds 101-110 was investigated using the MTT-viability assay 
(see also 6.2.4.5) and was performed by Katja Stefan. Tables 4.14 A-B give the obtained 
GI50 values using different MDR cell lines. Although the values differ between the cell lines, it 
can be said that the compounds are generally nontoxic. The most toxic compound was 104, 
which possessed in the tested cell lines GI50 values of around 20-30 µmol · L-1. With respect 
to MRP1 inhibition as stated in Table 4.10, its therapeutic ratio was about 40 (MDCK II 
MRP1; see section 6.3.6). Compared to activation, the compounds are over 10.000-fold 
more activating than toxic. Figures 4.22 A-F visualize the obtained biological data. 
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Table 4.14 A. GI50 and pGI50 values of compounds 101-110 obtained in the MTT-viability assay using H69AR, 
MDCK II MRP1 and MDCK II cells. 
 
no. 
 
 
H69AR 
GI50 ± SEM 
[µmol · L-1] 
H69AR 
pGI50 ± SEM 
MDCK II MRP1 
GI50 ± SEM 
[µmol · L-1] 
MDCK II MRP1 
pGI50 ± SEM 
MDCK II 
GI50 ± SEM 
[µmol · L-1] 
MDCK II 
pGI50 ± SEM 
101 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
102 62.1 ± 15.4 4.220 ± 0.161 > 100 > 4.000 66.9 ± 8.0 4.178 ± 0.079 
103 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
104 34.0 ± 3.6 4.471 ± 0.069 31.7 ± 1.1 4.499 ± 0.024 30.9 ± 0.3 4.510 ± 0.006 
105 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
106 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
107 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
108 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
109 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
110 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
 
 
Table 4.14 B. GI50 and pGI50 values of compounds 101-110 obtained in the MTT-viability assay using 
2008/MRP1, A2780/ADR and MDCK II BCRP cells. 
 
no. 
 
 
2008/MRP1 
GI50 ± SEM 
[µmol · L-1] 
2008/MRP1 
pGI50 ± SEM 
A2780/ADR 
GI50 ± SEM 
[µmol · L-1] 
A2780/ADR 
pGI50 ± SEM 
MDCK II BCRP 
GI50 ± SEM 
[µmol · L-1] 
MDCK II BCRP 
pGI50 ± SEM 
101 83.8 ± 5.7 4.078 ± 0.045 85.5 ± 0.6 4.068 ± 0.05 82.6 ± 5.1 4.084 ± 0.041 
102 70.2 ± 9.7 4.158 ± 0.091 65.2 ± 11.0 4.192 ± 0.111 36.6 ± 7.0 4.445 ± 0.125 
103 > 100 > 4.000 85.1 ± 4.2 4.071 ± 0.033 > 100 > 4.000 
104 35.4 ± 0.2 4.451 ± 0.005 32.5 ± 4.0 4.492 ± 0.082 18.2 ± 3.1 4.747 ± 0.112 
105 > 100 > 4.000 66.0 ± 4.1 4.182 ± 0.041 > 100 > 4.000 
106 > 100 > 4.000 > 100 > 4.000 > 100 > 4.000 
107 > 100 > 4.000 79.1 ± 6.7 4.104 ± 0.056 > 100 > 4.000 
108 > 100 > 4.000 63.6 ± 2.6 4.197 ± 0.027 84.5 ± 5.5 4.074 ± 0.074 
109 > 100 > 4.000 74.0 ± 8.7 4.134 ± 0.077 77.3 ± 7.7 4.114 ± 0.114 
110 > 100 > 4.000 36.8 ± 0.5 4.434 ± 0.009 > 100 > 4.000 
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Figures 4.22. MTT-viability assay of compounds 101-110 at concentrations of 1 (white bar), 10 (light grey bar) and 
100 µmol · L-1 (dark grey bar) compared to DMSO content of these dilutions (0.01, 0.1 and 1%); 100% cell viability 
is defined as pure cell culture medium without further supplements; 0% cell viability is caused by 10% DMSO. (A): 
H69AR. (B): MDCK II MRP1. (C): MDCK II. The dashed lines indicate 50 (lower), 100 (middle) and 150% (upper) 
cell viability. 
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Figures 4.22. MTT-viability assay of compounds 101-110 at concentrations of 1 (white bar), 10 (light grey bar) and 
100 µmol · L-1 (dark grey bar) compared to DMSO content of these dilutions (0.01, 0.1 and 1%); 100% cell viability 
is defined as pure cell culture medium without further supplements; 0% cell viability is caused by 10% DMSO (D): 
2008/MRP1. (E): A2780/ADR. (F): MDCK II BCRP. The dashed lines indicate 50 (lower), 100 (middle) and 150% 
(upper) cell viability. 
 
In most cases, DMSO had either no or a negative effect on cell viability. Interestingly, the 
data of the MRP1 transfected MDCK II cell line indicated that the compounds enhance cell 
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viability. But this could neither be confirmed by the biological data of the H69AR or 
2008/MRP1 cells. Compound 104 is the only compound that had in every cell line a negative 
influence on the cell viability. Except for the 2008/MRP1 cells, the compounds were well 
tolerated by MRP1 overexpressing cells. The differences between these cells might be 
explained by the different expression level of MRP1. 
 
 
4.2.6. MDR Reversal-efficacy of MRP1 Activators 
 
In contrast to the before stated MDR reversal-efficacy assay conducted for the already 
mentioned MRP1 inhibitors (see section 4.1.6), the MRP1 activators 101-110 were evaluated 
with respect to an enhanced resistance of MRP1 overexpressing cells toward daunorubicin. 
This was conducted by Katja Stefan. In theory, an activator should be able to reduce the 
intracellular concentration of the cytotoxic compound and therefore enhance the resistance. 
Unfortunately, this could only be observed for compound 110 at a much higher concentration 
than expected (1 and 10 µmol · L-1; Figure 4.23 A). Most compounds had either no influence 
on cell viability or reversed MDR in MDCK II MRP1 cells, as shown for compound 104 in 
Figure 4.23 B. The latter fact could be explained by the partially inhibiting feature of the 
compounds, especially 9-deazapurines. Compound 110 has the least inhibitory power toward 
MRP1 (see Tables 4.10-11) and increased cell viability over a period of 72 hours (Figure 
4.23 A).  
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Figure 4.23. (A): 1 µmol · L-1 (closed triangles) and 10 µmol · L-1 (closed squares) of compound 110 as activator of 
daunorubicin efflux enhancing resistance toward this cytotoxic agent, in comparison to control (closed circles) and 
the sensitive cell line MDCK II (open circles). Resistance could be increased about 50%, as indicated by the grey 
arrows. (B): 0.1 µmol · L-1 (closed squares) and 1 µmol · L-1 (closed triangles) of compound 104 sensitized MDCK 
II MRP1 cells (closed circles) to the left toward the sensitive cell line (open circles) as indicated by the grey arrow. 
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4.2.7. Analysis of Activation Type 
 
Compound 101 was used as representative of the MRP1 activators to analyze the type of 
activation. This was performed by Katja Stefan. Different concentrations of compound 101 
were combined with different concentrations of daunorubicin and analyzed according to 
Lineweaver-Burk, Hanes-Woolf and Cornish-Bowden. The basic mathematical equations can 
be found in reference [355]. A summary can be found in section 6.3.10. 
According to Segel’s “Enzyme Kinetics”, the compounds can be considered as nonessential 
activators.355 Regarding the double reciprocal plot of Lineweaver-Burk, activators are 
characterized by downward oriented lines. Although the tendency of the intersection of the 
lines in Figure 4.24 A is toward the ordinate, which would represent a competitive activation, 
a mixed-type activator as described by Segel is more likely. And although the additional plots 
of Hanes-Woolf and Cornish-Bowden (Figures 4.24 B-C) also indicate a competitive relation 
of activator and substrate, competitive nonessential activators have never been reported 
since enzymes cannot be occupied at the active site by an activator while the substrate has 
to be formed to the product in the same binding pocket. Only mixed-type systems are 
described, in which the used compound has the feature of an activator (noncompetitive) and 
inhibitor (competitive) at low and high concentrations, respectively. This is quite conceivable 
since the herein presented activators have also an inhibitory property. 
But one should handle the obtained results with care, since a transporter is not an enzyme. 
Although specific binding sites for P-gp have been reported,274 the transport process and its 
exact procedure is still unknown, so are binding sites for MRP1. And since it it is not known 
how many participants take part in the transport process of MRP1 (e.g. activator, substrate, 
GSH, GSSG, etc.), the system can be rather complex and might not be evaluated by basic 
enzymatic equations.  
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Figure 4.24. Kinetic evaluation of compound 101 with respect to the type of activation of MRP1-mediated 
transport of daunorubicin using H69AR cells. (A): Lineweaver-Burk plot of control (closed circles) and compound 
101 at 1.0 (closed squares), 3.2 (closed downward triangles), 10 (closed upward triangles), 100 (closed rhombs) 
and 1000 nmol · L-1 (closed stars); the intersection at the ordinate indicates a competitive relation; the downward 
oriented grey arrow indicates the activating character. (B): Corresponding Hanes-Woolf plot; the parallel lines 
indicate a competitive relation; the downward oriented grey arrow indicates the activating character. (C): Cornish-
Bowden plot of KM (closed circle) and Vmax (squares); open circle: outlier. 
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4.2.8. Summary of Evaluation of 7-N-alkyl, -aryl or -arylalkyl and 6-
aminoarylalkyl-9-deazapurines as well as 6-piperazinyl-purine Analogs 
 
The herein presented 9-deazapurines and purine analogs compounds inhibited MRP1-
mediated transport of calcein AM and daunorubicin as could be expected from their logP 
value. While the compounds with most lipophilicity (logP between 4 and 5; compounds 102 
and 104-106) had the best inhibitory activity around 1 µmol · L-1, the other representatives 
had rather low inhibitory power. Especially the purine derivatives were characterized by 
almost no inhibition of MRP1, which might be because purines form an own class of 
compounds and do not fulfill the requirements of the binding pocket(s) completely. 
Interestingly, the compounds were able to accelerate calcein AM and daunorubicin transport 
mediated by MRP1. At low concentrations between 1 and 100 nmol · L-1 the compounds led 
to a significant reduction of intracellular fluorescence of calcein in H69AR cells and 
daunorubicin in MDCK II MRP1 cells. The use of these two different MRP1 substrates and 
two different cell lines showed this effect being independent from these two parameters. The 
magnitude of the effect was different (calcein AM about a factor of 1.5; daunorubicin about a 
factor of 2). This could be explained by the lipophilicity of the substrates. Since no effects in 
the sensitive cell lines were observed, other mechanisms like disturbance of the membrane 
integrity or fluidity are highly unlikely. Additionally, the MTT-viability assay data suggests that 
the compound have no destructive but rather viability-enhancing influence on the cells. This 
was not observed for all MRP1 overexpressing cell lines, but this could be related to the 
different expression level of MRP1. Only compound 104 showed at high concentrations 
(around 100 µmol · L-1) a negative influence on cell viability.  
Unfortunately, the activating effect could not be transferred to an enhancement of MDR. 
Compound 110 was the only exception that increased the resistance toward daunorubicin, 
but at much higher concentration than could be expected from the assay data. One 
explanation why only this compound showed the described effect could be its low inhibitory 
power against MRP1 function while other compounds like 104 sensitized MDR cells in 
agreement to their inhibitory activity. Another mechanism which could explain the difference 
between the activating power in the calcein AM and daunorubicin assay and the lacking 
capability to enhance MDR could be related to the MRP1 expression. Since the cancer cells 
were exposed to the acitvators as well as the cytotoxic agent over a period of 72 hours, 
regulatory mechanisms could have reduced the amount of present MRP1. But this is rather 
speculative and needs to be clarified in future experiments. 
With respect to P-gp, only compound 104 showed inhibitory activity toward this transporter, 
but only in double-digit micromolar range. Referred to BCRP, only compounds 101 and 104 
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showed inhibitory power, but with rather poor effectiveness. No activation could be observed 
with respect to both transporters. 
Compound 104 represents a rare example of a triple inhibitor of MRP1, P-gp and BCRP, 
which can be a template for ongoing research. Compound 101 represents a dual inhibitor of 
MRP1 and BCRP. As stated in the introduction, almost nothing is known regarding this kind 
of inhibitors. 
Interestingly, the analysis of the activating part of the concentration-effect curves of 
compound 101 as representative of the MRP1 transport activators showed these compounds 
to be nonessential activators.355 According to Lineweaver-Burk, Cornish-Bowden and Hanes-
Woolf a competitive relation between compound 101 and daunorubicin can be deduced, 
although this interaction has never been reported before. According to Segel’s “Enzyme 
Kinetics”, a mixed-type nonessential activation is more likely. But the complexitiy of the 
system regarding reacting agents makes the interpretation rather difficult. 
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4.3. Evaluation of 7,8-alicyclic-, 7-N-alkyl-, -aryl- or -arylalkyl-, 
and 8,9-annulated-9-deazapurines with Heteroaromatic 
Variations 
 
Since several structural elements of formerly published MRP1 inhibitors were shown to be 
beneficial for activity, further 9-deazapurine derivatives with these variations were 
synthesized. These structural elements include heterocycles like furan (benzbromarone, 
Figure 1.7), indole (GF109203X, Figure 1.6; indomethacin, Figure 1.7), dioxindanes 
(bifendate-chalcone, Figure 1.19; piperine, Figure 1.20; cepharanthine, Figure 1.21), pyridine 
(biricodar, NIK-250, Figure 1.6; lonafarnib, Figure 1.8) or quinoline (MS-209, Figure 1.6; 
MK571, Figure 1.12), and methoxyphenyl (verapamil, biricodar, Figure 1.6; several 
flavonoids, Figure 1.9; schisandin B, Figure 1.10). The compounds and activities presented 
in this subchapter have already been published.356 
The synthesized compounds can be grouped into four classes, (i) 7,8-alicyclic-9-
deazapurines with a nitrogen heterocycle at position 6, (ii) 9-deazapurines with 4-(2-(1H-
indole-3-yl)ethyl)piperazine-1-yl residue at position 6 and alkyl, aryl or arylalkyl variations at 
position 7, (iii) 9-deazapurines with oxygen heterocycle at position 6 or oxygen containing 
residue at position 7 and (iv) 8,9-annulated-9-deazapurines with variations at position 6.  
The four classes are separately discussed. The biological evaluation using the daunorubicin 
assay, the calcein AM assay as well as the pheophorbide A assay was performed by Katja 
Stefan.  
 
4.3.1. Evaluation of 7,8-alicyclic-9-deazapurines with a Nitrogen 
Heterocycle at Position 6 
 
The starting point of this compound series was compound 29 (111) reported by Wang et al. 
in 2004 (compound 29 in ref. [271]. A variety of different derivatives was synthesized, such 
as enlargement of the cyclohexyl (111, 113-114, 116) to a cycloheptyl ring system at 
positions 7 and 8 (112, 115, 117) as well as change of the 4-(2-(1H-indole-3-
yl)ethyl)piperazine-1-yl substituent (111-112) at position 6 to either a (2-(1H-indole-3-
yl)ethyl)amino residue (113) or a pyridine containing substituent (114-117). Figure 4.25 
visualizes the screening of the compounds in all three applied assays. Table 4.15 A 
summarizes the corresponding biological data for all three tested ABC-transport proteins, 
MRP1, P-gp and BCRP. Table 4.15 B gives the pIC50 values of the compounds. 
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Figure 4.25. Screening of compound class (i) (111-117; 10 µmol · L-1) in the daunorubicin assay (MRP1, dark grey 
bark), calcein AM assay (P-gp, light grey bark), and pheophorbide A assay (BCRP, white bark) using H69AR 
(dark grey bark), A2780/ADR (light grey bark) and MDCK II BCRP (white bark) cells. 100% is defined as the effect 
of the standard inhibitors 74 (MRP1), cyclosporine A (P-gp) and Ko143 (BCRP) at a concentration of 10 µmol · L-1. 
Shown are at least three independent experiments with duplicate measurements. 
 
Table 4.15 A. Summary of inhibitory activity of compounds 111-117 obtained in the daunorubicin assay (MRP1), 
calcein AM assay (P-gp) and pheophorbide A assay (BCRP) using H69AR (MRP1), A2780/ADR (P-gp) and 
MDCK II BCRP (BCRP); n.d. = not determined due to lack of inhibitory activity (Imax ≤ 25%). The biological data 
was determined by Katja Stefan. 
 
   
 
 
no. 
 
 
 
 
R1 
 
 
 
 
R2 
 
 
 
 
R3 
 
 
 
 
daunorubicin  
(MRP1)  
IC50 ± SEM 
[µmol · L-1] 
 
calcein AM 
 (P-gp) 
IC50 ± SEM 
[µmol · L-1] 
 
pheophorbide A 
 (BCRP) 
IC50 ± SEM 
[µmol · L-1] 
111 4-(2-(1H-indole-3-yl)ethyl)piperazin-1-yl cyclohexyl 0.344 ± 0.018 5.62 ± 0.41 3.41 ± 0.20 
112 4-(2-(1H-indole-3-yl)ethyl)piperazin-1-yl cycloheptyl 0.289 ± 0.008 1.71 ± 0.14 n.d. 
113 (2-(1H-indole-3-yl)ethyl)amino cyclohexyl 0.957 ± 0.019 n.d. n.d. 
114 4-(2-(pyridin-4-yl)ethyl)piperazin-1-yl cyclohexyl 0.672 ± 0.034 n.d. 27.8 ± 4.3 
115 4-(2-(pyridin-4-yl)ethyl)piperazin-1-yl cycloheptyl 1.14 ± 0.07 n.d. 12.4 ± 0.4 
116 4-(pyridin-2-yl)piperazin-1-yl cyclohexyl 1.02 ± 0.02 n.d. 4.86 ± 0.36 
117 4-(pyridin-2-yl)piperazin-1-yl cycloheptyl n.d. n.d. n.d. 
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Table 4.15 B. Negative decadic logarithm of the IC50 values of compound 111-117 taken from Table 4.15 A. 
 
 
no. 
 
 
 
R1 
 
 
 
R2 
 
 
 
R3 
 
 
 
daunorubicin  
(MRP1)  
pIC50 ± SEM 
 
calcein AM 
 (P-gp) 
pIC50 ± SEM 
 
pheophorbide A 
 (BCRP) 
pIC50 ± SEM 
111 4-(2-(1H-indole-3-yl)ethyl)piperazin-1-yl cyclohexyl 6.464 ± 0.034 5.252 ± 0.048 5.468 ± 0.036 
112 4-(2-(1H-indole-3-yl)ethyl)piperazin-1-yl cycloheptyl 6.540 ± 0.018 5.768 ± 0.055 n.d. 
113 (2-(1H-indole-3-yl)ethyl)amino cyclohexyl 6.019 ± 0.013 n.d. n.d. 
114 4-(2-(pyridin-4-yl)ethyl)piperazin-1-yl cyclohexyl 6.173 ± 0.033 n.d. 4.561 ± 0.101 
115 4-(2-(pyridin-4-yl)ethyl)piperazin-1-yl cycloheptyl 5.944 ± 0.040 n.d. 4.906 ± 0.023 
116 4-(pyridin-2-yl)piperazin-1-yl cyclohexyl 5.993 ± 0.010 n.d. 5.313 ± 0.017 
117 4-(pyridin-2-yl)piperazin-1-yl cycloheptyl n.d. n.d. n.d. 
 
 
Since compound 104 inhibited all three transport proteins, the possibility of multiple inhibition 
was in focus of these investigations. Compound 111, which had already been reported to be 
a dual inhibitor of MRP1 and P-gp,271 inhibited also BCRP. The 7,8-alicyclic compounds 111 
and 112 had great inhibitory power toward MRP1, the latter represented a good dual inhibitor 
of MRP1 and P-gp. Compound 113, lacking the piperazine partial structure, was inferior 
compared to its piperazine-bearing counterparts 111 and 112. This underlines the fact that 
the piperazine structure is necessary, as already shown before (see subchapters 4.1-2). 
The pyridine derivatives 114 and 115 were good inhibitors with IC50 values around 1 µmol· L-1 
or less. The same applied for compound 116, which contained no ethylene linker between 
the pyridine and piperazine substructures. Similar compounds already presented above (77 
and 87) were inferior compared to compound 116. This compound is a rare example of a 
good dual inhibitor of MRP1 and BCRP. Unfortunately compound 117 could not be evaluated 
due to solubility issues. 
 
 
4.3.2. Evaluation of 9-deazapurines with 4-(2-(1H-indole-3-
yl)ethyl)piperazine-1-yl Residue at Position 6 and Alkyl or Arylalkyl 
Variations at Position 7 
 
Compound 92 was the most active representative of the subchapter (see Table 4.3) and 
compound 111 of subclass (i) (see Table  4.15 A-B) was a very good inhibitor as well. 
Therefore, the synthesis of a combination of structural features from both subclasses with 
specific variations at position 7 was performed (compared to compounds 88-99). Figure 4.26 
gives the screening results of the compounds. Table 4.16 A and B give a summary of the 
corresponding biological data. All synthesized compounds (118-125) were very good 
inhibitors of MRP1 with a concentration range of about 300-500 nmol · L-1, except for 
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compound 119. As was already found in section 4.1.3, higher molecular weight seemed to be 
preferred with respect to P-gp inhibition. This could also be seen in this subset of compounds 
in the screening data (Figure 4.26). Compounds 124 and 125 are both very effective P-gp 
inhibitors, although the former reached only 34% of the standard compound cyclosporine A 
at 10 µmol · L-1. With respect to BCRP both compounds were good inhibitors of this 
transporter with IC50 values in low single-digit micromolar concentration range. This 
contradicts the above stated finding that small molecules with low logP and low molecular 
weight are preferred regarding BCRP inhibition (see section 4.1.4). Hence, these compounds 
seem to have other attributes of greater importance, e.g. a more suitable residue for the 
binding pocket(s). 
As compound 125 reached in all three assays 75% inhibition in comparison to the 
corresponding standard compounds, it was further investigated with respect to its type of 
inhibition (see section 4.3.5) and MDR reversal (see section 4.3.7) toward MRP1, P-gp and 
BCRP. 
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Figure 4.26. Screening of compound class (ii) (118-125; 10 µmol · L-1) in the daunorubicin assay (MRP1, dark 
grey bark), calcein AM assay (P-gp, light grey bark), and pheophorbide A assay (BCRP, white bark) using H69AR 
(dark grey bark), A2780/ADR (light grey bark) and MDCK II BCRP (white bark) cells. 100% is defined as the effect 
of the standard compounds 74 (MRP1), cyclosporine A (P-gp) and Ko143 (BCRP) at a concentration of              
10 µmol · L-1. Shown are at least three independent experiments with duplicate measurements. 
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Table 4.16 A. Summary of inhibitory activity data of compounds 118-125 obtained in the daunorubicin assay 
(MRP1), calcein AM assay (P-gp) and pheophorbide A assay (BCRP) using H69AR (MRP1), A2780/ADR (P-gp) 
and MDCK II BCRP cells (BCRP); n.d. = not determined due to lack of inhibitory activity (Imax ≤ 25%). The 
biological data was determined by Katja Stefan. 
 
 
 
no. 
 
 
 
R1 
 
 
 
daunorubicin  
(MRP1)  
IC50 ± SEM [µmol · L-1] 
 
calcein AM 
 (P-gp) 
IC50 ± SEM [µmol · L-1] 
 
pheophorbide A 
 (BCRP) 
IC50 ± SEM [µmol · L-1] 
118 methyl 0.337 ± 0.020 n.d. n.d. 
119 ethyl 0.855 ± 0.063 n.d. 13.8 ± 1.0 
120 propyl 0.468 ± 0.012 n.d. n.d. 
121 cyclopropyl 0.316 ± 0.009 3.85 ± 0.36 18.9 ± 1.7 
122 phenyl 0.328 ± 0.022 1.28 ± 0.14 n.d. 
123 benzyl 0.405 ± 0.028 4.48 ± 0.25 4.07 ± 0.36 
124 phenethyl 0.524 ± 0.013 1.64 ± 0.04 1.39 ± 0.08 
125 phenylpropyl 0.501 ± 0.025 1.46 ± 0.10 1.69 ± 0.07 
 
 
Table 4.16 B. Negative decadic logarithm of the IC50 values of compounds 118-125 taken from Table 4.16 A. 
 
 
no. 
 
 
 
R1 
 
 
 
daunorubicin  
(MRP1)  
pIC50 ± SEM 
 
calcein AM 
 (P-gp) 
pIC50 ± SEM 
 
pheophorbide A 
 (BCRP) 
pIC50 ± SEM 
118 methyl 6.473 ± 0.039 n.d. n.d. 
119 ethyl 6.069 ± 0.048 n.d. 4.861 ± 0.048 
120 propyl 6.330 ± 0.017 n.d. n.d. 
121 cyclopropyl 6.501 ± 0.019 5.417 ± 0.062 4.725 ± 0.060 
122 phenyl 6.485 ± 0.045 5.896 ± 0.074 n.d. 
123 benzyl 6.394 ± 0.046 5.459 ± 0.047 5.392 ± 0.058 
124 phenethyl 6.281 ± 0.016 5.784 ± 0.047 5.859 ± 0.037 
125 phenylpropyl 6.301 ± 0.033 5.836 ± 0.043 5.772 ± 0.028 
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4.3.3. Evaluation of 9-deazapurines with Oxygen Heterocycle at    
Position 6 or Oxygen Containing Residue at Position 7 
 
Since several known inhibitors of MRP1 contain oxygen substituents or oxygen heterocylces 
like verapamil (Figure 1.6), biricodar (Figure 1.6) and piperine (Figure 1.20), derivatives with 
piperonyl and furanoyl substituents as well as alkoxy residues were synthesized. Figure 4.27 
shows the obtained screening data. Tables 4.17 A and B summarize the corresponding 
biological results. 
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Figure 4.27. Screening of compound class (iii) (126-135; 10 µmol · L-1) in the daunorubicin assay (MRP1, dark 
grey bark), calcein AM assay (P-gp, light grey bark), and pheophorbide A assay (BCRP, white bark) using H69AR 
(dark grey bark), A2780/ADR (light grey bark) and MDCK II BCRP (white bark) cells. 100% is defined as the effect 
of the standard compounds 74 (MRP1), cyclosporine A (P-gp) and Ko143 (BCRP) at a concentration of              
10 µmol · L-1. Shown are at least three independent experiments with duplicate measurements. 
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Table 4.17 A. Summary of inhibitory activity data of compounds 126-135 obtained in the daunorubicin assay 
(MRP1), calcein AM assay (P-gp) and pheophorbide A assay (BCRP) using H69AR (MRP1), A2780/ADR (P-gp) 
and MDCK II BCRP cells (BCRP); n.d. = not determined due to lack of inhibitory activity (Imax ≤ 25%). The 
biological data was determined by Katja Stefan. 
 
 
no. 
 
 
 
 
R1 
 
 
 
 
R2 
 
 
 
 
R3 
 
 
 
 
daunorubicin  
(MRP1)  
IC50 ± SEM 
[µmol · L-1] 
 
calcein AM 
 (P-gp) 
IC50 ± SEM 
[µmol · L-1] 
 
pheophorbide A 
 (BCRP) 
IC50 ± SEM 
[µmol · L-1] 
126 piperonyl cyclohexyl 0.322 ± 0.019 13.9 ± 1.4 14.6 ± 1.8 
127 piperonyl cycloheptyl 1.02 ± 0.04 5.71 ± 0.60 23.7 ± 4.0 
128 piperonyl phenyl H 0.751 ± 0.126 n.d. n.d. 
129 piperonyl phenethyl H 1.80 ± 0.16 n.d. n.d. 
130 furanoyl cyclohexyl 0.883 ± 0.060 n.d. 29.5 ± 1.4 
131 furanoyl cycloheptyl 1.01 ± 0.04 n.d. 12.9 ± 0.8 
132 phenethyl 2-methoxyphenyl H 0.638 ± 0.026 n.d. n.d. 
133 benzyl 2-methoxyphenyl H 0.327 ± 0.028 19.1 ± 0.7 37.9 ± 3.6 
134 phenethyl 4-ethoxyphenyl H 1.32 ± 0.10 n.d. n.d. 
135 benzyl 4-ethoxyphenyl H 0.859 ± 0.067 7.29 ± 0.44 n.d. 
 
 
Table 4.17 B. Negative decadic logarithm of IC50 values of compounds 126-135 taken from Table 4.17 A. 
 
 
 
no. 
 
 
 
R1 
 
 
 
R2 
 
 
 
R3 
 
 
 
daunorubicin  
(MRP1)  
pIC50 ± SEM 
 
calcein AM 
 (P-gp) 
pIC50 ± SEM 
 
pheophorbide A 
 (BCRP) 
pIC50 ± SEM 
126 piperonyl cyclohexyl 6.493 ± 0.040 4.858 ± 0.064 4.837 ± 0.079 
127 piperonyl cycloheptyl 5.991 ± 0.028 5.246 ± 0.069 4.632 ± 0.110 
128 piperonyl phenyl H 6.130 ± 0.110 n.d. n.d. 
129 piperonyl phenethyl H 5.746 ± 0.057 n.d. n.d. 
130 furanoyl cyclohexyl 6.055 ± 0.044 n.d. 4.531 ± 0.031 
131 furanoyl cycloheptyl 5.994 ± 0.027 n.d. 4.892 ± 0.043 
132 phenethyl 2-methoxyphenyl H 6.195 ± 0.027 n.d. n.d. 
133 benzyl 2-methoxyphenyl H 6.487 ± 0.056 4.719 ± 0.025 4.423 ± 0.063 
134 phenethyl 4-ethoxyphenyl H 5.882 ± 0.050 n.d. n.d. 
135 benzyl 4-ethoxyphenyl H 6.067 ± 0.051 5.138 ± 0.039 n.d. 
 
 
Referred to MRP1, the compounds showed to be moderately good inhibitors with IC50 values 
around 1 µmol · L-1, while the inhibitory power against P-gp as well as BCRP was negligible. 
The best compounds are 126 and 133. Both compounds are comparable to no. 104, 
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inhibiting all three transport proteins, but P-gp and BCRP with much less potency. Although 
the alkoxy partial structure has often been seen in P-gp inhibitors, the outcome of these 
results is rather poor. The same holds for BCRP inhibition, where activities were only in 
double-digit micromolar range. 
 
4.3.4. Evaluation of 8,9-annulated-9-deazapurines with Variations at 
Position 6 
 
The 8,9-annulated deazapurines had already been shown to be very effective MRP1 
inhibitors by Wang et al. in 2004.272 Therefore, the basic 5H-pyrimido[5,4-b]indole structure 
was combined with beneficial residues at position 6 as discussed in subchapter 4.1, 4.3.1 
and 4.3.3. The resultant 8,9-annulated-9-deazapurines contained either (a) aryl- or arylalkyl 
variations (136-139), (b) nitrogen containing residues (140-142) or (c) oxygen containing 
substituents (143-144). Figure 4.28 gives the obtained screening results. Tables 4.18 A and 
B summarize the biological data. 
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Figure 4.28. Screening of compound class (iv) (136-144; 10 µmol · L-1) in the daunorubicin assay (MRP1, dark 
grey bark), calcein AM assay (P-gp, light grey bark), and pheophorbide A assay (BCRP, white bark) using H69AR 
(dark grey bark), A2780/ADR (light grey bark) and MDCK II BCRP (white bark) cells. 100% is defined as the effect 
of the standard compounds 74 (MRP1), cyclosporine A (P-gp) and Ko143 (BCRP) at a concentration of              
10 µmol · L-1. Shown are at least three independent experiments with duplicate measurements. 
 
This class of compounds was not very effective with respect to inhibition of MRP1 or P-gp at 
a concentration of 10 µmol · L-1. They reached only 30-60% inhibition compared to the 
corresponding standard inhibitors. In contrast, 8,9-annulated-9-deazapurines potently 
inhibited BCRP. This has been shown for this compound class before.320 
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The first subset (a) (136-139) contained very good dual (139) and triple (136) inhibitors, with 
IC50 values ranging from 0.15 to 0.45 µmol · L-1. But with respect to MRP1 inhibition, one 
must take the insufficient Imax values into account (136 = 61%; 139 = 31%). The same holds 
for P-gp inhibition (Imax (136) = 26%; Imax (139) = 14%). The reason for this partial inhibition has 
not been elucidated until now. Solely BCRP inhibition was convincing, except for compound 
136 (Imax = 28%).  
The same applies for subset (b) (140-142). Most compounds had a maximum inhibition level 
of MRP1 and P-gp around 47-82% and 37-56%, respectively. Compound 140 was in this 
regard the most effective one in this subset (MRP1 = 82%; P-gp = 46%; BCRP = 71%). This 
applied also for its IC50 values, which ranged all in the single-digit micromolar concentration 
range. But it was not further investigated since the compound did not reach the necessary 
level of 75% inhibition in all three transporter assays. 
Subset (c) consisted only of compounds 143 and 144. For further investigations both 
compounds lacked the necessary effectiveness toward MRP1 and BCRP with respect to the 
chosen Imax values of 75%. Compound 143 was comparable to compound 140, as it turned 
out to be a moderately good triple inhibitor with IC50 values in the single-digit micromolar 
concentration range and Imax values of 60% (MRP1), 39% (P-gp) and 75% (BCRP). 
 
Table 4.18 A. Summary of inhibitory activity data of compounds 136-144 obtained in the daunorubicin assay 
(MRP1), calcein AM assay (P-gp) and pheophorbide A assay (BCRP) using H69AR (MRP1), A2780/ADR (P-gp) 
and MDCK II BCRP cells (BCRP); n.d. = not determined due to lack of inhibitory activity (Imax ≤ 25%). The 
biological data was determined by Katja Stefan. 
 
 
no. 
 
 
 
 
R1 
 
 
 
 
daunorubicin  
(MRP1)  
IC50 ± SEM 
[µmol · L-1] 
 
calcein AM 
 (P-gp) 
IC50 ± SEM 
[µmol · L-1] 
 
pheophorbide A 
 (BCRP) 
IC50 ± SEM 
[µmol · L-1] 
136 phenethyl 0.405 ± 0.019 1.11 ± 0.04 0.839 ± 0.054 
137 benzyl 0.363 ± 0.014 9.49 ± 0.67 6.08 ± 0.39 
138 benzhydryl 0.409 ± 0.030 2.33 ± 0.17 1.38 ± 0.12 
139 phenyl 0.146 ± 0.004 n.d. 1.10 ± 0.08 
140 2-(1H-indole-3-yl)ethyl 0.921 ± 0.012 3.50 ± 0.36 6.21 ± 0.30 
141 2-(pyridin-2-yl)ethyl 0.345 ± 0.012 10.7 ± 0.7 11.6 ± 0.7 
142 pyridin-2-yl 0.495 ± 0.037 5.00 ± 0.40 1.81 ± 0.10 
143 piperonyl 0.717 ± 0.030 3.92 ± 0.23 7.93 ± 0.51 
144 furanoyl 0.169 ± 0.005 n.d. 6.06 ± 0.30 
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Table 4.18 B. Negative decadic logarithm of the IC50 values of compounds 136-144 taken from Table 4.18 A. 
 
 
no. 
 
 
 
R1 
 
 
 
daunorubicin  
(MRP1)  
pIC50 ± SEM 
 
calcein AM 
 (P-gp) 
pIC50 ± SEM 
 
pheophorbide A 
 (BCRP) 
pIC50 ± SEM 
136 phenethyl 6.393 ± 0.031 5.953 ± 0.021 6.077 ± 0.042 
137 benzyl 6.440 ± 0.026 5.024 ± 0.046 5.217 ± 0.042 
138 benzhydryl 6.390 ± 0.026 5.632 ± 0.048 5.862 ± 0.055 
139 phenyl 6.836 ± 0.016 n.d. 5.957 ± 0.045 
140 2-(1H-indole-3-yl)ethyl 6.036 ± 0.009 5.458 ± 0.067 5.207 ± 0.032 
141 2-(pyridin-2-yl)ethyl 6.462 ± 0.022 4.972 ± 0.043 4.935 ± 0.042 
142 pyridin-2-yl 6.306 ± 0.050 5.306 ± 0.052 5.743 ± 0.036 
143 piperonyl 6.145 ± 0.028 5.407 ± 0.039 5.102 ± 0.042 
144 furanoyl 6.772 ± 0.020 n.d. 5.218 ± 0.032 
 
 
4.3.5. Investigation of the Interaction Type of Triple Inhibitor No. 125 
 
Many of the herein presented compounds inhibited all three tested ABC-transport proteins. 
But as one can see in Figures 4.29 A-C, not all of these were able to lead to a full inhibition 
at 10 µmol · L-1 compared to the standard compound of the corresponding test system. Only 
compound 125 reached more than 75% of the corresponding standard compound in all test 
systems with sufficient potency of around 1 µmol · L-.1. Therefore, this compound was further 
characterized with respect to its interaction with the corresponding substrates of MRP1, P-gp 
and BCRP. The assays were performed and analyzed by Katja Stefan. Compound 125 is a 
noncompetitive inhibitor of MRP1-mediated transport of daunorubicin, P-gp-mediated 
transport of calcein AM and BCRP-mediated transport of pheophorbide A, as indicated by 
the intersection at the abscissa. The basic mathematical equations behind this can be drawn 
from reference [355]. Experimental section 6.3.10.1 gives a short summary. 
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Figure 4.29. Lineweaver-Burk analysis of compound 125 using H69AR (MRP1, A), A2780/ADR (P-gp, B) and 
MDCK II BCRP cells (BCRP, C). Concentrations of compound 125 were as follows: 0.1 (closed squares), 0.25 
(closed upward triangles), 0.5 (closed downward triangles) and 2.5 µmol · L-1 (closed rhombs); closed circles: 
control. (A): Daunorubicin was used at 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 µmol · L-1; (B): Calcein AM was used at 0.1, 
0.2, 0.3, 0.4, 0.5, and 0.6 µmol · L-1; (C): Pheophorbide A was used at 0.2, 0.4, 0.5, 0.75, 1.0 and 1.5 µmol · L-1. 
 
4.3.6. Determination of Intrinsic Toxicity 
 
All synthesized 9-deazapurines of this subchapter were evaluated with respect to their 
intrinsic toxicity toward the used cell lines (H69AR, A2780/ADR and MDCK II BCRP as well 
as their sensitive counterparts). As in the screening experiments (see Figures 4.25-28), the 
compounds were used at 10 µmol · L-1. Figures 4.30 A-C summarize the biological data, 
which was determined by Katja Stefan. 
It can be seen that most compounds were nontoxic with respect to H69AR and H69 cells, 
except for compounds 118, 127 and 129, which possessed slight toxicity. With regard to 
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A2780/ADR and A2780 cells, the tested compounds reduced the cell viability to a value of 
approximately 60% except for compound 138, that was more toxic. Concerning MDCK II 
BCRP and wild type cells only the four compounds 117-118, 138 and 140 showed slight to 
severe toxicity, while all other compounds led to no reduction of cell viability. In summary, 
except for the stated compounds, the evaluated substances of this subchapter have no 
noteworthy toxicity up to a concentration of 10 µmol · L-1. 
Since compound 125 was the only representative of a very effective triple inhibitor, it was 
evaluated with respect to its full spectrum of cell toxicity at varying concentrations. Table 4.19 
gives the therapeutic ratio calculated for to all used cell lines. Since the values are around 10 
or higher, it represents a good candidate for clinical evaluation as MDR reverser in specific 
cancers that simultaneously overexpress the three herein presented MDR-conferring 
transport proteins. 
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Figure 4.30. MTT-viability assay results of compounds 111-144 at 10 µmol · L-1 with respect to the corresponding 
transporter-overexpressing cells (dark grey bar) and the sensitive counterpart (light grey bar). 100% is defined as 
pure cell culture medium and 0% cell viability by 10% DMSO, respectively. Shown is mean ± SEM of at least 
three independent experiments with duplicate measurements. (A): H69AR (dark grey bark) and H69 (light grey 
bark) cells. (B): A2780/ADR (dark grey bark) and A2780 (light grey bark) cells. (C) MDCK II BRCP (dark grey 
bark) and MDCK II (light grey bark) cells. Shown are at least three independent experiments with duplicate 
measurements. 
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Table 4.19. GI50 values of compound 125 with respect to the six evaluated cell lines as well as the calculated 
therapeutic ratio (tr) using the above stated IC50 values out of the corresponding test system (see Table 4.16 A 
and section 6.3.6). 
 
 
cell line 
 
GI50 ± SEM [µmol · L-1] 
 
pGI50 ± SEM 
 
IC50 ± SEM [µmol · L-1] 
 
tr 
H69AR 152 ± 20 3.822 ± 0.085 0.501 ± 0.025 303 
H69 55.4 ± 4.8 4.258 ± 0.057   
A2780/ADR 13.7 ± 0.3 4.863 ± 0.014 1.46 ± 0.10 9.38 
A2780 6.36 ± 0.11 5.196 ± 0.011   
MDCK II BCRP 23.2 ± 1.0 4.634 ± 0.027 1.69 ± 0.07 13.7 
MDCK II 37.2 ± 0.1 4.430 ± 0.001   
 
 
4.3.7. MDR Reversal-efficacy of Triple Inhibitor No. 125 
 
Restoration of sensitivity of cancer cells is the most important measure of compound 
evaluation. Compound 125 as the best and most promising triple inhibitor of the 9-
deazapurines was tested using H69AR, A2780/ADR and MDCK II BCRP cells as well as 
their sensitive counterparts. Figures 4.31 A-C show graphically the obtained concentration-
effect curves. Table 4.20 A lists the calculated EC50 values of daunorubicin (MRP1, P-gp) 
and SN-38 (BCRP) in combination with compound 125 as well as the corresponding 
resistance factor (rf; see section 6.3.7) and potentiation factor (pf; see section 6.3.8). This 
assay was performed by Katja Stefan. 
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Figure 4.31. Reversal of MRP1- (A), P-gp- (B), and BCRP (C)-mediated MDR using H69AR (A), A2780/ADR (B) 
and MDCK II BCRP (C) cells (control, closed circles) as well as their sensitive counterparts H69 (A), A2780 (B) 
and MDCK II (C) (open circles). Compound 125 was used at 0.1 (closed squares), 1 (upward closed triangles) 
and 10 µmol · L-1 (downward closed triangles). Daunorubicin was used for MRP1 and P-gp (A-B) and SN-38 for 
BCRP (C). Shown are at least three independent experiments with duplicate measurements. 
 
Table 4.20 A. MDR reversal-efficacy data obtained for compound 125 as well as calculated resistance and 
potentiation factors (see sections 6.3.7-8) with respect to the tested transporters in three different cell lines. 
Shown is also the degree of sensitization (°s; see section 6.3.9) determined at 10 µmol · L-1 compound 
concentration. 
   
 
ABC- 
Transporter 
 
 
resist. cells 
GI50 ± SEM 
[µmol · L-1] 
 
0.1 µM  
GI50 ± SEM 
[µmol · L-1] 
 
1 µM  
GI50 ± SEM 
[µmol · L-1] 
 
10 µM 
GI50 ± SEM 
[µmol · L-1] 
 
sens. cells 
GI50 ± SEM 
[µmol · L-1] 
 
°s 
[%] 
 
MRP1 3.84 ± 0.60 2.10 ± 0.29 1.17 ± 0.003 0.445 ± 0.003 0.361 ± 0.016 
81 rf 11 5.8 3.2 1.2 1 
pf 1 1.8 3.3 8.6 11 
P-gp 0.575 ± 0.005 0.286 ± 0.004 0.058 ± 0.001 0.044 ± 0.002  0.010 ± 0.001 
24 rf 54 27 5.5 4.1 1 
pf 1 2.0 9.8 13 54 
BCRP 1.71 ± 0.16 0.916 ± 0.054 0.211 ± 0.002 0.061± 0.007 0.086 ± 0.004 
140 rf 20 11 2.5 0.7 1 
pf 1 1.9 8.1 28 20 
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Compound 125 has the ability to sensitize all three MDR cell lines (see Tables 4.20 A-B). 
While the H69AR and MDCK II BCRP cells showed complete reversal of MDR, the 
A2780/ADR were only partially sensitized (°s = 24%). Although this value seems to be low, 
one must take the logarithmic scale into account. Compound 125 decreased the resistance 
of P-gp overexpressing A2780/ADR cells from a factor of 54 to a factor of only 4. This means 
compound 125 potentiated the toxicity of daunorubicin by a factor of 13. Figure 4.32 shows 
the pGI50 values taken from Table 4.20 A of the corresponding used cytotoxic agents plotted 
against the used concentrations of compound 125 (log [c]). As already explained in section 
4.1.6, the resultant EC50 represents the concentration of the inhibitor, at which the resistance 
of the corresponding cell line is reduced by 50%. These are 0.959 ± 0.126 (MRP1), 0.563 ± 
0.060 (P-gp) and 0.478 ± 0.053 (BCRP). This shows that submicromolar concentrations are 
necessary to reduce the resistance of the tested MDR cell lines by half. Triple inhibitors of 
this quality and effectiveness have never been described before. Being de facto a ‘dirty drug’, 
compound 125 is a noticeable aspirant for clinical evaluation. 
 
Table 4.20 B. Negative decadic logarithm of GI50 values taken from Table 4.20 A. 
 
ABC- 
transporter 
resist. cells 
pGI50 ± SEM 
0.1 µM 
pGI50 ± SEM 
1 µM 
pGI50 ± SEM 
10 µM 
pGI50 ± SEM 
sens. cells 
pGI50 ± SEM 
pEC50 
 
MRP1 5.421 ± 0.103 5.683 ± 0.091 5.934 ± 0.002 6.352 ± 0.005 6.444 ± 0.029 6.022 ± 0.086 
P-gp 6.240 ± 0.006 6.543 ± 0.010 7.233 ± 0.014 7.353 ± 0.027 7.972 ± 0.067 6.252 ± 0.070 
BCRP 5.768 ± 0.060 6.039 ± 0.039 6.676 ± 0.006 7.215 ±0.071 7.068 ± 0.032 6.323 ± 0.073 
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Figure 4.32. Evaluation of the efficacy of compounds 125 with respect to its MDR reversing potency using H69AR 
(closed circles), A2780/ADR (closed triangles) and MDCK II BCRP (closed upward triangles) cells. On the 
ordinate the determined pGI50 values of Table 4.20 B are plotted. On the abscissa, the used compound 
concentrations are presented. Each resultant curve is calculated from five data points and constrained to the data 
of the resistant (-∝, bottom) and sensitive cell line (∝, top). 
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4.3.8. Summary of Evaluation of 7,8-alicyclic-, 7-N-alkyl-, -aryl- or -
arylalkyl-, and 8,9-annulated-9-deazapurines with Heteroaromatic 
Variations 
 
9-deazapurines with heterocyclic elements were synthesized to obtain more new and potent 
inhibitors of MRP1, but also P-gp and BCRP, since the used structural elements were 
already known to be part of inhibitors of ABC-transport proteins. Containing compounds of 
rather poor selectivity, this compound class has promising members with respect to multiple 
inhibition of ABC transporters. Compounds 112, 122, and 135 are representatives of good 
dual MRP1/P-gp inhibitors, with low single-digit micromolar inhibitory activity, although the 
latter had an insufficient Imax with respect to MRP1 inhibition compared to the standard 
compound 74. 
Dual Inhibitors of MRP1 and BCRP were also found, which was more interesting due to lack 
of reports in literature. Compounds 116, 139 and 144 are promising structures for further 
experiments. 
Although compound 139 yielded the best IC50 determined in this work regarding MRP1, the 
compound failed to inhibit this transporter in comparable magnitude as the standard 
compound 74. The same holds for compound 144. 
Compound 125 is the best hit out of this subchapter. It had good inhibitory power toward all 
the herein tested ABC-transport proteins around 1 µmol · L-1. Additionally, the magnitude of 
the effect of 10 µmol · L-1 of compound 125 was comparable to the effect of the 
corresponding standard compounds at the same concentration. Furthermore, compound 125 
showed to be a noncompetitive inhibitor of daunorubicin (MRP1), calcein AM (P-gp) and 
pheophorbide A (BCRP) transport. While possessing only slight toxicity toward the 
corresponding cell lines having a therapeutic ratio of at least around 9, compound 125 was 
able to reverse resistance of H69AR (MRP1), A2780/ADR (P-gp) and MDCK II BCRP 
(BCRP) cells. Furthermore, it was found that submicromolar concentrations are sufficient to 
reduce cancer cell growth by half. A triple inhibitor with these characteristics has never been 
reported before in the literature and makes this compound a very good candidate for clinical 
evaluation against cancer cells that simultaneously overexpress the three herein presented 
MDR-conferring transport proteins. 
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5. Summary 
 
 
Expression of ABC-transport proteins is a major obstacle in cancer chemotherapy. Especially 
MRP1, P-gp and BCRP are expressed in different malignancies like lung cancer, colon 
carcinomas, leukemias, bladder cancer, myeloma, ovarian carcinomas or breast cancer, 
often simultaneously. These key proteins extrude a variety of structurally diverse 
antineoplastic agents out of cells, which results in the phenomenon called multidrug 
resistance (MDR). Many compounds of different origin were found to inhibit different ABC-
transporters, e.g. pharmacological drugs, natural compounds, intrinsic substrates and 
synthetic compounds derived from screening of huge compound libraries. But most of these 
inhibitors lacked the necessary potency and selectivity, and often led to severe side effects in 
clinical evaluations. Especially with respect to MRP1, only rare reports have been made for 
compounds in the submicromolar concentration range. Hence, the development of new 
compounds is desirable to obtain more potent inhibitors for this transport protein. 
The aim of the thesis was to develop new, potent, nontoxic and selective inhibitors of MRP1, 
based on earlier reports of pyrrolo- and indolopyrimidines. The compounds have been 
evaluated in two different assays, the calcein AM and daunorubicin assay. 
The substituents of the starting compound 74 were varied to elucidate the preferences with 
regard to MRP1 inhibition. It was found that the phenethylpiperazine side chain at position 6 
was superior in comparison to shortened alkyl linker or abolishing of the piperazine partial 
structure. Additionally, alkyl, aryl or arylalkyl substituents could be introduced at position 7 
leading to potent compounds in submicromolar range. Compound 92 with its cyclopropyl 
residue was shown to be the best inhibitor of the newly synthesized compounds. It was 
equally potent in comparison to the standard inhibitor and starting compound 74. But in 
contrast to the latter, the former had no inhibitory activity against P-gp and BCRP, which 
makes this compound a very selective inhibitor of MRP1. Compound 92 was able to reduce 
MDR of H69AR cells by half in submicromolar concentration range, reversed MRP1-
mediated MDR completely at 10 µmol · L-1 and possessed no noteworthy toxicity at this 
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concentration. Compound 92 is only six times less effective than the best known inhibitor of 
MRP1, and in contrast to the latter, it is absolutely selective, which makes it a great aspirant 
for clinical evaluation in cancer cell lines that overexpress MRP1. 
Purine analogs of 9-deazapurines showed only inhibitory power in upper double-digit 
concentration range, but were able to stimulate MRP1-mediated transport. This was found 
for calcein AM and daunorubicin in two different MRP1 expressing cell lines, H69AR and 
MDCK II MRP1. Several 9-deazapurines also stimulated MRP1-mediated transport, although 
long side chains at position 6 also gave compounds with moderate to good inhibitory power. 
These compounds gave biphasic concentration-effect curves. Most of the compounds were 
selective inhibitors of MRP1, only compound 104 affected all three transporters in an 
inhibitory way. It was the first herein reported triple inhibitor, although the inhibitory power 
toward P-gp and BCRP was rather low. The purine and 9-deazapurine activators were 
biologically evaluated with respect to their half-maximal activating concentration and 
activation ratio, which could only be observed with respect to MRP1. Analyzation of the type 
of activation of compound 101 as representative of the MRP1 activators showed that these 
compounds are nonessential activators, most likely “mixed-type” according to Segel’s 
“Enzyme Kinetics”. Although the compounds could reduce the intracellular concentration of 
the cytotoxic agent daunorubicin in the daunorubicin assay, this activating power could not 
be transferred to the MDR reversal-efficacy assay. Except for compound 110, none of the 
compounds enhanced MDR, on the contrary compounds with good inhibitory power rather 
reversed resistance in MRP1 overexpressing cancer cell lines (e.g. 104). 
Since pyrrolo- und indolopyrimidines were shown before to inhibit P-gp, but also BCRP, 
some 9-deazapurines were evaluated regarding their capability to inhibit all three 
transporters reported in this thesis. Besides some dual inhibitors, compound 125 was found 
as the best triple inhibitor ever reported until now. It was able to inhibit MRP1 in 
submicromolar range and P-gp as well as BCRP at low micromolar concentrations. It is a 
noncompetitive inhibitor of daunorubicin, calcein AM and pheophorbide A transport mediated 
by MRP1, P-gp and BCRP, respectively. Finally, the compound could reduce MDR in several 
cancer cell lines. The effectiveness of this MDR reversal was in submicromolar range, 
comparable to the data obtained for the standard inhibitor 74 and the best compound of this 
thesis, 92. This makes compound 125 also a great aspirant for clinical evaluation for use in 
cancers with multiple expression of ABC-transport proteins. 
Finally, the H69AR lung cancer cell line could be established as test system and compounds 
74 and 126 were established as standard inhibitors for the calcein AM and daunorubicin 
assay, superseding the former standard inhibitors indomethacin, cyclosporine A, MK571 and 
ONO-1078, which all lacked either the necessary selectivity, potency or reliability. 
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The results of this thesis give new insights in the field of MRP1-mediated MDR and the 
compound classes of purines and 9-deazapurines. These contain compounds that inhibit 
MRP1 with great potency and selectivity, which has rarely been reported. But also broad-
spectrum inhibitors have been found, which is a good starting point for clinical evaluation in 
oncology. Finally, the activating property of several representatives might be a good tool for 
further experiments to elucidate the mechanistic aspects of ABC-transport proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental Section  101 
 
 
 
 
 
 
6. Experimental Section 
 
 
6.1. Materials and Methods for Chemical Synthesis 
 
6.1.1. Chemicals and Solvents 
 
All chemicals and solvents were supplied by Acros Organics (Geel, Belgium), Alfa Aesar 
(Karlsruhe, Germany), Applichem GmbH (Darmstadt, Germany), ChemSolute (a brand of Th. 
Geyer GmbH & Co. KG, Renningen, Germany), Fisher Scientific GmbH (Waltham, MA, 
USA), Grüssing GmbH Analytika (Filsum, Germany), Julius Hösch GmbH und Co. KG 
(Düren, Germany), Merck Millipore (Billerica, MA, USA), Sigma-Aldrich (St. Louis, MO, USA), 
TCI Deutschland GmbH (Eschborn, Germany), VWR International GmbH (Darmstadt, 
Germany) and Wacker Chemie (München, Germany) and were used for synthesis without 
further purification. Demineralized water was generated using a WAT membrantec module 
(WAT membrantec water services GmbH, Erkrath, Germany) and ultrapure water was gained 
using PureLab flex purification system (Elga LabWater / Veolia Water Technologies, Celle, 
Germany). Table 6.1 summarizes used educts and building blocks for the compounds 
described in this work. Table 6.2 gives a summary of the used solvents. 
 
 
Table 6.1. List of used chemicals and building blocks for synthesis of intermediates 1-73 and compounds 74-144. 
 
 
name provider used for compound no. 
acetic anhydryide Grüssing 5 
2-aminobenzonitrile Alfa Aesar 5 
ammonia solution (25%) ChemSolute 45-58 
aniline Alfa Aesar 11,83 
azepan-2-one (syn. ε-caprolactam) Alfa Aesar 2 
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name provider used for compound no. 
1-benzhydrylpiperazine 
(syn. 1-(diphenylmethyl)piperazine) 
Fluka 76,86,109,138 
benzylamine Acros Organics 14,82,101-103 
1-benzylpiperazine Alfa Aesar 75,85,94,96,98,100,108,133,135,137 
3-(2-bromoethyl)-1H-indole Sigma-Aldrich 73 
6-chloropurine Alfa Aesar 107-110 
cyclopropylamine Alfa Aesar 10 
diisopropylethylamine (Hünig‘s base) TCI 73 
N,N-dimethylformamide dimethyl acetale Alfa Aesar 31-44 
dimethyl sulfate Sigma-Aldrich 1-2 
(ethoxymethylene)malononitrile Sigma-Aldrich 6-16 
4-ethoxyaniline (syn. p-phenethidine) Merck Millipore 13 
ethylamine hydrochloride Alfa Aesar 7 
ethyl bromoacetate Acros Organics 17-30 
1-furanoylpiperazine 
(syn. 1-(2-furoyl)piperazine) 
Alfa Aesar 130-131,144 
isopropylamine Alfa aesar 9 
magnesium sulfate VWR Chemicals 1-2 
malononitrile Sigma-Aldrich 3-4 
2-methoxyaniline (syn. o-anisidine) Merck Millipore 12 
methylamine hydrochloride Alfa Aesar 6 
1-methylpiperazine Fluka 78 
parrafin oil Wacker Chemie 1-2, 17-72 
phenethylamine Alfa Aesar 15,81,105 
1-phenethylpiperazine  
(syn. 1-(2-phenethyl)piperazine) 
Alfa Aesar 74,84,88-93,95,97,99,107,132,134,136 
1-phenylpiperazine Acros Organics 77,87,110,139 
phenylpropylamine Alfa Aesar 16,80,104,106 
phosphoryl chloride Acros Organics 59-72 
piperazine (anhydrous) Merck Millipore 73 
piperidin-2-one (syn. δ-valerolactam) Alfa Aesar 1 
1-piperonylpiperazine Acros Organics 126-129,143 
propylamine Alfa Aesar 8 
potassium carbonate Alfa Aesar 17-30 
1-(pyridin-2-yl)piperazine Acros Organics 116-117,142 
4-(2-(pyridin-2-yl)ethyl)piperazine Sigma-Aldrich 141 
1-(2-(pyridin-4-yl)ethyl)piperazine Sigma Aldrich 114-115 
sodium hydroxide VWR Chemicals 1-2, 45-58 
triethylamine (TEA) Acros Organics 6-7, 74-144 
tryptamine  
(syn. 2-(1H-indole-3-yl)ethan-1-amine) 
Sigma Aldrich 113 
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Table 6.2. List of used solvents for chemical synthesis, thin layer chromatography (TLC), column chromatography 
(CC), crystallization (cry.) of compounds 1-73 or NMR- or LC-MS analysis. 
 
name provider used for  
acetic acid Fisher Chemical synthesis (no. 45-58) 
acetic anhydride Grüssing synthesis (no. 5) 
acetone Julius Hösch TLC, CC 
acetonitrile Fisher Chemical synthesis (no. 73) 
ammonia solution (25%) ChemSolute synthesis (no. 45-58), TLC, CC 
benzene Applichem synthesis (no. 1-29 
CDCl3 Deutero NMR 
DMSO-d6  Deutero NMR 
ethanol Julius Hösch synthesis (no. 3-16, 45-58), TLC, CC, cry. 
methanol Sigma-Aldrich TLC, CC 
methanol, LC-MS grade VWR Chemicals LC-MS 
methylene chloride Julius Hösch TLC, CC 
N,N-dimethylformamide Fisher Chemical synthesis (no. 17-44) 
petroleum ether Julius Hösch synthesis (no. 31-44) TLC, CC, cry. 
phosphoryl chloride Acros Organics synthesis (no. 59-72) 
water, demineralized wat membrantec synthesis (no. 5, 17-30, 45-72) 
water, ultrapure Elga PureLab flex LC-MS 
 
 
 
6.1.2. Standard Operation Procedures for Chemical Synthesis 
 
6.1.2.1. Appliances Used for Chemical Synthesis 
 
The standard operation procedures for analogous synthesis were performed using the in 
Table 6.3 listed appliances. 
 
Table 6.3. List of appliances used for chemical synthesis. 
 
equipment provider 
Braun Injekt 10 mL syringe B. Braun Melsungen AG (Melsungen, Germany) 
diaphragm vacuum pump Vacuubrand GmbH + Co. KG (Wertheim, Germany) 
drying cabinet T 420 S0 Hereus Holding GmbH (Hanau, Germany) 
evaporator R-3 HB Büchi Labortechnik AG (Flawil, Switzerland) 
glass Pasteur pipettes (150 mm) Brand GmbH + Co. KG (Wertheim, Germany) 
hot-plate magnetic-stirrer C. Gerhardt GmbH & Co. KG ( Königswinter, Germany) 
hot-plate magnetic-stirrer RCT standard OKA-Werke GmbH Co. KG (Staufen, Germany) 
Katrin system towel M 2 Metsä tissue GmbH (Kreuzau, Germany) 
magnetic-stirrer MAG C. Gerhardt GmbH & Co. KG ( Königswinter, Germany) 
micro scale MC1 Analytic AC 210 S Sartorius AG (Göttingen, Germany) 
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equipment provider 
Microflex xceed powder-free nitrile examination 
gloves (M) 
Microflex (Reno, Nevada, United States of America) 
NORM-JECT tuberculin 1 mL syringe Henke Sass Wolf (Tuttlingen, Germany) 
Sterican 0.80 x 120 mm cannula B. Braun Melsungen AG (Melsungen, Germany) 
ultrasonic cleaner VWR International GmbH (Darmstadt, Germany) 
UV cabinet II Camag (Muttent, Switzerland) 
UV lamp Camag (Muttent, Switzerland) 
 
 
 
6.1.2.2. Microwave-assisted Synthesis 
 
Microwave-assisted synthesis was performed using a CEM Discover Microwave (CEM 
GmbH, Kamp-Lintfort, Germany). The reaction mixture in acetic anhydride (5) or N,N-
dimethylformamide (74-144) was heated to 100 °C (5) or 110 °C (74-144) at 200 W for 20-60 
minutes. 
 
6.1.2.3. Thin Layer Chromatography (TLC) 
 
Reaction progress was monitored by thin layer chromatography (TLC) using silica gel F254 
coated aluminum plates. A solution of compounds in methanol or methylene chloride was 
applied using glass capillaries (approx. 10 µL) about 1 cm above the edge of the plate. After 
the spots had dried, the plate was put into a glass TLC developing chamber and rested for 
the time of eluation until the solvent front moved about 1 cm distance to the top edge of the 
plate. The eluent was allowed to dry followed by detection of the spots via fluorescence 
quenching using an UV cabinet equipped with an UV lamp at 254 nm. Table 6.4 shows all 
used materials for TLC and Table 6.5 gives an overview of the used eluents.  
 
 
Table 6.4. Summary of used materials for thin layer chromatography (TLC). 
 
equipment provider 
glass capillaries 
Hilgenberg GmbH (Malsfeld, Germany; distributed by 
OMNILAB GmbH & Co. KG, Bremen, Germany) 
silica gel F254 coated aluminum plate Merck Millipore, Billerica, MA, USA 
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Table 6.5. Summary of used eluents for thin layer chromatography (TLC). 
 
eluent solvent mixture 
methylene chloride / acetone 18:1 
methylene chloride / acetone 9:1 
methylene chloride / acetone / methanol 18:1:1 
methylene chloride / acetone / methanol 9:1:1 
methylene chloride / acetone / ethanol / ammonia (25%) solution 1:1:1:0.5 
 
 
 
6.1.2.4. Column Chromatography (CC) 
 
Individual intermediates and all compounds were purified by column chromatography (CC). 
The glass column was packed with a slurry of silica gel 60 (43-60 µm; stationary phase) and 
the first solvent mixture (mobile phase) of the gradient elution, mostly petroleum ether or 
petroleum ether / methylene chloride (1:1). The viscous suspension of silica gel was poured 
into the glass column after a wad of glass wool had been put in the base of the CC tube. An 
aquarium pump was used to compress the gel and increase the throughput of solvent 
generating a constant flowing stream. When the gel surface was reached, the solved or 
suspended compound (solute) in methylene chloride was put on the silica gel using a glass 
Pasteur pipette. The elevated solvent level was reduced using the pump until the compound 
was fully transferred into the adsorbent resulting in a narrow transverse band. Finally, 
employing gradient elution (200 mL each step), the compounds were purified and the eluent 
solution was collected in small glass fraction tubes (10 mL). The collected fractions were 
spotted on a TLC plate and the relevant fractions combined, evaporated and the resulting 
compound crystallized from methanol / petroleum ether 1:10. Table 6.6 shows all used 
materials for column chromatography, while Table 6.7 gives an overview of the used eluents 
for CC. 
 
 
Table 6.6. Summary of used materials for column chromatography. 
 
equipment provider 
aquarium pump Optima (Hagen, Germany) 
glass fraction tubes (10 mL) Brand GmbH + Co. KG (Wertheim, Germany) 
glass Pasteur pipettes (230 mm) Brand GmbH + Co. KG (Wertheim, Germany) 
silica gel 60 (43-60 µm) Merck Millipore, Billerica, MA, USA 
 
 
 
 
 
 
 
 106 Experimental Section 
 
Table 6.7. Summary of used eluents for column chromatography. 
 
eluent solvent mixture 
pretroleum ether 1 
petroleum ether / methylene chloride 1:1 
methylene chloride 1 
methylene chloride / acetone 18:1 
methylene chloride / acetone 9:1 
methylene chloride / acetone / methanol 18:1:1 
methylene chloride / acetone / methanol 9:1:1 
methylene chloride / acetone / ethanol / ammonia (25%) solution 1:1:1:0.5 
methylene chloride / acetone / ethanol / ammonia (25%) solution 1:1:1:1 
 
 
 
6.1.2.5. Nuclear Magnetic Resonance (NMR) 
 
1H NMR spectroscopy was generally used to identify the intermediates 1-73 in case 
crystallization or solidification was possible. Additionally, the purified compounds 74-144 
were characterized with respect to identity and purity by 1H as well as 13C NMR 
spectroscopy. The NMR spectra were recorded in DMSO-d6 or CDCl3 employing a Bruker 
Avance 500 MHz (500/126 MHz). The chemical shifts (δ) are expressed as ppm calibrated to 
the solvent signal of DMSO (1H NMR δ 2.50; 13C NMR δ 39.5) or CDCl3 (1H NMR δ 7.26; 13C 
NMR δ 77.1). Distortionless enhancement by polarization transfer (DEPT) and attached 
proton test (APT) techniques were used to assign 13C signals. Spin multiplicities of the 
compounds 1-144 are depicted as singulet (s), doublet (d), doublet of doublets (dd), doublet 
of doublet of doublets (ddd), triplet of doublets (td), triplet (t), doublet of triplets (dt), quartet 
(q), quintet (quint), heptet (hept) and multiplet (m). The resulting raw data was analyzed 
using MestReNova. Table 6.8 gives a summary of the used materials and software with 
respect to NMR spectroscopy. This work was kindly performed by the technical assistants 
Sabine Terhart-Krabbe, Annette Reiner and Marion Schneider. 
 
 
Table 6.8. Summary of used materials and software for nuclear magnetic resonance. 
 
equipment provider 
Bruker Avance 500 MHz NMR spectrometer Bruker (Billerica, Massachusetts, United States of America) 
CDCl3 Deutero GmbH (Kastellaun, Germany) 
DMSO-d6  Deutero GmbH (Kastellaun, Germany) 
MestReNova (Version 6.0.2-5475) Mestrelab Research (Santiago de Compostella, Spain) 
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6.1.2.6. Liquid Chromatography-Mass Spectrometry (LC-MS) 
 
All target compounds were analyzed with regard to their molecular weight to determine their 
identity and purity. An Agilent 1100 series with photo diode array (DAD) detector with a 
Nucleodur column C18 was used to analyze the target compounds, followed by ESI mass 
spectrometry with an API 200 Triple Quadrupole mass spectrometer. 0.1-0.3 mg of the 
compound was solved in 8 µL of LC-MS grade methanol. Starting with 90% water and 10% 
methanol, gradient elution was performed with a constant flow of 300 µL · min-1. Compound 
detection was performed via photo diode array (DAD). Analysis was conducted using the 
Sciex Analyst Software. The purity of all investigated compounds in biological testing in this 
work was determined as ≥ 90%. Table 6.9 gives a summary of the used equipment and 
software in LC-MS analysis. This work was kindly performed by Marion Schneider. 
 
 
Table 6.9. Summary of used materials and softwares used for LC-MS. 
 
equipment provider 
Agilent 1100 HPLC system Agilent (Böblingen, Germany) 
API 2000 Triple Quadrupole mass spectrometer Applied Biosystems (Darmstadt, Germany) 
methanol, LC-MS grade VWR International GmbH (Darmstadt, Germany) 
Nucleodur column EC50 C18 Gravity 3 µm Macherey-Nagel (Düren, Germany) 
Sciex Analyst Software version 1.5.1 AB Sciex Germany GmbH 
 
 
 
6.1.3. Synthesis and Characterization of Intermediates 
 
6.1.3.1. O-methylation of Starting Compounds 
 
The corresponding lactam solved in an adequate volume of benzene was heated to reflux 
before dropwise addition of an equimolar amount of dimethyl sulfate. After 3-6 hours a          
4 mol · L-1 solution of sodium hydroxide was added to eliminate excess dimethyl sulfate, 
stirring for further 30 minutes. The benzene phase reaction was separated and the water 
phase was extracted three times with 50 mL benzene. The organic phases were combined 
and dried over magnesium sulfate. Filtration and evaporation resulted in an oil containing the 
methylated product that was used without further characterization and purification. 
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6.1.3.1.1. Synthesis of 6-methoxy-2,3,4,5-tetrahydropyridine (1)  
 
   
synonyms: SMS-A-1 
compound 1a (J. Med. Chem. 2016, 59, 3018−3033) 
educts: piperidin-2-one (syn. δ-valerolactam) and dimethyl sulfate (1 eq.) 
yield: not determined 
visual appearance: yellowish oil 
chemical formula: C6H11NO 
molecular weight: 113.16 Da 
LC-MS analysis: calculated: 113.08 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.1.2. Synthesis of 7-methoxy-3,4,5,6-tetrahydro-2H-azepine (2)  
 
N
O
   
synonyms: SMS-A-28 
compound 1b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: azepan-2-one (syn. ε-caprolactam) and dimethyl sulfate (1 eq.) 
yield: not determined 
visual appearance: yellowish oil 
chemical formula: C7H13NO 
molecular weight: 127.19 Da 
LC-MS analysis: calculated: 127.10 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.2. Synthesis of Malononitrile Derivatives 
 
To compounds 1 or 2 a saturated, equimolar solution of malononitrile in ethanol was added 
under stirring. The reaction progress was followed visibly as the resultant malononitrile 
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derivative precipitated after a reaction time of 5 to 30 minutes. The precipitate was rinsed 
with ethanol and diethyl ether and dried in a hot-air cabinet. 
 
6.1.3.2.1. Synthesis of 2-(piperidin-2-ylidene)malononitrile (3) 
 
   
synonyms: SMS-A-2 
compound 2a (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 6-methoxy-2,3,4,5-tetrahydropyridine (1) and malononitrile (1 eq.) 
yield: 77% 
visual appearance: white needles 
chemical formula: C8H9N3 
molecular weight: 147.18 Da 
LC-MS analysis: calculated: 147.08 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 9.01 (s, 1H), 3.23 (t, J = 6.0 Hz, 2H), 2.55 (t, J = 6.0 Hz, 2H), 
1.74-159 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 171.5, 117.2, 116.0, 45.3, 42.3, 26.8, 20.7, 18.0 
 
6.1.3.2.2. Synthesis of 2-(azepan-2-ylidene)malononitrile (4)  
 
    
synonyms: SMS-A-29 
compound 2b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 7-methoxy-3,4,5,6-tetrahydro-2H-azepine (2) and malononitrile (1 eq.) 
yield: 55% 
visual appearance: white needles 
chemical formula: C9H11N3 
molecular weight: 161.21 Da 
LC-MS analysis: calculated: 161.10 Da; found: not determined 
purity: not determined 
 
1H NMR: 500 MHz, DMSO-d6, δ 8.93 (s, 1H), 3.41-3.38 (m, 2H), 2.67-2.64 (m, 2H), 1.70-1.64 (m, 
2H), 1.58-1.55 (m, 2H), 1.52-1.46 (m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 177.1, 117.4, 115.9, 46.9, 44.8, 30.9, 29.2, 27.8, 24.2 
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6.1.3.3. N-acylation of 2-aminobenzonitrile 
 
2-aminobenzonitrile was dissolved in excess acetic anhydride and heated at 100 °C using 
microwave-assisted synthesis at 200 W and 2 hours. The reaction mixture was poured into 
water and the precipitate was rinsed with fresh water and filtered, giving the acylated 
intermediate. 
 
6.1.3.3.1. Synthesis of N-(2-cyanophenyl)acetamide (5)  
 
   
synonyms: SMS-A-163 
compound 36 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 2-aminobenzonitrile and acetic anhydride (excess) 
yield: 70% 
visual appearance: white needles 
chemical formula: C9H8N2O 
molecular weight: 160.18 Da 
LC-MS analysis: calculated: 160.06 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 10.11 (s, 1H), 7.78 (dd, J = 7.6, 1.4 Hz, 1H), (ddd, J = 8.3, 7.5, 
1.6 Hz, 1H), 7.57 (dd, J = 8.4, 0.9 Hz, 1H), 7.32 (td, J = 7.6, 1.2 Hz, 1H), 2.09 (s, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 168.8, 140.5, 133.9, 133.3, 125.7, 125.6, 117.0, 107.4, 23.3 
 
6.1.3.4. Nucleophilic Substitution of Primary Amines to Form Malononitrile Derivatives 
 
To the corresponding amine a saturated solution of (ethoxymethylene)malononitrile (1.2 eq.) 
in ethanol was added under stirring. In case of amine hydrochlorides 1.5 eq. of triethylamine 
(TEA) were additionally added. The reaction progress was followed visibly as the product 
precipitated after a reaction time of 5-60 minutes of stirring. The precipitate was rinsed with 
ethanol and diethyl ether and dried. 
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6.1.3.4.1. Synthesis of 2-((methylamino)methylene)malononitrile (6) 
 
   
synonyms: SMS-A-227 
compound 7a (J. Med. Chem. 2016, 59, 3018−3033) 
compound 1a (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: (ethoxymethylene)malononitrile, methylamine hydrochloride (1.2 eq.) and TEA (2 eq.) 
yield: 63% 
visual appearance: yellow needles 
chemical formula: C5H5N3 
molecular weight: 107.12 Da 
LC-MS analysis: calculated: 107.05 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.91 (s, 1H), 7.86 (s, 1H), 2.96 (s, 3H) 
13C NMR: not determined 
 
6.1.3.4.2. Synthesis of 2-((ethylamino)methylene)malononitrile (7) 
 
   
synonyms: SMS-A-472 
compound 7b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: (ethoxymethylene)malononitrile, ethylamine hydrochloride (1.2 eq.) and TEA (2 eq.) 
yield: 63% 
visual appearance: yellow needles 
chemical formula: C6H7N3 
molecular weight: 121.14 Da 
LC-MS analysis: calculated: 121.06 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.91 (s, 1H), 7.86 (s, 1H), 2.96 (s, 3H) 
13C NMR: not determined 
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6.1.3.4.3. Synthesis of 2-((propylamino)methylene)malononitrile (8) 
 
   
synonyms: SMS-A-479 
compound 7c (J. Med. Chem. 2016, 59, 3018−3033) 
educts: (ethoxymethylene)malononitrile and propylamine (1.2 eq.) 
yield: quantitative 
visual appearance: yellow needles 
chemical formula: C7H9N3 
molecular weight: 135.17 Da 
LC-MS analysis: calculated: 135.08 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 9.12 (s, 1H), 7.89 (d, J = 14.8 Hz, 1H), 3.28-3.24 (m, 2H), 1.11 
(t, J = 7.2 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.4.4. Synthesis of 2-((isopropylamino)methylene)malononitrile (9) 
 
   
synonyms: SMS-A-486 
compound 7d (J. Med. Chem. 2016, 59, 3018−3033) 
educts: (ethoxymethylene)malononitrile and isopropylamine (1.2 eq.) 
yield: quantitative 
visual appearance: orange needles 
chemical formula: C7H9N3 
molecular weight: 135.17 Da 
LC-MS analysis: calculated: 135.08 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 9.12 (s, 1H), 7.89 (d, J = 14.8 Hz, 1H), 3.28-3.24 (m, 2H), 1.11 
(t, J = 7.2 Hz, 3H) 
13C NMR: not determined 
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6.1.3.4.5. Synthesis of 2-((cyclopropylamino)methylene)malononitrile (10) 
 
   
synonyms: SMS-A-493 
compound 7e (J. Med. Chem. 2016, 59, 3018−3033) 
educts: (ethoxymethylene)malononitrile and cyclopropylamine (1.2 eq.) 
yield: quantitative 
visual appearance: yellow needles 
chemical formula: C7H7N3 
molecular weight: 133.15 Da 
LC-MS analysis: calculated: 133.06 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.4.6. Synthesis of 2-((phenylamino)methylene)malononitrile (11) 
 
   
synonyms: SMS-A-184 
compound 7f (J. Med. Chem. 2016, 59, 3018−3033) 
compound 1b (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: (ethoxymethylene)malononitrile and aniline (1.2 eq.) 
yield: 78% 
visual appearance: yellow needles 
chemical formula: C10H7N3 
molecular weight: 169.19 Da 
LC-MS analysis: calculated: 169.06 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 11.09 (s, 1H), 8.49 (s, 1H), 7.42 (d, J = 7.7 Hz, 2H), 7.37 (t, J = 
7.4 Hz, 2H), 7.17 (t, J = 7.3 Hz, 1H) 
13C NMR: not determined 
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6.1.3.4.7. Synthesis of 2-(((2-methoxyphenyl)amino)methylene)malononitrile (12) 
 
   
synonyms: SMS-A-292 
compound 31a (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: (ethoxymethylene)malononitrile and 2-methoxyaniline (1.2 eq.) 
yield: 46% 
visual appearance: yellow needles 
chemical formula: C11H9N3O 
molecular weight: 199.21 Da 
LC-MS analysis: calculated: 199.07 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.4.8. Synthesis of 2-(((4-ethoxyphenyl)amino)methylene)malononitrile (13) 
 
   
synonyms: SMS-A-277 
compound 31b (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: (ethoxymethylene)malononitrile and 4-ethoxyaniline (1.2 eq.) 
yield: 73% 
visual appearance: yellowish powder 
chemical formula: C12H11N3O 
molecular weight: 213.24 Da 
LC-MS analysis: calculated: 213.09 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 10.98 (s, 1H), 8.34 (s, 1H), 7.33 (d, J = 9.1 Hz, 2H), 6.91 (d, J = 
9.1 Hz, 2H), 4.00 (q, J = 7.0 Hz, 1H), 1.30 (t, J = 7.0 Hz, 3H) 
13C NMR: not determined 
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6.1.3.4.9. Synthesis of 2-((benzylamino)methylene)malononitrile (14) 
 
   
synonyms: SMS-A-197 
compound 7g (J. Med. Chem. 2016, 59, 3018−3033) 
compound 1c (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: (ethoxymethylene)malononitrile and benzylamine (1.2 eq.) 
yield: 61% 
visual appearance: yellow needles 
chemical formula: C11H9N3 
molecular weight: 183.21 Da 
LC-MS analysis: calculated: 183.08 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 9.58 (s, 1H), 8.08 (s, 1H), 7.40-7.35 (m, 2H), 7.34-7.28 (m, 3H), 
4.44 (s, 2H) 
13C NMR: not determined 
 
6.1.3.4.10. Synthesis of 2-((phenethylamino)methylene)malononitrile (15) 
 
   
synonyms: SMS-A-202 
compound 7h (J. Med. Chem. 2016, 59, 3018−3033) 
compound 1d (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: (ethoxymethylene)malononitrile and phenethylamine (1.2 eq.) 
yield: 61% 
visual appearance: white needles 
chemical formula: C12H11N3 
molecular weight: 197.24 Da 
LC-MS analysis: calculated: 197.10 Da; found: not determined 
purity: not determined 
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1H NMR: 500 MHz, DMSO-d6, δ 9.16 (s, 1H), 7.76 (s, 1H), 7.33-7.29 (m, 2H), 7.24-7.21 (m, 1H), 
7.21-7.18 (m, 2H), 3.49 (t, J = 7.1 Hz, 2H), 2.82 (t, J = 7.3 Hz, 2H) 
13C NMR: not determined 
 
6.1.3.4.11. Synthesis of 2-(((3-phenylpropyl)amino)methylene)malononitrile (16) 
 
   
synonyms: SMS-A-207 
compound 7i (J. Med. Chem. 2016, 59, 3018−3033) 
educts: (ethoxymethylene)malononitrile and phenylpropylamine (1.2 eq.) 
yield: 70% 
visual appearance: white needles 
chemical formula: C13H13N3 
molecular weight: 211.27 Da 
LC-MS analysis: calculated: 211.11 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 9.10 (s, 1H), 7.88 (s, 1H), 7.30-7.25 (m, 2H), 7.21-7.16 (m, 3H), 
3.26 (t, J = 7.1 Hz, 2H), 2.56 (t, J = 7.5 Hz, 2H), 1.86-1.79 (m, 2H) 
13C NMR: not determined 
 
6.1.3.5. Nucleophilic Substitution of Secondary Amines to Form Pyrrole Derivatives 
 
A solution of the corresponding malononitrile derivative in 20 mL N,N-dimethylformamide 
was heated to 100 °C in the presence of excess potassium carbonate followed by dropwise 
addition of an equimolar amount of ethyl bromoacetate. After a reaction duration 3 to 6 
hours, the reaction mixture was poured into ice-cold water and stirred for 1 hour. The 
resultant precipitate was filtered, rinsed with fresh water and dried, yielding the pyrrole 
derivative. 
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6.1.3.5.1. Synthesis of ethyl 2-amino-1-cyano-5,6,7,8-tetrahydroindolizine-3-carboxylate 
(17) 
 
  
synonyms: SMS-A-3 
compound 3a (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 2-(piperidin-2-ylidene)malononitrile (3) and ethyl bromoacetate (1 eq.) 
yield: quantitative 
visual appearance: white powder 
chemical formula: C12H15N3O2 
molecular weight: 233.27 Da 
LC-MS analysis: calculated: 233.12 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 5.75 (s, 2H), 4.19 (q, J = 7.1 Hz, 2H), 4.05 (t, J = 6.1 Hz, 2H), 
2.70 (t, J = 6.4 Hz, 2H), 1.88-1.83 (m, 2H), 1.74-1.69 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 160.7, 146.0, 142.5, 115.2, 104.0, 79.3, 59.0, 45.7, 22.4, 22.3, 
18.3, 14.6 
 
6.1.3.5.2. Synthesis of ethyl 2-amino-1-cyano-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-
a]azepine-3-carboxylate (18) 
 
  
synonyms: SMS-A-30 
compound 3b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 2-(azepan-2-ylidene)malononitrile (4) and ethyl bromoacetate (1 eq.) 
yield: 55% 
visual appearance: pale yellow powder 
chemical formula: C13H17N3O2 
molecular weight: 247.30 Da 
LC-MS analysis: calculated: 247.13 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 5.67 (s, 2H), 4.49-4.40 (m, 2H), 4.21 (q, J = 7.1 Hz, 2H), 2.77-
2.73 (m, 2H), 1.76-1.70 (m, 2H), 1.60-1.54 (m, 4H), 1.25 (t, J = 7.1 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 160.7, 148.6, 145.3, 115.3, 104.1, 80.7, 59.2, 46.1, 29.8, 27.5, 
26.1, 25.6, 14.6 
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6.1.3.5.3. Synthesis of ethyl 3-amino-4-cyano-1-methyl-1H-pyrrole-2-carboxylate (19) 
 
  
synonyms: SMS-A-228 
compound 8a (J. Med. Chem. 2016, 59, 3018−3033) 
compound 2a (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 2-((methylamino)methylene)malononitrile (6) and ethyl bromoacetate (1 eq.) 
yield: 53% 
visual appearance: brown powder 
chemical formula: C9H11N3O2 
molecular weight: 193.21 Da 
LC-MS analysis: calculated: 193.09 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.50 (s, 1H), 5.71 (s, 2H), 4.21 (q, J = 7.1 Hz, 2H), 3.69 (s, 3H), 
1.26 (t, J = 7.1 Hz, 3H)  
13C NMR: not determined 
 
6.1.3.5.4. Synthesis of ethyl 3-amino-4-cyano-1-ethyl-1H-pyrrole-2-carboxylate (20) 
 
  
synonyms: SMS-A-473 
compound 8b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 2-((ethylamino)methylene)malononitrile (7) and ethyl bromoacetate (1 eq.) 
yield: 23% 
visual appearance: brown powder 
chemical formula: C10H13N3O2 
molecular weight: 207.23 Da 
LC-MS analysis: calculated: 207.10 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.59 (s, 1H), 5.74 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 4.13 (q, J = 
7.1 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H)  
13C NMR: not determined 
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6.1.3.5.5. Synthesis of ethyl 3-amino-4-cyano-1-propyl-1H-pyrrole-2-carboxylate (21) 
 
  
synonyms: SMS-A-480 
compound 8c (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 2-((propylamino)methylene)malononitrile (8) and ethyl bromoacetate (1 eq.) 
yield: 66% 
visual appearance: orange powder 
chemical formula: C11H15N3O2 
molecular weight: 221.26 Da 
LC-MS analysis: calculated: 221.12 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.58 (s, 1H), 5.76 (s, 2H), 4.22 (q, J = 7.1 Hz, 2H), 4.06 (t, J = 
7.1 Hz, 2H), 1.66-1.58 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H), 0.77 (t, J = 7.4 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.5.6. Synthesis of ethyl 3-amino-4-cyano-1-isopropyl-1H-pyrrole-2-carboxylate (22) 
 
  
synonyms: SMS-A-487 
compound 8d (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 2-((isopropylamino)methylene)malononitrile (9) and ethyl bromoacetate (1 eq.) 
yield: quantitative 
visual appearance: white powder 
chemical formula: C11H15N3O2 
molecular weight: 221.26 Da 
LC-MS analysis: calculated: 221.12 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.73 (s, 1H), 5.73 (s, 2H), 5.09 (m, 1H), 4.23 (q, J = 7.1 Hz, 2H), 
1.31 (d, J = 6.7 Hz, 6H), 1.27 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
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6.1.3.5.7. Synthesis of ethyl 3-amino-4-cyano-1-cyclopropyl-1H-pyrrole-2-carboxylate 
(23) 
 
  
synonyms: SMS-A-494 
compound 8e (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 2-((cyclopropylamino)methylene)malononitrile (10) and ethyl bromoacetate (1 eq.) 
yield: 85% 
visual appearance: white powder 
chemical formula: C11H13N3O2 
molecular weight: 219.24 Da 
LC-MS analysis: calculated: 219.10 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.55 (s, 1H), 5.77 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.62-3.56 (m, 
1H), 1.27 (t, J = 7.1 Hz, 3H), 0.91-0.87 (m, 4H) 
13C NMR: not determined 
 
6.1.3.5.8. Synthesis of ethyl 3-amino-4-cyano-1-phenyl-1H-pyrrole-2-carboxylate (24) 
 
  
synonyms: SMS-A-185 
compound 8f (J. Med. Chem. 2016, 59, 3018−3033) 
compound 2b (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 2-((phenylamino)methylene)malononitrile (11) and ethyl bromoacetate (1 eq.) 
yield: 77% 
visual appearance: brown powder 
chemical formula: C14H13N3O2 
molecular weight: 255.28 Da 
LC-MS analysis: calculated: 255.10 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.72 (s, 1H), 7.45-7.38 (m, 3H), 7.33-7.30 (m, 2H), 5.96 (s, 2H), 
3.99 (q, J = 7.1 Hz, 2H), 0.95 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
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6.1.3.5.9. Synthesis of ethyl 3-amino-4-cyano-1-(2-methoxyphenyl)-1H-pyrrole-2-
carboxylate (25) 
 
  
synonyms: SMS-A-293 
compound 32a (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 2-(((2-methoxyphenyl)amino)methylene)malononitrile (12) and 
(ethoxymethylene)malononitrile (1 eq.) 
yield: quantitative 
visual appearance: brown powder 
chemical formula: C15H15N3O3 
molecular weight: 285.30 Da 
LC-MS analysis: calculated: 285.11 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.63 (s, 1H), 7.21 (d, J = 8.9 Hz, 2H), 6.93 (d, J = 9.0, 2H), 5.90 
(s, 2H), 4.05 (q, J = 7.0), 3.99 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.0 Hz, 3H), 0.97 (t, J = 
7.1 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.5.10. Synthesis of ethyl 3-amino-4-cyano-1-(4-ethoxyphenyl)-1H-pyrrole-2-
carboxylate (26) 
 
  
synonyms: SMS-A-278 
compound 32b (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 2-(((4-ethoxyphenyl)amino)methylene)malononitrile (13) and 
(ethoxymethylene)malononitrile (1 eq.) 
yield: 92% 
visual appearance: brown powder 
chemical formula: C16H17N3O3 
molecular weight: 299.33 Da 
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LC-MS analysis: calculated: 299.13 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.5.11. Synthesis of ethyl 3-amino-1-benzyl-4-cyano-1H-pyrrole-2-carboxylate (27) 
 
  
synonyms: SMS-A-198 
compound 8g (J. Med. Chem. 2016, 59, 3018−3033) 
compound 2c (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 2-((benzylamino)methylene)malononitrile (14) and ethyl bromoacetate (1 eq.) 
yield: 71% 
visual appearance: brown powder 
chemical formula: C15H15N3O2 
molecular weight: 269.30 Da 
LC-MS analysis: calculated: 269.12 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.78 (s, 1H), 7.33-7.29 (m, 2H), 7.26-7.22 (m, 1H), 7.09-7.05 (m, 
2H), 5.82 (s, 2H), 5.36 (s, 2H), 4.12 (q, J = 7.1 Hz, 2H), 1.13 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.5.12. Synthesis of ethyl 3-amino-4-cyano-1-phenethyl-1H-pyrrole-2-carboxylate 
(28) 
 
  
synonyms: SMS-A-203 
compound 8h (J. Med. Chem. 2016, 59, 3018−3033) 
compound 2d (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 2-((phenethylamino)methylene)malononitrile (15) and ethyl bromoacetate (1 eq.) 
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yield: 90% 
visual appearance: brown powder 
chemical formula: C16H17N3O2 
molecular weight: 283.33 Da 
LC-MS analysis: calculated: 283.13 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.39 (s, 1H), 7.30-7.26 (m, 2H), 7.23-7.18 (m, 1H), 7.15-7.12 (m, 
2H), 5.78 (s, 2H), 4.33 (t, J = 7.4 Hz, 2H), 4.26 (q, J = 7.1 Hz, 2H), 2.91 (t, J = 7.2 Hz, 
2H), 1.29 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.5.13. Synthesis of ethyl 3-amino-4-cyano-1-(3-phenylpropyl)-1H-pyrrole-2-
carboxylate (29) 
 
  
synonyms: SMS-A-208 
compound 8i (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 2-(((3-phenylpropyl)amino)methylene)malononitrile (16) and ethyl bromoacetate (1 eq.) 
yield: 92% 
visual appearance: brown powder 
chemical formula: C17H19N3O2 
molecular weight: 297.36 Da 
LC-MS analysis: calculated: 297.15 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.59 (s, 1H), 7.28-7.24 (m, 2H), 7.19-7.15 (m, 3H), 5.78 (s, 2H), 
4.19 (q, J = 7.1, 2H), 4.13 (t, J = 7.2 Hz, 2H), 2.52 (t, J = 7.6 Hz, 2H), 1.97-1.89 (m, 2H), 
1.17 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
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6.1.3.5.14. Synthesis of ethyl 3-amino-1H-indole-2-carboxylate (30) 
 
  
synonyms: SMS-A-166 
compound 37 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: N-(2-cyanophenyl)acetamide (5) and (ethoxymethylene)malononitrile (1 eq.) 
yield: 62% 
visual appearance: brown powder 
chemical formula: C13H14N2O3 
molecular weight: 246.27 Da 
LC-MS analysis: calculated: 246.10 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.05 (dt, J = 8.4, 0.8 Hz, 1H), 7.96 (ddd, J 7.9, 1.2, 0.7 Hz, 1H), 
7.48 (ddd, J = 8.5, 7.2, 1.3, 1H), 7.27 (ddd, J =8.0, 7.2, 1.0, 1H), 6.70 (s, 2H), 4.29 (q, J 
= 7.0 Hz, 2H), 2.37 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 171.3, 162.1, 144.5, 138.5, 130.0, 122.0, 121.8, 121.2, 115.2, 
104.3, 59.9, 26.5, 14.6 
 
6.1.3.6. Chain Elongation to Form the Formimidamid Derivatives. 
 
To a solution of the corresponding pyrrole derivative in N,N-dimethylformamide 3.5 to 5 
equivalents of N,N-dimethylformamide dimethyl acetale were added and the mixture was 
heated to 100 °C. After 2 to 5 hours the solvent was evaporated and petroleum ether was 
added to the viscous liquid. Full crystallization was achieved after stirring for 5 to 60 minutes, 
yielding the title compound, which was rinsed with petroleum ether and dried. Compounds 
that did not crystalize were used without further purification or characterization. 
 
6.1.3.6.1. Synthesis of ethyl 1-cyano-2-(((dimethylamino)methylene)amino)-5,6,7,8-
tetrahydroindolizine-3-carboxylate (31) 
 
  
synonyms: SMS-A-4 
compound 4a (J. Med. Chem. 2016, 59, 3018−3033) 
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educts: ethyl 2-amino-1-cyano-5,6,7,8-tetrahydroindolizine-3-carboxylate (17) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: 75% 
visual appearance: yellow needles 
chemical formula: C15H20N4O2 
molecular weight: 288.35 Da 
LC-MS analysis: calculated: 288.16 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.52 (s, 1H), 4.12 (t, J = 6.1 Hz, 2H), 4.07 (q, J = 7.1 Hz, 2H), 
2.97 (s, 3H), 2.91 (s, 3H), 2.75 (t, J = 6.4 Hz, 2H), 1.91-1.85 (m, 2H), 1.77-1.71 (m, 2H), 
1.17 (t, J = 7.1 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 160.5, 156.2 (2C), 148.7, 141.6, 115.7, 110.3, 86.5, 59.2, 46.0, 
33.8, 22.5, 22.5, 18.4, 14.0 
 
6.1.3.6.2. Synthesis of ethyl 1-cyano-2-(((dimethylamino)methylene)amino)-6,7,8,9-
tetrahydro-5H-pyrrolo[1,2-a]azepine-3-carboxylate (32) 
 
  
synonyms: SMS-A-31 
compound 4b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 2-amino-1-cyano-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepine-3-carboxylate (18) 
and N,N-dimethylformamide dimethyl acetale (3-5 eq.) 
yield: 40% 
visual appearance: yellow powder 
chemical formula: C16H22N4O2 
molecular weight: 302.38 Da 
LC-MS analysis: calculated: 302.17 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
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6.1.3.6.3. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-methyl-1H-
pyrrole-2-carboxylate (33) 
 
  
synonyms: SMS-A-229 
compound 9a (J. Med. Chem. 2016, 59, 3018−3033) 
compound 3a (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: ethyl 3-amino-4-cyano-1-methyl-1H-pyrrole-2-carboxylate (19) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: brown oil 
chemical formula: C12H16N4O2 
molecular weight: 248.29 Da 
LC-MS analysis: calculated: 248.13 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.6.4. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-ethyl-1H-
pyrrole-2-carboxylate (34) 
 
  
synonyms: SMS-A-474 
compound 9b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 3-amino-4-cyano-1-ethyl-1H-pyrrole-2-carboxylate (20) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: brown oil 
chemical formula: C13H18N4O2 
molecular weight: 262.31 Da 
LC-MS analysis: calculated: 262.14 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
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6.1.3.6.5. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-propyl-1H-
pyrrole-2-carboxylate (35) 
 
  
synonyms: SMS-A-481 
compound 9c (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 3-amino-4-cyano-1-propyl-1H-pyrrole-2-carboxylate (21) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: orange powder 
chemical formula: C14H20N4O2 
molecular weight: 276.34 Da 
LC-MS analysis: calculated: 276.16 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.68 (s, 1H), 7.55 (s, 1H), 4.14 (t, J = 7.2 Hz, 2H), 4.11 (q, J = 
7.1 Hz, 2H), 2.98 (s, 3H), 2.91 (s, 3H), 1.68-1.59 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H), 0.78 
(t, J = 7.4 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.6.6. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-isopropyl-
1H-pyrrole-2-carboxylate (36) 
 
  
synonyms: SMS-A-488 
compound 9d (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 3-amino-4-cyano-1-isopropyl-1H-pyrrole-2-carboxylate (22) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: brown oil 
chemical formula: C14H20N4O2 
molecular weight: 276.34 Da 
LC-MS analysis: calculated: 276.16 Da; found: not determined 
purity: not determined 
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1H NMR: 500 MHz, DMSO-d6, δ 7.68 (s, 1H), 7.55 (s, 1H), 4.14 (t, J = 7.2 Hz, 2H), 4.11 (q, J = 
7.1 Hz, 2H), 2.98 (s, 3H), 2.91 (s, 3H), 1.68-1.59 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H), 0.78 
(t, J = 7.4 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.6.7. Synthesis of ethyl 4-cyano-1-cyclopropyl-3-
(((dimethylamino)methylene)amino)-1H-pyrrole-2-carboxylate (37) 
 
  
synonyms: SMS-A-495 
compound 9e (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 3-amino-4-cyano-1-cyclopropyl-1H-pyrrole-2-carboxylate (23) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: brown oil 
chemical formula: C14H18N4O2 
molecular weight: 274.32 Da 
LC-MS analysis: calculated: 274.14 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.68 (s, 1H), 7.55 (s, 1H), 4.14 (t, J = 7.2 Hz, 2H), 4.11 (q, J = 
7.1 Hz, 2H), 2.98 (s, 3H), 2.91 (s, 3H), 1.68-1.59 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H), 0.78 
(t, J = 7.4 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.6.8. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-phenyl-1H-
pyrrole-2-carboxylate (38) 
 
  
synonyms: SMS-A-186 
compound 9f (J. Med. Chem. 2016, 59, 3018−3033) 
compound 3b (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: ethyl 3-amino-4-cyano-1-phenyl-1H-pyrrole-2-carboxylate (24) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
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yield: quantitative 
visual appearance: yellow needles 
chemical formula: C17H18N4O2 
molecular weight: 310.36 Da 
LC-MS analysis: calculated: 310.14 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.82 (s, 1H), 7.74 (s, 1H), 7.47-7.38 (m, 3H), 7.32-7.28 (m, 2H), 
3.92 (q, J = 7.1 Hz), 3.01 (s, 3H), 2.94 (s, 3H), 0.94 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.6.9. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-(2-
methoxyphenyl)-1H-pyrrole-2-carboxylate (39) 
 
  
synonyms: SMS-A-294 
compound 33a (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: ethyl 3-amino-4-cyano-1-(2-methoxyphenyl)-1H-pyrrole-2-carboxylate (25) and 
(ethoxymethylene)malononitrile (1 eq.) 
yield: 94% 
visual appearance: brown oil 
chemical formula: C18H20N4O3 
molecular weight: 340.38 Da 
LC-MS analysis: calculated: 340.15 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
 
 
 
 
 
 
 
 
 130 Experimental Section 
 
6.1.3.6.10. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-(4-
ethoxyphenyl)-1H-pyrrole-2-carboxylate (40) 
 
  
synonyms: SMS-A-279 
compound 33b (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: ethyl 3-amino-4-cyano-1-(4-ethoxyphenyl)-1H-pyrrole-2-carboxylate (26) and 
(ethoxymethylene)malononitrile (1 eq.) 
yield: 94% 
visual appearance: brown oil 
chemical formula: C19H22N4O3 
molecular weight: 354.41 Da 
LC-MS analysis: calculated: 354.17 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.6.11. Synthesis of ethyl 1-benzyl-4-cyano-3-(((dimethylamino)methylene)amino)-
1H-pyrrole-2-carboxylate (41) 
 
  
synonyms: SMS-A-199 
compound 9g (J. Med. Chem. 2016, 59, 3018−3033) 
compound 3c (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: ethyl 3-amino-1-benzyl-4-cyano-1H-pyrrole-2-carboxylate (27) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: brown powder 
chemical formula: C18H20N4O2 
molecular weight: 324.38 Da 
Experimental Section  131 
 
LC-MS analysis: calculated: 324.16 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.87 (s, 1H), 7.56 (s, 1H), 7.33-7.29 (m, 2H), 7.27-7.22 (m, 1H), 
7.10-7.06 (m, 2H), 5.46 (s, 2H), 4.03 (q, J = 7.1 Hz, 2H), 2.97 (s, 3H), 2.91 (s, 3H), 1.10 
(t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.6.12. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-
phenethyl-1H-pyrrole-2-carboxylate (42) 
 
  
synonyms: SMS-A-204 
compound 9h (J. Med. Chem. 2016, 59, 3018−3033) 
compound 3d (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: ethyl 3-amino-4-cyano-1-phenethyl-1H-pyrrole-2-carboxylate (28) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: orange powder 
chemical formula: C19H22N4O2 
molecular weight: 338.41 Da 
LC-MS analysis: calculated: 338.17 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.55 (s, 1H), 7.49 (s, 1H), 7.30-7.26 (m, 2H), 7.23-7.19 (m, 1H), 
7.16-7.13 (m, 2H), 4.40 (t, J = 7.5 Hz, 2H), 4.14 (q, J = 7.1 Hz), 2.99 (s, 3H), 2.94 (t, J = 
7.7 Hz, 2H), 2.92 (s, 3H), 1.19 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
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6.1.3.6.13. Synthesis of ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-(3-
phenylpropyl)-1H-pyrrole-2-carboxylate (43) 
 
  
synonyms: SMS-A-209 
compound 9i (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 3-amino-4-cyano-1-(3-phenylpropyl)-1H-pyrrole-2-carboxylate (29) and N,N-
dimethylformamide dimethyl acetale (3-5 eq.) 
yield: quantitative 
visual appearance: orange powder 
chemical formula: C20H24N4O2 
molecular weight: 352.44 Da 
LC-MS analysis: calculated: 352.19 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.69 (s, 1H), 7.54 (s, 1H), 7.29-7.24 (m, 2H), 7.19-7.15 (m, 3H), 
4.23 (t, J = 7.1 Hz, 2H), 4.10 (q, J = 7.1 Hz, 2H), 2.98 (s, 3H), 2.91 (s, 3H), 2.53 (t, J = 
7.6 Hz, 2H), 1.99-1.92 (m, 2H), 1.17 (t, J = 7.1 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.6.14. Synthesis of ethyl 1-acetyl-3-(((dimethylamino)methylene)amino)-1H-indole-
2-carboxylate (44) 
 
  
synonyms: SMS-A-167 
compound 38 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: ethyl 3-amino-1H-indole-2-carboxylate (30) and (ethoxymethylene)malononitrile (1 eq.) 
yield: 29% 
visual appearance: brown oil 
chemical formula: C16H19N3O3 
molecular weight: 301.35 Da 
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LC-MS analysis: calculated: 301.14 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.7. Cyclization to Pyrrimidinon Ring System 
 
A saturated solution of the corresponding pyrrole derivative in ethanol was piped with 
gaseous ammonia for 5 hours. After solvent evaporation, 10% (m/m) sodium hydroxide 
solution was added while stirring. After 30 minutes, the solution was neutralized using acetic 
acid, precipitating the title compound, which was rinsed with fresh water and dried. 
 
6.1.3.7.1. Synthesis of 4-oxo-3,4,6,7,8,9-hexahydropyrimido[4,5-b]indolizine-10-
carbonitrile (45) 
 
   
synonyms: SMS-A-5 
compound 5a (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 1-cyano-2-(((dimethylamino)methylene)amino)-5,6,7,8-tetrahydroindolizine-3-
carboxylate (31) and gaseous ammonia (excess) 
yield: 68% 
visual appearance: white powder 
chemical formula: C11H10N4O 
molecular weight: 214.23 Da 
LC-MS analysis: calculated: 214.09 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 12.21 (s, 1H), 7.90 (s, 1H), 4.35 (t, J = 6.4 Hz, 2H), 2.95 (t, J = 
6.4 Hz, 2H), 1.99-1.93 (m, 2H), 1.87-1.80 (m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.2, 146.3, 145.5, 144.8, 116.7, 114.3, 84.0, 45.6, 22.4, 21.8, 
18.3 
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6.1.3.7.2. Synthesis of 4-oxo-4,6,7,8,9,10-hexahydro-3H-pyrimido[4',5':4,5]pyrrolo[1,2-
a]azepine-11-carbonitrile (46) 
 
   
synonyms: SMS-A-32 
compound 5b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 1-cyano-2-(((dimethylamino)methylene)amino)-6,7,8,9-tetrahydro-5H-pyrrolo[1,2-
a]azepine-3-carboxylate (32) and gaseous ammonia (excess) 
yield: 12% 
visual appearance: white powder 
chemical formula: C12H12N4O 
molecular weight: 228.26 Da 
LC-MS analysis: calculated: 228.10 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 12.30 (s, 1H), 4.82-4.69 (m, 2H), 2.01-2.95 (m, 2H), 1.85-1.79 
(m, 2H), 1.72-1.63 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.5, 152.2, 144.8, 144.5, 117.0, 114.5, 85.5, 47.1, 30.0, 27.8, 
26.4, 25.7 
 
6.1.3.7.3. Synthesis of 5-methyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (47) 
 
   
synonyms: SMS-A-230 
compound 10a (J. Med. Chem. 2016, 59, 3018−3033) 
compound 4a (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-methyl-1H-pyrrole-2-carboxylate 
(33) and gaseous ammonia (excess) 
yield: 49% 
visual appearance: white powder 
chemical formula: C8H6N4O 
molecular weight: 174.16 Da 
LC-MS analysis: calculated: 174.05 Da; found: not determined 
purity: not determined 
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1H NMR: 500 MHz, DMSO-d6, δ 12.31 (s, 1H), 8.14 (s, 1H), 7.94 (s, 1H), 4.01 (s, 3H) 
13C NMR: not determined 
 
6.1.3.7.4. Synthesis of 5-ethyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (48) 
 
   
synonyms: SMS-A-475 
compound 10b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-ethyl-1H-pyrrole-2-carboxylate 
(34) and gaseous ammonia (excess) 
yield: 45% 
visual appearance: brown powder 
chemical formula: C9H8N4O 
molecular weight: 188.19 Da 
LC-MS analysis: calculated: 188.07 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 12.34 (s, 1H), 8.25 (s, 1H), 7.95 (s, 1H), 4.40 (q, J = 7.2 Hz, 2H), 
1.37 (t, J = 7.2 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.7.5. Synthesis of 4-oxo-5-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (49) 
 
   
synonyms: SMS-A-482 
compound 10c (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-propyl-1H-pyrrole-2-carboxylate 
(35) and gaseous ammonia (excess) 
yield: 24% 
visual appearance: brown powder 
chemical formula: C10H10N4O 
molecular weight: 202.22 Da 
LC-MS analysis: calculated: 202.08 Da; found: not determined 
purity: not determined 
 136 Experimental Section 
 
1H NMR: 500 MHz, DMSO-d6, δ 12.33 (s, 1H), 8.24 (s, 1H), 7.95 (s, 1H), 4.34 (t, J = 7.0 Hz, 2H), 
1.81-1.74 (m, 2H), 0.80 (t, J = 7.4 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.7.6. Synthesis of 5-isopropyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (50) 
 
   
synonyms: SMS-A-489 
compound 10d (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-isopropyl-1H-pyrrole-2-
carboxylate (36) and gaseous ammonia (excess) 
yield: 56% 
visual appearance: brown powder 
chemical formula: C10H10N4O 
molecular weight: 202.22 Da 
LC-MS analysis: calculated: 202.08 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 12.26 (s, 1H), 8.41 (s, 1H), 7.96 (s, 1H), 5.30 (m, 1H), 1.44 (d, J 
= 6.7 Hz, 6H) 
13C NMR: not determined 
 
6.1.3.7.7. Synthesis of 5-cyclopropyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (51) 
 
   
synonyms: SMS-A-496 
compound 10e (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 4-cyano-1-cyclopropyl-3-(((dimethylamino)methylene)amino)-1H-pyrrole-2-
carboxylate (37) and gaseous ammonia (excess) 
yield: 6% 
visual appearance: brown powder 
chemical formula: C10H8N4O 
molecular weight: 200.20 Da 
LC-MS analysis: calculated: 200.07 Da; found: not determined 
purity: not determined 
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1H NMR: 500 MHz, DMSO-d6, δ 8.13 (s, 1H), 7.94 (s, 1H), 4.10-4.04 (m, 1H), 1.09-0.98 (m, 4H) 
13C NMR: not determined 
 
6.1.3.7.8. Synthesis of 4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (52) 
 
   
synonyms: SMS-A-187 
compound 10f (J. Med. Chem. 2016, 59, 3018−3033) 
compound 4b (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-phenyl-1H-pyrrole-2-carboxylate 
(38) and gaseous ammonia (excess) 
yield: 21% 
visual appearance: white powder 
chemical formula: C13H8N4O 
molecular weight: 236.23 Da 
LC-MS analysis: calculated: 236.07 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 12.44 (s, 1H), 8.48 (s, 1H), 8.05 (s, 1H), 7.56-7.45 (m, 5H) 
13C NMR: not determined 
 
6.1.3.7.9. Synthesis of 5-(2-methoxyphenyl)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (53) 
 
  
synonyms: SMS-A-295 
compound 34a (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-(2-methoxyphenyl)-1H-pyrrole-2-
carboxylate (39) and gaseous ammonia (excess) 
yield: quantitative 
visual appearance: greywhite powder 
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chemical formula: C14H10N4O2 
molecular weight: 266.26 Da 
LC-MS analysis: calculated: 266.08 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.7.10. Synthesis of 5-(4-ethoxyphenyl)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (54) 
 
   
synonyms: SMS-A-280 
compound 34b (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-(4-ethoxyphenyl)-1H-pyrrole-2-
carboxylate (40) and gaseous ammonia (excess) 
yield: quantitative 
visual appearance: greywhite powder 
chemical formula: C15H12N4O2 
molecular weight: 280.10 Da 
LC-MS analysis: calculated: 280.29 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.7.11. Synthesis of 5-benzyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (55) 
 
  
synonyms: SMS-A-200 
compound 10g (J. Med. Chem. 2016, 59, 3018−3033) 
compound 4c (Biochim. Biophys. Acta 2017, 1859, 69–79) 
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educts: ethyl 1-benzyl-4-cyano-3-(((dimethylamino)methylene)amino)-1H-pyrrole-2-carboxylate 
(41) and gaseous ammonia (excess) 
yield: 47% 
visual appearance: yellow powder 
chemical formula: C14H10N4O 
molecular weight: 250.26 Da 
LC-MS analysis: calculated: 250.09 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.31 (s, 1H), 7.97 (s, 1H), 7.35-7.24 (m, 5H), 5.63 (s, 2H) 
13C NMR: not determined 
 
6.1.3.7.12. Synthesis of 4-oxo-5-phenethyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (56) 
 
   
synonyms: SMS-A-205 
compound 10h (J. Med. Chem. 2016, 59, 3018−3033) 
compound 4d (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-phenethyl-1H-pyrrole-2-
carboxylate (42) and gaseous ammonia (excess) 
yield: 43% 
visual appearance: yellow powder 
chemical formula: C15H12N4O 
molecular weight: 264.29 Da 
LC-MS analysis: calculated: 264.10 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 7.97 (s, 1H), 7.96 (s, 1H), 7.28-7.24 (m, 2H), 7.21-7.17 (m, 1H), 
7.15-7.12 (m, 2H), 4.61 (t, J = 7.2), 3.08 (t, J = 7.3, 2H) 
13C NMR: not determined 
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6.1.3.7.13. Synthesis of 4-oxo-5-(3-phenylpropyl)-4,5-dihydro-3H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (57) 
 
  
synonyms: SMS-A-210 
compound 10i (J. Med. Chem. 2016, 59, 3018−3033) 
educts: ethyl 4-cyano-3-(((dimethylamino)methylene)amino)-1-(3-phenylpropyl)-1H-pyrrole-2-
carboxylate (43) and gaseous ammonia (excess) 
yield: 21% 
visual appearance: white powder 
chemical formula: C16H14N4O 
molecular weight: 278.32 Da 
LC-MS analysis: calculated: 278.12 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.09 (s, 1H), 7.93 (s, 1H), 7.26-7.22 (m, 2H), 7.18-7.14 (m, 3H), 
4.43 (t, J = 7.0, 2H), 2.54 (t, J = 7.7, 2H), 2.13-2.05 (m, 2H) 
13C NMR: not determined 
 
6.1.3.7.14. Synthesis of 3,5-dihydro-4H-pyrimido[5,4-b]indole-4-one (58) 
 
  
synonyms: SMS-A-133 
compound 39 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: ethyl 1-acetyl-3-(((dimethylamino)methylene)amino)-1H-indole-2-carboxylate (44) and 
(ethoxymethylene)malononitrile (1 eq.) 
yield: 40% 
visual appearance: grey powder 
chemical formula: C10H7N3O 
molecular weight: 185.19 Da 
LC-MS analysis: calculated: 185.06 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 12.32 (s, 1H), 12.03 (s, 1H), 7.98 (s, 1H), 7.98 (dt, J 8.0, 0.9 Hz, 
1H), 7.52 (dt, J = 8.3, 0.8, 1H), 7.45 (ddd, J = 8.2, 6.9, 1.2, 2H), 7.22 (ddd, J = 7.9, 6.9, 
1.0, 1H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.7, 141.5, 138.7, 138.3, 127.1, 122.7, 121.3, 120.4, 120.3, 
112.9 
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6.1.3.8. Chlorination and Aromatization to Pyrimidine Ring System 
 
The corresponding pyrimidinon derivative was dissolved in phosphoryl chloride (10 mL) and 
refluxed overnight. The reaction mixture was poured into ice cold water and the pyrimidine 
derivative was precipitated, which was filtered off, rinsed with fresh water and dried in a hot-
air cabinet. 
 
6.1.3.8.1. Synthesis of 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-
carbonitrile (59) 
 
   
synonyms: SMS-A-6 
compound 6a (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-oxo-3,4,6,7,8,9-hexahydropyrimido[4,5-b]indolizine-10-carbonitrile (45) and 
phosphoryl chloride (excess) 
yield: 42% 
visual appearance: white needles 
chemical formula: C11H9ClN4 
molecular weight: 232.67 Da 
LC-MS analysis: calculated: 232.05 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.71 (s, 1H), 4.52 (t, J = 6.2 Hz, 2H), 3.15 (t, J = 6.4 Hz, 2H), 
2.09-2.03 (m, 2H), 1.91-1.85 (m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.8, 151.3, 150.8, 142.1, 123.5, 113.4, 83.8, 46.0, 23.6, 21.8, 
17.8 
 
6.1.3.8.2. Synthesis of 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-
a]azepine-11-carbonitrile (60) 
 
N
N
N
N
Cl
   
synonyms: SMS-A-33 
compound 6b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-oxo-4,6,7,8,9,10-hexahydro-3H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(46) and phosphoryl chloride (excess) 
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yield: 71% 
visual appearance: brown needles 
chemical formula: C12H11ClN4 
molecular weight: 246.70 Da 
LC-MS analysis: calculated: 246.07 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.73 (s, 1H), 4.80-4.75 (m, 2H), 3.20-3.16 (m, 2H), 1.90-1.71 (m, 
6H) 
13C NMR: 126 MHz, DMSO-d6, δ 160.1, 150.8, 150.8, 141.5, 123.6, 113.6, 85.4, 47.00, 29.3, 27.1, 
26.9, 25.2 
 
6.1.3.8.3. Synthesis of 4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (61) 
 
   
synonyms: SMS-A-231 
compound 11a (J. Med. Chem. 2016, 59, 3018−3033) 
compound 5a (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 5-methyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (47) and 
phosphoryl chloride (excess) 
yield: 66% 
visual appearance: brown powder 
chemical formula: C8H5ClN4 
molecular weight: 192.61 Da 
LC-MS analysis: calculated: 192.02 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.79 (s, 1H), 8.76 (s, 1H), 4.14 (s, 3H) 
13C NMR: not determined 
 
6.1.3.8.4. Synthesis of 4-chloro-5-ethyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (62) 
 
   
synonyms: SMS-A-476 
compound 11b (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 5-ethyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (48) and phosphoryl 
chloride (excess) 
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yield: 79% 
visual appearance: brown powder 
chemical formula: C9H9ClN4 
molecular weight: 208.65 Da 
LC-MS analysis: calculated: 208.05 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.86 (s, 1H), 8.80 (s, 1H), 4.56 (q, J = 7.2 Hz, 2H), 1.45 (t, J = 
7.2 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.8.5. Synthesis of 4-chloro-5-propyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (63) 
 
   
synonyms: SMS-A-483 
compound 11c (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-oxo-5-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (49) and 
phosphoryl chloride (excess) 
yield: 94% 
visual appearance: brown powder 
chemical formula: C10H9ClN4 
molecular weight: 220.66 Da 
LC-MS analysis: calculated: 220.05 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.86 (s, 1H), 8.81 (s, 1H), 4.48 (t, J = 7.2 Hz, 2H), 1.88-1.81 (m, 
2H), 0.87 (t, J = 7.4 Hz, 3H) 
13C NMR: not determined 
 
6.1.3.8.6. Synthesis of 4-chloro-5-isopropyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile 
(64) 
 
   
synonyms: SMS-A-490 
compound 11d (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 5-isopropyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (50) and 
phosphoryl chloride (excess) 
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yield: 32% 
visual appearance: brown powder 
chemical formula: C10H9ClN4 
molecular weight: 220.66 Da 
LC-MS analysis: calculated: 220.05 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 9.05 (s, 1H), 8.80 (s, 1H), 5.40 (m, 1H), 1.54 (d, J = 6.6 Hz, 6H) 
13C NMR: not determined 
 
6.1.3.8.7. Synthesis of 4-chloro-5-cyclopropyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile 
(65) 
 
   
synonyms: SMS-A-497 
compound 11e (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 5-cyclopropyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (51) and 
phosphoryl chloride (excess) 
yield: quantitative 
visual appearance: brown powder 
chemical formula: C10H7ClN4 
molecular weight: 218.64 Da 
LC-MS analysis: calculated: 218.04 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.83 (s, 1H), 8.80 (s, 1H), 3.93-3.88 (m, 1H), 1.28-1.14 (m, 4H) 
13C NMR: not determined 
 
6.1.3.8.8. Synthesis of 4-chloro-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (66) 
 
N
N
N
N
Cl
   
synonyms: SMS-A-188 
compound 11f (J. Med. Chem. 2016, 59, 3018−3033) 
compound 5b (Biochim. Biophys. Acta 2017, 1859, 69–79) 
 
Experimental Section  145 
 
educts: 4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (52) and 
phosphoryl chloride (excess) 
yield: 94% 
visual appearance: brown powder 
chemical formula: C13H7ClN4 
molecular weight: 254.68 Da 
LC-MS analysis: calculated: 254.04 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 9.01 (s, 1H), 8.91 (s, 1H), 7.68-7.65 (m, 2H), 7.63-7.57 (m, 3H) 
13C NMR: not determined 
 
6.1.3.8.9. Synthesis of 4-chloro-5-(2-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (67) 
 
   
synonyms: SMS-A-296 
compound 35a (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 5-(2-methoxyphenyl)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (53) 
and phosphoryl chloride (excess) 
yield: quantitative 
visual appearance: greywhite powder 
chemical formula: C14H9ClN4O 
molecular weight: 284.70 Da 
LC-MS analysis: calculated: 284.05 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.94 (s, 1H), 8.89 (s, 1H), 7.63-7.58 (m, 2H), 7.28 (dd, J = 8.8, 
1.1 Hz, 1H), 7.15 (td, J = 7.6, 1.2 Hz, 1H), 3.74 (s, 3H) 
13C NMR: not determined 
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6.1.3.8.10. Synthesis of 4-chloro-5-(4-ethoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (68) 
 
   
synonyms: SMS-A-281 
compound 35b (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 5-(4-ethoxyphenyl)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (54) 
and phosphoryl chloride (excess) 
yield: quantitative 
visual appearance: greywhite powder 
chemical formula: C15H11ClN4O 
molecular weight: 298.73 Da 
 
LC-MS analysis: calculated: 298.06 Da; found: not determined 
purity: not determined 
1H NMR: not determined 
13C NMR: not determined 
 
6.1.3.8.11. Synthesis of 5-benzyl-4-chloro-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (69) 
 
   
synonyms: SMS-A-201 
compound 11g (J. Med. Chem. 2016, 59, 3018−3033) 
compound 5c (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 5-benzyl-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (55) and 
phosphoryl chloride (excess) 
yield: 83% 
visual appearance: brown powder 
chemical formula: C14H9ClN4 
molecular weight: 268.70 Da 
LC-MS analysis: calculated: 268.05 Da; found: not determined 
purity: not determined 
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1H NMR: 500 MHz, DMSO-d6, δ 8.98 (s, 1H), 8.83 (s, 1H), 7.36-7.32 (m, 2H), 7.31-7.27 (m, 1H), 
7.16- 7.12 (m, 2H), 5.81 (s, 2H) 
13C NMR: not determined 
 
6.1.3.8.12. Synthesis of 4-chloro-5-phenethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile 
(70) 
 
   
synonyms: SMS-A-206 
compound 11h (J. Med. Chem. 2016, 59, 3018−3033) 
compound 5d (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 4-oxo-5-phenethyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (56) and 
phosphoryl chloride (excess) 
yield: 88% 
visual appearance: brown powder 
chemical formula: C15H11ClN4 
molecular weight: 282.73 Da 
LC-MS analysis: calculated: 282.07 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.81 (s, 1H), 8.65 (s, 1H), 7.28-7.24 (m, 2H), 7.21-7.19 (m, 1H), 
7.15-7.11 (m, 2H), 4.77 (t, J = 7.4, 2H), 3.15 (t, J = 7.4, 2H) 
13C NMR: not determined 
 
6.1.3.8.13. Synthesis of 4-chloro-5-(3-phenylpropyl)-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (71) 
 
  
synonyms: SMS-A-211 
compound 11i (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-oxo-5-(3-phenylpropyl)-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (57) 
and phosphoryl chloride (excess) 
yield: 69% 
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visual appearance: brown powder 
chemical formula: C16H13ClN4 
molecular weight: 296.76 Da 
LC-MS analysis: calculated: 296.08 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 8.84 (s, 1H), 8.79 (s, 1H), 7.26-7.22 (m, 2H), 7.20-7.13 (m, 
3H), 4.55 (t, J = 7.3, 2H), 2.66 (t, J = 7.5, 2H), 2.20-2.13 (m, 2H) 
13C NMR: not determined 
 
6.1.3.8.14. Synthesis of 4-chloro-5H-pyrimido[5,4-b]indole (72) 
 
   
synonyms: SMS-A-134 
compound 40 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 3,5-dihydro-4H-pyrimido[5,4-b]indole-4-one (44) and phosphoryl chloride (excess) 
yield: 52% 
visual appearance: brown powder 
chemical formula: C10H6ClN3 
molecular weight: 203.63 Da 
LC-MS analysis: calculated: 203.03 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 12.33 (s, 1H), 8.84 (s, 1H), 8.25 (dt, J 8.0, 1.0 Hz, 1H), 7.70 
(ddd, J = 7.8, 6.6, 1.0, 1H), 7.68 (dt, J = 8.3, 1.3, 2H), 7.37 (ddd, J = 8.0, 6.6, 1.4, 1H) 
13C NMR: 126 MHz, DMSO-d6, δ 148.7, 147.0, 141.9, 141.4, 130.9, 128.2, 121.7, 121.2, 120.0, 
113.1 
 
6.1.3.9. Alkylation of Piperazine 
 
To 3-(2-bromoethyl)-1H-indole dissolved in 50 mL acetonitrile was added to a saturated 
solution of piperazine (4 eq.) in the same solvent at room temperature. The reaction was 
started by addition of 6 eq. Hünig’s base started the reaction at room temperature. After 24 
hours, the Hünig’s base hydrochloride was filtered off and the clear filtrate was evaporated, 
resulting in an orange oil containing the piperazine derivative. Column chromatography 
performed as stated above yielded the purified alkylated product. 
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6.1.3.9.1. Synthesis of 3-(2-(piperazine-1-yl)ethyl)-1H-indole (73) 
 
   
synonyms: SMS-A-8 
compound 30 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 3-(2-bromoethyl)-1H-indole, piperazine (4 eq.) and Hünig’s base (6 eq.) 
yield: quantitative 
visual appearance: orange oil 
chemical formula: C14H19N3 
molecular weight: 229.33 Da 
LC-MS analysis: calculated: 229.16 Da; found: not determined 
purity: not determined 
1H NMR: 500 MHz, DMSO-d6, δ 10.74 (s, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 
7.13 (d, 2.3 Hz, 1H), 7.04 (ddd, J = 8.1, 7.0, 1.1 Hz), 6.95 (ddd, J = 7.9 Hz, 7.0, 1.0 Hz), 
2.85-2.81 (m, 2H), 2.81-2.76 (m, 4H), 2.59-2.53 (m, 2H), 2.48-2.40 (m, 4H), 1.87 (s, 1H) 
13C NMR: 126 MHz, DMSO-d6, δ 136.3, 127.4, 122.6, 120.9, 118.4, 118.2, 112.7, 111.4, 59.5, 
53.2 (2C), 45.2 (2C), 22.3 
 
6.1.4. Synthesis and Characterization of Target Compounds via 
Nucleophilic Substitution at the Aromatic Ring System 
 
The purine or 9-deazapurine intermediates 59-72 were dissolved in 0.5 mL N,N-
dimethylformamide and added to 1.5 eq. of the corresponding primary or secondary amine in 
0.5 mL of N,N-dimethylformamide. Additionally, 1.5 eq. of TEA were added. The reaction 
was performed using microwave-assisted synthesis at 200 W and 110 °C for 20-60 minutes. 
The reaction mixture was directly put onto a column and purified as stated above. The 
products were crystallized from a mixture of ethanol and petroleum ether (1:1). 
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6.1.4.1. Synthesis of 4-(4-phenethylpiperazine-1-yl)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (74) 
 
   
synonyms: SMS-A-50 
compound 12 (J. Med. Chem. 2016, 59, 3018−3033) 
compound SC12 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
compound 75 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 66% 
visual appearance: yellow needles 
chemical formula: C23H26N6 
molecular weight: 386.50 Da 
LC-MS analysis: calculated: 386.22 Da; found: 387.4 Da [M+H]+ 
purity: 95% 
1H NMR: 500 MHz, DMSO-d6, δ 8.46 (s, 1H), 7.29-7.22 (m, 4H), 7.19-7.15 (m, J = 7.1, 1.6 Hz, 
1H), 3.34-3.29 (m, 4H), 4.35 (t, J = 5.6 Hz, 2H), 3.11 (t, J = 6.5 Hz, 2H), 2.78 (t, J = 7.2 
Hz, 2H), 2.61-2.68 (m, 4H), 2.58 (t, J = 7.4 Hz, 2H), 1.98-1.87 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.4, 151.2, 151.0, 150.2, 140.5, 128.8 (2C), 128.4 (2C), 126.0, 
118.2, 114.4, 83.6, 59.8, 52.2 (2C), 50.4 (2C), 46.1, 32.84, 22.9, 22.6, 18.4 
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6.1.4.2. Synthesis of 4-(4-benzylpiperazine-1-yl)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (75) 
 
  
synonyms: SMS-A-53 
compound 13 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-
benzylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 48% 
visual appearance: yellow needles 
chemical formula: C22H24N6 
molecular weight: 372.48 Da 
LC-MS analysis: calculated: 372.21 Da; found: 372.5 Da [M+H]+ 
purity: 94% 
1H NMR: 500 MHz, DMSO-d6, δ 8.45 (s, 1H), 7.34-7.31 (m, 4H), 7.28-7.23 (m, 1H), 4.33 (t, J = 
5.6 Hz, 2H), 3.36-3.30 (m, 4H), 3.54 (s, 2H), 3.10 (t, J = 6.5 Hz, 2H), 2.66-2.51 (m, 4H), 
2.03-1.81 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.3, 151.2, 150.9, 150.2, 138.1, 129.1 (2C), 128.3 (2C), 127.1, 
118.2, 114.4, 83.6, 62.2, 52.3 (2C), 50.3 (2C), 46.1, 22.9, 22.6, 18.4 
 
6.1.4.3. Synthesis of 4-(4-benzhydrylpiperazine-1-yl)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (76) 
 
  
synonyms: SMS-A-51 
compound 14 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-
benzhydrylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
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yield: 70% 
visual appearance: white needles 
chemical formula: C28H28N6 
molecular weight: 448.57 Da 
LC-MS analysis: calculated: 448.24 Da; found: 449.4 Da [M+H]+ 
purity: 92% 
1H NMR: 500 MHz, DMSO-d6, δ 8.45 (s, 1H), 7.49-7.47 (m, 4H), 7.33-7.27 (m, 4H), 7.21-7.16 (m, 
2H), 4.37 (s, 1H, CH), 4.31 (t, 5.5 Hz, 2H), 3.30-3.40 (m, 4H), 3.09 (t, J = 6.5 Hz, 2H), 
2.49-2.60 (m, 4H), 1.82-1.95 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.2, 151.3, 150.9, 150.13, 142.9 (2C), 128.7 (4C), 127.7 (4C), 
127.1 (2C), 118.2, 114.4, 83.6, 75.4, 51.3 (2C), 50.4 (2C), 46,0, 22.9, 22.6, 18.4 
 
6.1.4.4. Synthesis of 4-(4-phenylpiperazine-1-yl)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (77) 
 
N
N
N
N
N
N
   
synonyms: SMS-A-52 
compound 15 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-
phenylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 13% 
visual appearance: white needles 
chemical formula: C21H22N6 
molecular weight: 358.45 Da 
LC-MS analysis: calculated: 358.19 Da; found: 359.4 Da [M+H]+ 
purity: 92% 
1H NMR: 500 MHz, DMSO-d6, δ 8.50 (s, 1H), 7.24 (dd, J = 8.7, 7.3 Hz, 2H), 7.00 (d, J = 8.6 Hz, 
2H), 6.81 (t, J = 7.3 Hz 1H), 4.40 (t, J = 5.6 Hz, 2H), 3.50-3.43 (m, 4H), 3.36-3.31 (m, 
4H), 3.13 (t, J = 6.4 Hz, 2H), 2.00-1.88 (m, 4H) 
13C NMR: 126 MHz DMSO-d6) δ 154.3, 151.3, 150.1, 150.1, 150.3, 129.1 (2C), 119.4, 118.4, 
115.8 (2C), 114.4, 83.6, 50.3 (2C), 48.1 (2C), 46.1, 23.0, 22.6, 18.4 
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6.1.4.5. Synthesis of 4-(4-methylpiperazine-1-yl)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (78) 
 
   
synonyms: SMS-A-123 
compound 16 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-
methylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 45% 
visual appearance: white powder 
chemical formula: C21H22N6 
molecular weight: 296.38 Da 
LC-MS analysis: calculated: 296.17 Da; found: 297.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.45 (s, 1H), 4.34 (t, J = 5.6 Hz, 2H), 3.31-3.25 (m, 4H), 3.10 (t, J 
= 6.5 Hz, 2H), 2.56-2.51 (m, 4H), 2.23 (s, 3H), 1.99-1.88 (m, 4H) 
13C NMR: 126 MHz DMSO-d6, δ 154.4, 151.2, 151.0, 150.2, 118.2, 114.5, 83.6, 54.2 (2C), 50.2 
(2C), 46.1, 45.8, 22.9, 22.6, 18.4 
 
6.1.4.6. Synthesis of 4-(piperazine-1-yl)-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-
carbonitrile (79) 
 
   
synonyms: SMS-A-7 
compound 17 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-piperazine (4 
eq.) and TEA (1.5 eq.) 
yield: 59% 
visual appearance: white powder 
chemical formula: C15H18N6 
molecular weight: 282.35 Da 
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LC-MS analysis: calculated: 282.16 Da; found: 283.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.45 (s, 1H), 4.34 (t, J = 5.6 Hz, 2H), 3.23 (t, J = 4.6 Hz, 4H), 
3.10 (t, J 6.5 Hz, 2H), 2.86 (J = 4.8 Hz, 4H), 1.98-1.86 (m, 4H) 
13C NMR: 126 MHz DMSO-d6, δ 154.7, 151.3, 150.8, 150.2, 118.2, 114.5, 83.6, 51.6 (2C), 46.1, 
45.2 (2C), 22.9, 22.6, 18.4 
 
6.1.4.7. Synthesis of 4-((3-phenylpropyl)amino)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (80) 
 
  
synonyms: SMS-A-694 
compound 18 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 
phenylpropylamine (1.5 eq.) and TEA (1.5 eq.) 
yield: 40% 
visual appearance: yellow needles 
chemical formula: C20H21N5 
molecular weight: 331.42 Da 
LC-MS analysis: calculated: 331.18 Da; found: 332.1 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 8.20 (s, 1H), 7.25 (t, J = 7.5 Hz, 2H), 7.20 (d, J = 7.2 Hz, 2H), 
7.15 (t, J = 7.2 Hz, 1H), 6.80 (t, J 5.4 Hz, 1H), 4.37 (t, J = 6.1 Hz, 2H), 3.52-3.47 (m, 
2H), 2.99 (t, J = 6.3 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 2.03-1.98 (m, 2H), 1.95-1.89 (m, 
2H), 1.86-1.80 (m, 2H) 
13C NMR: 126 MHz DMSO-d6, δ 152.2, 150.0, 147.7, 147.7, 142.1, 128.5 (2C), 128.5 (2C), 125.9, 
115.1, 114.0, 82.8, 45.7, 33.0, 30.7, 23.1, 22.1, 18.2 
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6.1.4.8. Synthesis of 4-(phenethylamino)-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-
carbonitrile (81) 
 
  
synonyms: SMS-A-652 
compound 19 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 
phenethylamine (1.5 eq.) and TEA (1.5 eq.) 
yield: 18% 
visual appearance: yellow needles 
chemical formula: C19H19N5 
molecular weight: 317.40 Da 
LC-MS analysis: calculated: 317.16 Da; found: 318.1 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.24 (s, 1H), 7.29 (t, J = 7.4 Hz, 2H), 7.25 (d, J = 6.9 Hz, 2H), 
7.20 (t, J = 7.3 Hz, 1H), 6.92 (t, J = 5.5 Hz, 1H), 4.34 (t, J = 6.1 Hz, 2H), 3.73-3.63 (m, 
2H), 3.00 (t, J = 6.3 Hz, 2H), 2.90 (t, J = 7.4, 2H), 2.04-1.97 (m, 2H), 1.97-1.80 (m, 2H) 
13C NMR: 126 MHz DMSO-d6, δ 152.2, 149.7, 147.7, 147.6, 139.8, 128.8 (2C), 128.5 (2C), 126.2, 
114.9, 114.0, 82.9, 45.6, 42.1, 35.1, 23.0, 22.0, 18.1 
 
6.1.4.9. Synthesis of 4-(benzylamino)-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-
carbonitrile (82) 
 
   
synonyms: SMS-A-604 
compound 20 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), benzylamine 
(1.5 eq.) and TEA (1.5 eq.) 
yield: 26% 
visual appearance: yellow needles 
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chemical formula: C18H17N5 
molecular weight: 303.37 Da 
LC-MS analysis: calculated: 303.15 Da; found: 304.1 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.17 (s, 1H), 7.46 (d, J = 6.4 Hz, 1H), 7.36 (d, J = 7.3 Hz, 2H), 
7.28 (t, J = 7.6 Hz, 2H), 7.20 (t, J = 7.3 Hz, 1H), 4.71 (d, J = 5.8 Hz, 2H), 4.47 (t, J = 6.1 
Hz, 2H), 3.01 (t, J = 6.3 Hz, 2H), 2.06-2.00 (m, 2H), 1.88-1.82 (m, 2H) 
13C NMR: 126 MHz DMSO-d6, δ 152.1, 149.6, 148.8, 147.8, 140.1, 128.3 (2C), 127.3 (2C), 126.7, 
114.9, 113.9, 82.9, 45.8, 43.5, 23.1, 22.1, 18.2 
 
6.1.4.10. Synthesis of 4-(phenylamino)-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-
carbonitrile (83) 
 
   
synonyms: SMS-A-556 
compound 21 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), aniline (1.5 eq.) 
and TEA (1.5 eq.) 
yield: 19% 
visual appearance: yellow needles 
chemical formula: C17H15N5 
molecular weight: 289.34 Da 
LC-MS analysis: calculated: 289.13 Da; found: 290.1 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 8.49 (s, 1H), 8.31 (s, 1H), 7.55 (d, J = 7.7 Hz, 2H), 7.33 (t, J = 
7.9 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 4.57 (t, J = 6.1 Hz, 2H), 3.08 (t, J = 6.4 Hz, 2H), 
2.07-2.02 (m, 2H), 1.90-1.85 (m, 2H) 
13C NMR: 126 MHz DMSO-d6, δ 151.5, 149.6, 149.2, 147.8, 139.6, 128.6 (2C), 123.4, 122.4 (2C), 
114.9, 114.7, 83.22, 45.7, 23.2, 22.1, 18.3 
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6.1.4.11. Synthesis of 4-(4-phenethylpiperazine-1-yl)-7,8,9,10-tetrahydro-6H-
pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (84) 
 
  
synonyms: SMS-A-64 
compound 22 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-(2-phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 16% 
visual appearance: yellow needles 
chemical formula: C24H28N6 
molecular weight: 400.53 Da 
LC-MS analysis: calculated: 400.24 Da; found: 401.3 Da [M+H]+ 
purity: 96% 
1H NMR: 500 MHz, DMSO-d6, δ 8.47 (s, 1H), 7.29-7.22 (m, 4H), 7.19-7.15 (m, 1H), 4.59-4.39 (m, 
2H), 3.40-3.28 (m, 4H), 3.14-3.03 (m, 2H), 2.77 (t, J = 7.2 Hz, 2H), 2.69-2.62 (m, 4H), 
2.59 (t, J = 7.2 Hz, 2H), 1.90-1.81 (m, 2H), 1.81-1.70 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 156.6, 153.7, 151.0, 149.6, 140.5, 128.8 (2C), 128.3 (2C), 126.0, 
117.9, 114.6, 85.4, 59.7, 52.1 (2C), 49.8 (2C), 47.4, 32.8, 29.9, 27.9, 27.1, 25.6 
 
6.1.4.12. Synthesis of 4-(4-phenethylpiperazine-1-yl)-7,8,9,10-tetrahydro-6H-
pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (85) 
 
  
synonyms: SMS-A-67 
compound 23 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-benzylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
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yield: 36% 
visual appearance: white needles 
chemical formula: C23H26N6 
molecular weight: 386.50 Da 
LC-MS analysis: calculated: 386.22 Da; found: 387.4 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 8.46, (s, 1H), 7.35-7.31 (m, 4H), 7.28-7.22 (m, 1H), 4.52-4.40 
(m, 2H), 3.36-3.28 (m, 4H), 3.54 (s, 2H), 3.12-3.04 (m, 2H), 2.69-2.51 (m, 4H), 1.87-
1.79 (m, 2H), 1.80-1.67 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 156.6, 153.7, 151.1, 149.6, 138.1, 129.0 (2C), 128.4 (2C), 127.2, 
117.9, 114.6, 85.3, 62.1, 52.1 (2C), 49.7 (2C), 47.4, 27.9, 27.9, 27.1, 25.6 
 
6.1.4.13. Synthesis of 4-(4-benzhydrylpiperazine-1-yl)-7,8,9,10-tetrahydro-6H-
pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (86) 
 
  
synonyms: SMS-A-65 
compound 24 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-benzhydrylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 51% 
visual appearance: white needles 
chemical formula: C29H30N6 
molecular weight: 462.60 Da 
LC-MS analysis: calculated: 462.25 Da; found: 463.3 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 8.46 (s, 1H), 7.48-7.43 (m, 4H), 7.32-7.27 (m, 4H), 7.21-7.16 (m, 
2H), 4.49-4.39 (m, 2H), 4.38 (s, 1H), 3.40-3.29 (m, 4H), 3.11-2.99 (m, 2H), 2.56-2.50 
(m, 4H), 1.84-1.76 (m, 2H), 1.76-1.63 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 156.5, 153.6, 151.1, 149.8, 142.8 (2C), 128.7 (4C), 127.7 (4C), 
127.1 (2C), 114.6, 117.9, 85.2, 75.2, 51.1 (2C), 49.8 (2C), 47.4, 29.9, 27.8, 27.1, 25.6 
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6.1.4.14. Synthesis of 4-(4-phenylpiperazine-1-yl)-7,8,9,10-tetrahydro-6H-
pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (87) 
 
   
synonyms: SMS-A-66 
compound 25 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-phenylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 52% 
visual appearance: yellow needles 
chemical formula: C22H24N6 
molecular weight: 372.48 Da 
LC-MS analysis: calculated: 372.21 Da; found: 373.4 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 8.51 (s, 1H), 7.27-7.20 (m, 2H), 7.03-6.98 (m, 2H), 6.84-6.78 (m, 
1H), 4.56-4.49 (m, 2H), 3.47-3.41 (m, 4H), 3.38-3.31 (m, 4H), 3.14-3.09 (m, 2H), 1.90 -
1.72 (m, 6H) 
13C NMR: 126 MHz, DMSO-d6, δ 156.8, 153.7, 151.1, 151.0, 149.7, 129.1 (2C), 119.4, 118.0, 
115.9 (2C), 114.6, 85.3, 49.7 (2C), 47.9 (2C), 47.5, 29,9, 27.8, 27.1, 25.6 
 
6.1.4.15. Synthesis of 5-methyl-4-(4-phenethylpiperazine-1-yl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (88) 
 
   
synonyms: SMS-A-340 
compound 26 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (61), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
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yield: 72% 
visual appearance: yellow needles 
chemical formula: C20H22N6 
molecular weight: 346.44 Da 
LC-MS analysis: calculated: 346.19 Da; found: 347.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.50 (s, 1H), 8.44 (s, 1H), 7.29-7.25 (m, 2H), 7.25-7.22 (m, 2H), 
7.19-7.15 (m, 1H), 4.01 (s, 3H), 3.41-3.34 (m, 4H), 2.77 (t, J = 7.3 Hz, 2H), 2.68-2.61 
(m, 4H), 2.58 (t, J = 7.4 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.3, 150.1, 141.5, 140.5, 128.8 (2C), 128.4 (2C), 126.0, 
118.6, 114.4, 85.4, 59.8, 52.2 (2C), 50.1 (2C), 36.8, 32.8 
 
6.1.4.16. Synthesis of 5-ethyl-4-(4-phenethylpiperazine-1-yl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (89) 
 
   
synonyms: SMS-A-478 
compound 27 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-ethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (62), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 64% 
visual appearance: white needles 
chemical formula: C21H24N6 
molecular weight: 360.47 Da 
LC-MS analysis: calculated: 360.21 Da; found: 361.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.61 (s, 1H), 8.54 (s, 1H), 7.29-7.22 (m, 4H), 7.19-7.15 (m, 1H), 
4.34 (q, J = 7.2 Hz, 2H), 3.36-3.30 (m, 4H), 2.78 (t, J = 7.2 Hz, 2H), 2.70-2.62 (m, 4H), 
2.59 (t, J = 7.3 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.4, 150.6, 140.6, 140.5, 128.8 (2C), 128.4 (2C), 126.0, 
117.8, 114.3, 86.1, 59.7, 52.2 (2C), 50.1 (2C), 44.1, 32.8, 16.1 
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6.1.4.17. Synthesis of 4-(4-phenethylpiperazine-1-yl)-5-propyl-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (90) 
 
   
synonyms: SMS-A-485 
compound 28 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-propyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (63), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 72% 
visual appearance: white needles 
chemical formula: C22H26N6 
molecular weight: 374.49 Da 
LC-MS analysis: calculated: 374.22 Da; found: 375.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.61 (s, 1H), 8.54 (s, 1H), 7.29-7.22 (m, 4H), 7.19-7.15 (m, 1H), 
4.34 (q, J = 7.2 Hz, 2H), 3.36-3.30 (m, 4H), 2.78 (t, J = 7.2 Hz, 2H), 2.70-2.62 (m, 4H), 
2.59 (t, J = 7.3 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.4, 150.6, 140.6, 140.5, 128.8 (2C), 128.4 (2C), 126.0, 
117.8, 114.3, 86.1, 59.7, 52.2 (2C), 50.1 (2C), 44.1, 32.8, 16.1 
 
6.1.4.18. Synthesis of 5-isopropyl-4-(4-phenethylpiperazine-1-yl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (91) 
 
   
synonyms: SMS-A-492 
compound 29 (J. Med. Chem. 2016, 59, 3018−3033) 
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educts: 4-chloro-5-isopropyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (64), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 18% 
visual appearance: pale yellow needles 
chemical formula: C22H26N6 
molecular weight: 374.49 Da 
LC-MS analysis: calculated: 374.22 Da; found: 373.3 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.81 (s, 1H), 8.55 (s, 1H), 7.29-7.22 (m, 4H), 7.19-7.15 (m, 1H), 
4.99 (hept, J = 6.7 Hz, 1H), 3.32-3.30 (m, 4H), 2.78 (t, J = 7.2 Hz, 2H), 2.70-2.61 (m, 
4H), 2.59 (t, J = 7.2 Hz, 2H), 1.44 (d, J = 6.6 Hz, 6H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.3, 150.3, 140.5, 138.3, 128.8 (2C), 128.4 (2C), 126.0, 
117.3, 114.4, 87.0, 59.7, 52.1 (2C), 50.0, 49.9 (2C), 32.8, 23.1 (2C) 
 
6.1.4.19. Synthesis of 5-cyclopropyl-4-(4-phenethylpiperazine-1-yl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (92) 
 
   
synonyms: SMS-A-499 
compound 30 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-cyclopropyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (65), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 47% 
visual appearance: yellow needles 
chemical formula: C22H24N6 
molecular weight: 372.48 Da 
LC-MS analysis: calculated: 372.21 Da; found: 373.3 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.46 (s, 1H), 8.45 (s, 1H), 7.29-7.21 (m, 4H), 7.19-7.15 (m,1H), 
3.97 (quint, J = 3.8 Hz, 1H), 3.56-3.48 (m, 4H), 2.77 (t, J = 7.2 Hz, 2H), 2.64-2.60 (m, 
4H), 2.57 (t, J = 7.4 Hz, 2H), 1.14-1.03 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.4, 151.3, 150.3, 140.5, 140.2, 128.8 (2C), 128.4 (2C), 126.0, 
118.6, 114.4, 85.7, 59.8, 52.4 (2C), 49.7 (2C), 32.8, 32.2, 8.5 (2C) 
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6.1.4.20. Synthesis of 4-(4-phenethylpiperazine-1-yl)-5-phenyl-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (93) 
 
   
synonyms: SMS-A-308 
compound 31 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (66), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 50% 
visual appearance: yellow needles 
chemical formula: C25H24N6 
molecular weight: 408.51 Da 
LC-MS analysis: calculated: 408.21 Da; found: 409.4 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.74 (s, 1H), 8.58 (s, 1H), 7.61-7.57 (m, 2H), 7.54-7.48 (m, 3H), 
7.25-7.21 (m, 2H), 7.17-7.12 (m, 3H), 3.12-3.00 (m, 4H), 2.61 (t, J = 7.4 Hz, 2H) 2.34 (t, 
J = 7.5 Hz, 2H), 2.12-2.02 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.2, 151.8, 151.2, 141.4, 140.4, 137.9, 129.6 (2C), 128.7 (2C), 
128.5, 128.3 (2C), 125.9, 125.3 (2C), 115.3, 114.1, 88.2, 59.6, 51.4 (2C), 48.7 (2C), 
32.5 
 
6.1.4.21. Synthesis of 4-(4-benzylpiperazine-1-yl)-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-
7-carbonitrile (94) 
 
  
synonyms: SMS-A-311 
compound 32 (J. Med. Chem. 2016, 59, 3018−3033) 
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educts: 4-chloro-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (66), 1-benzylpiperazine 
(1.5 eq.) and TEA (1.5 eq.) 
yield: 15% 
visual appearance: yellow needles 
chemical formula: C24H22N6 
molecular weight: 394.48 Da 
LC-MS analysis: calculated: 394.19 Da; found: 395.3 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.73 (s, 1H), 8.57 (s, 1H), 7.58-7.49 (m, 3H), 7.49-7.45 (m, 2H), 
7.30-7.25 (m, 2H), 7.25-7.21 (m, 1H), 719-7.16 (m, 2H), 3.31 (s, 2H), 312-3.00 (m, 4H), 
2.04-1.91 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.1, 151.8, 151.2, 141.4, 137.9, 137.7, 129.6 (2C), 128.9 (2C), 
128.5, 128.3 (2C), 127.1, 125.3 (2C), 115.3, 114.1, 88.1, 61.9, 51.3 (2C), 48.7 (2C) 
 
6.1.4.22. Synthesis of 4-(4-benzylpiperazine-1-yl)-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-
7-carbonitrile (95) 
 
  
synonyms: SMS-A-316 
compound 33 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 5-benzyl-4-chloro-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (69), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 41% 
visual appearance: yellow needles 
chemical formula: C26H26N6 
molecular weight: 422.54 Da 
LC-MS analysis: calculated: 422.22 Da; found: 423.3 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.65 (s, 1H), 8.56 (1H), 7.33-7.11 (m, 10H), 5.52 (s, 2H), 3.39-
3.30 (m, 4H), 2.76 (t, J = 7.2 Hz, 2H), 2.68-2.60 (m, 4H), 2.58 (t, J = 7.2 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.2, 151.7, 151.0, 141.7, 140.5, 137.0, 128.9 (2C), 128.8 (2C), 
128.4 (2C), 128.1, 127.1 (2C), 126.0, 117.9, 114.1, 87.0, 59.7, 52.2 (2C), 52.1, 50.0 
(2C), 32.8 
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6.1.4.23. Synthesis of 5-benzyl-4-(4-benzylpiperazine-1-yl)-5H-pyrrolo[3,2-d]pyrimidine-
7-carbonitrile (96) 
 
  
synonyms: SMS-A-319 
compound 34 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 5-benzyl-4-chloro-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (69), 1-benzylpiperazine 
(1.5 eq.) and TEA (1.5 eq.) 
yield: 13% 
visual appearance: yellow solid 
chemical formula: C25H24N6 
molecular weight: 408.51 Da 
LC-MS analysis: calculated: 408.21 Da; found: 409.4 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 8.64 (s, 1H), 8.55 (s, 1H), 7.35-7.22 (m, 8H), 7.13-7.09 (m, 2H), 
5.51 (s, 2H), 3.54 (m, 2H), 3.36-3.30 (m, 4H), 2.57-2.52 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.1, 151.7, 151.0, 141.7, 138.0, 136.9, 129.1 (2C), 128.9 (2C), 
128.3 (2C), 128.1, 127.2, 127.1 (2C), 117.9, 114.0, 86.9, 62.1, 52.1 (2C), 52.1, 49.9 
 
6.1.4.24. Synthesis of 5-phenethyl-4-(4-phenethylpiperazine-1-yl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (97) 
 
  
synonyms: SMS-A-324 
compound 35 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-phenethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (70), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
 166 Experimental Section 
 
yield: 60% 
visual appearance: yellow needles 
chemical formula: C27H28N6 
molecular weight: 436.56 Da 
LC-MS analysis: calculated: 436.24 Da; found: 437.5 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.55 (s, 1H), 8.49 (s, 1H), 730-7.21 (m, 4H), 7.20-7.09 (m, 4H), 
7.00-6.96 (m, 2H), 4.55 (t, J = 7.1 Hz, 2H), 3.27-3.18 (m, 4H), 3.00 (t, J = 7.1 Hz, 2H), 
2.77 (t, J = 7.2 Hz, 2H), 2.69-2.60 (m, 4H), 2.58 (t, J = 7.3 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.3, 150.4, 141.1, 140.5, 137.3, 128.8 (2C), 128.7 (2C), 
128.4 (2C), 128.2 (2C), 126.7, 126.0, 118.1, 114.3, 86.2, 59.8, 52.2 (2C), 50.3, 50.0 
(2C), 37.2, 32.7 
 
6.1.4.25. Synthesis of 4-(4-benzylpiperazine-1-yl)-5-phenethyl-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (98) 
 
  
synonyms: SMS-A-327 
compound 36 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-phenethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (70), 1-benzylpiperazine 
(1.5 eq.) and TEA (1.5 eq.) 
yield: 25% 
visual appearance: white needles 
chemical formula: C26H26N6 
molecular weight: 422.54 Da 
LC-MS analysis: calculated: 422.22 Da; found: 423.3 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.54 (s, 1H), 8.48 (s, 1H), 7.36-7.30 (m, 4H), 7.29-7.24 (m, 1H), 
7.18-7.10 (m, 3H), 6.99-6.95 (m, 2H), 4.52 (t, J = 7.2 Hz, 2H), 3.54 (s, 2H), 3.27-3.20 
(m, 4H), 3.00 (t, J = 7.1 Hz, 2H), 2.61-2.52 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ = 154.8, 151.3, 150.4, 141.0, 137.9, 137.2, 129.0 (2C), 128.7 
(2C), 128.3 (2C). 128,2 (2C), 127.1, 126.7, 118.0, 117.2, 86.1, 62.2, 52.1 (2C), 50.2, 
49.9 (2C), 37.1 
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6.1.4.26. Synthesis of 4-(4-phenethylpiperazine-1-yl)-5-(3-phenylpropyl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (99) 
 
   
synonyms: SMS-A-332 
compound 37 (J. Med. Chem. 2016, 59, 3018−3033) 
educts: 4-chloro-5-(3-phenylpropyl)-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (71), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 37% 
visual appearance: yellow needles 
chemical formula: C28H30N6 
molecular weight: 450.59 Da 
LC-MS analysis: calculated: 450.25 Da; found: 451.5 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 8.62 (s, 1H), 8.53 (s, 1H), 7.30-7.25 (m, 2H), 7.25-7.21 (m, 4H), 
7.20-7.16 (m, 1H), 7.16-7.12 (m, 1H), 7.10-7.07 (m, 2H), 4.31 (t, J = 7.5 Hz, 2H), 3.25-
3.15 (m, 4H), 2.75 (t, J = 7.2 Hz, 2H), 2.54 (t, J = 7.4 Hz, 2H), 2.53-2.50 (m, 4H), 2.48-
2.45 (m, 2H), 2.13-2.05 (m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.0, 151.4, 150.4, 140.9, 140.5, 128.8 (2C), 128.5 (2C), 128.4 
(2C), 128.3 (2C), 126.2, 126.0, 118.0, 114.3, 86.2, 59.6, 52.1 (2C), 50.0 (2C), 48.6, 
32.8, 32.0, 32.0 
 
6.1.4.27. Synthesis of 4-(4-benzylpiperazine-1-yl)-5-(3-phenylpropyl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (100) 
 
  
synonyms: SMS-A-335 
compound 38 (J. Med. Chem. 2016, 59, 3018−3033) 
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educts: 4-chloro-5-(3-phenylpropyl)-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (71), 
1benzylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 29% 
visual appearance: yellow needles 
chemical formula: C27H28N6 
molecular weight: 436.56 Da 
LC-MS analysis: calculated: 436.24 Da; found: 437.5 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.61 (s, 1H), 8.52 (s, 1H), 7.35-7.30 (m, 4H), 7.27-7.22 (m, 3H), 
7.20-7.16 (m, 1H), 7.10-7.06 (m, 2H), 4.30 (t, J = 7.4 Hz, 2H), 3.50 (s, 2H), 3.25-3.14 
(m, 4H), 2.46 (t, J = 7.3 Hz, 2H), 2.45-2.37 (m, 4H), 2.11-2.04 (m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.4, 150.4, 140.9, 140.5, 138.0, 129.0 (2C), 128.5 (2C), 
128.3 (4C), 127.2, 126.2, 118.0, 114.3, 86.2, 62.0, 52.0 (2C), 50.0 (2C), 48.6, 32.0, 32.0 
 
6.1.4.28. Synthesis of 4-(benzylamino)-5-methyl-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (101) 
 
  
synonyms: SMS-A-715 
compound 6 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (61), benzylamine (1.5 eq.) 
and TEA (1.5 eq.) 
yield: 33% 
visual appearance: pale yellow crystals 
chemical formula: C15H13N5 
molecular weight: 263.30 Da 
LC-MS analysis: calculated: 263.12 Da; found: 264.0 Da [M+H]+ 
purity: 95% 
1H NMR: 500 MHz, DMSO-d6, δ 8.21 (s, 2H), 7.59 (t, J = 5.8 Hz, 1H), 7.37 (d, J = 7.3 Hz, 2H), 
7.29 (t, J = 7.6 Hz, 2H), 7.20 (t, J = 7.3 Hz, 2H) 4.74 (d, J = 5.9 Hz, 2H), 4.12 (s, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 152.3, 150.4, 148.3, 139.9, 128.3 (2C), 127.2 (2C), 126.7, 114.9, 
114.8, 84.2, 43.5, 37.7 
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6.1.4.29. Synthesis of 4-(benzylamino)-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (102) 
 
  
synonyms: SMS-A-700 
compound 7 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 4-chloro-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (66), benzylamine (1.5 eq.) 
and TEA (1.5 eq.) 
yield: 42% 
visual appearance: pale yellow crystals 
chemical formula: C20H15N5 
molecular weight: 325.38 Da 
LC-MS analysis: calculated: 325.13 Da; found: 326.1 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 8.54 (s, 1H), 8.39 (s, 1H), 7.64-7.54 (m, 5H), 7.28 (t, J = 7.6 Hz, 
2H), 7.20 (t, J = 7.3 Hz, 3H), 5.59 (t, J = 5.6 Hz, 1H), 4.60 (d, J = 5.6 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 152.7, 149.8, 148.4, 139.6, 139.0, 137.4, 130.1 (2C), 129.7, 
128.5 (2C), 127.1 (2C), 127.0, 126.4 (2C), 114.4, 113.7, 87.4, 43.9 
 
6.1.4.30. Synthesis of 5-benzyl-4-(benzylamino)-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (103) 
 
  
synonyms: SMS-A-705 
compound 8 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 5-benzyl-4-chloro-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (69), benzylamine (1.5 eq.) 
and TEA (1.5 eq.) 
yield: 54% 
visual appearance: brown crystals 
chemical formula: C21H17N5 
molecular weight: 339.40 Da 
LC-MS analysis: calculated: 339.15 Da; found: 340.4 Da [M+H]+ 
purity: 98% 
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1H NMR: 500 MHz, DMSO-d6, δ 8.46 (s, 1H), 8.23 (s, 1H), 7.35-7.26 (m, 4H), 7.20-7.13 (m, 3H), 
7.02 (dd, J = 6.5, 3.0 Hz, 2H), 6.96 (t, J = 7.3, 2.1 Hz, 2H), 5.78 (s, 2H), 4.65 (d, J = 5.8 
Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 152.4, 149.9, 149.0, 139.7, 139.4, 137.1, 129.1 (2C), 128.3 (2C), 
128.1, 126.9 (2C), 126.7, 126.4 (2C), 114.6, 114.2, 85.6, 52.6, 43.3 
 
6.1.4.31. Synthesis of 5-benzyl-4-((3-phenylpropyl)amino)-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (104) 
 
   
synonyms: SMS-A-707 
compound 9 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 5-benzyl-4-chloro-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (69), phenylpropylamine 
(1.5 eq.) and TEA (1.5 eq.) 
yield: 22% 
visual appearance: pale yellow crystals 
chemical formula: C23H21N5 
molecular weight: 367.46 Da 
LC-MS analysis: calculated: 367.18 Da; found: 368.1 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 8.41 (s, 1H), 8.26 (s, 1H), 7.34-7.29 (m, 2H), 7.27-7.22 (m, 3H), 
7.16-7.12 (m, 1H), 7.08-7.03 (m, 4H), 6.65 (t, J = 5.5, 1H), 5.74 (s, 2H), 3.41 (dd, J = 
12.5, 6.9 Hz, 2H), 2.40-2.35 (m, 2H), 1.72 (dt, J = 14.6, 7.3 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 152.6, 150.2, 148.8, 141.9, 139.5, 137.2, 129.2 (2C), 128.5 (4C), 
128.2, 126.4 (2C), 125.9, 114.7, 114.3, 85.5, 52.6, 32.5, 30.4 
 
6.1.4.32. Synthesis of 5-phenethyl-4-(phenethylamino)-5H-pyrrolo[3,2-d]pyrimidine-7-
carbonitrile (105) 
 
   
synonyms: SMS-A-711 
compound 10 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
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educts: 4-chloro-5-phenethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (70), phenethylamine 
(1.5 eq.) and TEA (1.5 eq.) 
yield: 16% 
visual appearance: white crystals 
chemical formula: C23H21N5 
molecular weight: 367.46 Da 
LC-MS analysis: calculated: 367.18 Da; found: 368.1 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 8.33 (s, 1H), 7.95 (s, 1H), 7.30-7.13 (m, 8H), 7.00 (t, J = 5.3 Hz, 
1H), 6.93-6.90 (m, 2H), 4.62 (t, J = 7.1 Hz, 2H), 3.80-3.74 (m, 2H), 2.97 (t, J = 7.2 Hz, 
2H), 2.83 (t, J = 7.1 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 152.3, 150.1, 148.6, 139.7, 138.8, 137.2, 128.9 (2C), 128.9 (2C), 
128.5 (2C), 128.4 (2C), 126.8, 126.3, 114.7, 114.0, 84.5, 50.8, 42.0, 37.2. 34.8 
 
6.1.4.33. Synthesis of 5-phenethyl-4-((3-phenylpropyl)amino)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (106) 
 
N
N
N
N
HN
   
synonyms: SMS-A-712 
compound 11 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 4-chloro-5-phenethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (70), phenylpropylamine 
(1.5 eq.) and TEA (1.5 eq.) 
yield: 29% 
visual appearance: white crystals 
chemical formula: C24H23N5 
molecular weight: 381.48 Da 
LC-MS analysis: calculated: 381.20 Da; found: 382.1 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 8.28 (s, 1H), 8.00 (s, 1H), 7.27 (t, J = 7.5 Hz, 2H), 7.23-7.20 (m, 
4H), 7.20-7.14 (m, 2H) 7.02 (d, J = 6.8 Hz, 2H), 6.94 (t, J = 5.4 Hz, 1H), 4.69 (t, J = 7.2 
Hz, 2H), 3.54 (dd, J = 13.0, 6.9 Hz, 2H), 2.99 (t, J = 7.1 Hz, 2H), 2.69 (t, J = 7.6 Hz, 2H), 
1.99-1.92 (m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 152.2, 150.3, 148.6, 141.9, 138.7, 137.2, 128.9 (2C), 128.5 (2C), 
128.4 (2C), 128.4 (2C), 126.8, 125.9, 114.7, 114.0, 84.5, 50.8, 42.0, 37.4. 32.9, 30.7 
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6.1.4.34. Synthesis of 6-(4-phenethylpiperazine-1-yl)-7H-purine (107) 
 
  
synonyms: SMS-H-3 
compound 12 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 6-chloropurine, 1-(2-phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 52% 
visual appearance: white crystals 
chemical formula: C17H20N6 
molecular weight: 308.39 Da 
LC-MS analysis: calculated: 308.17 Da; found: 309.1 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 13.00 (s, 1H), 8.19 (s, 1H), 8.09 (s, 1H), 7.29-7.21 (m, 4H), 7.19-
7.15 (m, 1H), 4.32-4.08 (m, 4H), 2.78 (t, J = 7.3 Hz, 2H), 2.64-2.51 (m, 6H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.3, 151.9, 151.5, 140.5, 138.2, 128.8, 128.4, 126.0, 118.9, 
59.8, 52.8 (2C), 45.8 (2C), 32.7 
 
6.1.4.35. Synthesis of 6-(4-benzylpiperazine-1-yl)-7H-purine (108) 
 
  
synonyms: SMS-H-6 
compound 13 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 6-chloropurine, 1-benzylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 41% 
visual appearance: white crystals 
chemical formula: C16H18N6 
molecular weight: 294.36 Da 
LC-MS analysis: calculated: 294.16 Da; found: 294.2 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 12.98 (s, 1H), 8.18 (s, 1H), 8.09 (s, 1H), 7.32 (d, J = 4.5 Hz, 4H), 
7.27-7.23 (m, 1H), 4.32-4.15 (m, 4H), 3.29 (s, 2H), 2.48-2.45 (m, 4H) 
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13C NMR: 126 MHz, DMSO-d6, δ 153.3, 151.9, 151.6, 138.3, 138.0, 129.1 (2C), 128.3 (2C), 127.1, 
118.9, 62.2, 52.8 (2C), 44.6 (2C) 
 
6.1.4.36. Synthesis of 6-(4-benzhydrylpiperazine-1-yl)-7H-purine (109) 
 
  
synonyms: SMS-H-4 
compound 14 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
educts: 6-chloropurine, 1-benzhydrylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 48% 
visual appearance: white crystals 
chemical formula: C22H22N6 
molecular weight: 370.46 Da 
LC-MS analysis: calculated: 370.19 Da; found: 294.2 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 12.97 (s, 1H), 8.17 (s, 1H), 8.07 (s, 1H), 7.14 (dd, J = 8.2, 1.1 
Hz, 4H), 7.32-7.28 (m, 4H), 7.21-7.17 (m, 2H), 4.35 (s, 1H), 4.31-4.11 (m, 4H), 2.44-
2.40 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.2, 151.9, 151.5, 142.6 (2C), 138.2, 128.7 (4C), 127.8 (4C), 
127.1 (2C), 118.9, 75.0, 51.6 (2C), 44.8 (2C) 
 
6.1.4.37. Synthesis of 6-(4-phenylpiperazine-1-yl)-7H-purine (110) 
 
  
synonyms: SMS-H-5 
compound 15 (Biochim. Biophys. Acta 2017, 1859, 69–79) 
 
educts: 6-chloropurine, 1-phenylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 50% 
visual appearance: white crystals 
chemical formula: C15H16N6 
molecular weight: 280.34 Da 
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LC-MS analysis: calculated: 280.14 Da; found: 281.1 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 13.03 (s, 1H), 8.23 (s, 1H), 8.13 (s, 1H), 7.26-7.20 (m, 2H), 6.99 
(dt, J = 9.2, 1.7 Hz, 2H), 6.80 (tt, J 7.4, 1.0 Hz, 1H), 4.48-4.22 (m, 4H), 2.27-2.24 (m, 
4H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.3, 152.0, 151.6, 151.1, 138.4, 129.1 (2C), 119.4, 119.0, 
116.0 (2C), 48.6 (2C), 44.6 (2C) 
 
6.1.4.38. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-6,7,8,9-
tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (111) 
 
  
synonyms: SMS-A-9 
compound 41 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 3-(2-
(piperazine-1-yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 58% 
visual appearance: yellow powder 
chemical formula: C25H27N7 
molecular weight: 425.54 Da 
LC-MS analysis: calculated: 425.23 Da; found: 426.4 Da [M+H]+ 
purity: 91% 
1H NMR: 500 MHz, DMSO-d6, δ 10.76 (s, 1H), 8.47 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.32 (dt, J = 
8.2, 0.8 Hz, 1H), 7.15 (d, J = 2.3 Hz, 1H), 7.05 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 6.96 (ddd, 
J = 7.9, 7.0; 1.0 Hz, 1H), 4.36 (t, J = 5.6 Hz, 2H), 3.37-3.32 (m, 4H), 3.11 (t, J = 6.5 Hz, 
2H), 2.89 (t, J = 7.3 Hz, 2H), 2.71-2.65 (m, 6H), 1.98-1.88 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.4, 151.3, 151.0, 150.2, 136.3, 127.4, 123.6, 120.9 (2C), 
118.4, 118.3, 114.5, 112.7, 111.5, 83.6, 58.9, 52.4 (2C), 50.4 (2C), 46.1, 22.9, 22.6, 
22.6, 18.4 
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6.1.4.39. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-7,8,9,10-tetrahydro-
6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (112) 
 
  
synonyms: SMS-A-35 
compound 42 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 3-(2-(piperazine-1-yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 58% 
visual appearance: pale yellow crystals 
chemical formula: C26H29N7 
molecular weight: 439.57 Da 
LC-MS analysis: calculated: 439.25 Da; found: 440.3 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 10.74 (s, 1H), 8.48 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 
8.1, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.05 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.96 (ddd, J = 
7.9, 7.1; 0.8 Hz, 1H), 4.55-4.42 m, 2H), 3.41-3.30 (m, 4H), 3.09 (t, J = 5.5 Hz, 2H), 2.89 
(t, J = 7.3 Hz, 2H), 2.75-2.62(m, 6H), 1.91-1.82 (m, 2H), 1.80-1.71 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 156.6, 153.7, 151.1, 149.6, 136.2, 127.4, 122.6, 120.9, 118.4, 
118.3, 117.9, 114.6, 112.6, 111.4, 85.3, 58.9, 52.2 (2C), 49.8 (2C), 47.4, 29.9, 27.9, 
27.1, 25.6, 22.5 
 
6.1.4.40. Synthesis of 4-((2-(1H-indole-3-yl)ethyl)amino)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (113) 
 
  
synonyms: SMS-A-695 
compound 43 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
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educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), tryptamine (1.5 
eq.) and TEA (1.5 eq.) 
yield: 13% 
visual appearance: pale yellow crystals 
chemical formula: C21H20N6 
molecular weight: 356.43 Da 
LC-MS analysis: calculated: 356.17 Da; found: 357.2 Da [M+H]+ 
purity: 96% 
1H NMR: 500 MHz, DMSO-d6, δ 10.80 (s, 1H), 8.27 (s, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 
8.1 Hz, 1H), 7.20 (d, J = 2.1 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.97 (t, J = 7.4 Hz, 1H), 
6.92 (t, J = 5.6 Hz, 1H), 4.32 (t, J = 6.2 Hz, 2H), 3.75 (dd, J = 14.0, 6.0 Hz, 2H), 3.04-
2.98 (m, 4H), 2.03-1.95 (m, 2H), 1.86-1.79 (m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 152.2, 149.8, 147.6, 147.5, 136.4, 127.6, 122.8, 121.1, 118.5, 
118.3, 115.0, 113.9, 112.1, 111.5, 82.1, 45.6, 41.4, 25.0, 23.0, 22.1, 18.1 
 
6.1.4.41. Synthesis of 4-(4-(2-(pyridin-4-yl)ethyl)piperazine-1-yl)-6,7,8,9-
tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (114) 
 
   
synonyms: SMS-A-129 
compound 44 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-(2-(pyridin-4-
yl)ethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 42% 
visual appearance: yellow powder 
chemical formula: C22H25N7 
molecular weight: 387.49 Da 
LC-MS analysis: calculated: 387.22 Da; found: 388.3 Da [M+H]+ 
purity: 96% 
1H NMR: 500 MHz, DMSO-d6, δ 8.46 (s, 1H), 8.44 (dd, J = 4.4, 1.6. Hz, 2H), 7.28 (dd, J = 4.4, 1.6 
Hz, 2H), 4.34 (t, J = 5.6 Hz, 2H), 3.38-3.31 (m, 4H), 3.11 (t, J = 6.5 Hz, 2H), 2.80 (t, J = 
7.3 Hz, 2H), 2.71-2.60 (m, 6H), 1.98-1.87 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.3, 151.2, 151.0, 150.2, 149.5 (2C), 136.3, 124.4 (3C), 118.2, 
114.4, 83.6, 58.1, 52.6 (2C), 50.2, 46.0 (2C), 31.8, 22.9, 22.6, 18.4 
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6.1.4.42. Synthesis of 4-(4-(2-(pyridin-4-yl)ethyl)piperazine-1-yl)-7,8,9,10-tetrahydro-6H-
pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (115) 
 
  
synonyms: SMS-A-130 
compound 45 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-(2-(pyridin-4-yl)ethyl)piperazine and (1.5 eq.) and TEA (1.5 eq.) 
yield: 42% 
visual appearance: pale yellow crystals 
chemical formula: C23H27N7 
molecular weight: 401.52 Da 
LC-MS analysis: calculated: 401.23 Da; found: 402.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.49 (s, 1H), 8.46 (d, J = 4.6 Hz, 2H), 7.29 (d, J = 4.7 Hz, 2H), 
4.52-4.45 (m, 2H), 3.20-3.17 (m, 4H), 3.12 (t, J = 6.4 Hz, 2H), 2.82 (t, J = 7.3 Hz, 2H), 
2.70-2.59 (m, 6H), 1.91-1.83 (m, 2H), 1.83-1.71 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 156.6, 153.7, 151.1, 149.6, 149.5, 149.5 (2C), 124.4 (3C), 117.9, 
114.6, 85.3, 58.2, 52.0 (2C), 49.7 (2C), 47.4, 31.8, 29.9, 27.9, 27.1, 25.6 
 
6.1.4.43. Synthesis of 4-(4-(pyridin-2-yl)piperazine-1-yl)-6,7,8,9-tetrahydropyrimido[4,5-
b]indolizine-10-carbonitrile (116) 
 
   
synonyms: SMS-A-158 
compound 46 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-(pyridin-2-
yl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
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yield: 55% 
visual appearance: pale yellow crystals 
chemical formula: C20H21N7 
molecular weight: 359.44 Da 
LC-MS analysis: calculated: 359.19 Da; found: 360.1 Da [M+H]+ 
purity: 93% 
1H NMR: 500 MHz, DMSO-d6, δ 8.49 (s, 1H), 8.15-8.12 (m, 1H), 7.56 (ddd, J = 8.9, 6.9, 2.0 Hz 
1H), 6.88 (d, J = 8.6 Hz), 6.68 (dd, J = 7.1, 4.9 Hz, 1H), 4.42 (t, J = 5.5 Hz, 2H), 3.67 (t, 
J = 5.3 Hz, 4H), 3.42 (t, J = 5.2 Hz, 4H), 3.13 (t, J = 6.4 Hz, 2H), 1.99-1.88 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 159.2, 154.4, 151.3, 151.1, 150.3, 147.7, 137.8, 118.4, 114.4, 
113.6, 107.5, 83.6, 50.1 (2C), 46.1, 44.5 (2C), 23.0, 22.6, 18.4 
 
6.1.4.44. Synthesis of 4-(4-(pyridin-2-yl)piperazine-1-yl)-7,8,9,10-tetrahydro-6H-
pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (117) 
 
   
synonyms: SMS-A-160 
compound 47 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-(pyridin-2-yl)piperazine and (1.5 eq.) and TEA (1.5 eq.) 
yield: 58% 
visual appearance: yellow crystals 
chemical formula: C21H23N7 
molecular weight: 373.46 Da 
LC-MS analysis: calculated: 373.20 Da; found: 374.2Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.51 (s, 1H), 8.14 (ddd, J = 4.8, 1.9, 0.7 Hz, 1H), 7.57 (ddd, J = 
8.8, 6.8, 2.0 Hz, 1H), 6.90 (d, J = 8.6 Hz), 6.68 (ddd, J = 7.1, 4.9, 0.6 Hz, 1H), 4.57-4.50 
(m, 2H), 3.76-3.63 (m, 4H), 3.44-3.35 (m, 4H), 3.11 (t, J = 5.0 Hz, 2H), 1.89-1.73 (m, 
6H) 
13C NMR: 126 MHz, DMSO-d6, δ 159.1, 156.8, 155.6, 154.3, 149.7, 141.1, 137.8, 118.3, 114.6, 
113.6, 107.5, 79.6, 49.5 (2C), 47.5, 44.3 (2C), 30.3, 30.0, 27.8, 25.6 
 
 
 
 
Experimental Section  179 
 
6.1.4.45. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-methyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (118) 
 
   
synonyms: SMS-A-339 
compound 48 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (61), 3-(2-(piperazine-1-
yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 29% 
visual appearance: yellow crystals 
chemical formula: C22H23N7 
molecular weight: 385.47 Da 
LC-MS analysis: calculated: 385.20 Da; found: 386.3 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 10.74 (s, 1H), 8.51 (s, 1H), 8.44 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 
7.32 (dt, J = 8.1, 0.9 Hz, 1H), 7.16 (d, J = 2.3 Hz, 1H), 7.05 (ddd, J = 8.1, 7.0, 1.1 Hz, 
1H), 6.96 (ddd, J = 7.9, 7.0; 1.0 Hz, 1H), 4.01 (s, 3H), 3.42-3.37 (m, 4H), 2.89 (t, J = 7.3 
Hz, 2H), 2.73-2.65 (m, 6H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.4, 150.1, 141.5, 136.3, 127.4, 122.6, 121.0, 118.6, 
118.4, 118.3, 114.4, 112.6, 111.5, 85.4, 58.9, 52.3 (2C), 50.2 (2C), 36.8, 22.5 
 
6.1.4.46. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-ethyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (119) 
 
N
N
N
N
N
N
NH    
synonyms: SMS-A-477 
compound 49 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
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educts: 4-chloro-5-ethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (62), 3-(2-(piperazine-1-
yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 25% 
visual appearance: yellow crystals 
chemical formula: C23H25N7 
molecular weight: 399.50 Da 
LC-MS analysis: calculated: 399.22 Da; found: 400.2 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 10.76 (s, 1H), 8.61 (s, 1H), 8.55 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 
7.32 (d, J = 8.1 Hz, 1H), 7.16 (d, J = 2.2 Hz, 1H), 7.06 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 
6.96 (ddd, J = 7.9, 7.0; 1.0 Hz, 1H), 4.35 (q, J = 7.2 Hz, 2H) 3.38-3.33 (m, 4H), 2.90 (t, J 
= 7.4 Hz, 2H), 2.76-2.66 (m, 6H), 1.38 (t, J = 7.2 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.0, 151.4, 150.6, 140.6, 136.3, 127.4, 122.7, 121.0, 118.4, 
118.3, 117.9, 114.4, 112.6, 111.5, 86.2, 58.9, 52.4 (2C), 50.2 (2C), 44.1, 22.6, 16.1 
 
6.1.4.47. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-propyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (120) 
 
  
synonyms: SMS-A-484 
compound 50 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-propyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (63), 3-(2-(piperazine-1-
yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 21% 
visual appearance: white crystals 
chemical formula: C24H27N7 
molecular weight: 413.53 Da 
LC-MS analysis: calculated: 413.23 Da; found: 414.3 Da [M+H]+ 
purity: 91% 
1H NMR: 500 MHz, DMSO-d6, δ 10.74 (s, 1H), 8.60 (s, 1H), 8.56 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 
7.32 (dt, J = 8.1, 0.8 Hz, 1H), 7.16 (d, J = 2.3 Hz, 1H), 7.05 (ddd, J = 8.1, 7.0, 1.1 Hz, 
1H), 6.96 (ddd, J = 7.9, 7.0; 1.0 Hz, 1H), 4.27 (t, J = 7.4 Hz, 2H) 3.38-3.32 (m, 4H), 2.90 
(t, J = 7.3 Hz, 2H), 2.72-2.64 (m, 6H), 1.76 (p, J = 7.3 Hz, 2H), 0.72 (t, J = 7.4 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.1, 151.4, 150.6, 141.2, 136.3, 127.4, 122.6, 120.9, 118.4, 
118.3, 118.0, 114.3, 112.6, 111.5, 85.9, 58.9, 52.5 (2C), 50.8, 50.2 (2C), 24.2, 22.5, 
10.7 
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6.1.4.48. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-cyclopropyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (121) 
 
   
synonyms: SMS-A-498 
compound 51 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-cyclopropyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (65), 3-(2-(piperazine-
1-yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 39% 
visual appearance: white crystals 
chemical formula: C24H25N7 
molecular weight: 411.51 Da 
LC-MS analysis: calculated: 411.22 Da; found: 412.2 Da [M+H]+ 
purity: 96% 
1H NMR: 500 MHz, DMSO-d6, δ 10.74 (s, 1H), 8.47 (s, 1H), 8.46 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 
7.32 (d, J = 8.1, 1H), 7.15 (d, J = 2.3 Hz, 1H), 7.04 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 6.96 
(ddd, J = 7.9, 7.1; 1.0 Hz, 1H), 3.97 (p, J = 3.6 Hz, 1H) 3.60-3.50 (m, 4H), 2.88 (t, J = 
7.8 Hz, 2H), 2.70-2.62 (m, 6H), 1.15-1.02 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.4, 151.3, 150.1, 140.2, 136.3, 127.4, 122.6, 120.9, 118.5, 
118.4, 118.2, 114.4, 112.6, 111.4, 85.6, 58.9, 52.5 (2C), 49.8 (2C), 32.1, 22.5, 8.5 (2C) 
 
6.1.4.49. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-phenyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (122) 
 
N
N
N
N
N
N
NH   
synonyms: SMS-A-307 
compound 52 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
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educts: 4-chloro-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (66), 3-(2-(piperazine-1-
yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 11% 
visual appearance: yellow crystals 
chemical formula: C27H25N7 
molecular weight: 447.55 Da 
LC-MS analysis: calculated: 447.22 Da; found: 448.1 Da [M+H]+ 
purity: 93% 
1H NMR: 500 MHz, DMSO-d6, δ 10.70 (s, 1H), 8.74 (s, 1H), 8.58 (s, 1H), 7.62-7.58 (m, 2H), 7.54-
7.50 (m, 3H), 7.43 (d, J = 7.8 Hz, 1H), 7.30 (dt, J = 8.1, 0.8 Hz, 1H), 7.07 (d, J = 2.3 Hz, 
1H), 7.03 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 6.94 (ddd, J = 7.9, 7.0; 1.0 Hz, 1H), 3.12-3.06 
(m, 4H) 2.71 (t, J = 8.3 Hz, 2H), 2.44 (t, J = 8.2 Hz, 2H), 2.16-2.08 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.2, 151.9, 150.2, 141.4, 137.9, 136.3, 129.6 (2C), 128.5, 
127.3, 125.3 (2C), 122.5, 120.9, 118.3, 118.2, 115.3, 114.1, 112.5, 111.4, 88.1, 58.7, 
51.5 (2C), 48.8 (2C), 22.2 
 
6.1.4.50. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-benzyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (123) 
 
N
N
N
N
N
N
NH   
synonyms: SMS-A-315 
compound 53 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-benzyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (69), 3-(2-(piperazine-1-
yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 18% 
visual appearance: white crystals 
chemical formula: C28H27N7 
molecular weight: 461.57 Da 
LC-MS analysis: calculated: 461.23 Da; found: 462.0 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 10.74 (s, 1H), 8.65 (s, 1H), 8.56 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 
7.33-7.28 (m, 3H), 7.27-7.23 (m, 1H), 7.16-7.14 (m, 1H), 7.14-7.13 (m, 1H), 7.43 (d, J = 
7.8 Hz, 1H), 7.04 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 6.96 (ddd, J = 7.9, 7.0; 1.0 Hz, 1H), 
5.54 (s, 2H), 3.39-3.33 (m, 4H) 2.90-2.85 (m, 2H), 2.71-2.61 (m, 6H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.2, 151.7, 150.9, 141.7, 137.0, 136.3, 128.8 (2C), 128.1, 
127.4, 127.1 (2C), 122.6, 120.9, 118.4, 118.3, 117.9, 114.00, 112.6, 111.4, 87.0, 58.3, 
52.3 (2C), 52.1, 50.0 (2C), 22.5 
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6.1.4.51. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-phenethyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (124) 
 
  
synonyms: SMS-A-323 
compound 54 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-phenethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (70), 3-(2-(piperazine-1-
yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 9% 
visual appearance: white crystals 
chemical formula: C29H29N7 
molecular weight: 475.60 Da 
LC-MS analysis: calculated: 475.25 Da; found: 476.2 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 10.73 (s, 1H), 8.55 (s, 1H), 8.50 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 
7.33 (dt, J = 8.1, 0.8 Hz, 1H), 7.18-7.09 (m, 4H), 7.05 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 
7.01-6.95 (m, 3H), 4.56 (t, J = 7.2 Hz, 2H), 3.29-3.26 (m, 4H) 3.01 (t, J = 7.1 Hz, 2H), 
2.88 (t, J = 7.2 Hz, 2H), 2.71-2.61 (m, 6H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.0, 151.4, 150.4, 141.1, 137.3, 136.3, 128.7 (2C), 128.2 (2C), 
127.4, 126.7, 122.6, 121.0, 118.4, 118.3, 118.1, 114.3, 112.6, 111.5, 86.2, 59.0, 52.3 
(2C), 50.3, 50.0 (2C), 37.2, 22.4 
 
6.1.4.52. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5-(3-phenylpropyl)-
5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (125) 
 
  
synonyms: SMS-A-331 
compound 55 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
 184 Experimental Section 
 
educts: 4-chloro-5-phenylpropyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (71), 3-(2-
(piperazine-1-yl)ethyl)-1H-indole (73) and (1.5 eq.) and TEA (1.5 eq.) 
yield: 16% 
visual appearance: pale yellow crystals 
chemical formula: C30H31N7 
molecular weight: 489.63Da 
LC-MS analysis: calculated: 489.26 Da; found: 490.3 Da [M+H]+ 
purity: 95% 
1H NMR: 500 MHz, DMSO-d6, δ 10.75 (s, 1H), 8.62 (s, 1H), 8.54 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 
7.33 (d, J = 8.1 Hz, 1H), 7.23 (t, J = 7.5 Hz, 2H), 7.16 (d, J = 2.1 Hz, 1H), 7.14 (t, J = 7.4 
Hz, 1H), 7.09 (d, J = 7.0 Hz, 2H), 7.05 (m, 1H), 6.97 (m, 1H), 4.33 (t, J = 7.3 Hz, 2H) 
3.27-3.23 (m, 6H), 2.87 (t, J = 7.2 Hz, 2H), 2.62 (t, J = 7.2 Hz, 2H), 2.59-2.51 (m, 4H), 
2.09 (p, J = 7.5 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 155.0, 151.4, 150.4, 140.9, 140.5, 136.3, 128.5 (2C), 128.3 (2C), 
127.3, 126.2, 122.6, 120.9, 118.4, 118.3, 118.0, 114.3, 112.6, 111.5, 86.2, 58.8, 52.2 
(2C), 50.1 (2C), 48.6, 32.0, 32.0, 22.5 
 
6.1.4.53. Synthesis of 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-yl)-6,7,8,9-
tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (126) 
 
  
synonyms: SMS-A-54 
compound 56 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-
piperonylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 46% 
visual appearance: white crystals 
chemical formula: C23H24N6O2 
molecular weight: 416.48 Da 
LC-MS analysis: calculated: 416.20 Da; found: 417.1 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 8.45 (s, 1H), 6.88 (d, J = 1.5 Hz, 1H), 6.84 (d, J = 7.9 Hz, 1H), 
6.77 (dd, J = 7.9, 1.5 Hz, 1H), 5.98 (s, 2H), 4.33 (t, J = 5.6 Hz, 2H), 3.45 (s, 2H), 3.36-
3.29 (m, 4H), 3.10 (t, J = 6.4 Hz, 2H), 2.61-2.50 (m, 4H), 1.98-1.84 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.3, 151.2, 150.9, 150.2, 147.4, 146.4, 131.9, 122.2, 118.2, 
114.4, 109.3, 108.0, 100.9, 83.6, 61.9, 52.1 (2C), 50.4 (2C), 46.1, 22.9, 22.6, 18.4 
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6.1.4.54. Synthesis of 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-yl)-7,8,9,10-
tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (127) 
 
  
synonyms: SMS-A-68 
compound 57 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-piperonylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 35% 
visual appearance: pale yellow crystals 
chemical formula: C24H26N6O2 
molecular weight: 430.51 Da 
LC-MS analysis: calculated: 430.21 Da; found: 431.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.46 (s, 1H), 6.88 (d, J = 1.5 Hz, 1H), 6.84 (d, J = 7.8 Hz, 1H), 
6.77 (dd, J = 7.9, 1.6 Hz, 1H), 5.98 (s, 2H), 4.54-4.40 (m, 2H), 3.45 (s, 2H), 3.35-3.29 
(m, 4H), 3.12-3.04 (m, 2H), 2.61-2.49 (m, 4H), 1.89-1.80 (m, 2H), 180-168 m, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 156.6, 153.7, 151.1, 149.6, 147.4, 146.3, 131.9, 122.2, 117.9, 
114.6, 109.3, 108.0, 100.9, 85.3, 61.8, 51.9 (2C), 49.8 (2C), 47.4, 29.9, 27.9, 27.2, 25.6 
 
6.1.4.55. Synthesis of 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-yl)-5-phenyl-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (128) 
 
  
synonyms: SMS-A-703 
compound 58 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-phenyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (66), 1-piperonylpiperazine 
(1.5 eq.) and TEA (1.5 eq.) 
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yield: 37% 
visual appearance: yellow crystals 
chemical formula: C25H22N6O2 
molecular weight: 438.49 Da 
LC-MS analysis: calculated: 438.18 Da; found: 439.1 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 8.80 (s, 1H), 8.64 (s, 1H), 7.58-7.46 (m, 5H), 707 (s, 1H), 6.97 
(s, 1H), 6.90 (s, 1H), 6.06 (s, 1H), 4.17-3.97 (m, 2H), 3.73-3.40 (m, 4H), 315-2.96 (m, 
4H) 
13C NMR: 126 MHz, DMSO-d6, δ 151.7, 151.4, 147.5, 141.7, 137.5, 129.5 (3C), 128.6, 125.4 (3C), 
115.5, 113.9, 101.6, 88.2, 49.1 (2C), 45.2 (2C) 
 
6.1.4.56. Synthesis of 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-yl)-5-phenethyl-
5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (129) 
 
  
synonyms: SMS-A-713 
compound 59 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-phenethyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (70), 1-
piperonylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 20% 
visual appearance: white crystals 
chemical formula: C27H26N6O2 
molecular weight: 466.55 Da 
LC-MS analysis: calculated: 466.21 Da; found: 467.3 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 8.55 (s, 1H), 8.48 (s, 1H), 7.17-7.11 (m, 3H), 6.98-6.95 (m, 2H), 
6.87 (d, J = 1.4 Hz, 1H), 6.85 (d, J = 7.9 Hz, 1H), 6.76 (dd, J = 7.9, 1.5 Hz, 1H), 5.98 (s, 
2H) ,4.52 (t, J = 7.2 Hz, 2H), 3.44 (s, 2H), 3.26-3.20 (m, 4H), 3.00 (t, J = 7.1 Hz, 2H), 
2.57-2.51 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 154.9, 151.4, 150.5, 147.4, 146.4, 141.1, 137.3, 131.8, 128.7 
(2C), 128.3 (2C), 126.8, 122.3, 118.1, 114.3, 109.3, 108.3, 101.0, 86.2, 61.8, 52.0 (2C), 
50.3, 50.0 (2C), 37.2 
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6.1.4.57. Synthesis of 4-(4-(furan-2-carbonyl)piperazine-1-yl)-6,7,8,9-
tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (130) 
 
  
synonyms: SMS-A-127 
compound 60 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile (59), 1-(2-
furoyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 37% 
visual appearance: yellow crystals 
chemical formula: C20H20N6O2 
molecular weight: 376.42 Da 
LC-MS analysis: calculated: 376.16 Da; found: 377.2 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 8.49 (s, 1H), 7.85 (dd, J = 1.7, 0.7 Hz, 1H), 7.03 (dd, J = 3.5, 0.7 
Hz, 1H), 6.64 (dd, J = 3.4, 1.8 Hz, 1H), 4.40 (t, J = 5.6 Hz, 2H), 3.94-3.82 (m, 4H), 3.39 
(t, J = 5.0 Hz, 4H), 3.13 (t, J = 6.4 Hz, 2H), 2.02-1.86 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 158.7, 153.9, 151.2, 151.1, 150.3, 147.0, 144.9, 118.2, 115.9, 
114.4, 111.5, 83.6, 60.4, 46.0 (2C), 40.4 (2C), 23.0, 22.6, 18.3 
 
6.1.4.58. Synthesis of 4-(4-(furan-2-carbonyl)piperazine-1-yl)-7,8,9,10-tetrahydro-6H-
pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile (131) 
 
  
synonyms: SMS-A-128 
compound 61 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-7,8,9,10-tetrahydro-6H-pyrimido[4',5':4,5]pyrrolo[1,2-a]azepine-11-carbonitrile 
(60), 1-(2-furoyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
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yield: 37% 
visual appearance: white crystals 
chemical formula: C21H22N6O2 
molecular weight: 390.45 Da 
LC-MS analysis: calculated: 390.18 Da; found: 391.2 Da [M+H]+ 
purity: 96% 
1H NMR: 500 MHz, DMSO-d6, δ 8.50 (s, 1H), 7.85 (dd, J = 1.8, 0.8 Hz, 1H), 7.04 (dd, J = 3.5, 0.8 
Hz, 1H), 6.64 (dd, J = 3.5, 1.8 Hz, 1H), 4.54-4.46 (m, 2H), 3.95-3.81 (m, 4H), 3.40-3.35 
(m, 4H), 3.11 (t, J = 5.4 Hz, 2H), 1.89-1.72 (m, 6H) 
13C NMR: 126 MHz, DMSO-d6, δ 158.7, 156.9, 153.4, 151.0, 149.8, 147.0, 145.0, 117.9, 116.0, 
114.5, 111.5, 85.3, 56.1 (2C), 49.8, 47.5 (2C), 29.9, 27.8, 27.2, 25.6 
 
6.1.4.59. Synthesis of 5-(2-methoxyphenyl)-4-(4-phenethylpiperazine-1-yl)-5H-
pyrrolo[3,2-d]pyrimidine-7-carbonitrile (132) 
 
  
synonyms: SMS-A-436 
compound 62 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-(2-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (67), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 22% 
visual appearance: pale yellow crystals 
chemical formula: C26H26N6O 
molecular weight: 438.54 Da 
LC-MS analysis: calculated: 438.22 Da; found: 439.3 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.57 (s, 1H), 8.56 (s, 1H), 7.54 (ddd, J = 8.4, 7.5, 1.7 Hz, 1H), 
7.42 (dd, J = 7.8, 1.6 Hz, 1H), 7.30 (dd, J = 8.4, 1.1 Hz, 1H), 7.26-7.20 (m, 2H), 7.19-
7.08 (m, 4H), 3.74 (s, 3H), 3.10-2.59 (m, 4H), 2.63-2.57 (m, 2H), 2.38-2.31 (m, 2H), 
2.05-1.93 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 158.5, 153.1, 151.7, 150.9, 141.4, 137.8, 130.9, 128.9 (2C), 
128.3 (2C), 127.1, 126.7 (2C), 115.6, 115.2 (2C), 114.2, 87.6, 63.8, 62.1, 51.5 (2C), 
48.8 (2C), 14.7 
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6.1.4.60. Synthesis of 4-(4-benzylpiperazine-1-yl)-5-(2-methoxyphenyl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (133) 
 
  
synonyms: SMS-A-439 
compound 63 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-(2-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (67), 1-
benzylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 20% 
visual appearance: yellow crystals 
chemical formula: C25H24N6O 
molecular weight: 424.51 Da 
LC-MS analysis: calculated: 424.20 Da; found: 425.2 Da [M+H]+ 
purity: 100% 
1H NMR: 500 MHz, DMSO-d6, δ 8.56 (s, 1H), 8.55 (s, 1H), 7.53 (ddd, J = 8.4, 7.5, 1.7 Hz, 1H), 
7.41 (dd, J = 7.8, 1.6 Hz, 1H), 7.32-7.21 (m, 4H), 7.20-7.16 (m, 2H), 7.10 (td, J 7.6, 1.2 
Hz, 1H), 3.71 (s, 3H), 3.31 (s, 2H), 3.09-2.96 (m, 4H), 1.97-1.87 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 153.9, 153.8, 151.7, 150.2, 141.5, 137.7, 130.7, 128.9 (2C), 
128.3 (2C), 128.0, 127.1, 126.6, 120.8, 117.0, 114.0, 112.9, 87.7, 61.9, 56.0, 51.4 (2C), 
49.1 (2C) 
 
6.1.4.61. Synthesis of 5-(4-ethoxyphenyl)-4-(4-phenethylpiperazine-1-yl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (134) 
 
  
synonyms: SMS-A-412 
compound 64 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
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educts: 4-chloro-5-(4-ethoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (68), 1-(2-
phenethyl)piperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 22% 
visual appearance: pale yellow crystals 
chemical formula: C27H28N6O 
molecular weight: 452.56 Da 
LC-MS analysis: calculated: 452.23 Da; found: 453.2 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 8.66 (s, 1H), 8.55 (s, 1H), 7.41 (d, J = 8.8 Hz, 2H), 7.42 (t, J = 
7.5 Hz, 2H), 7.15 (t, J = 7.9 Hz, 3H), 7.11 (d, J = 8.8 Hz, 2H), 4.11 (q, J = 6.9 Hz, 2H), 
3.11-3.04 (m, 4H), 2.60 (t, J = 8.3 Hz, 2H), 2.38 (t, J = 8.4 Hz, 2H), 2.13-2.07 (m, 4H), 
1.33 (t, J = 6.9 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 158.5, 153.2, 151.7, 150.9, 141.4, 140.4, 130.9, 128.7 (2C), 
128.4 (2C), 126.8 (2C), 126.0, 115.7, 115.2 (2C), 114.2, 87.6, 63.8, 59.7, 51.4 (2C), 
48.9 (2C), 32.4, 14.7 
 
6.1.4.62. Synthesis of 4-(4-benzylpiperazine-1-yl)-5-(4-ethoxyphenyl)-5H-pyrrolo[3,2-
d]pyrimidine-7-carbonitrile (135) 
 
  
synonyms: SMS-A-415 
compound 65 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5-(4-ethoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile (68), 1-
benzylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 20% 
visual appearance: pale yellow crystals 
chemical formula: C26H26N6O 
molecular weight: 438.54 Da 
LC-MS analysis: calculated: 438.22 Da; found: 439.1 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, DMSO-d6, δ 8.64 (s, 1H), 8.54 (s, 1H), 7.40-7.36 (m, 2H), 7.31-7.26 (m, 2H), 
7.24-7.20 (m, 1H), 7.20-7.17 (m, 2H), 7.11-7.07 (m, 2H), 4.14 (q, J = 7.0 Hz, 2H), 3.31 
(s, 2H), 3.14-3.02 (m, 4H), 2.08-1.96 (m, 4H), 1.39 (t, J = 7.0 Hz, 3H) 
13C NMR: 126 MHz, DMSO-d6, δ 158.5, 153.1, 151.7, 150.9, 141.4, 137.8, 130.9, 128.9 (2C), 
128.3 (2C), 127.1, 126.7 (2C), 115.6, 115.2 (2C), 114.2, 87.6, 63.8, 62.1, 51.5 (2C), 
48.8 (2C), 14.7 
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6.1.4.63. Synthesis of 4-(4-phenethylpiperazine-1-yl)-5H-pyrimido[5,4-b]indole (136) 
 
  
synonyms: SMS-A-137 
compound 69 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 1-(2-phenethyl)piperazine (1.5 eq.) and TEA 
(1.5 eq.) 
yield: 18% 
visual appearance: pale yellow crystals  
chemical formula: C22H23N5 
molecular weight: 357.46 Da 
LC-MS analysis: calculated: 357.20 Da; found: 358.1 Da [M+H]+ 
purity: 94% 
1H NMR: 500 MHz, DMSO-d6, δ 11.27 (s, 1H), 8.46 (s, 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.61 (dt, J = 
8.3, 0.9 Hz, 1H), 7.53 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.30-7.21 (m, 5H), 7.20-7.16 (m, 
1H), 3.80 (t, J = 4.9 Hz, 4H), 2.80 (dd, J = 9.1, 6.6 Hz, 2H), 2.65 (t, J = 5.0 Hz, 4H), 2.61 
(dd, J = 9.0, 6.7 Hz, 2H) 
13C NMR: 126 MHz, DMSO-d6, δ 151.1, 149.1, 144.8, 140.5, 140.0, 128.8 (2C), 128.4 (3C), 126.0, 
120.7, 120.5, 119.9, 118.5, 112.7, 59.8, 52.8 (2C), 46.1 (2C), 32.8 
 
6.1.4.64. Synthesis of 4-(4-benzylpiperazine-1-yl)-5H-pyrimido[5,4-b]indole (137) 
 
  
synonyms: SMS-A-140 
compound 70 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 1-benzylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 36% 
visual appearance: yellow crystals 
chemical formula: C21H21N5 
molecular weight: 343.43 Da 
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LC-MS analysis: calculated: 343.18 Da; found: 344.1 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, CDCL3, δ 9.09 (s, 1H), 8.61 (s, 1H), 8.20 (d, J = 7.9 Hz, 1H), 7.50-7.42 (m, 
2H), 7.33-7.30 (m, 4H), 7.27-7.25 (m, 1H), 7.24-7.20 (m, 1H), 3.90 (t, J = 4.9 Hz, 4H), 
3.55 (s, 2H), 2.61 (t, J = 4.9 Hz, 4H) 
13C NMR: 126 MHz, CDCl3, δ 151.3, 149.6, 145.1, 139.9, 137.1, 129.3 (2C), 128.9, 128.4 (2C), 
127.4, 121.2, 121.2, 120.8, 118.9, 112.1, 62.9, 52.8 (2C), 46.3 (2C) 
 
6.1.4.65. Synthesis of 4-(4-benzhydrylpiperazine-1-yl)-5H-pyrimido[5,4-b]indole (138) 
 
  
synonyms: SMS-A-138 
compound 71 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 1-benzhydrylpiperazine (1.5 eq.) and TEA (1.5 
eq.) 
yield: 54% 
visual appearance: pale yellow crystals 
chemical formula: C27H25N5 
molecular weight: 419.53 Da 
LC-MS analysis: calculated: 419.21 Da; found: 420.4 Da [M+H]+ 
purity: 97% 
1H NMR: 500 MHz, CDCL3, δ 9.02 (s, 1H), 8.47 (s, 1H), 8.18 (d, J = 7.9 Hz, 1H), 7.49-7.37 (m, 
6H), 7.30-7.25 (m, 4H), 7.21-7.17 (m, 3H), 4.28 (s, 1H), 3.95-3.89 (m, 4H), 2.61-2.54 
(m, 4H) 
13C NMR: 126 MHz, CDCL3, δ 151.2, 142.0, 139.8 (2C), 129.1, 128.7 (4C), 128.7 (4C), 127.2 
(3C), 121.3, 121.0, 118.3, 112.2, 76.0, 51.8, 52.8 (2C), 46.7 (2C) 
 
3.1.4.66. Synthesis of (4-phenylpiperazine-1-yl)-5H-pyrimido[5,4-b]indole (139) 
 
   
synonyms: SMS-A-139 
compound 72 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
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educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 1-phenylpiperazine (1.5 eq.) and TEA (1.5 eq.) 
yield: 41% 
visual appearance: pale yellow crystals 
chemical formula: C20H19N5 
molecular weight: 329.41 Da 
LC-MS analysis: calculated: 329.16 Da; found: 330.1 Da [M+H]+ 
purity: 96% 
1H NMR: 500 MHz, CDCL3, δ 8.70 (s, 1H), 8.39 (s, 1H), 8.27 (d, J = 7.9 Hz, 1H), 7.56-7.48 (m, 
2H), 7.32-7.26 (m, 3H), 6.97-6.93 (m, 2H), 6.90 (t, J = 7.3 Hz, 1H), 4.01 (t, J = 5.2 Hz, 
4H), 3.37 (t, J = 5.1 Hz, 4H) 
13C NMR: 126 MHz, CDCL3, δ 151.4, 151.0, 150.4, 146.4, 139.9, 129.3 (2C), 129.0, 121.8, 121.4, 
121.0, 120.4, 119.3, 116.4 (2C), 111.9, 49.3 (2C), 46.5 (2C) 
 
6.1.4.67. Synthesis of 4-(4-(2-(1H-indole-3-yl)ethyl)piperazine-1-yl)-5H-pyrimido[5,4-
b]indole (140) 
 
  
synonyms: SMS-A-136 
compound 66 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 3-(2-(piperazine-1-yl)ethyl)-1H-indole (73, 1.5 
eq.) and TEA (1.5 eq.) 
yield: 28% 
visual appearance: white crystals 
chemical formula: C24H24N6 
molecular weight: 396.50 Da 
LC-MS analysis: calculated: 396.21 Da; found: 397.2 Da [M+H]+ 
purity: 99% 
1H NMR: 500 MHz, DMSO-d6, δ 11.70 (s, 1H), 11.34 (s, 1H), 10.97 (s, 1H), 8.57 (s, sH), 8.33 (d, 
J = 7.9 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.57 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.37 (d, J = 
8.1 Hz, 1H) ,7.29-7.24 (m, 2H), 7.11-7.07 (m, 1H), 7.03-6.98 (m, 1H), 4.70-4.48 (m, 2H), 
3.85-3.60 (m, 4H), 3.49-3.38 (m, 2H), 3.27-3.03 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 150.4, 148.8, 145.1, 140.4, 136.4, 128.8, 126.9, 123.3, 121.4, 
120.7, 120.5, 120.2, 118.8, 118.6, 118.5, 112.8, 111.7, 119.4, 55.9, 50.8 (2C), 43.4 
(2C), 19.8 
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6.1.4.68. Synthesis of 4-(4-(2-(pyridin-2-yl)ethyl)piperazine-1-yl)-5H-pyrimido[5,4-
b]indole (141) 
 
  
synonyms: SMS-A-143 
compound 67 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 4-(2-(pyridin-2-yl)ethyl)piperazine (1.5 eq.) and 
TEA (1.5 eq.) 
yield: 33% 
visual appearance: pale yellow crystals 
chemical formula: C21H22N6 
molecular weight: 358.45 Da 
LC-MS analysis: calculated: 358.19 Da; found: 359.0 Da [M+H]+ 
purity: 89% 
1H NMR: 500 MHz, CDCL3, δ 9.15 (s, 1H), 8.65 (s, 1H), 8.51 (d, J = 4.5 Hz, 1H), 8.23 (d, J = 7.9 
Hz, 1H), 7.60 (td, J = 7.7, 1.6 Hz, 1H), 7.53-7.47 (m, 2H), 7.27-7.24 (m, 1H), 7.18 (d, J = 
7.8 Hz, 1H), 7.13 (dd, J = 7.1, 5.2 Hz, 1H), 3.87 (t, J = 4.5 Hz, 4H), 3.02-2.97 (m, 2H), 
2.84-2.80 (m, 2H), 2.64 (t, J = 4.6 Hz, 4H) 
13C NMR: 126 MHz, CDCL3, δ 159.7, 151.3, 150.0, 149.2, 146.0, 140.1, 136.6, 128.9, 123.3, 
121.6, 121.5, 121.3, 120.8, 119.2, 112.1, 58.1, 52.7 (2C), 46.2 (2C), 35.3 
 
6.1.4.69. Synthesis of 4-(4-(pyridin-2-yl)piperazine-1-yl)-5H-pyrimido[5,4-b]indole (142) 
 
   
synonyms: SMS-A-177 
compound 68 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 1-(pyridin-2-yl)piperazine (1.5 eq.) and TEA (1.5 
eq.) 
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yield: 46% 
visual appearance: pale yellow crystals 
chemical formula: C19H18N6 
molecular weight: 330.39 Da 
LC-MS analysis: calculated: 330.16 Da; found: 331.1 Da [M+H]+ 
purity: 96% 
1H NMR: 500 MHz, CDCL3, δ 8.92 (s, 1H), 8.69 (s, 1H), 8.24 (d, J = 7.9 Hz, 1H), 8.19 (dd, J = 
5.3, 1.6 Hz, 1H), 7.53-7.45 (m, 3H), 7.30-7.25 (m, 1H), 6.66 (t, J = 3.4 Hz, 1H), 6.64 (s, 
1H), 4.00 (t, J = 5.2 Hz, 4H), 3.73 (t, J = 5.2 Hz, 4H) 
13C NMR: 126 MHz, CDCL3, δ 159.1, 151.5, 150.1, 148.0, 146.1, 140.0, 137.7, 129.0, 121.6, 
121.3, 120.9, 119.3, 113.8, 112.0, 107.1, 46.1 (2C), 44.9 (2C) 
 
6.1.4.70. Synthesis of 4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine-1-yl)-5H-
pyrimido[5,4-b]indole (143) 
 
  
synonyms: SMS-A-141 
compound 73 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 1-piperonylpiperazine (1.5 eq.) and TEA (1.5 
eq.) 
yield: 43% 
visual appearance: pale yellow crystals 
chemical formula: C22H21N5O2 
molecular weight: 387.44 Da 
LC-MS analysis: calculated: 387.17 Da; found: 388.2 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 11.26 (s, 1H), 8.45 (s, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.60 (d, J = 
8.2 Hz, 1H), 7.55-7.49 (m, 1H), 7.25-7.20 (m, 1H), 6.93-6.89 (m, 1H), 6.86 (d, J = 7.8 
Hz, 1H), 6.80 (d, J = 7.9 Hz, 1H), 5.99 (s, 2H), 3.84-3.71 (m, 4H), 3.54-3.43 (m, 2H), 
2.64-2.51 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 151.1, 149.1, 147.4, 146.4, 144.8, 140.0, 131.8, 128.4, 122.3, 
120.7, 120.5, 119.9, 118.5, 112.7, 109.4, 198.0, 100.9, 61.8, 52.5 (2C), 46.1 (2C) 
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6.1.4.71. Synthesis of (4-(5H-pyrimido[5,4-b]indole-4-yl)piperazine-1-yl)(furan-2-
yl)methanone (144) 
 
  
synonyms: SMS-A-142 
compound 74 (J. Med. Chem. 2017, accepted 10th of October, 2017) 
educts: 4-chloro-5H-pyrimido[5,4-b]indole (72), 1-(2-furoyl)piperazine (1.5 eq.) and TEA (1.5 
eq.) 
yield: 75% 
visual appearance: pale yellow crystals 
chemical formula: C19H17N5O2 
molecular weight: 347.38 Da 
LC-MS analysis: calculated: 347.14 Da; found: 348.0 Da [M+H]+ 
purity: 98% 
1H NMR: 500 MHz, DMSO-d6, δ 11.39 (s, 1H), 8.50 (s, 1H), 8.11 (d, J = 7.9 Hz, 1H), 7.87 (dd, J = 
1.7, 0.7 Hz, 1H), 7.63 (d, J = 8.2 Hz, 1H), 7.55 (ddd, J = 8.2, 7.1, 1.1 Hz, 1H), 7.25 (ddd, 
J = 7.8, 7.0, 0.8 Hz, 1H), 7.06 (dd, J = 3.4, 0.7 Hz, 1H), 6.65 (dd, J = 3.4, 1.8 Hz, 1H), 
3.95-3.90 (m, 4H), 3.90-3.84 (m, 4H) 
13C NMR: 126 MHz, DMSO-d6, δ 158.6, 150.9, 149.1, 147.1, 145.0, 144.9, 140.1, 128.5, 120.7, 
120.6, 120.0, 118.6, 115.9, 112.7, 111.5, 55.7 (2C), 46.0 (2C) 
 
6.2. Materials and Methods for Biological Investigation 
 
6.2.1. Materials 
 
6.2.1.1. Chemicals for Biological Testing 
 
Table 6.10 summarizes reference compounds, fluorescence dyes, chemicals and solvents 
used in the cell laboratory. 
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Table 6.10. Summary of used reference compounds, fluorescence dyes, chemicals and solvents. 
 
chemical provider 
calcein AM Calbiochem (EMD Chemicals (San Diego, CA, USA), supplied by Merck 
KGaA (Damstadt, Germany) 
calcium chloride dihydrate Merck KGaA (Darmstadt, Germany) 
cyclosporine A Tocris Bioscience (Bristol, IO, USA) 
daunorubicin  Sigma (Oakville, ON, Canada) 
D-glucose monohydrate Merck KGaA (Darmstadt, Germany) 
DMSO Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
HEPES Carl Roth GmbH & Co KG (Karlsruhe, Germany) 
indomethacin Sigma-Aldrich (St. Louis, MO, USA) 
Ko143 Tocris Bioscience (Bristol, IO, USA) 
magnesium sulfate heptahydrate Merck KGaA (Darmstadt, Germany) 
methanol Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
MK571 sodium salt hydrate Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
MTT  Carl Roth GmbH & Co KG (Karlsruhe, Germany) 
pheophorbide A Frontier Scientific Inc. (Logan, UT, USA) 
potassium chloride Merck KGaA (Darmstadt, Germany) 
potassium dihydrogen phosphate Merck KGaA (Darmstadt, Germany) 
pranlukast hemihydrate Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
sodium chloride Th.Greyer GmbH & Co KG (Renningen, Germany) 
sodium hydrogen carbonate Merck KGaA (Darmstadt, Germany) 
sodium hydroxide VWR Chemicals (Darmstadt, Germany) 
Water, ultrapure (Elix Millipore) Merck KGaA (Darmstadt, Germany) 
 
 
 
 
6.2.1.2. Buffers for Biological Testing 
 
Since cell culture media and their ingredients (see section 6.2.1.3) contain enzymes, proteins 
or other macromolecules that might interfere with fluorescence measurement, the Krebs-
HEPES-buffer (KHB) was used for measurement with the microplate reader (see section 
6.2.1.5). The buffer ensured survival of cells over the assay time. Since the KHB was used 
extensively for serial dilution, fluorescence dye dilutions, or cell-based fluorescence assays 
in general, the stock solution of KHB was prepared fivefold concentrated. Table 6.11 gives 
the ingredients. The weighed salts were dissolved in 500 mL of ultra pure water, aliquoted 
into 50 mL falcons and stored at -20 °C.  
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Table 6.11. Ingredients and necessary weighed portion for 500 mL of a fivefold concentrated Krebs-HEPES-buffer 
solution. 
 
ingredient molecular weight [Da] weighed portion [g] 
D-glucose monohydrate 198.17 5.796 
HEPES 238.31 5.958 
potassium chloride 74.54 0.876 
potassium dihydrogen phosphate 136.09 0.408 
sodium chloride 58.44 17.330 
sodium hydrogen carbonate 84.01 0.882 
 
 
 
The onefold KHB solution was prepared as follows: eight 50 mL aliquots of the fivefold 
concentrated, frozen KHB solution were defrosted. The resultant 400 mL of fivefold 
concentrated KHB was diluted to 1.8 L with ultrapure water followed by addition of 2.6 mL 
and 2.4 mL of a calcium chloride and magnesium sulfate solution, respectively (both 1 mol · 
L-1). The solution was adjusted to pH = 7.4 with sodium hydroxide (10 mol · L-1). The buffer 
was filled up to 2.0 L with ultrapure water and aliquoted into 50 mL tubes. Table 6.12 gives 
the prevailing concentration of every ingredient in the onefold concentrated KHB solution. 
 
 
Table 6.12. Calculated concentrations of the incredients in the onefold Krebs-HEPES-buffer as used in the 
assays. 
 
 
ingredient  
 
concentration [mmol · L-1] 
calcium chloride dihydrate 1.3 
D-glucose 11.7 
HEPES 10.0 
potassium chloride 4.7 
potassium dihydrogen phosphate 1.2 
magnesium sulfate 1.2 
sodium chloride 118.6 
sodium hydrogen carbonate 4.2 
 
 
 
6.2.1.3. Solutions for Cell Culture 
 
Different solutions were used for cell maintenance, rinsing, counting or subculturing (see 
section 6.2.3). Table 6.13 gives the used cell culture media and with cell culture associated 
solutions. 
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Tabl. 6.13. Cell culture media and necessary ingredients for cell culture used in the cell laboratory and assays. 
 
equipment provider 
CASY ton solution OMNI Life Science GmbH + Co. KG (Bremen, Germany) 
Dulbecco’s modified Eagle’s medium (“DMEM”) Sigma Life Science (Steinheim, Germany) 
Fetal Bovine Serum (FBS) Sigma Life Science (Steinheim, Germany) 
L-glutamine (“L-Glu”) PAN Biotech GmbH (Aidenbach, Germany) 
Penicillin G / 50 Streptomycin (“PenStrep”) PAN Biotech GmbH (Aidenbach, Germany) 
phosphate-buffered saline (PBS) PAN Biotech GmbH (Aidenbach, Germany) 
RPMI-1640 cell culture medium PAN Biotech GmbH (Aidenbach, Germany) 
Trypsin-EDTA solution 0.05%/0.02% PAN Biotech GmbH (Aidenbach, Germany) 
 
 
 
6.2.1.4. Materials for Biological Testing 
 
Several appliances were used for different operations in the cell laboratory, e.g. 
cryopreservation (6.2.3.1.2), subculturing (see section 6.2.3.3), or preparation of serial 
dilution (6.2.4.1). Table 6.14 gives an overview of all used appliances. 
 
 
Table 6.14. Summary of used materials for cell culture, assay preparation and execution. 
 
equipment provider 
accu-jet pro Brand GmbH + Co. KG (Wertheim, Germany) 
96-well microplate, F-bottom, clear  Greiner bio one (Frickenhausen, Germany) 
96-well microplate, U-shaped, clear  Greiner bio one (Frickenhausen, Germany) 
96-well tissue-culture treated plates Starlab GmbH (Hamburg, Germany) 
cryopreservation tank MVE cryosystem 4000 cryo solutions (GmbH Rheinberg, Germany) 
falcon tube 15 mL Greiner bio one (Frickenhausen, Germany) 
falcon tube 50 mL Greiner bio one (Frickenhausen, Germany) 
Finnpipette 0.5-10 µL Thermo Fisher Scientific (Waltham, MA, USA) 
Finnpipette 2-20 µL Thermo Fisher Scientific (Waltham, MA, USA) 
Finnpipette 5-50 µL Thermo Fisher Scientific (Waltham, MA, USA) 
Finnpipette 10-100 µL Thermo Fisher Scientific (Waltham, MA, USA) 
Finnpipette 20-200 µL Thermo Fisher Scientific (Waltham, MA, USA) 
Finnpipette 200-1000 µL Thermo Fisher Scientific (Waltham, MA, USA) 
Finnpipette 1000-5000 µL Thermo Fisher Scientific (Waltham, MA, USA) 
glass Pasteur pipettes (230 mm) Brand GmbH + Co. KG (Wertheim, Germany) 
Microflex xceed powder-free nitrile examination 
gloves (M) 
Microflex (Reno, NV, USA) 
microtubes 1.5 mL Sarstedt, AG & Co. (Nürnbrecht, Germany) 
microtubes 2.0 mL MCT-200-C Axygen scientific (Union City, CA, USA) 
Nalgene System 100 cryogenic tubes Thermo Fisher Scientific (Waltham, MA, USA) 
pipette 0.5-10 µL Eppendorf (Hamburg, Germany) 
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equipment provider 
pipette 10-100 µL Eppendorf (Hamburg, Germany) 
pipette 20-200 µL Eppendorf (Hamburg, Germany) 
pipette 100-1000 µL Eppendorf (Hamburg, Germany) 
reagent reservoirs, sterile VWR International GmbH (Darmstadt, Germany) 
serological pipette 10 mL Sarstedt, AG & Co. (Nürnbrecht, Germany) 
serological pipette 25 mL Sarstedt, AG & Co. (Nürnbrecht, Germany) 
syringe Braun Injekt 20 mL  
 
ALMO-Erzeugnisse, Erwin Busch GmbH (Bad Arolsen, 
Germany) 
T25 cell culture flasks Greiner bio one (Frickenhausen, Germany) 
T75 cell culture flasks Greiner bio one (Frickenhausen, Germany) 
T175 cell culture flasks Greiner bio one (Frickenhausen, Germany) 
tip, 5 mL Brand GmbH + Co. KG (Wertheim, Germany) 
TipOne 10 µL graduated tips Starlab GmbH (Hamburg, Germany) 
TipOne 200 µL yellow, bevelled tips Starlab GmbH (Hamburg, Germany) 
TipOne 1000 µL blue, graduated tips Starlab GmbH (Hamburg, Germany) 
Transferpipette S 1000 µL Brand GmbH + Co. KG (Wertheim, Germany) 
Transferpipette S 5000 µL Brand GmbH + Co. KG (Wertheim, Germany) 
Whatman FP 30/0.2 µM CA-S filter units GE Healthcare UK limited (Buckinghamshire, UK) 
 
 
 
6.2.1.5. Instruments for Basic Operations 
 
Many instruments were used in the cell laboratory for preparation or postprocessing of 
assays, aseptic operations or proper storage of cells or stock solutions. Table 6.15 shows all 
used instruments except for analytical instruments (see section 6.2.1.6). 
 
 
Table 6.15. List of used instruments for basic operations in the cell laboratory. 
 
equipment provider 
autoclave VX-95 Systec GmbH (Wettenberg, Germany) 
Avanti J-25 centrifuge Beckmann Coulter (Krefeld, Germany) 
coulter counter CASY1 model TT with 
Epson LQ-400 printer 
Schärfe System GmbH (Reutlingen, Germany) 
 
cell culture incubator Münchener Medizin Mechanik GmbH (Planegg, Germany) 
Herafreezer -80 °C Heraeus Holding GmbH (Hanau, Germany) 
laminar air flow Bio-Flow Technik GmbH (Meckenheim, Germany) 
microscope Axiovert 25 Carl Zeiss AG (Feldbach, Swizzerland) 
refrigerator Bosch (Stuttgart, Germany) 
refrigerator Premium NoFrost -20 °C Liebherr-International Deutschland GmbH (Biberach an der Riß, 
Germany) 
multi channel pipette Transferpette©-8 
electronic 10-200 µL 
Brand GmbH + Co. KG (Wertheim, Germany) 
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equipment provider 
multi channel pipette Xplorer plus Eppendorf (Hamburg, Germany) 
ThermoStat plus Eppendorf (Hamburg, Germany) 
scale KERN 430-33 Kern &Sohn GmbH (Balingen-Frommern, Germany) 
vortexer vortex-genie 2 Scientific Industries (Bohemia, NY, USA) 
waterbath Julabo TW 12 Julabo GmbH (Seelbach, Germany) 
vacuum pump unit BVC 21 Vacuubrand GmbH + Co. KG (Wertheim, Germany) 
 
 
 
6.2.1.6. Instruments for Biological Investigations 
 
Table 6.16 gives an overview of the used analytical instruments for cell-based fluorescence 
assays, MTT-viability or MDR reversal-efficacy assays. 
 
 
Table 6.16. Listing of analytical instruments used in this thesis. 
 
equipment provider 
Ex Multiscan microplate photometer Thermo Fisher Scientific (Waltham, MA, USA) 
FACSCalibur© flow cytometer Becton Dickinson Biosciences (Heidelberg, Germany) 
Fluostar Optima microplate reader BMG-Labtech (Ortenberg, Germany; software version 2.00R2 and 2.20) 
Fluostar Polarstar microplate reader BMG-Labtech (Ortenberg, Germany; software version 4.11-0) 
LS 55 Luminescence Spectrometer Perkin Elmer (Waltham, MA, USA) 
 
 
 
6.2.2. Cell lines 
 
6.2.2.1. H69AR and H69 
 
The adherent growing doxorubicin-selected small cell lung cancer cell line H69AR 
overexpressing MRP1 and its sensitive counterpart H69 (syn. NCL-H69) growing as 
suspension were provided by American Type Culture Collection (ATCC CRL-11351 and 
ATCC HTB-119, respectively). The cells were cultivated using RPMI-1640 cell culture 
medium supplemented with 20% (V/V) FBS, 2 mmol · L-1 L-glutamine, 50 U/mL penicillin G 
and 50 µg/mL streptomycin. 
 
 
6.2.2.2. MDCK II MRP1 and MDCK II 
 
The Madin-Darby Canine Kidney (MDCK) cell line transfected with the cDNA of human 
MRP1 (MDCK II MRP1) and their sensitive counterpart MDCK II were a generous gift of Prof. 
Dr. P. Borst and Dr. A. Schinkel from The Netherlands Cancer Institute (Amsterdam, The 
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Netherlands). Cultivation was performed using Dulbecco’s modified Eagle’s medium 
complemented with 10% (V/V) FBS, 2 mmol · L-1 L-glutamine, 50 U/mL penicillin G and 50 
µg/mL streptomycin. 
 
6.2.2.3. 2008/MRP1 and 2008 
 
The human ovarian carcinoma cell line 2008/MRP1 stably transfected with human MRP1 
cDNA and their sensitive counterpart 2008 were a generous gift of Prof. Dr. P. Borst and Dr. 
A. Schinkel from The Netherlands Cancer Institute (Amsterdam, The Netherlands). The cells 
were cultivated using RPMI-1640 cell culture medium supplemented with 10% (V/V) FBS, 2 
mmol · L-1 L-glutamine, 50 U/mL penicillin G and 50 µg/mL streptomycin. 
 
 
6.2.2.4. A2780/ADR and A2780 
 
The doxorubicin-selected human ovarian carcinoma cell line A2780/ADR (ECACC no. 
931123120) overexpressing P-gp as well as its sensitive counterpart A2780 (ECACC no. 
93112519) were provided by European Collection of Animal Cell Culture (ECACC). 
Cultivation was performed in RPMI-1640 medium complemented with 10% FBS, 2 mmol · L-1 
L-glutamine, 50 U/mL penicillin G and 50 µg/mL streptomycin. 
 
 
6.2.2.5. MDCK II BCRP 
 
The MDCK II BCRP cell line is stably transfected with human wildtype cDNA of BCRP and 
additionally C-terminally linked to green fluorescent protein (GFP), which allowed the 
observation of the expression level of BCRP. The cells were also a generous gift by Prof. Dr. 
P. Borst and Dr. A. Schinkel (The Netherlands Cancer Institute, Amsterdam, The 
Netherlands). Cultivation was performed as stated for the MDCK II MRP1 and MDCK II cell 
lines. 
 
 
6.2.3. Cell Culture 
 
6.2.3.1. Cell Line Back-Ups 
 
6.2.3.1.1. Defrosting 
 
The cryopreservation vials were taken out of the cryopreservation tank and handwarmed. 
The content was transferred into a 15 mL conic tube and 5 mL of warmed (37 °C) cell culture 
medium was added. The cell suspension was centrifuged at 266 x g and 4 °C for 4 minutes. 
The supernatant was sucked off with a vacuum pump. After resuspension in fresh, warmed 
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cell culture medium, the pellet was transferred into a T25, T75 or T175 cell culture flask 
followed by storage at 37 °C and under 5% CO2-humidified atmosphere. The cells were 
subcultured as stated below (see section 6.2.3.3) before using in biological experiments. 
 
6.2.3.1.2. Cryopreservation 
 
Cryopreservation was performed under liquid nitrogen (Air Liquide, Düsseldorf, Germany) in 
a cryoconservation tank at approximately -196 °C. At a confluence of 90-100%, the cells 
were trypsinated as stated below (6.2.3.2). The obtained cell pellet from six T175 cell culture 
flasks was suspended in 20 mL cell culture medium. 900 µL cell suspension was pipetted 
into 1 mL cryopreservation vials followed by addition of 100 µL of DMSO to prevent cell 
damage by freezing. The vials were transferred quickly into a -80 °C refrigerator and kept for 
30 minutes with frequent shaking every 10 minutes to maintain homogenous conditions 
within the vials. After one day, the vials were transferred into the liquid nitrogen tank.  
 
 
6.2.3.2. Trypsination 
 
The necessary cell culture medium, the trypsin-EDTA solution or any other needed buffer 
(KHB, PBS) was taken out of the storage refrigerator and transferred into a warmed 37 °C 
water bath. All work with living cells used for defrosting, subculturing, biological testing or 
cryopreservation was performed in the laminar air flow cabinet to maintain aseptic conditions. 
The cell culture flasks containing the adherent growing cells at a confluence between 90-
100% were taken out of the incubator. The cell layer was rinsed three times with PBS, and 
the supernatant containing cell debris was sucked off. The necessary amount of warmed 
trypsin-EDTA solution (0.05%/0.02%) was transferred into the cell culture flasks (T25 cell 
culture flask: 1 mL; T75 cell culture flask: 3-5 mL; T175 cell culture flask: 5-10 mL; dependent 
on the cell confluence). Incubation time depended on confluence and cell type (H69AR; 
A2780/ADR, A2780, 2008/MRP1 and 2008: ≤ 5 min; transfected and parental MDCK II cell 
lines: 15-30 min). Afterwards, the trypsin was deactivated by pouring fresh and warmed 
culture medium into the flasks. The bottom was rinsed at least three times to remove still 
adherent cells using an electronic pipette and a 10 mL serological pipette. The whole volume 
was transferred into a 15 mL or 50 mL tube, dependent on the volume, and centrifuged at 
266 x g and 4 °C for 4 minutes. The supernatant was sucked off by a pump using 3 mL 
Pasteur pipettes and the resultant pellet was suspended in fresh warmed cell culture 
medium. The resultant suspension was prepared for cell counting or subculturing. 
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For the suspension cells H69 no trypsination was necessary, since the cell culture medium 
can easily be put into the 50 mL tubes and centrifuged at 266 x g and 4 °C for 4 minutes. The 
resultant pellet was treated as stated above. 
 
6.2.3.3. Subculturing 
 
The necessary amount of cells was taken either after cell counting as stated below (6.2.3.4) 
or as partial volume (percentage) and transferred into an already with warmed cell culture 
medium filled cell culture flask. For T25 flasks, 10 mL of medium was sufficient for each cell 
line. For the T75 flasks, 18-20 mL of cell culture medium was taken in case of 2008/MRP1, 
2008, A2780 adr, A2780 and all MDCK II cells (transfected or parental). H69AR cells grow 
slowly while consuming cell culture medium in high magnitude. Hence, a higher volume of 
cell culture medium was needed (at least 30 mL). T175 flasks were used to generate cell line 
back-ups. Here, between 50 and 100 mL cell culture medium was used, dependent on the 
state of growing. 
While for all other cell lines a population of 3-4 million cells is sufficient to start reproductive 
cell growth and reach a confluence of up to 100% after 3-5 days, H69AR cells must be 
transferred at least with approximately 30% of the total volume or 8-10 million cells, to 
guarantee a homogenous and constant cell growth. The same policy accounts for the 
parental cell line H69. 
 
 
6.2.3.4. Cell Counting 
 
20 µL of the freshly prepared cell suspension (see section 6.2.3.2) was transferred into       
10 mL of CASY® solution, which was sterilized by filtration with membrane filters (0.2 µm 
pore diameter) using a 20 mL syringe. The solution was shaked carefully at least 10 times. 
The created suspension was counted employing a coulter counter CASY1 model TT using a 
150 µm capillary. Measuring the electric resistance dependent on the cell diameter, the 
necessary amount of cells was taken to conduct the procedures stated below. The cell 
diameter was individually limited dependent on the cell lines. Table 6.17 summarizes used 
cell lines, their usage in fluorescence-based assays, needed amount of cells and the 
measured cell diameter. 
 
 
 
 
 
Experimental Section  205 
 
Table 6.17. Summary of used cell lines in different cell-based fluorescence assays and needed cell amount as 
well as the determined cell diameters. 
 
cell line assay (section) cell amount cell diameter [µm] 
H69AR (MRP1) 
 
calcein AM assay (6.2.4.2) 
daunorubicin assay (6.2.4.3) 
60,000 
60,000 
7.5-30 
 
    
H69 daunorubicin assay (6.2.4.3) 60,000 3-30 
    
MDCK II MRP1 
 
calcein AM assay (6.2.4.2) 
daunorubicin assay (6.2.4.3) 
60,000 
60,000 
8-30 
 
MDCK II 
 
 
calcein AM assay (6.2.4.2) 
daunorubicin assay (6.2.4.3) 
pheophorbide A assay (6.2.4.4) 
60,000 
60,000 
45,000 
8-30 
    
2008/MRP1 calcein AM assay (6.2.4.2) 30,000 8-30 
    
A2780/ADR (P-gp) calcein AM assay (6.2.4.2) 30,000 8-30 
    
A2780 calcein AM assay (6.2.4.2) 30,000 8-30 
    
MDCK II BCRP pheophorbide A assay (6.2.4.4) 45,000 8-30 
 
 
 
6.2.4. Cell-based Fluorescence Assays 
 
6.2.4.1. Preparation of Serial Dilution and 96 Well Plate 
 
The serial dilution for biological evaluation was prepared in KHB. The 10 mmol · L-1 
compound stock solution in DMSO was used as starting concentration. The solubility of 
compounds depended on temperature and solvent content. The 1 mmol · L-1 concentration 
was prepared by dilution of 100 µL stock solution and adjusted to 1000 µL with either 
methanol or a mixture of methanol and KHB, in case the solubility of the compound allowed 
this procedure. Further dilutions were created using mixtures of KHB and methanol to the        
100 µmol · L-1 concentration, continued by usage of KHB only. 20 µL of every compound 
dilution was pipetted to each well of a 96-well microplate with duplicate determination. The 
compounds were usually evaluated in a concentration range from 10 nM to 10 µM. In case of 
transport activators, lower concentrations were applied. Compounds with low inhibitory 
potential were sometimes also evaluated up to 100 µM, as far as solubility, intrinsic toxicity, 
and solvent content allowed a reproducible determination. 
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6.2.4.2. Calcein AM Assay 
 
6.2.4.2.1. General Information 
 
Calcein AM is a substrate of MRP1 and P-gp.357,358 While this hydrophobic molecule diffuses 
easily through cell membranes, it becomes effluxed out of cells mediated by these two 
transport proteins. In case of efflux inhibition the intracellular calcein AM gets hydrolyzed by 
intracellular unspecific esterases to the fluorescence dye calcein. This molecule is due to its 
five carboxy groups highly hydrophilic and not able to leave cells through passive diffusion. In 
P-gp overexpressing cells, the amount of built calcein is completely trapped intracellularly. In 
case of MRP1 overexpressing cells, the produced calcein is still a substrate of MRP1, which 
is generally known to transport organic anions. But the affinity toward calcein is by a factor of 
5000 lower than to the acetoxymethyl ester calcein AM,357 and the effluxed calcein is still 
measured in a microplate reader as it registers all fluorescence inside a well. 
The amount of intracellularly persisting calcein AM is dependent on the pump rate of the 
transport protein. If the transport protein is inhibited, the amount of calcein AM increases, 
which automatically leads to an increased cleavage of the ester to the fluorescent product 
calcein. Vice versa, transport activation leads to a decreased presence of calcein AM and 
therefore to a decreased fluorescence. In the beginning of an experiment, the extracellular 
concentration of calcein AM is almost constant due to the large excess in the extracellular 
space and the intracellular concentration equals zero. Due to active export and hydrolysis 
sink conditions exist, that lead to a constant passive diffusion into the cell in spite of 
reduction of total amount of calcein AM. Though, the instantaneous fluorescence increase is 
linear, and the slope can be calculated using a specific time interval, which was checked per 
assay individually. In general, the slope was evaluated between minutes 5 and 20 to 35. 
Figure 6.1 gives a simplified overview of the prevailing processes. 
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Figure 6.1. Simplified depiction of processes involved in the calcein AM assay. Calcein AM diffuses through 
biomembranes into e.g. MRP1 overexpressing cells and gets pumped out by this transporter. In case of inhibition, 
the persistence of calcein AM leads to increased cleavage to the fluorescence dye calcein mediated by unspecific 
intracellular esterases. The same mechanism applies for P-gp overexpressing cells. 
 
 
6.2.4.2.2 General Procedure 
 
The calcein AM assay for MRP1258,260,293,359 and P-gp359,360,361,362  was performed as already 
described before with small adaptions. The biological data presented in subchapter 4.3 was 
determined by Katja Stefan. The cell suspension was prepared as described above (see 
section 6.2.3.2) and the necessary amount of cells was calculated (see section 6.2.3.4). 
Table 6.18 gives used parameters of the assays. 
In short, a 96 well plate was pipetted with 20 µL of the compounds at different concentrations 
between 100 nM and 100 µM. The plate was incubated for 30 minutes at 37 °C and CO2-
humidified atmosphere after addition of 160 µL of a cell suspension containing the necessary 
amount of cells per well. A 3.125 µmol · L-1 solution of calcein AM was added (20 µL) before 
measuring the fluorescence increase as a function of time in a microplate reader. 
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Table 6.18. Summary of important parameters for the calcein AM assay for MRP1 and P-gp. 
 
calcein AM assay parameter 
cell lines and cells per well (transporter) 
 
 
 
 
 
H69AR, 60,000 (MRP1) 
MDCKII MRP1, 60,000 (MRP1) 
MDCK II, 60,000 
2008/MRP1, 30,000 (MRP1) 
2008, 30,000  
A2780/ADR, 30,000 (P-gp) 
  
compound dilution 20 µL 
  
cell suspension volume per well 160 µL 
  
incubation time and conditions 30 min, 37 °C, CO2-humidified atmosphere 
  
calcein AM and final concentration 
 
20 µL of 3.125 µmol · L-1 stock 
final: 0.3125 µmol · L-1 
  
analytical instrument and instrument parameters 
 
 
 
 
 
 
microplate reader 
plate scan mode 
horizontal measurement 
485 nm excitation wavelength 
520 nm emission wavelength 
60 cycles à 10 stimuli · s-1 
20% required value 
 
 
 
The fluorescence increase over time is a function of the degree of inhibition of the 
corresponding transport protein. Plotting of the slope of the linear fluorescence increase 
(between minutes 5 and 20 to 35) and the logarithmic compound concentration gave 
sigmoidal concentration-effect curves, that were evaluated with respect to their IC50 and Imax 
value by nonlinear regression analysis using GraphPad Prism (four-parameter logistic 
equation with either variable Hill slope (4 parameter model) or Hill slope = 1 (three parameter 
model); see section 6.3.2.2). 
 
 
6.2.4.2.3 Characterization of H69AR Cells via Calcein AM Assay 
 
The MDCK II MRP1 as well as the 2008/MRP1 cell lines were already characterized with 
respect to calcein AM and calcein accumulation by Stefan Leyers before.293 The linear 
correlation between calcein accumulation in uninhibited H69AR cells dependent on the used 
calcein AM concentration can be seen in Figure 6.2 A. The fluorescence increase over time 
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is linear between 0.1 and 0.7 µmol · L-1. The already established concentration293,363 of 
0.3125 µmol · L-1 was also used for the calcein AM assay and H69AR cells. Figure 6.2 B 
shows the linear correlation between used calcein AM concentration and the slope of the 
fluorescence increase over time. 
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Figure 6.2. (A): Fluorescence increase over time dependent on the used calcein AM concentration. (B): Linear 
correlation between used calcein AM concentration and slope of fluorescence increase calculated from lines of 
graphic (A) determined between minutes 5 and 35. Depicted is a representative experiment out of at least three 
independent experiments; a.u. = arbitrary units. 
 
 
The fact that the second line does not cross the origin might be caused by unspecific 
secondary effects, e.g. protein binding. But the linear relationship makes the assay 
applicable for compound evaluation. The next step was to see whether inhibition of MRP1 
leads to a saturable increase of fluorescence. Figures 6.3 A-B show corresponding graphics 
for indomethacin. 
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Figure 6.3. (A): Indomethacin as a representative of a known inhibitor of MRP1-mediated transport of calcein AM. 
Increase of the indomethacin concentration enhances intracellular calcein accumulation and fluorescence. The 
calculated slopes plotted against the logarithmic indomethacin concentrations give a sigmoidal concentration-
effect curve as seen in graphic (B). Shown is a representative experiment out of at least three independent 
experiments; a.u. = arbitrary units. 
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The effect of indomethacin as a representative of a specific MRP1 inhibitor and cyclosporine 
A as representative of an unspecific MRP1 inhibitor was determined in three MRP1 
overexpressing cell lines, H69AR, MDCK II MRP1 and 2008/MRP1. Tables 6.19 A-B 
summarize the obtained biological data. 
 
 
Table 6.19 A. Summary of IC50 values obtained using H69AR, MDCK II MRP1 and 2008/MRP1 cells with respect 
to the MRP1 standard inhibitors indomethacin (specific) and cyclosporine A (unspecific). 
 
standard 
inhibitor 
H69AR 
IC50 ± SEM  [µmol · L-1] 
MDCK II MRP1 
IC50 ± SEM  [µmol · L-1] 
2008/MRP1 
IC50 ± SEM  [µmol · L-1] 
indomethacin 8.69 ± 0.722 10.8 ± 0.725 8.34 ± 0.400 
cyclosporine A 3.55 ± 0.225 3.37 ± 0.483 3.30 ± 0.237 
 
 
 
Table 6.19 B. Summary of pIC50 values and Hill slopes deduced from concentration-effect curves obtained using 
H69AR, MDCK II MRP1 and 2008/MRP1 cells with respect to the MRP1 standard inhibitors indomethacin 
(specific) and cyclosporine A (unspecific); nH = Hill slope. 
 
standard 
inhibitor 
H69AR 
pIC50 ± SEM 
nH ± SEM MDCK II MRP1 
pIC50 ± SEM 
nH ± SEM 2008/MRP1 
pIC50 ± SEM 
nH ± SEM 
indomethacin 5.062 ± 0.055  = 1 4.966 ± 0.044 = 1 5.030 ± 0.028 = 1 
cyclosporine A 5.450 ± 0.041 2.56 ± 0.18 5.477 ± 0.094 1.90 ± 0.48 5.483 ± 0.047 2.25 ± 0.32 
 
 
Cyclosporine A is a rare example of a compound in this thesis with a Hill coefficient 
significantly different from one, so that the three parameter model of the logistic equation was 
inappropriate (see section 6.3.2.2). Most compounds including indomethacin had a slope of 
one, which is an indicator of the molecularity of the reaction.364 Furthermore, several known 
MRP1 inhibitors were compared to IC50 and pIC50 values determined by Stefan Leyers in the 
calcein AM assay using 2008/MRP1 cells as can be seen in Table 6.20. 
 
 
Table 6.20. Inhibition data using H69AR cells of the leukotriene receptor antagonists MK571 (verlukast) and 
ONO-1078 (pranlukast) as well as indomethacin and cyclosporine A compared to the data determined by Stefan 
Leyers with 2008/MRP1 cells;293 nH = Hill slope. 
 
 
standard  
inhibitor 
 
 
H69 AR 
IC50 ± SEM  
 [µmol · L-1] 
 
H69 AR 
pIC50 ± SEM 
 
nH ± SEM 
 
2008/MRP1293 
IC50 ± SEM 
 [µmol · L-1] 
 
2008/MRP1293 
pIC50 ± SEM 
MK571 7.73 ± 0.178 5.112 ± 0.015 3.97 ± 0.29 6.51 ± 0.72 5.189 ± 0.073 
ONO-1078 6.94 ± 0.224 5.159 ± 0.021 3.91 ± 0.18 n.t. n.t. 
indomethacin 8.69 ± 0.722 5.062 ± 0.055 = 1 11.4 ± 0.779 4.945 ± 0.045 
cyclosporine A 3.55 ± 0.225 5.450 ± 0.041 2.56 ± 0.18 4.83 ± 0.293 5.317 ± 0.040 
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6.2.4.2.3. Anomalies of the Calcein AM Assay 
 
Figure 6.4 shows found concentration-effect curves of the standard inhibitors cyclosporine A 
and indomethacin as well as compounds 74, 119 and 126. These differ with respect to the 
maximum inhibition level (Imax). This effect occurs not only in H69AR cells, but also in MDCK 
II MRP1 and 2008/MRP1 cells (see Figures 6.5 A-B), and was already found in P-gp 
overexpressing cells, too.281  
As already shown before by Leyers et al.,293  the MDCK II MRP1 as well as 2008/MRP1 cells 
express a natively occurring P-gp. This applies also to the parental cell lines. Figure 6.5 C 
shows a representative experiment of compound 74 using MDCK II MRP1 and wild type 
cells. The sensitive cell line gives also a sigmoidal concentration effect curve. This effect was 
obtained for most herein presented compounds. Though, this effect disguises the real value 
of full inhibition. Hence, the alleged top value indicated by the sensitive cell lines cannot be 
used. 
Although the sensitive H69 cells have not been reported to express other transport proteins, 
their use in microplate reader-based assays was not applicable due to several reasons: (i) 
these suspension cells are morphologically different compared to their selected counterparts, 
as they are smaller and grow as agglomerates. This affects partitioning of test compounds 
and fluorescence dyes; (ii) the cell counting is difficult, since the cells are partially smaller 
than the measurement window of the coulter-counting system, which makes the calculation 
of the correct amount of cells difficult; (iii) as the cells are not attached on the cell culture 
flask bottom, dead cells or other cell debris cannot be separated, which makes the 
measurement in the microplate reader problematic.  
Otherwise, the evaluation of the compounds using the sensitive H69 cells was possible in the 
daunorubicin assay (see section 6.2.4.3) since this assay is based on the measurement of 
intracellular fluorescence of single cells. Furthermore, this effect of partial inhibition could not 
be observed in the daunorubicin assay (Figure 6.5 D) despite of rare exceptions (compounds 
136-144). 
Different Imax values could be explained by disturbance of the membrane integrity, which 
would lead to different passive diffusion velocities of the fluorescence probes. But flow 
cytometry data excluded this possibility since no effect could be seen in sensitive cell lines 
(see Figure 4.19). Furthermore, MTT-viability assays showed that the evaluated compounds 
did not have a negative influence on cell growth in a long-term period (see sections 4.1.5, 
4.2.5 and 4.3.6). 
Taken together, this makes a substrate specific effect and even partial inhibition of MRP1-
mediated calcein AM transport more likely. This assumption is supported by experiments 
showing the compounds to be noncompetitive inhibitors of MRP1-mediated transport of 
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calcein AM as well as daunorubicin (see sections 4.1.2 and 4.3.5), except for the activation 
part (see section 4.2.7). 
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Figure 6.4. Concentration-effect curves of the known MRP1 standard inhibitors cyclosporine A (open circles) and 
indomethacin (open squares) in comparison to compounds of this thesis giving different Imax values (74, black 
closed squares; 119, black closed downward triangles; 126, black closed circles) determined in the calcein AM 
assay. Shown are at least three independent experiments. 
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Figure 6.5. (A): Concentration-effect curves of cyclosporine A (closed circles) and indomethacin (closed squares) 
using MDCK II MRP1 cells (calcein AM). (B): Concentration-effect curves of cyclosporine A (closed circles) and 
indomethacin (closed squares) using 2008/MRP1 cells (calcein AM). (C): Representative experiment of 
compound 74 using MDCK II MRP1 (closed circles) and MDCK II (open circles) determined in the calcein AM 
assay. (D): Representative concentration-effect curves of compound 74 (closed squares), 119 (closed downward 
triangles) and 126 (closed circles) in the daunorubicin assay.  
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Since most compounds resulted in the same top value in the daunorubicin assay but nearly 
none did so in the calcein AM assay, the question arose whether the IC50 value calculated 
constraining to the Imax indicated by a standard inhibitor is a proper measure for compound 
evaluation. This specific IC50 value will be termed absolute IC50 in the following. Figure 6.6 
gives the concentration-effect curves of compounds 74, 119 and 126. The latter represented 
100% transport inhibition since it gave similar Imax values like cyclosporine A, MK571 or 
ONO-1078 but with much better inhibitory activity. As one can see, the absolute IC50 
changed dependent on the Imax of the unconstrained concentration-effect curve as seen in 
Figure 6.4. The lower the Imax value of a concentration-effect curve, the higher the absolute 
IC50 value. 
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Figure 6.6. Concentration-effect curves of compounds 74 (closed squares), 119 (closed downward triangles) and 
126 (closed circles) with Imax values constrained to compound 126 (calcein AM assay). Shown are at least three 
independent experiments with duplicate measurements. 
 
 
The absolute pIC50 values were experimentally determined using compound 126 as 100% 
control and plotted against the absolute pIC50 obtained in the daunorubicin assay (Figure 6.7 
A). This data did not correlate well, as the slope of 0.69 ± 0.08 and the R2 value of 0.75 
indicate. In other words, the daunorubicin assay gives inhibitory activity data indicating a 
higher potency of the compounds than the data obtained in the calcein AM assay. For 
example, pIC50 values in the daunorubicin assay of 5.5, 6.0 or 6.5 give absolute pIC50 values 
in the calcein AM assay of approximately 4.0, 4.75 and 5.5, respectively. 
On the other hand, the relative pIC50 values of the calcein AM assay correlated much better 
with the data of the daunorubicin assay (Figure 6.7 B), as can be seen from the slope of  
0.93 ± 0.07 and a R2 value of 0.88. This led to the conclusion that the calcein AM assay is a 
proper measure and reflects the inhibitory power of the compounds in the right manner. This 
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was also shown in Figures 4.1 A and 4.13 A. The latter gave the evidence that the relative 
pIC50 value of the calcein AM assay correlated directly with the MDR reversal potency of the 
compound. Table 6.21 gives the determined relative and absolute IC50 values, pIC50 values, 
and Imax values obtained in the calcein AM assay for compounds 74-100 in comparison to the 
determined daunorubicin assay data as already shown in Tables 4.1-3. 
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Figure 6.7. (A): Correlation between absolute pIC50 values determined in the calcein AM and daunorubicin assays 
of compounds 74-100. The slope of the linear regression line is 0.69 ± 0.08, the R2 = 0.75. (B): Correlation of 
relative pIC50 values obtained in the calcein AM assay and the absolute pIC50 value determined in the 
daunorubicin assay; the slope of the linear regression line is 0.93 ± 0.07, the R2 = 0.88. 
 
 
Table 6.21. List of relative IC50 values, pIC50 values, and corresponding Imax values obtained in the calcein AM 
assay as already presented in Tables 4.1-3 in comparison to the absolute IC50 values of the calcein AM (Imax 
constrained to compound 126) and daunorubicin (see Tables 4.1-3) assays of compounds 74-100. 
 
no. 
 
 
 
calcein AM 
relative IC50 
± SEM 
[µmol · L-1] 
calcein AM 
relative pIC50 
± SEM 
calcein AM 
Imax [%] 
± SEM 
calcein AM 
absolute IC50 
± SEM 
[µmol · L-1] 
calcein AM 
absolute pIC50 
± SEM 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
 
daunorubicin  
pIC50 
± SEM 
74 0.369 ± 0.007 6.433 ± 0.012 51.1 ± 1.7 1.48 ± 0.06 5.829 ± 0.024 0.195 ± 0.012 6.710 ± 0.041 
75 0.672 ± 0.041 6.173 ± 0.040 26.6 ± 2.3 5.47 ± 0.24 5.262 ± 0.029 0.634 ± 0.028 6.198 ± 0.029 
76 1.62 ± 0.07 5.791 ± 0.027 37.1 ± 4.2 10.2 ± 1.5 5.128 ± 0.098 1.07 ± 0.03 5.971 ± 0.020 
77 2.54 ± 0.23 5.598 ± 0.059 27.7 ± 2.5 20.1 ± 1.7 4.658 ± 0.054 2.90 ± 0.07 5.538 ± 0.015 
78 5.06 ± 0.15 5.296 ± 0.020 17.7 ± 0.8 69.7 ± 5.3 4.157 ± 0.050 2.85 ± 0.19 5.546 ± 0.043 
79 26.6 ± 3.0 4.578 ± 0.075 25.7 ± 2.2 228 ± 41 3.649 ± 0.117 10.8 ± 0.2 4.966 ± 0.015 
80 2.46 ± 0.28 5.611 ± 0.076 19.3 ± 4.5 114 ± 34 3.959 ± 0.192 2.82 ± 0.18 5.550 ± 0.042 
81 8.22 ± 0.90 5.088 ± 0.072 23.5 ± 2.2 118 ± 11 3.915 ± 0.064 4.97 ± 0.27 5.305 ± 0.036 
82 14.2 ± 1.2 4.851 ± 0.054 29.0 ± 6.0 179 ± 30 3.754 ± 0.110 8.72 ± 0.66 5.061 ± 0.050 
83 14.1 ± 0.8 4.850 ± 0.037 36.9 ± 7.2 121 ± 22 3.924 ± 0.120 9.40 ± 0.30 5.027 ± 0.021 
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no. 
 
 
 
calcein AM 
relative IC50 
± SEM 
[µmol · L-1] 
calcein AM 
relative pIC50 
± SEM 
calcein AM 
Imax [%] 
± SEM 
calcein AM 
absolute IC50 
± SEM 
[µmol · L-1] 
calcein AM 
absolute pIC50 
± SEM 
daunorubicin  
IC50 ± SEM 
[µmol · L-1] 
 
daunorubicin  
pIC50 
± SEM 
84 0.833 ± 0.022 6.080 ± 0.022 42.7 ± 0.5 3.15 ± 0.16 5.502 ± 0.033 0.641 ± 0.037 6.194 ± 0.038 
85 1.06 ± 0.02 5.976 ± 0.013 18.7 ± 2.8 14.3 ± 1.1 4.845 ± 0.051 0.980 ± 0.041 6.009 ± 0.028 
86 1.94 ± 0.08 5.712 ± 0.026 34.1 ± 3.7 10.6 ± 1.3 4.976 ± 0.081 1.01 ± 0.02 5.998 ± 0.016 
87 8.90 ± 0.84 5.053 ± 0.062 13.4 ± 0.8 73.5 ± 9.8 4.578 ± 0.088 15.1 ± 1.4 4.824 ± 0.060 
88 0.712 ± 0.032 6.148 ± 0.029 12.3 ± 0.6 11.4 ± 1.1 4.945 ± 0.062 0.695 ± 0.049 6.159 ± 0.046 
89 1.05 ± 0.05 5.977 ± 0.031 13.9 ± 1.5 15.6 ± 2.1 4.812 ± 0.087 0.785 ± 0.053 6.106 ± 0.045 
90 0.540 ± 0.035 6.269 ± 0.043 11.8 ± 0.7 14.0 ± 0.8 4.855 ± 0.038 0.417 ± 0.016 6.380 ± 0.025 
91 0.813 ± 0.064 6.091 ± 0.052 12.2 ± 1.3 9.72 ± 0.64 5.013 ± 0.043 1.23 ± 0.07 5.909 ± 0.036 
92 0.243 ± 0.018 6.615 ± 0.049 12.1 ± 0.8 4.65 ± 0.53 5.335 ± 0.075 0.199 ± 0.014 6.703 ± 0.047 
93 0.752 ± 0.052 6.130 ± 0.046 18.8 ± 4.2 10.2 ± 0.9 4.992 ± 0.058 0.340 ± 0.004 6.469 ± 0.008 
94 1.20 ± 0.14 5.923 ± 0.079 10.2 ± 2.2 31.4 ± 3.7 4.506 ± 0.077 0.863 ± 0.042 6.064 ± 0.032 
95 1.00 ± 0.05 6.002 ± 0.031 18.2 ± 3.0 9.30 ± 0.32 5.032 ± 0.023 0.619 ± 0.052 6.210 ± 0.055 
96 2.74 ± 0.21 5.563 ± 0.051 33.9 ± 4.8 21.7 ± 3.0 4.668 ± 0.091 0.876 ± 0.019 6.058 ± 0.015 
97 0.920 ± 0.067 6.037 ± 0.048 22.6 ± 7.3 11.0 ± 1.4 4.962 ± 0.082 1.11 ± 0.08 5.955 ± 0.046 
98 0.891 ± 0.131 6.055 ± 0.096 26.5 ± 4.4 22.9 ± 0.4 4.640 ± 0.011 0.973 ± 0.097 6.014 ± 0.066 
99  0.947 ± 6.025 ± 0.046 13.8 ± 1.8 17.5 ± 2.3 4.761 ± 0.088 0.585 ± 0.015 6.233 ± 0.017 
100 3.15 ± 0.11 5.502 ± 0.024 31.4 ± 2.3 16.8 ± 0.7 4.775 ± 0.027 2.36 ± 0.07 5.628 ± 0.020 
 
 
 
6.2.4.2.3. Establishing of Compounds 74 and 126 as Standard Inhibitors 
 
The previous section showed that known inhibitors of MRP1 gave different Imax values in the 
calcein AM assay. Additionally, most standard compounds of MRP1 are not reliable and give 
severely varying concentration-effect curves. Cyclosporine A for example, a compound 
widely used as standard MRP1 inhibitor, differs in its solubility, dependent on the batch. This 
results mostly in concentration-effect curve with reduced response, as depicted in Figure 6.8 
A. Here, two different experiments are shown. The upper curve shows the concentration-
effect curve of cyclosporine A resulting in a measured plateau, and indicated the maximum 
inhibition of this test system. Otherwise, the lower curve shows cyclosporine A with solubility 
issues. The values between 10 and 56 µmol · L-1 are too low, resulting in fluorescence values 
different from the absolute maximum as indicated by the upper curve (~ 18 µmol · L-1). This 
raises also the question whether the upper curve is a real plateau or is likewise caused by 
solubility problems. 
The solution could be using cyclosporine A only up to a concentration of 10 µmol · L-1, as this 
is common for screening evaluations. But this reveals another problem: As one can see in 
Figure 6.8 B, the resulting concentration-effect curve with a final used concentration of        
10 µmol · L-1 depends on the effect value (fluorescence measure) of exactly this 
concentration. It is a critical concentration range (dashed grey circle), in which small changes 
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in the measured fluorescence can result in severe changes of the extrapolated 
concentration-effect curves (dark and light grey curves). 
Though, relative IC50 values are measurable, but cyclosporine A is not a proper standard 
compound when it comes to determe the maximum inhibition level or as fix point for multiple 
data sets. Furthermore, the inhibitory activity of cyclosporine A is rather poor, which also 
disqualifies it as a proper standard inhibitor. 
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Figure 6.8 Concentration-effect curves of cyclosporine A in the calcein AM assay using H69AR cells. (A): different 
experiments of cyclosporine A that resulted in a measured plateau (closed circles) or curves with reduced 
response (closed squares) due to solubility issues. Data points not used are marked as open squares. The 
tendency of the measured effect with decreased solubility is marked as grey arrow. Shown are at least three 
independent experiments with duplicate measurements. (B): The concentration-effect curve of graphic (A) marked 
as black curve (closed circles) in comparison to simulated concentration-effect curves (dark and light grey curves) 
with slightly varying effect-value of the last concentration (10 µmol · L-1). The grey arrow indicates the tendency of 
resultant top values. 
 
The leukotriene receptor antagonist MK571 (verlukast), the most used standard inhibitor of 
MRP1 in the literature, gives the same problems as already stated for cyclosporine A (Figure 
6.9 A). But contrary to the latter, solubility issues have never been observed. As it contains a 
carboxylic acid function, it is a rather water- and buffer-soluble molecule. Though, the reason 
for the observed effect must be a different one, e.g. influence on intracellular pH or cell 
toxicity. Although an IC50 can be determined by not considering the highest concentrations, 
this method increases the uncertainty, since it is not clear which concentrations should be left 
out. Here applies the same argumentation as for cyclosporine A: the mere existence of a 
measured plateau does not automatically mean that this represents the maximal possible 
inhibition of the MRP1-mediated transport. 
Figure 6.9 B shows the concentration-effect curve of another leukotriene receptor antagonist, 
ONO-1078. Here, an opposite effect is observed compared to MK571. Effect values 
observed at concentrations above 10 µmol · L-1 contain a huge error. There is up to now no 
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explanation for this effect. Fluorescence measurements at these concentrations showed this 
compound not having any auto-fluorescence. Neither was this observed for other herein 
evaluated compounds. Again, reasonable concentration-effect curves can be obtained by 
omitting the questionable concentrations, but this leaves the question which concentration 
should be considered and which should not and disqualifies this compound as standard 
inhibitor for MRP1 in the calcein AM assay. 
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Figure 6.9. Concentration-effect curves of MK571 (verlukast; A; closed circles) and ONO-1078 (pranlukast; B; 
closed circles) in the calcein AM assay using H69AR cells in comparison to compound 126 (closed squares). The 
questionable concentrations of the standard MRP1 inhibitors are shown as open circles, and the tendency of the 
observed effect is depicted as grey arrow. Shown are at least three independent experiments with duplicate 
measurements. 
 
 
Taken together, the commonly used standard inhibitors of MRP1, cyclosporine A, 
indomethacin, MK571 or ONO-1078, cannot be used in the calcein AM assay as these 
compounds give no reliable data. Although relative IC50 values can be determined, and these 
calculated values have been shown to correlate with literature data, the maximum inhibition 
level varies significantly. The sensitive cell line H69 cannot be used as a reference since 
these cells are morphologically different to their selected counterpart. Though, another 
solution must be found to define the boundaries of the microplate reader-based calcein AM 
assay to determine the quality and quantity of MRP1 inhibition. 
Hence, compound 74 as an already known, very effective MRP1 inhibitor271 as well as 
compound 126 were established as standard inhibitors of MRP1 in the calcein as well as 
daunorubicin assay. Figures 6.10 A-B show the fluorescence increase of totally inhibited 
H69AR cells mediated by the stated compounds. These graphics are in analogy to Figure 6.2 
B and prove that the measured fluorescence is linear within the used concentration range. 
This makes the cell number of 60,000 cells per well as well as the used calcein AM 
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concentration applicable for the assay. Furthermore, these compounds are more reliable, 
because the inhibitory activity is in nanomolar range. 
Finally, since compound 74 was shown to be a noncompetitive inhibitor of calcein AM 
transport mediated by MRP1 (see section 4.1.2), Figure 6.11 shows the evaluation of 
compound 126 with respect to this manner. As one can see, compound 126 is also a 
noncompetitive inhibitor of calcein AM transport. 
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Figure 6.10. Fluorescence increase dependent on the used calcein AM concentration in fully inhibited H69AR 
cells caused by compounds 74 (A) and 126 (B). These are two representative experiments out of at least three 
independent experiments; a.u. = arbitrary units. 
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Figure 6.11. Lineweaver-Burk plot of the standard inhibitor 126 with respect to MRP1-mediated transport of 
calcein AM. Calcein AM was used at concentrations of 0.2, 0.3, 0.5, 0.6 and 0.7 µmol · L-1; compound 126 was 
used at concentrations of 0.10 (closed squares), 0.21 (closed upward triangles), 0.47 (closed downward triangles) 
1.00 (closed rhombs) µmol · L-1. The control is depicted as closed circles. The grey upward oriented arrow 
indicates the inhibitory manner. 
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6.2.4.3. Daunorubicin Assay 
 
6.2.4.3.1. General Information 
 
The daunorubicin assay was performed as stated before.281,282,284,365,366 It was adapted and 
established for MRP1 overexpressing cells by Katja Stefan. In short, daunorubicin diffuses 
through the cell membrane and becomes effluxed by MRP1 since it is a good MRP1 
substrate. Inhibition of MRP1 enhances the presence of daunorubicin inside the cell and 
therefore increases the measured fluorescence. Figure 6.12 summarizes the prevailing 
processes. 
 
 
 
Figure 6.12. Schematic presentation of the daunorubicin assay. Daunorubicin accumulates inside the cell through 
passive diffusion. Since it is a good MRP1 subtrate, it gets effluxed out of the cell (left). In case of inhibition (right), 
the increased intracellular concentration of daunorubicin can be detected by fluorescence measurement and is 
linear to the degree of inhibition. 
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6.2.4.3.2. General Procedure 
 
The cell suspension was prepared as stated above (see section 6.2.3.2) and the necessary 
amount of cells was calculated (see section 6.2.3.4). Table 6.22 gives the parameters of this 
assay. 
In short, a 96 well plate was pipetted with 20 µL of the compounds at different concentrations 
between 100 nmol · L-1 and 100 µmol · L-1. After addition of 160 µL of a cell suspension 
containing the necessary amount of cells per well, the plate was pre-incubated for 15 
minutes at 37 °C and CO2-humidified. Afterwards, 20 µL of a 30 µmol · L-1 solution of 
daunorubicin was added followed by a second incubation period. The plate was evaluated in 
a flow-cytometer. 
 
Table 6.22. Summary of important parameters for the daunorubicin assay for MRP1. 
 
daunorubicin assay parameter 
cell lines and cells per well (transporter) 
 
 
 
H69AR, 60,000 (MRP1) 
H69, 60,000 
MDCKII MRP1, 60,000 (MRP1) 
MDCK II, 60,000 
  
compound dilution 20 µL 
  
cell suspension volume per well 160 µL 
  
pre-incubation and conditions 15 min, 37 °C, CO2-humidified atmosphere 
  
daunorubicin and final concentration 
 
20 µL of 30 µmol · L-1 stock 
final: 3 µmol · L-1 
  
incubation time 180 min, 37 °C, CO2-humidified atmosphere 
  
analytical instrument and instrument parameter 
 
 
 
fluorescence-activated cell sorting 
resuspension of cells before measurement 
488 nm excitation wavelength 
≥ 670 nm emission wavelength (FL3 channel) 
 
 
 
The amount of fluorescence is a function of the degree of inhibition of MRP1. The linearity 
with respect to used daunorubicin concentrations can be seen in Figure 6.13. Plotting of the 
measured fluorescence values and the logarithmic corresponding compound concentration 
gave sigmoidal concentration-effect curves, which were analyzed by nonlinear regression, 
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using GraphPad Prism (four-parameter logistic equation with either variable Hill slope (4 
parameter model) or Hill slope = 1 (three parameter model); see section 6.3.2.2). In case of 
transport activation, the intracellular fluorescence was decreased in comparison to the basal 
value (no compound supplementation). In this case the sigmoidal curve was evaluated with 
respect to the AC50 value and Amax value (as shown in Table 4.13 B).  
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Figure 6.13. Linearity between effect value (measured fluorescence) and used daunorubicin concentration in fully 
activated state (by compound 101 at 10 nmol · L-1; closed circles) and fully inhibited state (by compound 74 at 10 
µmol · L-1; closed squares). Shown is a representative experiment out of at least three independent experiments. 
 
 
6.2.4.4. Pheophorbide A Assay 
 
6.2.4.4.1. General Information 
 
The pheophorbide A assay was performed as already stated in the literature317,337,367,368 by 
Katja Stefan via flow cytometry. In short, the chlorophyll breakdown product pheophorbide A 
is a substrate of BCRP, which diffuses passively through the membrane and becomes 
effluxed by BCRP. Inhibition of BCRP increases the presence of pheophorbide A inside the 
cell and therefore increases the measured fluorescence. Figure 6.14 gives a simplified 
overview. 
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Figure 6.14. Summary of the pheophorbide A assay. While this fluorescence dye can easily diffuse passively 
through the cell membrane, pheophorbide A gets effluxed by BCRP (left). In analogy to the daunorubicin assay, 
BCRP inhibition leads to increased intracellular fluorescence (right). 
 
 
6.2.4.4.2. General Procedure 
 
In short, the cell suspension was prepared as described above (see section 6.2.3.2) and the 
necessary cell amount determined (see section 6.2.3.4). Table 6.23 shows the most 
important parameters of this assay.  
In short, a 96 well plate was pipetted with 20 µL of compound at different concentrations 
between 100 nmol · L-1 and 100 µmol · L-1. After addition of 160 µL of a cell suspension 
containing the necessary amount of cells per well, the plate was pre-incubated for 20 
minutes at 37 °C and CO2-humidified atmosphere. Afterwards, 20 µL of a 5 µmol · L-1 
solution of pheophorbide A was added followed by a second incubation period. The plate 
was evaluated in a flow-cytometer. 
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Table 6.23. Summary of important parameters for the pheophorbide A assay for BCRP. 
 
pheophorbide A assay parameter 
cell lines and cells per well (transporter) 
 
MDCK II BCRP, 45,000 (BCRP) 
MDCK II, 45,000 
  
compound dilution 20 µL 
  
cell suspension volume per well 160 µL 
  
pre-incubation and conditions 20 min, 37 °C, CO2-humidified atmosphere 
  
pheophorbide A and final concentration 
 
20 µL of 5 µmol · L-1 stock 
final: 0.5 µmol · L-1 
  
incubation time 120 min, 37 °C, CO2-humidified atmosphere 
  
analytical instrument and instrument parameter 
 
 
 
fluorescence-activated cell sorting 
resuspension of cells before measurement 
488 nm excitation wavelength 
≥ 670 nm emission wavelength (FL3 channel) 
 
 
 
The amount of fluorescence reflects the degree of BCRP inhibition. The measured 
intracellular fluorescence and the logarithmic corresponding compound concentration can be 
plotted against each other, resulting in sigmoidal concentration-effect curves that were 
analyzed by nonlinear regression using GraphPad Prism. The four-parameter logistic 
equation with either variable hill slope (4 parameter model) or Hill slope = 1 (three parameter 
model; see section 6.3.2.2), were used whichever was statistically preferred. Transport 
activation would lead to decreased intracellular fluorescence in comparison to basal transport 
velocity (no compound supplementation). 
 
 
6.2.4.5. MTT-viability Assay 
 
6.2.5.5.1. General Information 
 
Intrinsic toxicity is an important value for the evaluation of a compound, e.g. for clinical 
purpose or calculation of the therapeutic ratio. Due to several reasons xenobiotics can lead 
to reduced cell growth and enhanced cell death. Dead cells contain no functional 
mitochondria. Reductase enzymes located in mitochondria can reduce the tetrazole ring 
system of MTT to the blue colored formazan. From the magnitude of formazan production 
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the cell viability and half-maximal growth inhibition value (GI50) can be deduced.369 Figure 
6.15 shows a simplified view of the reaction. 
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Figure 6.15. Principle of the MTT-viability assay. MTT diffuses passively through the membrane and becomes 
reduced by intra-mitochondrial reductases to the blue coloured formazane. Dead cells are not able to do so, 
which allows an evaluation of the influence of compounds on the cell viability. 
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6.2.5.5.2. General Procedure 
 
The assay was performed as already reported in the literature359,369,370 by Katja Stefan. The 
serial dilution of the compounds was performed with cell culture medium. Table 6.24 
summarizes the main parameter of this assay. 
In short, a 96 well plate was pipetted with 20 µL of compound at different concentrations 
between 100 nM and 100 µM. 180 µL of a cell suspension containing the necessary amount 
of cells per well was added followed by an incubation period of  72 hours at 37 °C and CO2-
humidified atmosphere. After that, 40 µL of a 0.015 µmol · L-1 solution of MTT was added per 
well. The plate was incubated a second time for 60 minutes at 37 °C and CO2-humidified 
atmosphere. The supernatant was removed and 100 µL of DMSO was added. Colorimetric 
measurement of the absorbance of the built formazan followed. 
 
Table 6.24. Summary of important parameters for the MTT-viability assay. 
 
MTT-viability assay parameter 
cell lines and cells per well (transporter) 
 
H69AR, 20,000 (MRP1) 
H69, 20,000 
MDCKII MRP1, 3,000 (MRP1) 
MDCK II, 3,000 
2008/MRP1, 8,000 (MRP1) 
2008, 8,000  
A2780/ADR, 8,000 (P-gp) 
A2780, 8,000  
MDCK II BCRP, 3,000 (BCRP) 
  
compound dilution 20 µL 
  
cell suspension volume per well 180 µL 
  
first incubation and conditions 72 h, 37 °C, CO2-humidified atmosphere 
  
MTT 40 µL of 0.015 µmol · L-1 stock 
final: 0.003 µmol · L-1 
  
incubation time and further process 60 min, 37 °C, CO2-humidified atmosphere followed 
by 
supernatant removal and addition of 100 µL DMSO 
  
analytical instrument and instrument parameter 
 
microplate photometer 
570 nm absorbance wavelength 
690 nm background correction 
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6.2.4.6. MDR reversal-efficacy Assay 
 
6.2.5.5.1. General Information 
 
One major measure of compound evaluation is the possibility of the compounds to sensitize 
MDR cells. In principle, the assay equals the MTT-viability assay. But additionally, an 
anticancer agent is present. If a compound is a good inhibitor of the corresponding transport 
protein, the intracellular concentration of the antineoplastic drug is increased, resulting in 
enhanced cell death. As already stated in the MTT-viability assay, cell death can be deduced 
from the lack of formazan production by the cells. Figure 6.16 gives a simplified picture of the 
principle reactions. 
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Figure 6.16. Summary of the prevailing processes of the MDR reversal-efficacy assay. The antineoplastic drug 
(red) diffuses passively through the membrane and gets effluxed by a transport protein. In case of inhibition of the 
transporter, the cytotoxic agent accumulates intracellularly (right). The degree of cell death is reflected in the 
amount of built formazan mediated by intra-mitochondrial reductases as already stated in 6.2.4.5. 
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6.2.5.5.2. General Procedure 
 
Table 6.25 summarizes the parameters used in the MDR reversal-efficacy assay, which was 
performed by Katja Stefan. The main difference to the MTT-viability assay is the presence of 
an antineoplastic compound. 
In short, a 96 well plate was pipetted with 20 µL of compound at specific concentrations, 
mostly 0.1, 1, 5 and 10 µmol · L-1. 160 µL of a cell suspension containing the necessary 
amount of cells was added. Additionally, 20 µL of a dilution series of the corresponding 
cytotoxic agent was added to the wells. An incubation period of 72 hours at 37 °C and CO2-
humidified atmosphere followed. After that, 40 µL of a 0.015 µmol · L-1 solution of MTT was 
added per well. The plate was incubated a second time for 60 minutes at 37 °C and CO2-
humidified atmosphere. The supernatant was removed and 100 µL of DMSO was added to 
each well. Colorimetric measurement of the absorbance of the formed formazan followed. 
 
Table 6.25. Summary of important parameters for the MDR reversal-efficacy assay 
 
MDR reversal-efficacy assay parameter 
cell lines and cells per well (transporter) 
 
H69AR, 20,000 (MRP1) 
H69, 20,000 
MDCK II MRP1, 3,000 (MRP1) 
A2780/ADR, 8,000 (P-gp) 
A2780, 8,000 
MDCK II BCRP, 3,000 (BCRP) 
MDCK II, 3,000 
  
compound (1,10,50 and 100 µmol · L-1) 20 µL 
  
cell suspension volume per well 160 µL 
  
dilution of antineoplastic drug 20 µL of daunorubicin (MRP1 and P-gp) 
20 µL of SN-38 (BCRP) 
  
first incubation and conditions 72 h, 37 °C, CO2-humidified atmosphere 
  
MTT 40 µL of 0.015 µmol · L-1 stock 
final: 0.003 µmol · L-1 
  
incubation time and further process 60 min, 37 °C, CO2-humidified atmosphere followed by 
supernatant removal and addition of 100 µL DMSO 
  
analytical instrument and instrument parameter microplate photometer 
570 nm absorbance wavelength 
690 nm background correction 
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6.3. Mathematical Operations 
 
6.3.1. Statistical Values 
 
6.3.1.1. Average (!#) 
 
 
 $̅ 	' 	∑ $)*)+,-  
 
 
Equation 6.1. Basic mathematical equation for determination of the arithmetic mean; xi = measured value; n = 
sample size. 
 
 
6.3.1.2. Standard Error of the Mean (SEM) 
 
 
 ./0	 ' 	1∑ 2$) 3 $̅45*)+, -  
 
 
Equation 6.2. Basic mathematical equation for determination of the standard error of the mean. $	#= arithmetic 
mean (see 6.3.1.1 and Equation 6.1); xi = measured value; n = sample size. 
 
6.3.1.3. One-sample t-Test 
 
The one-sample t-test compares the mean of a measurement with a hypothetical value. In 
this thesis, this hypothetical value was defined as basal transport velocity in presence of 
DMSO (see Figures 4.17 and 4.18 A-B). From the formula below, GraphPad Prism 
calculated a P value dependent on the degree of freedom, which is defined as sample size 
minus one. The resultant significance is given as *: P ≤ 0.05, **: P ≤ 0.01, ***: P ≤ 0.001, ****: 
P ≤ 0.0001. 
 
 
 6	 ' 	 $̅789:;< 3	 $̅=>:? =< )!8;./0  
 
 
Equation 6.3. Basic mathematical equation to perform the one-sample t-test;	$	# sample = arithmetic mean of the 
sample; $	# hypothetical = arithmetic mean of the reference; SEM = standard error of the mean. 
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6.3.2. Regression 
 
6.3.2.1. Linear Regression 
 
The basic function of linear regression is as follows: 
 
 y	 ' 		#	 ∙ $ % & 
 
Equation 6.4. Mathematical basis behind linear regression; a = slope; b = Y-intercept. 
 
6.3.2.2. Nonlinear Regression of Concentration-Effect curves 
 
For compound evaluation the logistic equation was used, either with variable slope or with 
standard slope (Hill slope = 1). The equation can be seen below (Eq. 6.5). 
 
 
 
 y	 ' 	bottom	 %	 26+, 3 &+66+-41 % 102012	23456	470128!94∙*:4 
 
Equation 6.5. Four-parameter logistic equation. y represents the measured fluorescence value in arbitrary units. 
The bottom and top value is defined as the intra- and extrapolation of the calculated sigmoidal concentration-
effect curve. The EC50 value represents the inflection of the sigmoidal concentration-effect curve and is the half-
maximal effect between bottom and top. In case of inhibition, it is called half-maximum inhibition concentration 
(IC50); in case of activation, it is called  half-maximal activation concentration (AC50); in case of growth inhibition 
(MTT-viability or MDR reversal-efficacy assays) it is called half-maximal growth inhibition concentration (GI50). nH 
represents the Hill slope. Four-parameter model: nH variable; three-parameter model: nH = 1. 
 
 
All standard inhibitors and synthesized target compounds were evaluated with respect to 
their Hill slope. Statistical analysis showed that most yielded concentration-effect curves with 
slopes not significantly different from one, which indicates a 1:1 reaction between transport 
protein and inhibitor. The only exceptions were cyclosporine A, MK571 and ONO-1078. 
 
6.3.2.3. Logit Transformation 
 
Inhibitory activity was always correlated to the logit of the Imax value of the screening results 
of the corresponding compound. The logit function can be expressed as inversed 
concentration-effect curves according to the logistic equation as was stated above (see 
section 6.3.2.2). 
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 logit ' log	2 >??>@6	A#BC>	8%9100 3 >??>@6	A#BC>	8%94 
Equation 6.6. Mathematical basis behind the logit transformation. The effect value was taken as expressed 
percentage from screening experiments referred to a standard compound at a specific concentration. 
 
 
6.3.3. Calculation of the Maximal Inhibition Level (Imax) 
 
The Imax value represents the maximal inhibition of a calculated concentration-effect curve in 
comparison to a standard compound. In this thesis, compound 126 was used in the calcein 
AM assay to define 100% inhibition. 0% inhibition is defined by the point without compound 
supplementation (basal transport velocity). The used equation to determine the Imax value is 
given below. 
 
 
 
 E98F ' 	 26+,!?9:?G*H 3	&+66+-!?9:?G*H426+,7 8*H8IH	)*=)J) ?I 3	&+66+-7 8*H8IH	)*=)J) ?I4 	 ∙ 100 
 
 
Equation 6.7. Calculation of the maximal inhibition level in the calcein AM assay. Numerator: response of the 
evaluated compound. Denominator: response of the standard inhibitor. In case of the calcein AM assay, 
compound 126 was used as 100% control, while compound 74 was the 50% control. 
 
 
6.3.4. Calculation of Transport Velocity-related Values 
 
6.3.4.1. Calculation of the Flux Ratio (Pump Rate) 
 
Assuming first order kinetics, the influx or efflux velocity of a substrate (in this thesis a 
cytotoxic agent or fluorescence dye) can be expressed as the product of substrate 
concentration and velocity constant (Eq. 6.8 A). 
 
 
 
 A ' K	 ∙ @ 
 
 
Equation 6.8 A. Influx or efflux velocity (v) of a substrate described as the product of the velocity constant (k) and 
the used concentration of the substrate (c). 
 
 
Considering both, passive and active transport, under steady state conditions the 
simultaneous process of influx and efflux can be expressed as shown in equation 6.8 B. 
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 A:,?G 	' A:,)* % A8,)* 
 
 
Equation 6.8 B. Under steady state conditions the passive influx velocity (vp,out) equals the sum of passive (vp,in) 
and active (va,in) efflux; out = from outside to inside the cell; in = from inside to outside the cell. 
 
 
Combining Equations 6.8 A and B yields Equation 6.8 C. 
 
 
 K: 	 ∙ 	@?G 	' 2K: %	K84	 ∙ @)* 
  
Equation 6.8 C. Under steady state conditions the passive influx expressed as product of the velocity constant of 
passive diffusion through the cell membrane (kp) and the extracellular concentration (cout) equals the sum of 
passive (kp) and active (ka) efflux velocity constants multiplied with the intracellular concentration (cin). 
 
 
Equation 6.8 C can be rearranged giving the flux ratio, also called pump rate. This value 
represents the ratio of active efflux to passive diffusion. It can also be expressed as the ratio 
between intra- and extracellular concentration. Equation 6.8 D gives the derivation of the 
relationship. 
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Equation 6.8 D. Calculation of the flux ratio (pump rate) as the division of extra- and intracellular concentration of 
the used substrate minus one; kout = ka + kp. 
 
This mathematical relationship between active efflux and passive diffusion can also be 
graphically presented as a hyperbolic relationship (Figure 6.17). It is in agreement with 
findings with respect to specific anthracyclines, where cancer cells were less resistant to 
more lipophilic compounds with higher diffusion velocity.371 Since the intracellular calcein and 
daunorubicin concentration correlated with the measured fluorescence over a wide 
concentration range as shown in Figures 6.10 A-B and 6.13, the calculated bottom and top 
value of a sigmoidal concentration-effect curve can be taken as surrogates for cin and cout. At 
low kout, small changes in the pump velocity lead to significant reduction of intracellular 
concentrationon of the substrate or fluorescence dye. In resistant cells (e.g. H69AR), a high 
active efflux (ka) is already present, which makes a strong increase in the pump velocity 
necessary for a noticeable further decrease of the intracellular concentration of the substrate 
or fluorescence dye.  
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Figure. 6.17. Hyperbolic relationship between active and passive transport (kout/kin) and ratio of intra- (cin) and 
extracellular (cout) substrate concentration. 
 
 
6.3.4.2. Calculation of the Activation Ratio (Ar) 
 
The activation ratio is the ratio between the flux ratio of a compound and the standard 
inhibitor 126 (or 2 times the flux ratio of compound 74) in the calcein AM assay or both 
compounds with equal magnitude in the daunorubicin assay and is calculated according to 
Equation 6.9. 
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Equation 6.9. Calculation of the activation ratio of a compound in comparison to standard inhibitors 74 or 126. 
 
6.3.5. Calculation of the Selectivity Ratio (sr) 
 
The selectivity ratio gives the factor by which an inhibitor is more potent toward one target. It 
is calculated by division of the IC50 value of both targets. 
 
 
 sr ' 	 ERST	2 8IU< 	V4ERST	2 8IU< 	W4	 
 
 
Equation 6.10. Calculation of the selectivity ratio (sr). 
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6.3.6. Calculation of the Therapeutic Ratio (tr) 
 
The therapeutic ratio gives the factor by which the tested compound is more potent toward a 
target than toxic toward the cells. It can easily be calculated by division of the corresponding 
half-maximal growth inhibition value (GI50) and the determined half-maximal inhibitory 
concentration (IC50). 
 
 
 
 tr ' 	XEST	2!?9:?G*H4ERST	2!?9:?G*H4	 
 
 
Equation 6.11. Calculation of the therapeutic ratio (tr). 
 
 
6.3.7. Calculation of the Resistance Factor (rf) 
 
The resistance factor gives the ratio between the GI50 value of a compound toward the 
sensitive and resistant cell line. It is determined by division of the GI50 of the corresponding 
antineoplastic agents in the resistant cell line and the GI50 of the sensitive cell line. 
 
 
 
 rf ' 	XEST	2	I<7)7 8* 	!<;;	;)*<4XEST	27<*7) )Z<	!<;;	;)*<4  
 
 
Equation 6.12. Calculation of the resistance factor (rf). 
 
6.3.8. Calculation of the Potentiation Factor (pf) 
 
The potentiation factor gives the factor by which a compound (e.g. inhibitor of a transporter) 
enhances sensitivity toward an antineoplastic drug. It is defined as the division of the GI50 of 
the cytotoxic agent in the resistant cell line and the GI50 of the same cytotoxic agent in 
combination with an inhibitor. 
 
 
 
 pf ' 	 XEST	2I<7)7 8* 	!<;;	;)*<4XEST	2I<7)7 8* 	!<;;	;)*<	)*	!?9J)*8 )?*	\) =	!?9:?G*H4 
 
 
Equation 6.13. Potentiation factor (pf) as calculated using a resistant cell line. 
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6.3.9. Calculation of the Degree of Sensitization (°s) 
 
The degree of sensitization (°s) is the ratio between potentiation factor of the compound at a 
specific concentration and the resistance factor of the resistant cell line. It gives the 
percentage of how much the cells have been sensitized compared to the maximal resistance. 
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Equation 6.13. Potentiation factor (pf) as calculated using a resistant cell line. 
 
6.3.10. Kinetic Evaluations 
 
6.3.10.1. Lineweaver-Burk 
 
The double-reciprocal plot of Lineweaver-Burk is based on the Michaelis-Menten kinetic as 
depicted below: 
 
 
 
 v ' 	_98F 	 ∙ 8.9`9 % 8.9  
 
 
Equation 6.14. Michaelis-Menten equation. 
 
Inverting of equation 6.14. gives the Lineweaver-Burk equation. 
 
 
 
 1A ' 	 `9_98F 	 ∙ 	 18.9 %	 1_98F 
 
 
Equation 6.15. Double-reciprocal Lineweaver-Burk equation. 
 
Four basic types of inhibition are present: competitive, noncompetitive, mixed-type or 
uncompetitive inhibition. In case of the first, the intersection of lines is on the ordinate. This 
means that Vmax remains constant while Km increases, which equals a lowered affinity of the 
substrate toward the target protein caused by competition with the inhibitor. In case of 
noncompetitive inhibition, the Vmax value decreases while the substrate affinity (Km) remains 
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constant. This can be seen by an intersection on the negative abscissa. A mixed-type 
inhibitor gives a mixture of both and can be explained by a compound that interacts with two 
binding sites, where one is the same as for the substrate. The intersection in this case is in 
the upper left quadrant of the coordinate system. A rare case is uncompetitive inhibition, 
which is indicated by parallel lines. This occurs rarely and was not observed in this thesis. 
Additionally, nonessential activation can occur, which can be seen as noncompetitive or 
mixed-type activation of the enzyme. The latter case occurs with activators that also have an 
inhibitory property. One must be aware that these kinetical equations are limited to enzymatic 
systems, and transporters are different from those proteins. 
 
6.3.10.2. Hanes-Woolf 
 
Rearrangement and inversion of the Michaelis-Menten equation (6.14) results in the Hanes-
Woolf equation. 
 
 
 
 8.9A ' 	 8.9_98F %	 `9_98F 
 
 
Equation 6.16. Hanes-Woolf equation. 
 
A competitive inhibition type can be recognized by parallel lines. A noncompetitive inhibition 
is indicated by an intersection of the lines at the negative abscissa. 
 
6.3.10.3. Cornish-Bowden 
 
Rearrangement and inversion of the Michaelis-Menten equation (6.14) results in the basic 
mathematical coherence of Cornish-Bowden. 
 
 
 
 1_98F ' 	 1A 3	 `9_98F 	 ∙ 8.9 
 
 
Equation 6.17. Cornish-Bowden equation. 
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